

Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024

I, Sarah Syme, as delegate of the Secretary of the Department of Health and Aged Care, make the following instrument.

Dated 28 May 2024

Sarah Syme

Assistant Secretary  
Regulatory Engagement Branch  
Health Products Regulation Group  
Department of Health and Aged Care

Contents

Reader’s guide i

Introduction i

Classification iii

Principles of scheduling iv

Reading the schedules v

Availability of poisons vii

Appendices viii

Appendix A (General exemptions) viii

Appendix B (Substances considered not to require control by scheduling) ix

Appendix C (blank) ix

Appendix D (Additional controls on possession or supply of poisons included in Schedule 4 or 8) ix

Appendix E (First aid instructions for poisons) ix

Appendix F (Warning statements and general safety directions for poisons) x

Appendix G (Dilute preparations) x

Appendix H (Schedule 3 medicines permitted to be advertised) x

Appendix I (blank) x

Appendix J (Conditions for availability and use of certain poisons included in Schedule 7) x

Appendix K (Human medicines required to be labelled with a sedation warning) x

Appendix L (Requirements for dispensing labels for medicines) x

Appendix M (blank) x

Poisons Information Centre telephone numbers for first aid instructions, warning statements and general safety directions for poisons xi

Part 1—Preliminary and interpretation 1

1 Name 1

2 Commencement 1

3 Authority 1

4 Repeal and transitional provisions 1

5 Reader’s guide and Index 2

6 Definitions 2

7 References to substances 10

8 References to concentration, strength or quantity of substances 11

9 References to boiling or distillation temperatures 11

10 References to standards 11

Part 2—Controls on substances 12

Division 1—Preliminary 12

11 Application of Part 2 12

12 Preparations containing poisons included in different schedules 12

Division 2—Labels 13

Subdivision A—General 13

13 General requirements 13

14 Immediate wrapper 13

Subdivision B—Primary packs and immediate containers 13

15 Primary packs and immediate containers 13

16 Signal words 14

17 Cautionary statement—possession without authority illegal 14

18 Cautionary statement—keep out of reach of children 15

19 Cautionary statement—fire and explosion hazard 15

20 Cautionary statement—burns skin and throat 15

21 Cautionary statements for aqueous solution of paraquat 16

22 Cautionary statement—read safety directions 16

23 Cautionary statement—flammable 17

24 Cautionary statement—for animal treatment only 17

25 Cautionary statement—do not swallow 17

26 Approved name and quantity, proportion or strength 17

27 Statement—an anticholinesterase compound 18

28 Directions for use 18

29 Safety directions 19

30 Warning statements 19

31 First aid 20

32 Name and address of manufacturer or distributor 20

33 Warning statements and sedation warnings for certain medicines for human use 21

Subdivision C—Statements of quantity, proportion or strength 21

34 Statements of quantity, proportion or strength 21

Subdivision D—Exemptions from labelling requirements 22

35 Selected containers and measure packs 22

36 Ampoules, pre‑filled syringes and injection vials 23

37 Transport containers and wrappings 23

38 Dispensary, industrial, laboratory and manufacturing poisons 23

39 Exemptions from label requirements in certain circumstances 24

40 Dispensed medicines 24

41 Gas cylinders 24

42 Paints 24

43 Camphor and naphthalene 25

Subdivision E—Prohibitions 25

44 Prohibitions 25

Division 3—Containers 27

45 General requirements 27

46 Containers for poisons other than poisons included in Schedule 5 27

47 Containers for poisons included in Schedule 5 27

48 Approved containers 28

49 Child‑resistant closures 28

50 Poisons included in Schedule 8 30

51 Exemptions 30

52 Camphor and naphthalene 31

53 Prohibitions—use of containers for poisons 31

Division 4—Storage 32

54 General storage requirements 32

Division 5—Disposal 33

55 General disposal requirements 33

Division 6—Record keeping 34

56 General record‑keeping requirements 34

Division 7—Advertising 35

57 General advertising requirements 35

Division 8—Supply, prescribing, possession or use 36

58 Poisons included in Schedule 2 36

59 Poisons included in Schedule 3 36

60 Poisons included in Schedule 4 37

61 Poisons included in Schedules 5 and 6 37

62 Poisons included in Schedule 7 37

63 Poisons included in Schedule 10 38

64 Poisons included in Schedule 4 or 8 and Appendix D 38

65 Hawking 39

Division 9—Paints and tinters 40

66 General requirements 40

67 Definition of *first group paint* 40

68 Definition of *second group paint* 41

Schedule 1—Blank 42

Schedule 2—Pharmacy medicines 43

Schedule 3—Pharmacist only medicines 61

Schedule 4—Prescription only medicines and prescription animal remedies 70

Schedule 5—Caution 174

Schedule 6—Poisons 208

Schedule 7—Dangerous poisons 262

Schedule 8—Controlled drugs 275

Schedule 9—Prohibited substances 280

Schedule 10—Substances of such danger to health as to warrant prohibition of supply and use 288

Appendix A—General exemptions 294

1 Exempt preparations and products 294

Appendix B—Substances considered not to require control by scheduling 297

1 Reasons for including substances in the table in clause 3 297

2 Areas of use in relation to substances included in the table in clause 3 297

3 Substances exempt in certain uses 299

Appendix C—Blank 307

Appendix D—Additional controls on possession or supply of poisons included in Schedule 4 or 8 308

1 Poisons available for human use only from or on the prescription or order of an authorised medical practitioner 308

2 Poisons available for human use only from or on the prescription or order of a specialist physician or a dermatologist 308

3 Poisons available only from or on the prescription or order of a medical practitioner approved or authorised under section 19 of the Act 309

4 Poisons available only from or on the order of a specialist physician 309

5 Poisons for which possession without authority is illegal 309

6 Poisons available for human use only from or on the prescription or order of a specialist physician 311

7 Poisons available for human use only from or on the prescription or order of a dermatologist 311

8 Poisons available for initial treatment of a patient only if authorised by certain health practitioners 311

9 Poisons which must be stored in a locked container to prevent unauthorised access 312

10 Poisons available only when prescribed or authorised in certain circumstances 312

Appendix E—First aid instructions for poisons 313

1 Standard statements for first aid instructions 313

2 Poisons information centre contact information in statements 314

3 First aid instructions for poisons 314

Appendix F—Warning statements and general safety directions for poisons 325

1 Warning statements 325

2 Safety directions—general 329

3 Poisons information centre contact information in statements 331

4 Poisons that must be labelled with warning statements and safety directions 331

Appendix G—Dilute preparations 346

1 Substances exempt at or below certain concentrations 346

Appendix H—Schedule 3 medicines permitted to be advertised 348

1 Schedule 3 medicines permitted to be advertised 348

Appendix I—Blank 350

Appendix J—Conditions for availability and use of certain poisons included in Schedule 7 351

1 Conditions for supply of certain poisons included in Schedule 7 351

Appendix K—Human medicines required to be labelled with a sedation warning 354

1 Human medicines required to be labelled with a sedation warning 354

Appendix L—Requirements for dispensing labels for medicines 359

1 General 359

2 Additional warning statements for certain human medicines 359

Appendix M—Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist 362

Index 363

Reader’s guide

Introduction

This instrument is made under paragraph 52D(2)(b) of the *Therapeutic Goods Act 1989* (the ***Act***), and is a compilation of decisions made under section 52D of the Act. This instrument should be read in conjunction with the *Scheduling Policy Framework* (the ***SPF***) of the Australian Health Ministers’ Advisory Council. Further information on the scheduling amendments and the SPF can be viewed on the Therapeutic Goods Administration’s website (www.tga.gov.au). Refer to section 6 for definitions of specific terms used in this document including “medicine” and “poison” (noting that the definition of poison includes medicine).

This instrument serves 2 key purposes.

Firstly, this instrument contains the decisions of the Secretary of the Department of Health and Aged Care or the Secretary’s delegates regarding the classification of poisons into Schedules, as recommendations to Australian States and Territories. The scheduling classification sets the level of control on the availability of poisons. The scheduling of poisons is implemented through relevant State and Territory legislation. Certain advertising, labelling and packaging requirements may also be a consequence of scheduling, but are the subject of other Commonwealth registration schemes.

Secondly, this instrument includes provisions for labelling, containers, storage, disposal, record‑keeping, supply and possession of poisons in general which are intended to be adopted for use in each jurisdiction of Australia. Other government agencies may also impose controls on certain products.

The requirements for labelling and containers in this instrument are intended to integrate with existing legislative instruments for labelling and containers. Advertising, labelling and packaging of therapeutic goods and agricultural and veterinary chemicals are also dealt with through the respective product registration schemes provided for in Commonwealth legislation.

Poisons which are packed and sold solely for industrial, manufacturing, laboratory or dispensary use are exempt from all labelling requirements included in this instrument as they are covered by labelling requirements under applicable jurisdictional Work Health and Safety laws, as amended from time to time. Note, however that this exemption does not extend to controls on supply of these poisons.

This instrument is presented with a view to promoting uniform:

* scheduling of poisons throughout Australia; and
* signal headings on labels for poisons throughout Australia; and
* labelling and packaging requirements for poisons throughout Australia; and
* additional controls on the availability and use of poisons in Australia.

The various Commonwealth Acts, legislative instruments and other documents, which integrate with this instrument include the following:

* the Act;
* the *Agricultural and Veterinary Chemicals Code Act 1994*;
* the *Agricultural and Veterinary Chemicals Code Regulations 1995*;
* the *Therapeutic Goods Order No. 91 ‑ Standard for labels of prescription and related medicines*;
* the *Therapeutic Goods Order No. 92 ‑ Standard for labels of non‑prescription medicines*;
* the *Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 2017*;
* the *Therapeutic Goods Order No. 95* ‑ *Child‑resistant packaging requirements for medicines 2017* (TGO 95);
* the *Therapeutic Goods (Standard for Therapeutic Vaping Goods) (TGO 110) Order 2021*;
* the *Therapeutic Goods (Medicines Advisory Statements) Specification 2021* – Schedule 1 Required Advisory Statements for Medicine Labels No. 6 (RASML).

Classification

Poisons are classified according to the Schedules in which they are included. The following is a general description of the Schedules. For the legal definitions, however, it is necessary to check with each relevant State or Territory authority.

| Schedule | Title | Description |
| --- | --- | --- |
| Schedule 1 | Blank | This Schedule is intentionally blank. |
| Schedule 2 | Pharmacy medicines | Substances, the safe use of which may require advice from a pharmacist and which should be available from a pharmacy or, where a pharmacy service is not available, from a licensed person. |
| Schedule 3 | Pharmacist only medicines | Substances, the safe use of which requires professional advice but which should be available to the public from a pharmacist without a prescription. |
| Schedule 4 | Prescription only medicines and prescription animal remedies | Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription. |
| Schedule 5 | Caution | Substances with a low potential for causing harm, the extent of which can be reduced through the use of appropriate packaging with simple warnings and safety directions on the label. |
| Schedule 6 | Poisons | Substances with a moderate potential for causing harm, the extent of which can be reduced through the use of distinctive packaging with strong warnings and safety directions on the label. |
| Schedule 7 | Dangerous poisons | Substances with a high potential for causing harm at low exposure and which require special precautions during manufacture, handling or use. These poisons should be available only to specialised or authorised users who have the skills necessary to handle them safely. Special regulations restricting their availability, possession, storage or use may apply. |
| Schedule 8 | Controlled drugs | Substances which should be available for use but require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or psychological dependence. |
| Schedule 9 | Prohibited substances | Substances which may be abused or misused, the manufacture, possession, supply or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities. |
| Schedule 10 (previously Appendix C) | Substances of such danger to health as to warrant prohibition of supply and use | Substances which are prohibited for the purpose or purposes listed for each poison. |

Principles of scheduling

Poisons are not scheduled on the basis of a universal scale of toxicity. Although toxicity is one of the factors considered, and is itself a complex of factors, the decision to include a substance in a particular Schedule also takes into account many other criteria such as the purpose of use, potential for abuse, safety in use and the need for the substance.

This instrument lists poisons in 10 Schedules according to the degree of control recommended to be exercised over their availability to the public.

Poisons for therapeutic use (medicines) are mostly included in Schedules 2, 3, 4 and 8 with progression through these Schedules signifying increasingly restrictive regulatory controls.

For some medicines and agricultural, domestic and industrial poisons, Schedules 5, 6 and 7 represent increasingly stricter container and labelling requirements with special regulatory controls over the availability of the poisons listed in Schedule 7. Products for domestic use must not include poisons listed in Schedule 7.

Schedule 9 contains substances that should be available only for teaching, training, medical or scientific research including clinical trials conducted with the approval of Commonwealth and/or State and Territory health authorities. Although appearing as a Schedule in this instrument, the method by which it is implemented in the States and Territories may vary.

Schedule 10 (previously Appendix C) contains a list of substances or preparations, the supply or use of which should be prohibited because of their known dangerous properties.

Substances in products which have been considered for scheduling, but have been exempted from this instrument, may be listed in either Appendix A (general exemptions) or Appendix B (substances considered not to require control by scheduling).

Reading the schedules

Schedule entries have been designed to be as simple as possible while retaining readability, legal integrity and as much freedom from ambiguity and contradiction as possible. As a result, they are expressed in a number of ways, though this number has been kept to a minimum. It is necessary to keep this variety of expression in mind when searching or interpreting Schedule entries.

Firstly, poisons are scheduled individually using their approved names wherever practicable although exceptions are necessary in some cases. Some of those are mentioned below. Older group entries are revised and replaced by individual entries as time permits, although in some of these cases a group term has also been retained to deal with any members of the group or class that may have escaped attention but should be scheduled.

Secondly, Schedule entries have been expressed in either positive or negative terms and care must be taken to distinguish between the 2 different forms of expression. Thus, selenium is in Schedule 6 only when one of the clauses in this Schedule entry applies, while fluorides are in Schedule 6 unless one of the exempting clauses applies.

Where exceptions are included in an entry, these have been emphasised by printing the word “**except**” in bold type.

Where the Schedule entries for a poison make a specific exclusion or exemption, the requirements of this instrument do not apply to that poison within the constraints of that exclusion or exemption although controls under other legislation, such as pesticide registration, may apply.

Where a Schedule entry for a poison requires a specific statement to be included on a label as a condition for a product to qualify for an exemption (“reverse scheduling”), then in cases where it is impracticable for a supplier to use the exact wording of such a statement, its wording may be varied provided that the full intent and meaning of the statement is not changed.

Where a poison has been included in more than one Schedule, the principal entry, where practicable, has been included in the most restrictive Schedule with references to the other Schedule(s) involved.

It is important to remember that a Schedule entry includes preparations containing the poison in any concentration and all salts and derivatives of the poison unless it specifically states otherwise (see section 7).

It is important to note that a substance is not classed as a derivative on the basis of a single, prescriptive set of criteria. Classification of a substance as a derivative of a scheduled poison relies on a balanced consideration of factors to decide if a substance has a similar nature (e.g. structurally, pharmacologically, and toxicologically) to a scheduled poison or is readily converted (either physically or chemically) to a scheduled poison. However, a substance is only considered a derivative of a scheduled poison if it is not individually listed elsewhere in the Schedules, or captured by a more restrictive group or class entry. Additionally, some entries specifically exclude derivatives. Once a substance is determined to be a derivative of a scheduled poison, the same scheduling requirements as the scheduled poison, including limits on access, supply and availability, will apply.

Finally, when using this instrument to determine the scheduling status of a poison, it may be necessary to search each relevant Schedule as well as Appendices A, B and the Index. In this process, if the poison is not found under its “approved name” it may be shown under a group term such as:

| Group | Example |
| --- | --- |
| the parent acid of salts | “oxalic acid” to find sodium oxalate |
| the radical of a salt | “chromates” to find potassium chromate |
| the element | “arsenic” to find arsenic trioxide |
| a chemical group with similar toxicological or pharmacological activity | “hydrocarbons, liquid” to find kerosene |
| a pharmacological group | “anabolic steroidal agents” to find “androsterone” |

Availability of poisons

The purpose of classification is to group substances into Schedules that require similar regulatory controls over their availability.

These Schedules have been developed over a long period and contain poisons that may be obsolete for various reasons. Also, as part of the move to harmonise the Australian and New Zealand classifications, many substances have been added to the Schedules for that purpose, irrespective of their availability in either country.

Inclusion of a poison in a Schedule indicates the degree of control required if it is marketed. It does not:

* indicate that the poison is available; or
* indicate that it is has been approved or is efficacious for any use that may be specified in a Schedule; or
* negate any obligation for registration of therapeutic goods, or agricultural or veterinary chemical product containing that poison.

Appendices

Some substances in certain circumstances are also subject to exemptions or additional restrictions as described in the Appendices of this instrument. The table below summarises the purpose of each of the Appendices and the controls imposed on substances included in them.

| Appendix | Title | Purpose/controls imposed |
| --- | --- | --- |
| Appendix A | General exemptions | List of preparations and products exempted from this instrument. |
| Appendix B | Substances considered not to require control by scheduling | List of poisons exempted from scheduling. |
| Appendix C | Appendix is intentionally left blank | See Schedule 10. |
| Appendix D | Additional controls on possession or supply of poisons included in Schedule 4 or 8 | List of poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply. |
| Appendix E | First aid instructions for poisons | First aid instructions for poisons (other than agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |
| Appendix F | Warning statements and general safety directions for poisons | Warning statements and general safety directions for poisons (other than human medicines, agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |
| Appendix G | Dilute preparations | Concentration cut‑offs for specified poisons, below which the requirements of this instrument do not apply |
| Appendix H | Schedule 3 medicines permitted to be advertised | List of medicines included in Schedule 3 that are permitted to be advertised to the public. |
| Appendix I | Appendix is intentionally left blank |  |
| Appendix J | Conditions for availability and use of Schedule 7 poisons | List of poisons included in Schedule 7 where additional specified conditions apply to their availability and use. |
| Appendix K | Human medicines required to be labelled with a sedation warning | List of poisons in medicines for human use required to be labelled with a warning regarding their sedation potential. |
| Appendix L | Requirements for dispensing labels for medicines | Requirements applying to labels attached to medicines at the time of dispensing. |
| Appendix M | Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist  Appendix is intentionally left blank and is reserved for future use. |  |

Appendix A (General exemptions)

Appendix A lists preparations and products that are exempted from this instrument.

Appendix B (Substances considered not to require control by scheduling)

Substances for which the available information suggests that inclusion in the Poisons Schedules is not necessary, or not the most appropriate means of controlling the risk to public health, have been considered at various times.

Inclusion in Appendix B indicates that a decision has been taken not to include substances anywhere in the Schedules, either for a specific purpose, or generally. It is an inclusive, but not an exhaustive, list (that is, there may be substances not included in the Schedules, and not included in Appendix B, which may be hazardous or non‑hazardous, but have not been considered in relation to the need for scheduling).

Substances may be included in Appendix B because they have intrinsically low toxicity, or where other factors suggest that the potential public health risk would be minimal. Factors which are considered when determining an Appendix B entry include:

* the toxicology profile was adequately characterised and not consistent with inclusion in any of the Schedules;
* the use, purpose or product presentation minimised any hazard to the public such as to not require scheduling; or
* the public access was limited such that scheduling was inappropriate or unnecessary.

The list of substances included in Appendix B was developed from scheduling files and historical records. For transparency, where the reason for entry and/or purpose or use for the substance was apparent in the consideration, this has been included in the columns “Reason for Entry” and “Area of Use”.

Inclusion in Appendix B will not prevent reconsideration of the scheduling of a substance where adverse information becomes available about the Appendix B entry for that substance.

Applications are considered for scheduling. Applications for inclusion in Appendix B will not be accepted.

Appendix C (blank)

Appendix C is intentionally blank.

Appendix D (Additional controls on possession or supply of poisons included in Schedule 4 or 8)

Appendix D lists poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply.

Appendix E (First aid instructions for poisons)

Under poisons legislation, scheduled substances and their preparations are required to be labelled with appropriate directions for first aid attention in case of poisoning. It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the first aid instructions included on the label of a poison are appropriate for a specific product. Standard statements have been prepared as a guide for health authorities and manufacturers in drafting suitable first aid directions for this purpose. Standard statements specified in Appendix E may be varied provided that the intent is not changed.

The directions listed for any particular substance may require modification to take into account combination of that substance with other substances, both toxic and non‑toxic, in a formulation, as well as the physical form and presentation of the product. Any such modification should be concise and readily understood.

The First Aid Instructions include action to be taken in case of eye contamination from substances recognised as causing direct poisoning via the eye, causing severe eye damage or requiring prolonged flushing to free the absorbed substance from the eye tissue. However, it is recognised that many other substances or preparations will require a statement of varying nature depending on the detailed formulation. While the necessity to flush the eyes in case of accident will be so self‑evident as not to justify label space in many instances, a statement such as “If in eyes rinse well with water” may be appropriate.

Appendix F (Warning statements and general safety directions for poisons)

It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the purchaser or user of a product is given sufficient information to be able to use it correctly and safely.

Under poisons legislation, scheduled substances, which may be harmful to the user, must be labelled with appropriate warning statements and/or safety directions. The selection of warning statements and safety directions will depend on the formulation of the product, and the use for which it is sold or supplied. Warning statements and safety directions have been prepared as a guide for this purpose.

The wording of warning statements and safety directions specified in Appendix F may be varied provided that the intent is not changed. Additional statements also may be added to ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid any deleterious effects.

Appendix G (Dilute preparations)

Appendix G lists concentration cut‑offs for specified substances, below which the requirements of this instrument do not apply.

Appendix H (Schedule 3 medicines permitted to be advertised)

Appendix H lists medicines included in Schedule 3 that are permitted to be advertised to the public.

Appendix I (blank)

Appendix I is intentionally blank.

Appendix J (Conditions for availability and use of certain poisons included in Schedule 7)

All poisons included in Appendix J are not to be available except to authorised or licensed persons.

The use of a poison may be restricted for a particular purpose. Controls recommended for the Schedule 7 poisons included in Appendix J may be implemented through poisons controls or other State or Territory legislation.

Appendix K (Human medicines required to be labelled with a sedation warning)

Medicines for human use that contain a poison included in Appendix K are required to be labelled with a warning regarding their sedation potential.

Appendix L (Requirements for dispensing labels for medicines)

Appendix L sets out the requirements for labels attached to medicines at the time of dispensing.

Appendix M (blank)

Appendix M is intentionally blank and is reserved for future use.

Poisons Information Centre telephone numbers for first aid instructions, warning statements and general safety directions for poisons

Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.

Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand must meet the following criteria:

1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and

2. calls must be logged and submitted for incorporation into the official collection of poisoning data.

Part 1—Preliminary and interpretation

1 Name

(1) This instrument is the *Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024*.

(2) This instrument may also be cited as the Standard for the Uniform Scheduling of Medicines and Poisons No. 44.

Note: This instrument is the ***current Poisons Standard*** for the purposes of the Act until a document is prepared in substitution for it (see sections 52A and 52D of the Act).

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 June 2024. | 1 June 2024 |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under paragraph 52D(2)(b) of the *Therapeutic Goods Act 1989*.

4 Repeal and transitional provisions

Repeal

(1) The *Therapeutic Goods (Poisons Standard*—*February 2024) Instrument 2024* is repealed.

Saving—things done under the repealed instrument

(2) If:

(a) a thing was done for a particular purpose under the *Therapeutic Goods (Poisons Standard*—*February 2024) Instrument 2024* as in force immediately before that instrument was repealed; and

(b) the thing could be done for that purpose under this instrument;

the thing has effect for the purposes of this instrument as if it had been done for that purpose under this instrument.

(3) Without limiting subsection (2), a reference in that subsection to a thing being done includes a reference to an approval, authorisation, certificate, exemption, requirement or other instrument being given, made, granted or issued.

5 Reader’s guide and Index

(1) The Reader’s guide is not part of this instrument.

(2) The Index is not part of this instrument.

6 Definitions

Note 1: The following expressions used in this instrument are defined in the Act:

(a) current Poisons Standard;

(b) poison;

(c) Register;

(d) Secretary;

(e) supply;

(f) therapeutic goods.

Note 2: The definition of ***poison*** in the Act is as follows:

***poison*** means an ingredient, compound, material or preparation which, or the use of which, may cause death, illness or injury and includes any ingredient, compound, material or preparation referred to in a schedule to the current Poisons Standard.

In this instrument:

***Act*** means the *Therapeutic Goods Act 1989*.

***agricultural chemical*** means:

(a) a substance that is represented, imported, manufactured, supplied or used as a means of directly or indirectly:

(i) destroying, stupefying, repelling, inhibiting the feeding of, or preventing infestation by or attacks of, any pest in relation to a plant, a place or a thing; or

(ii) destroying a plant; or

(iii) modifying the physiology of a plant or pest so as to alter its natural development, productivity, quality or reproductive capacity; or

(iv) modifying an effect of another agricultural chemical; or

(v) attracting a pest for the purpose of destroying it; or

(b) an active ingredient included in a product declared by regulation under the *Agricultural and Veterinary Chemicals Code Act 1994* to be an agricultural chemical product;

but does not include a veterinary chemical.

***agricultural chemical product*** has the same meaning as in the Agricultural and Veterinary Chemicals Code set out in the Schedule to the *Agricultural and Veterinary Chemicals Code Act 1994*.

***animal*** means any animal (other than a human being), whether vertebrate or not, and whether a food producing species or not, and includes mammals, birds, bees, reptiles, amphibians, fish, crustaceans and molluscs.

***animal feed premix*** means a concentrated preparation, containing one or more poisons, for mixing with food ingredients to produce a bulk feed for a group of animals (including fish or birds), but does not include a preparation for mixing with an individual animal’s food.

***appropriate authority***: each of the following is an ***appropriate authority***:

(a) each person who is the head of the body (however described) in a State or Territory that is responsible for the administration of matters relating to health in that State or Territory;

(b) the Deputy Secretary of the Department with responsibility for the part of the Department known as the Therapeutic Goods Administration, or their delegate;

(c) the Chief Executive Officer of the Australian Pesticides and Veterinary Medicines Authority, or their delegate.

***approved name*** means:

(a) for a poison that is for human therapeutic use—the name for the poison in the Australian Approved Names List within the meaning of the *Therapeutic Goods Regulations 1990*; or

(b) for a poison that is for animal or agricultural use—the name approved for use by the Australian Pesticides and Veterinary Medicines Authority under the Agricultural and Veterinary Chemicals Code set out in the Schedule to the *Agricultural and Veterinary Chemicals Code Act 1994*; or

(c) for any other poison—the name for the poison mentioned in the first‑occurring of the following paragraphs that applies to the poison:

(i) the name used for the poison in this instrument;

(ii) the name recommended by Standards Australia as the common name for the poison;

(iii) the English name given to the poison by the International Organization for Standardization;

(iv) the name given to the poison by the British Standards Institution;

(v) the English name given to the poison by the European Committee for Standardization (CEN);

(vi) the international non‑proprietary name recommended for the poison by the World Health Organization;

(vii) the International Nomenclature Cosmetic Ingredient name for the poison listed in the *International Cosmetic Ingredient Dictionary & Handbook* published by the Personal Care Products Council of America;

(viii) the accepted scientific name or the name descriptive of the true nature and origin of the poison.

***Australian Dangerous Goods Code*** means the *Australian Code for the Transport of Dangerous Goods by Road & Rail*, published by the National Transport Commission, as existing from time to time.

Note: The Australian Dangerous Goods Code could in 2022 be viewed on the Commission’s website (www.ntc.gov.au).

***authorised prescriber*** means any of the following:

(a) a dental practitioner;

(b) a medical practitioner;

(c) a veterinarian;

(d) a person for whom an authorisation, given for the purposes of this paragraph by an appropriate authority, is in effect.

***blood*** means whole blood extracted from human donors.

***blood components*** means therapeutic components that have been manufactured from blood (including red cells, white cells, stem cells, platelets and plasma), except for products derived through fractionation of plasma.

***child‑resistant closure*** means:

(a) a closure that complies with the requirements for a child‑resistant closure in Australian Standard AS 1928‑2007, *Child‑resistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2015, MOD)*; or

(b) a closure that complies with the requirements for child‑resistant closures specified in *Therapeutic Goods Order No. 95* ‑ *Child‑resistant packaging requirements for medicines 2017* (TGO 95); or

(c) a closure that is taken to comply with the requirements mentioned in paragraph (b) under *Therapeutic Goods (Standard for Therapeutic Vaping Goods) (TGO 110) Order 2021*; or

(d) in the case of a can fitted with a press‑on lid, a lid of the design known as “double tight” or “triple tight”.

Note: See also the definition of ***non‑access packaging***.

***child‑resistant packaging*** means packaging that:

(a) complies with the requirements of Australian Standard AS 1928‑2007, *Child resistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2015, MOD)*; or

(b) is reclosable and complies with the requirements of at least one of the following:

(i) the International Organization for Standardization Standard ISO 8317:2015, *Child‑resistant packaging—Requirements and testing procedures for reclosable packages*;

(ii) the British Standards Institution Standard BS EN ISO 8317:2004, *Child‑resistant packaging—Requirements and testing procedures for reclosable packages*;

(iii) the Canadian Standards Association Standard CSA Z76.1‑06, *Reclosable Child‑Resistant Packages*;

(iv) the United States Code of Federal Regulations, Title 16, Section 1700.15, *Poison prevention packaging standards* and Section 1700.20, *Testing procedure for special packaging*, as in force from time to time; or

(c) a closure that complies with the requirements for child‑resistant packaging specified in *Therapeutic Goods Order No. 95* ‑ *Child‑resistant packaging requirements for medicines 2017* (TGO 95); or

(d) a closure that is taken to comply with the requirements mentioned in paragraph (c) under *Therapeutic Goods (Standard for Therapeutic Vaping Goods) (TGO 110) Order 2021*; or

(e) is in the form of blister or strip packaging:

(i) in which a unit of use is individually protected until the time of release; and

(ii) that complies with section 3 (Requirements for non‑reclosable packages) of Australian Standard AS 1928‑2001, *Child‑resistant packages*.

Note: See also the definition of ***non‑access packaging***.

***compounded*** in relation to a substance means combined with one or more other therapeutically active substances in such a way that it cannot be separated from them by simple dissolution or other simple physical means.

***cosmetic*** means a substance or preparation intended for placement in contact with any external part of the human body, including:

(a) the mucous membranes of the oral cavity; and

(b) the teeth;

with a view to:

(c) altering the odours of the body; or

(d) changing its appearance; or

(e) cleansing it; or

(f) maintaining it in good condition; or

(g) perfuming it; or

(h) protecting it.

***debitterised neem seed oil*** means highly purified oil from the neem seed containing only fatty acids and glycerides of fatty acids.

***dental practitioner*** means a person who is registered, in a State or internal Territory, as a dental practitioner (other than a dental therapist, dental hygienist, dental prosthetist or oral health therapist).

***dermal use*** means application to the skin primarily for localised effect.

***designated solvent*** means the following:

(a) acetone;

(b) dimethylformamide;

(c) *N*‑(*N*‑dodecyl)‑2‑pyrrolidone;

(d) hydrocarbons, liquid;

(e) methanol when included in Schedule 5;

(f) methyl ethyl ketone;

(g) methyl isoamyl ketone;

(h) methyl isobutyl ketone;

(i) *N*‑methyl‑2‑pyrrolidone;

(j) *N*‑(*N*‑octyl)‑2‑pyrrolidone;

(k) phenyl methyl ketone;

(l) styrene;

(m) tetrachloroethylene;

(n) 1,1,1‑trichloroethane.

***dispensing label***, for a substance for therapeutic use, means the label attached to the immediate container of the substance at the time of dispensing.

Note: See section 40 and Appendix L.

***distributor*** means a person who imports or supplies a poison.

***divided preparation*** means a preparation manufactured and packed as discrete pre‑measured dosage units prior to supply, and includes tablets, capsules, cachets, single dose powders or single dose sachets of powders or granules.

***dosage unit*** means an individual dose of a poison for therapeutic use and includes a tablet, capsule, cachet, single dose powder or single dose sachet of powders or granules.

***drug*** means a poison intended for human or animal therapeutic use.

***essential oils*** means:

(a) products obtained from natural raw materials by distillation with water or steam or from the epicarp of citrus fruits by a mechanical process, or by dry distillation; or

(b) oils of equivalent composition to products mentioned in paragraph (a) that are derived through synthetic means; or

(c) prepared mixtures of oils of equivalent composition to products mentioned in paragraph (a) that comprise a mixture of synthetic and natural components.

***external*** in relation to the use of a poison means application in the ears, eyes or nose or to a body surface other than in the mouth, rectum, vagina, urethra or other body orifice.

***first group paint***: see section 67.

***free formaldehyde*** includes all hydrated and non‑hydrated formaldehyde present in aqueous solution, including methylene glycol and formaldehyde released from formaldehyde donors.

***graphic material*** means the material which is to be deposited on another material by a graphic instrument during writing, drawing or marking and includes cores of pencils, school pastels or crayons, blackboard chalks, finger or showcard colours, poster paints and watercolour blocks.

***hand sanitiser preparation***means an antimicrobial skin care product that:

(a) consists of, contains or generates one or more antimicrobial active substances; and

(b) is represented in any way to be, or is likely to be taken to be (whether because of the way in which it is presented or for any other reason):

(i) for use on hands when soap and water are not available; and

(ii) applied to the hands without rinsing off; and

(iii) intended to destroy, deter, render harmless, prevent the action of, or otherwise exert a controlling effect on any microbes on the skin.

***hawking*** means to supply (including peddle or distribute or cause to be distributed) in a public place.

***height*** in relation to letters used for words, expressions or statements on labels means the height of capital letters or lower case letters having an ascender or a descender.

***hemp seed oil*** means the oil obtained by cold expression from the ripened fruits (seeds) of Cannabis sativa.

***immediate container*** includes all forms of containers in which a poison is directly packed but does not include any such container intended for consumption or any immediate wrapper.

***immediate wrapper*** means metal foil, plastic foil, waxed paper, or any other such material not intended for consumption, when used as the first wrapper for a dosage unit or dressing.

***internal use*** means administration:

(a) orally, except for topical effect in the mouth; or

(b) for absorption and the production of a systemic effect:

(i) by way of a body orifice other than the mouth; or

(ii) parenterally, other than by application to unbroken skin.

***label***:

(a) means a written statement on a container of a poison; and

(b) in relation to therapeutic goods, includes a display of printed information about the product:

(i) on, or attached to, the goods; or

(ii) on, or attached to, a container or primary pack in which the goods are supplied; or

(iii) supplied with such a container or pack.

***main label***, for a container of poison, means:

(a) the part of the label that is most likely to be displayed, presented, shown, or examined under ordinary or customary conditions of display; and

(b) if there are 2 or more labels:

(i) the label or the part of the label where the product name is more or most conspicuously shown; or

(ii) if the product name is equally more or most conspicuously displayed on more than one of those labels—each of the labels on which the product name is equally more or most conspicuously displayed.

***manufacturer*** of a poison means a person who manufactures, produces, or packs a poison.

***marker dyes or pigments*** means any product that is added to a liquid used in agricultural or veterinary chemicals to identify or distinguish treated from untreated objects, land or organisms by temporarily imparting colour on the relevant object, land or organism through, for example, spot‑ or boom‑spraying.

***measure pack*** means a sealed container which contains a measured quantity of poison for use on one occasion as a pesticide or domestic product and one or more of which is enclosed in a primary pack.

***medical practitioner*** means a person who is registered, in a State or internal Territory, as a medical practitioner.

***medicine*** means any poison for therapeutic use.

***midwife*** means a person who is registered, in a State or internal Territory, as a midwife.

***non‑access packaging***, for a product that is not intended for human therapeutic use, means packaging that complies with the requirements of AS 4710‑2001, *Packages for chemicals not intended for access or contact with their contents by humans*.

Note: See also the definitions of ***child‑resistant closure*** and ***child‑resistant packaging***.

***non‑volatile content*** in relation to a paint or tinter means that portion of a paint or tinter determined to be the non‑volatile content by Method 301.1 of Australian Standard AS 1580‑301.1‑2005, *Paints and related materials – Methods of test – Non‑volatile content by mass*.

***nurse*** means a person who is registered, in a State or internal Territory, as a nurse.

***oromucosal use*** means administration to the oral mucosa, specifically the oral cavity and/or the pharynx.

***paint*** includes any substance used or intended to be used for application as a colouring or protective coating to any surface but does not include graphic material or paints for therapeutic use.

***pesticide*** means any substance or mixture of substances used or intended to be used:

(a) for preventing, destroying, repelling, attracting, inhibiting or controlling any insects, rodents, birds, nematodes, bacteria, fungi, weeds or other forms of plant or animal life or viruses, which are pests; or

(b) as a plant regulator, promoter, defoliant or desiccant for food storage, household, industrial, commercial, agricultural and non‑agricultural application, but does not include veterinary drugs, stock medicines, stock feeds, stock feed additives, drugs for human use, food additives or fertilisers.

***pharmacist*** means a person who is registered, in a State or internal Territory, as a pharmacist.

***primary pack***, in relation to a poison, means the pack in which the poison and its immediate container or immediate wrapper or measure pack are presented for supply.

***product sample*** means a packed poison supplied directly to a consumer:

(a) free of charge or for a nominal charge; and

(b) as a mechanism to promote the supply of the product; and

(c) in the form of:

(i) a small pack produced specifically for the purposes of promotion; or

(ii) a normal commercial pack that in other circumstances could be purchased by the consumer.

***public place*** means any place where members of the public are lawfully entitled, invited or permitted to be present in their capacity as members of the public.

Note: Examples of a public place include a street, road, footway, court, alley or thoroughfare that the public may use in any residential premises or to get from door to door, place to place or house to house.

***required advisory statements for medicine labels*** means the *Therapeutic Goods (Medicines Advisory Statements) Specification 2021*.

***restricted flow insert*** means a restriction:

(a) that is fitted or moulded in the neck of a container; and

(b) that cannot readily be removed from the container by manual force; and

(c) that limits the delivery of the contents of the container to drops each of which is not more than 200 microlitres.

***second group paint***: see section 68.

***selected container*** means:

(a) an injection vial having a nominal capacity of 10 ml or less; or

(b) a single use syringe; or

(c) any other container for substances for therapeutic use having a nominal capacity of 10 ml or less.

***solid*** includes powder.

***substance*** has the same meaning as in Part 6‑3 of the Act.

Note 1: In general terms, that definition covers an ingredient, compound, material or preparation which, or the use of which, may cause death, illness or injury to persons or animals.

Note 2: See also section 7.

***therapeutic use*** means use in or in connection with:

(a) preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in human beings or animals; or

(b) influencing, inhibiting or modifying a physiological process in human beings or animals; or

(c) testing the susceptibility of human beings or animals to a disease or ailment; or

(d) influencing, controlling or preventing conception in human beings or animals; or

(e) testing for pregnancy in human beings or animals; or

(f) the replacement or modification of parts of the anatomy in human beings or animals.

***tinter*** means any pigment or admixture of pigment with other substances, in powder, semi‑solid or liquid form, sold or supplied for the purpose of adding to paint in order to change the colour of the paint.

***topical use*** means application of a poison for the purpose of producing a localised effect on the surface of the organ or within the tissue to which it is applied.

***toy*** means an object or number of objects manufactured, designed, labelled or marketed as a plaything for a child or children up to the age of 14 years.

***transdermal use*** means application to the skin primarily for systemic effect.

***veterinarian*** means a person who is registered under the law of a State or Territory as a veterinarian, a veterinary practitioner or a veterinary surgeon.

***veterinary chemical*** means:

(a) a substance that is represented as being suitable for, or is manufactured, supplied or used for, administration or application to an animal by any means, or consumption by an animal, as a way of directly or indirectly:

(i) preventing, diagnosing, curing or alleviating a disease or condition in the animal or an infestation of the animal by a pest; or

(ii) curing or alleviating an injury suffered by the animal; or

(iii) modifying the physiology of the animal:

(A) so as to alter its natural development, productivity, quality or reproductive capacity; or

(B) so as to make it more manageable; or

(iv) modifying the effect of another veterinary chemical; or

(b) any vitamin, mineral substance, or additive, if, and only if, the vitamin, substance or additive is used for a purpose mentioned in paragraph (a); or

(c) any active ingredient included in a product declared by regulation under the *Agricultural and Veterinary Chemicals Code Act 1994* to be a veterinary chemical product;

but does not include an agricultural chemical.

***veterinary chemical product*** has the same meaning as in the Agricultural and Veterinary Chemicals Code set out in the Schedule to the *Agricultural and Veterinary Chemicals Code Act 1994*.

7 References to substances

In this instrument, unless the contrary intention appears, a reference to a substance includes the following:

(a) that substance prepared from natural sources or artificially;

(b) if the substance is a plant (other than a plant included in Schedule 8 or 9)—that plant or any part of that plant when packed or prepared for therapeutic use;

(c) every salt, active principle or derivative of the substance, including esters and ethers, and every salt of such an active principle or derivative;

(d) every alkaloid of the substance and every salt of such an alkaloid;

(e) every stereoisomer of the substance and every salt of such a stereoisomer;

(f) every recombinant form of the substance;

(g) a preparation or admixture containing any proportion of the substance.

Note: Part 2 (controls on substances) does not apply in relation to certain substances (see section 11).

8 References to concentration, strength or quantity of substances

In this instrument, for a reference to a concentration, strength or quantity of a substance:

(a) if the substance is present as a salt, active principle or derivative (including an ester or ether), the concentration, strength or quantity is calculated as the equivalent amount of the substance; and

(b) the expression “1%” means:

(i) in the case of a liquid preparation, 1 g of the substance per 100 mL of the preparation; or

(ii) in the case of a solid, semi‑solid or pressurised spray aerosol preparation, 1 g of the substance per 100 g of the preparation; and

(iii) any expression of greater or lesser percentages shall have a corresponding meaning; and

(c) in the case of codeine, such concentration, strength or quantity is calculated as anhydrous codeine.

9 References to boiling or distillation temperatures

In this instrument, a reference to a boiling or distillation temperature means that temperature at an atmospheric pressure of 101.325 kPa (760 mm of mercury).

10 References to standards

A reference in this instrument to an Australian standard, an international standard or a standard of a foreign country is a reference to that standard as it exists from time to time.

Part 2—Controls on substances

Division 1—Preliminary

11 Application of Part 2

This Part applies to a substance or preparation included in a schedule to this instrument, other than the following:

(a) a preparation or product included in the table in clause 1 of Appendix A;

(b) a substance included in the table in clause 3 of Appendix B when used in an area, sub‑area or sub‑sub‑area of use specified in the table in relation to that substance;

(c) a substance included in the table in clause 1 of Appendix G at a concentration not exceeding the concentration specified in that table in relation to that substance;

(d) any other substance included in Schedules 1 to 6, at a concentration not exceeding 10 mg per litre or 10 mg per kilogram, unless that substance is also included in Schedule 7 or 8;

(e) any substance present as an impurity in a pesticide, at a concentration at or below the maximum content for that substance, specified for the pesticide in the *Agricultural and Veterinary Chemicals Code (Agricultural Active Constituents) Standards 2022*, published by the Australian Pesticides and Veterinary Medicines Authority, as existing from time to time.

Note: For paragraph (e), the *Agricultural and Veterinary Chemicals Code (Agricultural Active Constituents) Standards 2022* is a legislative instrument that could in 2023 be accessed at www.legislation.gov.au.

12 Preparations containing poisons included in different schedules

(1) If a preparation contains 2 or more poisons, the provisions relating to each of the schedules in which those poisons are included apply to the preparation.

(2) However, if it is not possible to comply both with a provision relating to one of those schedules and with a provision relating to another of those schedules, the provision relating to the more restrictive schedule applies, unless a contrary intention is indicated in the schedules or relevant State or Territory legislation.

(3) The Schedules listed in order of greatest to least restrictiveness are 9, 10, 8, 4, 7, 3, 2, 6, 5.

Note: Schedule 1 is not currently in use.

Division 2—Labels

Subdivision A—General

13 General requirements

(1) A poison must not be supplied unless it is labelled in accordance with this Division.

(2) Any word, expression or statement required by this instrument to be written on a label or container must be written:

(a) on the outside face of the label or container; and

(b) in English; and

(c) in durable characters; and

(d) in a colour or colours to provide a distinct contrast to the background colour; and

(e) in letters at least 1.5 mm in height.

(3) Paragraph (2)(e) does not apply to a word, expression or statement on a container which has a capacity of 20 ml or less, or on the label of such a container if:

(a) an appropriate authority approves the use of smaller letters; and

(b) the letters are at least 1 mm in height.

(4) The label must be printed on, or securely attached to:

(a) the outside of the immediate container; and

(b) if the immediate container is enclosed in a primary pack—the outside of that primary pack.

14 Immediate wrapper

If a poison is enclosed in an immediate wrapper:

(a) the poison must be contained in a primary pack labelled in accordance with section 15; and

(b) the immediate wrapper must be conspicuously labelled with:

(i) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for that poison; and

(ii) the approved name of the poison; and

(iii) a statement of the quantity, proportion or strength of the poison in accordance with section 34.

Subdivision B—Primary packs and immediate containers

15 Primary packs and immediate containers

This Subdivision sets out how the primary pack and immediate container of a poison must be labelled.

16 Signal words

(1) The signal word or words for the poison, as shown in the following table, must be written:

(a) on the first line or lines of the main label; and

(b) in bold‑face sans serif capital letters of uniform thickness; and

(c) subject to subsection (3), in letters at least half the height of the largest letter or numeral on the label; and

(d) with nothing else other than the following written on the same line or lines:

(i) if the poison is included in Schedule 5—a class label as specified in the Australian Dangerous Goods Codeor a statement of the principal hazard of the poison;

(ii) if the poison is not included in Schedule 5—a class label as specified in theAustralian Dangerous Goods Code.

| Signal word or words for poisons | | | |
| --- | --- | --- | --- |
| Item | For a poison included in the following schedule … | that is to be used for the following purpose … | the signal word or words are … |
| 1 | Schedule 2 | for any purpose | PHARMACY MEDICINE |
| 2 | Schedule 3 | for any purpose | PHARMACIST ONLY MEDICINE |
| 3 | Schedule 4 | for human use | PRESCRIPTION ONLY MEDICINE |
| 4 | Schedule 4 | for animal use | PRESCRIPTION ANIMAL REMEDY |
| 5 | Schedule 5 | for any purpose | CAUTION |
| 6 | Schedule 6 | for any purpose | POISON |
| 7 | Schedule 7 | for any purpose | DANGEROUS POISON |
| 8 | Schedule 8 | for any purpose | CONTROLLED DRUG |

(2) For the purposes of paragraph (1)(c), the largest letter or numeral does not include:

(a) a single letter or numeral which is larger than other lettering on the label; or

(b) an affix forming part of the trade name for the poison; or

(c) in the case of a poison for therapeutic use—numerals used to distinguish the strength of a preparation from the strengths of other preparations of the same poison.

(3) For the purposes of paragraph (1)(c), the letters need not be larger than:

(a) 6 mm on labels for packages having a nominal capacity of 2 L or less; or

(b) 15 mm on labels for packages having a nominal capacity of more than 2 L.

17 Cautionary statement—possession without authority illegal

If the poison is included in Schedule 8, the cautionary statement:

**POSSESSION WITHOUT AUTHORITY ILLEGAL**

must be written:

(a) on a separate line or lines immediately below the signal words required by section 16; and

(b) in bold‑face sans serif capital letters of uniform thickness; and

(c) in letters at least four‑tenths the height of the letters used for the signal words; and

(d) with no other statement written on the same line or lines.

18 Cautionary statement—keep out of reach of children

The cautionary statement:

**KEEP OUT OF REACH OF CHILDREN**

must be written:

(a) on a separate line or lines:

(i) immediately below the signal word or words required by section 16; or

(ii) if the cautionary statement “POSSESSION WITHOUT AUTHORITY ILLEGAL” is required by section 17—immediately below that statement; and

(b) in bold‑face sans serif capital letters of uniform thickness; and

(c) in letters at least four‑tenths the height of the letters used for the signal word or words; and

(d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines.

19 Cautionary statement—fire and explosion hazard

(1) If the poison is a dry chlorinating compound containing more than 10% of available chlorine, the cautionary statement:

**FIRE AND EXPLOSION HAZARD**

must be written:

(a) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; and

(b) in bold‑face sans serif capital letters of uniform thickness; and

(c) in letters at least four‑tenths the height of the letters used for the signal word or words; and

(d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines.

(2) This section does not apply to a preparation certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code.

20 Cautionary statement—burns skin and throat

If the poison is an alkaline salt in a dishwashing machine product, the cautionary statement:

**BURNS SKIN AND THROAT**

must be written:

(a) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; and

(b) in bold‑face sans serif capital letters of uniform thickness; and

(c) in letters at least four‑tenths the height of the letters used for the signal word; and

(d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines of the main label.

21 Cautionary statements for aqueous solution of paraquat

If the poison is an aqueous solution of paraquat, the cautionary statements:

**CAN KILL IF SWALLOWED**

**DO NOT PUT IN DRINK BOTTLES**

**KEEP LOCKED UP**

must be written:

(a) on separate lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; and

(b) in bold‑face sans serif capital letters of uniform thickness; and

(c) in letters at least four‑tenths the height of the letters used for the signal words; and

(d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same lines of the main label.

22 Cautionary statement—read safety directions

(1) If safety directions are required on the label by section 29, the following cautionary statement:

**READ SAFETY DIRECTIONS BEFORE OPENING OR USING**

or the following cautionary statement:

**READ SAFETY DIRECTIONS**

must be written:

(a) on a separate line or lines:

(i) immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by section 18; or

(ii) if one or more other cautionary statements is required to be on the line immediately below “KEEP OUT OF REACH OF CHILDREN”, immediately below that statement or those statements; and

(b) in bold‑face sans serif capital letters of uniform thickness; and

(c) in letters at least four‑tenths the height of the letters used for the signal word or words; and

(d) with nothing, other than a class label as specified in the Australian Dangerous Goods Code, written on the same line or lines.

(2) This section does not apply to a medicine for human use that is labelled in accordance with the required advisory statements for medicine labels.

23 Cautionary statement—flammable

If the poison meets the criteria for a “flammable liquid” in the Australian Dangerous Goods Code, the cautionary statement:

**FLAMMABLE**

must be written on the main label in bold‑face sans serif capital letters of uniform thickness, unless already present in accordance with the requirements of the Australian Dangerous Goods Code.

24 Cautionary statement—for animal treatment only

If the poison is only for the treatment of animals, the cautionary statement:

**FOR ANIMAL TREATMENT ONLY**

must be written on the main label in bold‑face sans serif capital letters of uniform thickness.

25 Cautionary statement—do not swallow

If the poison is included in Schedule 5 and is intended for any purpose other than internal or pesticidal use, the cautionary statement:

**DO NOT SWALLOW**

must be written in sans serif capital letters on the main label or as part of the directions for use.

26 Approved name and quantity, proportion or strength

(1) The approved name of the poison and a statement of the quantity, proportion or strength of the poison in accordance with section 34 must be:

(a) if the poison is for human therapeutic use—written on the main label in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or

(b) if the poison is not for human therapeutic use—written in bold‑face sans serif capital letters on the main label, unless:

(i) a list of approved names is required; and

(ii) it is impractical to include the list on the main label; and

(iii) it is included on another part of the label in accordance with an authorisation given by an appropriate authority.

(2) If the poison is included in Schedule 5 and is referred to in column 1 of an item of the following table, the appropriate name in column 2 of that item may be used as the approved name.

| Appropriate names for poisons | | |
| --- | --- | --- |
| Item | Column 1 Poison | Column 2 Appropriate name |
| 1 | Alkaline salts | Alkaline salts |
| 2 | Amines for use as curing agents for epoxy resins (unless separately specified in the Schedules) | Aliphatic amines or aromatic amines |
| 3 | Epoxy resins, liquid | Liquid epoxy resins |
| 4 | Hydrocarbons, liquid | Liquid hydrocarbons |
| 5 | Quaternary ammonium compounds | Quaternary ammonium compound(s) |

(3) If a poison contains a mixture of designated solvents in excess of 25% of the total volume of the poison but the proportion of one or more individual designated solvents in the mixture is equal to or less than 25%, the approved names of those solvents may be expressed as follows:

(a) where the designated solvent is a liquid hydrocarbon—as “liquid hydrocarbons”;

(b) where the designated solvent is a ketone—as “ketones”;

(c) in any other case—as “solvents” or “other solvents”.

27 Statement—an anticholinesterase compound

(1) If the poison is an organophosphorus compound or carbamate for pesticidal use or for the treatment of animals, the following expression:

**AN ANTICHOLINESTERASE COMPOUND**

must be written immediately below the approved name or the list of declared contents on the label.

(2) This section does not apply to:

(a) dazomet, mancozeb, metiram, propineb, thiram, tri‑allate, zineb or ziram; or

(b) an organophosphorus compound or carbamate contained in impregnated plastic resin strips, medallions or granules; or

(c) an organophosphorus compound or carbamate contained in a pressurised spray pack for household use.

28 Directions for use

If the poison is prepared, packed or sold for a specific purpose, it must be labelled with clear and adequate directions for use, unless:

(a) it is a medicine for human use that is labelled in accordance with:

(i) *Therapeutic Goods Order No. 91 ‑ Standard for labels of prescription and related medicines*; or

(ii) *Therapeutic Goods Order No. 92 ‑ Standard for labels of non‑prescription medicines*; or

(b) it is in an agricultural or veterinary chemical product labelled in compliance with the *Agricultural and Veterinary Chemicals Code Act 1994*; or

(c) it is included in Schedule 4 or 8; or

(d) all of the following apply:

(i) it is impractical to include such directions on the label;

(ii) the primary pack and the immediate container are labelled with the statement “DIRECTIONS FOR USE: See package insert”;

(iii) an appropriate authority has authorised the directions for use to be written on a package insert instead of the label;

(iv) the insert is enclosed in the primary pack.

29 Safety directions

(1) If the poison is included in the table in clause 4 of Appendix F, it must be labelled with each safety direction required for the poison by that clause, grouped together as a distinct section of the label and prefaced by the words:

**SAFETY DIRECTIONS**

written in bold‑face capital letters.

(2) This section does not apply to the following:

(a) a poison that:

(i) is a medicine for human use; and

(ii) is labelled in accordance with the required advisory statements for medicine labels;

(b) a poison that:

(i) is an agricultural chemical or a veterinary chemical; and

(ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the *Agricultural and Veterinary Chemicals Code Act 1994*.

30 Warning statements

(1) If the poison is included in the table in clause 4 of Appendix F, it must be labelled with each warning statement required for the poison by that clause, grouped together:

(a) if safety directions are included on the label—immediately after the words “SAFETY DIRECTIONS”; or

(b) if there are no safety directions—immediately preceding the directions for use.

(2) This section does not apply to the following:

(a) a poison that:

(i) is a medicine for human use; and

(ii) is labelled in accordance with the required advisory statements for medicine labels;

(b) a poison that:

(i) is an agricultural chemical or a veterinary chemical; and

(ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the *Agricultural and Veterinary Chemicals Code Act 1994*.

31 First aid

(1) If the poison is included in the table in clause 3 of Appendix E, it must be labelled with each statement required for the poison by clause 3 of Appendix E:

(a) grouped together and prefaced by the following words:

**FIRST AID**

written in bold‑face capital letters; or

(b) if a primary pack contains 2 or more immediate containers of poisons each requiring different first aid instructions:

(i) written on each immediate container as specified in paragraph (a); and

(ii) replaced on the primary pack with the statement:

FIRST AID: See inner packs.

(2) This section does not apply to the following:

(a) a poison that:

(i) is for human internal use; and

(ii) is included in Schedule 3, 4 or 8;

(b) a poison that:

(i) is a medicine for human use; and

(ii) is labelled in accordance with the required advisory statements for medicine labels;

(c) a poison that:

(i) is an agricultural chemical or a veterinary chemical; and

(ii) is a registered chemical product within the meaning of the Agricultural and Veterinary Chemicals Code set out in the Schedule to the *Agricultural and Veterinary Chemicals Code Act 1994*.

32 Name and address of manufacturer or distributor

(1) The poison must be labelled with the name and address of its manufacturer or distributor. The address:

(a) must be a physical address in Australia; and

(b) must not be a post office, cable, telegraphic or code address.

(2) However, if the manufacturer or distributor is a company incorporated under the law of a State or Territory, or a firm registered under a law of a State or Territory dealing with business names, the name and address may be:

(a) the registered name of the corporation or firm, or its branch or division; and

(b) the city or town in which a registered office of the company or firm is situated.

33 Warning statements and sedation warnings for certain medicines for human use

Warning statements for certain medicines

(1) A dispensed medicine for human use containing a poison included in column 1 of the table in clause 2 of Appendix L must be clearly labelled with each warning statement required for the poison by that clause.

Sedation warning for certain medicines

(2) A dispensed medicine for human use containing a poison included in Appendix K must be clearly labelled with a warning statement set out in item 39, 40 or 90 of the table in clause 1 of Appendix F.

Subdivision C—Statements of quantity, proportion or strength

34 Statements of quantity, proportion or strength

(1) The statement of the quantity, proportion or strength of a poison must be expressed in the most appropriate of the following forms:

(a) if the poison is for human therapeutic use—the manner required by the standards for the goods specified in orders made under subsection 10(1) of the Act;

(b) if the poison is for a purpose or purposes other than human therapeutic use—as follows:

(i) if the poison is in a pressurised spray aerosol preparation—as the mass of the poison per stated mass of the preparation;

(ii) if the poison is a liquid in a liquid preparation—as the mass or volume of the poison per stated volume of the preparation;

(iii) if the poison is a liquid in a solid or semi‑solid preparation—as the mass or volume of the poison per stated mass of the preparation;

(iv) if the poison is a solid or semi‑solid in a liquid preparation—as the mass of the poison per stated volume of the preparation;

(v) if the poison is a solid or semi‑solid in a solid or semi‑solid preparation—as the mass of the poison per stated mass of the preparation;

(vi) if the poison is a gas in a liquid preparation—as the mass of the poison per stated volume of the preparation;

(vii) if the poison is a gas in a solid or semi‑solid preparation—as the mass of the poison per stated mass of the preparation;

(viii) if the poison is a gas in a gaseous preparation—as the mass of the poison per stated mass of the preparation;

(c) if the poison is a solution of a mineral acid, the proportion of the acid (un‑neutralised by any bases present in the preparation) in a preparation may be expressed as the un‑neutralised mass of the acid per stated mass of the preparation;

(d) if the poison is an inorganic pigment, the proportion may be expressed as a percentage of the metal present using one of the following expressions as appropriate:

(i) “contains not more than 10 per cent of (*insert name of the metal*)”;

(ii) “contains not more than 30 per cent of (*insert name of the metal*)”;

(iii) “contains more than 30 per cent of (*insert name of the metal*)”;

(e) if the poison is included in a paint, other than a paint for therapeutic or cosmetic use, the proportion may be expressed as a range provided that the limits of the range do not differ by more than 5% of the product;

(f) if the poison is a lead‑based pigment included in automotive paint, the proportion may be expressed as the maximum content of the lead that may be present in the non‑volatile content of the paint;

(g) if a preparation contains more than one derivative of a poison, the quantity or proportion of the poison may be expressed as the equivalent quantity or proportion of one of the derivatives present which it would contain if all of the derivatives were that derivative.

(2) In paragraph (1)(g):

***derivative*** includes alkaloid.

Note: For requirements to state the quantity, proportion or strength of a poison, see subparagraph 14(b)(iii), section 26 and sub‑subparagraphs 35(b)(ii)(B) and 36(1)(b)(ii)(A) and (2)(b)(iii)(B).

Subdivision D—Exemptions from labelling requirements

35 Selected containers and measure packs

The requirements of Subdivision B do not apply to an immediate container of poison that is a measure pack or a selected container (other than an ampoule, a pre‑filled syringe or an injection vial to which subsections 36(1) or (2) applies) if:

(a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or

(b) the immediate container is:

(i) packed in a primary pack labelled in accordance with Subdivision B; and

(ii) labelled with:

(A) the signal word or words for the poison as shown in the table in subsection 16(1); and

(B) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with section 34; and

(C) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and

(D) if the poison is only for the treatment of animals—the cautionary statement:

FOR ANIMAL TREATMENT ONLY

written in sans serif capital letters.

36 Ampoules, pre‑filled syringes and injection vials

(1) The requirements of Subdivision B do not apply to a selected container of poison or an ampoule of poison (other than an ampoule to which subsection (2) applies) when:

(a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or

(b) the selected container or ampoule is:

(i) packed in a primary pack labelled in accordance with Subdivision B; and

(ii) labelled with:

(A) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with section 34; and

(B) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and

(C) if the poison is only for the treatment of animals—the cautionary statement:

FOR ANIMAL TREATMENT ONLY

written in sans serif capital letters.

(2) The requirements of Subdivision B do not apply to a selected container of poison that is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip when:

(a) the poison is therapeutic goods and is labelled in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act; or

(b) the poison is not therapeutic goods and all of the following apply:

(i) the ampoule is packed in a primary pack labelled in accordance with Subdivision B;

(ii) the strip is labelled in accordance with this section;

(iii) the ampoule is labelled with:

(A) the approved name of the poison or the trade name of the poison; and

(B) the quantity, proportion or strength of the poison in accordance with section 34.

37 Transport containers and wrappings

The labelling requirements of this instrument do not apply to a transparent cover, or to any wrapper, hamper, packing case, crate or other cover used solely for the purposes of transport or delivery.

38 Dispensary, industrial, laboratory and manufacturing poisons

The labelling requirements of this instrument do not apply to a poison that:

(a) is packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes; and

(b) is labelled in accordance with requirements under applicable jurisdictional work health and safety laws, as in force from time to time.

39 Exemptions from label requirements in certain circumstances

(1) A requirement specified in Subdivision B or section 35 or 37 does not apply to a poison if an appropriate authority has granted a labelling exemption under this subsection in relation to that requirement for the poison.

(2) A labelling exemption granted by an appropriate authority under subsection (1) remains in force:

(a) if the exemption relates to a product that is indicated for the treatment or prevention of the coronavirus known as COVID‑19:

(i) for the period specified in the exemption; or

(ii) if no period is specified—until revoked by the appropriate authority; or

(b) in any other case:

(i) for the period, specified in the exemption, that is 12 months or less from the date of commencement of the exemption; or

(ii) if no period is specified—12 months from the date of commencement of the exemption.

(3) For the avoidance of doubt, this section does not apply to an authorisation given under subparagraph 28(d)(iii).

40 Dispensed medicines

Unless otherwise specified in relevant State or Territory legislation and subject to section 33, the labelling requirements of this instrument do not apply to a medicine that:

(a) is:

(i) supplied by an authorised prescriber; or

(ii) supplied on and in accordance with a prescription written by an authorised prescriber; or

(iii) prepared and supplied by a pharmacist for an individual patient; and

(b) is labelled in accordance with the requirements of clause 1 of Appendix L.

41 Gas cylinders

The requirements of paragraph 16(1)(d) and paragraphs 18(d) and 22(1)(d) do not apply to a cylinder containing a poison that is a compressed gas.

42 Paints

The requirements of Subdivision B do not apply to:

(a) a paint (other than a paint for therapeutic or cosmetic use) that contains only poisons included in Schedule 5; or

(b) a first group paint or second group paint that is labelled with:

(i) the word “WARNING”, written in bold‑face sans serif capital letters, the height of which is not less than 5 mm, on the first line of the main label with no other words written on that line; and

(ii) the expression “KEEP OUT OF REACH OF CHILDREN”, written in bold‑face sans serif capital letters, the height of which is not less than 2.5 mm, on a separate line immediately below the word “WARNING”; and

(iii) the appropriate warnings required for the paint by clause 4 of Appendix F, written immediately below the expression “KEEP OUT OF REACH OF CHILDREN”; and

(iv) the name and proportion of the first group or second group poisons it contains, provided that where the substance is a metal or metal salt the proportion is expressed as the metallic element present “calculated on the non‑volatile content” or “in the dried film” of the paint; or

(c) a tinter which contains only poisons included in Schedule 5; or

(d) a tinter that contains a poison mentioned in a table in section 67 or 68, if:

(i) the tinter is labelled with the name and proportion of the poison; and

(ii) if the poison is a metal or metal salt—the proportion is expressed as the metallic element present as “calculated on the non‑volatile content” or “in the dried film”.

43 Camphor and naphthalene

The labelling requirements of paragraph 13(2)(d) and Subdivision B do not apply to a device that contains camphor or naphthalene in block, ball, disc, pellet or flake form if the device:

(a) complies with section 52; and

(b) is sold or supplied in a primary pack labelled in accordance with section 13 and Subdivision B.

Subdivision E—Prohibitions

44 Prohibitions

(1) A label used in connection with a poison must not include:

(a) any reference to this instrument, or any comment on, reference to, or explanation of any expression required by this instrument that directly or by implication contradicts, qualifies or modifies such expression; or

(b) any expression or device suggesting or implying that the poison is safe, harmless, non‑toxic, non‑poisonous, or is recommended or approved by a government or government authority unless required by legislation; or

(c) any expression or device which is false or misleading in any particular concerning the safety of the poison or any of its ingredients; or

(d) any trade name or description that:

(i) represents any single constituent of a compound preparation; or

(ii) misrepresents the composition or any property or quality of the poison; or

(iii) gives any false or misleading indication of origin or place of manufacture of the poison.

(2) A label must not be attached to the immediate container or primary pack used in connection with any poison in such a manner as to obscure any of the ribs or any expression required by this instrument to be written or embossed on the container or pack.

Division 3—Containers

45 General requirements

A poison must not be supplied unless the requirements of this Division for the immediate container for the poison are met.

46 Containers for poisons other than poisons included in Schedule 5

(1) If a poison, other than a poison included in Schedule 5, is supplied in a container with a nominal capacity of 2 L or less, the container must comply with Australian Standard AS 2216‑1997, *Packaging for poisonous substances*.

(2) Despite subsection (1), a poison included in Schedule 6 that is an essential oil may be packed in an amber glass container which does not comply with the tactile identification requirements of Australian Standard AS 2216‑1997, *Packaging for poisonous substances*, if:

(a) other safety factors are not diminished; and

(b) the container has a restricted flow insert and a child‑resistant closure.

(3) If a poison, other than a poison included in Schedule 5, is supplied in a container with a nominal capacity of more than 2 L:

(a) the container must comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216‑1997, *Packaging for poisonous substances*; and

(b) the word “POISON” must be embossed, or indelibly written in a colour in distinct contrast to the background colour, on the side or shoulder of the container, in sans serif capital letters the height of which is at least one thirty‑second part of the length, height or width of the container, whichever is the greatest.

47 Containers for poisons included in Schedule 5

(1) The container in which a poison included in Schedule 5 is supplied must:

(a) comply with the container requirements of subsection 46(1) or (3); or

(b) comply with subsection (2).

(2) A container complies with this subsection if:

(a) it is readily distinguishable from a container in which food (including a condiment) or drink is sold; and

(b) it complies with subsection 1.4 (General Requirements) of Australian Standard AS 2216‑1997, *Packaging for poisonous substances*, excluding paragraph 1.4.3; and

(c) it is securely closed and, except when containing a preparation for use on one occasion only, is capable of being re‑closed to prevent spillage of its contents; and

(d) the expression “POISON”, “NOT TO BE TAKEN” or “NOT TO BE USED AS A FOOD CONTAINER” is:

(i) embossed or indelibly written on the container; or

(ii) printed on a label that complies with subsection (3) that is attached to the container.

(3) For the purposes of subparagraph (2)(d)(ii), the label must be a permanent adhesive label designed to adhere to a substrate without lifting and which cannot be removed without damaging either the label or the substrate.

(4) Despite subsection (1), the following poisons included in Schedule 5:

(a) methylated spirit(s);

(b) liquid hydrocarbons when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid;

(c) petrol;

(d) toluene;

(e) xylene;

must not be supplied in a bottle or jar having a nominal capacity of 2 L or less, unless the immediate container complies with the container requirements of subsection 46(1).

48 Approved containers

Despite subsections 46(1) and (3) and section 47, a poison may be packed in a container that does not comply with the tactile identification requirements of AS2216‑1997 (*Packaging for poisonous substances*) or the requirements of paragraph 46(3)(b) or 47(2)(d) if:

(a) other safety factors are not diminished; and

(b) the container is for a specific purpose; and

(c) an appropriate authority has approved the use of the container for that purpose.

49 Child‑resistant closures

(1) If a poison specified in column 1 of an item of the following table is supplied in a container having a nominal capacity specified in column 2 of the item, it must be closed with a child‑resistant closure that:

(a) is appropriate for the container and the poison; and

(b) will retain its child‑resistant properties for the expected life of the poison.

| Poisons that must be closed with a child‑resistant closure | | |
| --- | --- | --- |
| Item | Column 1 Poison | Column 2 Nominal capacity of container |
| 1 | Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine tablets | All sizes |
| 2 | Alkaline salts included in Schedule 5, when packed and labelled as dishwashing machine liquids, solids or gels | 5 L/kg or less |
| 3 | Alkaline salts included in Schedule 5, when packed and labelled as a food additive | 2.5 L or less |
| 4 | Anise oil when included in Schedule 5 | 200 mL or less |
| 5 | Basil oil when included in Schedule 5 | 200 mL or less |
| 6 | Bay oil when included in Schedule 6 | 200 mL or less |
| 7 | Cajuput oil when included in Schedule 6 | 200 mL or less |
| 8 | Cassia oil when included in Schedule 5 | 200 mL or less |
| 9 | Cineole when included in Schedule 6 | 2 L or less |
| 10 | Cinnamon bark oil when included in Schedule 5 | 200 mL or less |
| 11 | Cinnamon leaf oil when included in Schedule 6 | 200 mL or less |
| 12 | Clove oil when included in Schedule 6 | 200 mL or less |
| 13 | CYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2) when included in Schedule 6, when presented in a wipe | All sizes |
| 14 | Essential oils when included in Schedule 6 because of their natural camphor component | 200 mL or less |
| 15 | Ethylene glycol when included in Schedule 6 | 5 L or less |
| 16 | Ethylene glycol when included in Schedule 5 in preparations containing more than 50% of ethylene glycol | 5 L or less |
| 17 | Eucalyptus oil when included in Schedule 6 | 2 L or less |
| 18 | Eugenol when included in Schedule 6 | 200 mL or less |
| 19 | Fennel oil when included in Schedule 5 | 200 mL or less |
| 20 | Hydrocarbons, liquid, when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid | 5 L or less |
| 21 | Hydrochloric acid when included in Schedule 6 | 5 L or less |
| 22 | Leptospermum scoparium oil (manuka oil) when included in Schedule 6 | 200 mL or less |
| 23 | Marjoram oil when included in Schedule 5 | 200 mL or less |
| 24 | Melaleuca oil (tea‑tree oil) when included in Schedule 6 | 200 mL or less |
| 25 | Methylated spirit excluding preparations or admixtures | 5 L or less |
| 26 | Methyl salicylate and preparations containing more than 50% of methyl salicylate | 200 mL or less |
| 27 | Nicotine in liquid preparations when included in Schedule 4. | All sizes |
| 28 | Nutmeg oil when included in Schedule 5 | 200 mL or less |
| 29 | Oil of turpentine | 5 L or less |
| 30 | Paracetamol included in Schedule 4, when packed and labelled for the treatment of animals | All sizes |
| 31 | Pennyroyal oil when included in Schedule 6 | 200 mL or less |
| 32 | Potassium hydroxide as such | 2.5 L or less |
| 33 | Potassium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 **except** when in pressurised spray packs | 5 L or less |
| 34 | **D**‑Pulegone when included in Schedule 6 | 200 mL or less |
| 35 | Sage oil (Dalmatian) when included in Schedule 6 | 200 mL or less |
| 36 | Sodium hydroxide as such | 2.5 L or less |
| 37 | Sodium hydroxide in oven, hot plate or drain cleaners when included in Schedule 6 **except** when in pressurised spray packs | 5 L or less |
| 38 | Thujone when included in Schedule 6 | 200 mL or less |
| 39 | Thyme oil when included in Schedule 5 | 200 mL or less |

(2) This section does not apply to a poison included in therapeutic goods that are packaged in accordance with the standards for the goods specified in orders made under subsection 10(1) of the Act.

50 Poisons included in Schedule 8

(1) If a poison included in Schedule 8 is supplied, it must be packaged in such a way that its primary pack is so sealed that, when the seal is broken, it is readily distinguishable from other sealed primary packs.

(2) This paragraph does not apply to the supply of a poison included in Schedule 8:

(a) by an authorised prescriber or other authorised supplier; or

(b) by a pharmacist on the prescription of an authorised prescriber; or

(c) by a pharmacist employed at a hospital, on the written requisition of:

(i) a medical practitioner or dental practitioner; or

(ii) the nurse or midwife in charge of the ward in which the poison is to be used or stored; or

(d) by a nurse or midwife on the direction in writing of an authorised prescriber.

51 Exemptions

(1) Subsections 46(1) and (3) and section 47 do not apply to the immediate container of a poison prepared, packed and sold:

(a) for human internal or animal internal use; or

(b) as a solid or semi‑solid preparation for human external or animal external use; or

(c) as a paint, other than a paint for therapeutic or cosmetic use; or

(d) in containers having a nominal capacity of 15 mL or less; or

(e) for use in automatic photographic or photocopy processing machines if the container is specifically designed to fit into the machines; or

(f) solely for dispensary, industrial, laboratory or manufacturing purposes.

(2) Section 49 does not apply to a poison prepared, packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes.

(3) The tactile identification or embossing required by subsections 46(1) and (3) and section 47 or Australian Standard AS 2216‑1997, *Packaging for poisonous substances*, do not apply to a container that is an aerosol container, a collapsible tube, or a measure pack which is a flexible sachet.

52 Camphor and naphthalene

(1) The container requirements of subsection 46(1) do not apply to a device that contains only camphor or naphthalene in block, ball, disc, pellet or flake form for domestic use, if the device:

(a) in normal use, prevents removal or ingestion of its contents; and

(b) is incapable of reacting with the poison; and

(c) is sufficiently strong to withstand the ordinary risks of handling, storage or transport; and

(d) has the word “POISON” and the approved name of the poison embossed or indelibly printed on it.

(2) Camphor or naphthalene must not be supplied in ball, block, disc, pellet or flake form for domestic use unless the balls, blocks, discs, pellets or flakes are enclosed in a device which prevents removal or ingestion of its contents.

53 Prohibitions—use of containers for poisons

(1) A poison must not be supplied in a container that is embossed or indelibly marked with the name of another poison.

(2) A container that complies with subsection 46(1) or (3) or section 47 must not be used to supply a poison for internal use.

(3) A container that complies with subsection 46(1) or (3) or section 47 must not be used to supply food (including a condiment) or drink.

(4) A poison must not be supplied in a container that is not readily distinguishable from a container in which food (including a condiment) or drink is sold.

Division 4—Storage

54 General storage requirements

Poisons included in Schedule 2

(1) A poison included in Schedule 2 that is stored at premises for supply to the public must be stored in such a way that public access to advice from a pharmacist is available if required.

Poisons included in Schedules 3 and 4

(2) A poison included in Schedule 3 or 4 that is stored at premises for supply to the public must be stored in a part of the premises to which the public does not have access.

Poisons included in Schedule 6

(3) A poison included in Schedule 6 that is stored at premises for supply by way of retail sale must be stored in such a way as to prevent access by children.

Poisons included in Schedule 7

(4) A poison included in Schedule 7 that is stored at premises for supply by retail sale must be stored in an area of the premises, and in a manner, that allows physical access only by the following:

(a) the owner of the retail establishment;

(b) an employee of the owner;

(c) a person who is legally permitted to purchase the poison and is under the supervision of the owner or an employee of the owner.

Division 5—Disposal

55 General disposal requirements

A poison included in Schedule 5, 6 or 7 must not be disposed of in any place or manner that constitutes or is likely to constitute a risk to public health or safety.

Note: Controls on the disposal of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation.

Division 6—Record keeping

56 General record‑keeping requirements

(1) If a poison included in Schedule 7 is supplied, a record of the following must be kept:

(a) the name and address of the supplier and of the purchaser;

(b) the date of the order and supply;

(c) the approved name or trade name of the poison;

(d) the quantity supplied or sold;

(e) if an authorisation is required for purchase of the poison under the law of the jurisdiction in which the purchaser purchases the poison—proof that the purchaser has the required authorisation.

(2) The records mentioned in subsection (1) must be kept for at least 5 years.

Note: Controls on record keeping for the supply of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation.

Division 7—Advertising

57 General advertising requirements

Poisons included in Schedule 3, 4 and 8

(1) A reference to a poison included in:

(a) Schedule 3, unless included in Appendix H; or

(b) Schedule 4; or

(c) Schedule 8;

must not be included in any advertisement except in genuine professional or trade journals or other publications intended for circulation only within the medical, nursing, veterinary, dental or pharmaceutical professions or the wholesale drug industry.

Poisons included in Schedules 9 and 10

(2) A reference to a poison included in Schedule 9 or Schedule 10 must not be included in any advertisement.

Note: Schedule 10 includes poisons previously listed in Appendix C.

Division 8—Supply, prescribing, possession or use

58 Poisons included in Schedule 2

(1) A poison included in Schedule 2 must not be supplied by a person other than:

(a) a person who:

(i) is a pharmacist (or an assistant under the direction of a pharmacist) or a medical practitioner, dental practitioner or veterinarian; and

(ii) is acting in the lawful practice of the person’s profession; or

(b) a person who is licensed to supply the poison under the law of the jurisdiction from which the person will supply the poison.

(2) A person is not eligible to be granted a licence to supply a poison included in Schedule 2 unless:

(a) the person is carrying on the business of supplying goods by retail sale; and

(b) the premises from which the poison will be supplied is more than 25 km by the shortest practicable route from the nearest pharmacy; and

(c) if required by the law of the jurisdiction from which the person will supply the poison—the person produces evidence that the person is a fit and proper person to be so licensed.

(3) Subsection (1) does not apply to the supply of a poison included in Schedule 2 by way of wholesale dealing to:

(a) a pharmacist, medical practitioner, dental practitioner or veterinarian; or

(b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison.

59 Poisons included in Schedule 3

(1) A poison included in Schedule 3 must not be supplied by a person other than a person who:

(a) is a pharmacist, medical practitioner, dental practitioner or veterinarian; and

(b) is acting in the lawful practice of the person’s profession.

(2) The following requirements apply if a poison included in Schedule 3 is supplied:

(a) adequate instructions for use, either written or verbal, must be provided at the time of supply;

(b) the container of the poison must be labelled with:

(i) the name of the supplier or the name of the pharmacy (as applicable); and

(ii) the address from which it was supplied;

(c) if required by the law of the jurisdiction from which the supplier supplies the poison—a record of the transaction must be made in a prescription book or other approved recording system.

(3) This section does not apply to the supply of a poison included in Schedule 3 by way of wholesale dealing to:

(a) a pharmacist, medical practitioner, dental practitioner or veterinarian; or

(b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison.

60 Poisons included in Schedule 4

(1) A poison included in Schedule 4 must not be supplied by a person other than:

(a) a person who:

(i) is a medical practitioner, dental practitioner or veterinarian; and

(ii) is acting in the lawful practice of the person’s profession; or

(b) a pharmacist dispensing a legal prescription for the poison; or

(c) a pharmacist supplying the poison without a prescription as permitted by subsection (2).

(2) A poison included in Schedule 4 may be supplied to a person (the ***patient***) by a pharmacist without a prescription if:

(a) the poison is not excepted from this provision by the law of the jurisdiction from which the pharmacist supplies the poison; and

(b) the patient is under medical treatment with the poison and continuation of medication is essential; and

(c) the quantity supplied does not exceed 3 days’ medication; and

(d) the pharmacist is satisfied that an emergency exists.

(3) Subsection (1) does not apply to the supply of a poison included in Schedule 4 by way of wholesale dealing to:

(a) a pharmacist, medical practitioner, dental practitioner or veterinarian; or

(b) another person who is licensed or otherwise authorised, under the law of the jurisdiction from which the person supplies the poison, to possess or supply the poison.

61 Poisons included in Schedules 5 and 6

(1) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in any manner unless the recipient has the opportunity to refuse at the time of supply.

(2) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in an unsolicited manner (for example by post or by attaching the sample to another product).

(3) A product sample containing a poison included in Schedule 5 or 6 must not be supplied in a manner that does not promote disposal in accordance with Division 5.

62 Poisons included in Schedule 7

Possession or use for domestic or domestic garden purposes prohibited

(1) A poison included in Schedule 7 must not be possessed or used for domestic or domestic garden purposes.

Supply for domestic or domestic garden purposes prohibited

(2) A poison included in Schedule 7 must not be supplied for domestic or domestic garden purposes.

Supply of liquid preparations containing paraquat

(3) A poison included in Schedule 7 that is a liquid preparation containing paraquat must not be supplied unless it is coloured blue or green and contains sufficient stenching agent to produce an offensive smell.

Supply if authorisation required by appropriate authority

(4) A poison included in Schedule 7 for which an authorisation to purchase, possess or use is required by the appropriate authority must not be supplied unless the purchaser produces the required authorisation.

Product samples prohibited

(5) A product sample containing a poison included in Schedule 7 must not be supplied.

Supply of poisons included in Appendix J

(6) A poison included in Schedule 7 that is included in the table in clause 1 of Appendix J may be supplied only in accordance with that clause.

63 Poisons included in Schedule 10

A poison included in Schedule 10 must not be possessed, supplied or used for a purpose indicated in relation to that poison in Schedule 10.

Note: Schedule 10 includes poisons previously listed in Appendix C.

64 Poisons included in Schedule 4 or 8 and Appendix D

(1) This section applies to a poison included in Schedule 4 or 8.

Supply or prescribing

(2) A poison included in a table in clause 1, 2, 3, 4, 6 or 7 of Appendix D must not be supplied, other than by way of wholesale dealing, or prescribed, except in accordance with the clause that contains the table.

(3) A poison referred to in clause 8 or 10 of Appendix D must not be supplied, other than by way of wholesale dealing, or prescribed, except in accordance with clause 8 or 10 (as applicable) of Appendix D.

Possession

(4) A poison included in the table in clause 5 of Appendix D must not be possessed by a person without authority under the law of the jurisdiction in which the possession occurs.

Storage

(5) A poison included in the table in clause 9 of Appendix D must be stored in a locked container to prevent unauthorised access.

65 Hawking

A poison included in Schedule 7 must not be supplied by way of hawking.

Note: Controls on supply by way of hawking of poisons included in Schedules 2, 3, 4 and 8 are dealt with in State and Territory legislation.

Division 9—Paints and tinters

Note: Paints and tinters are poisons that were previously listed in Appendix I.

66 General requirements

(1) A first group paint must not be manufactured, supplied or used for application to:

(a) a roof or any surface to be used for the collection or storage of potable water; or

(b) furniture; or

(c) any fence, wall, post, gate or building (interior or exterior) other than a building that is used exclusively for industrial purposes or mining or as an oil terminal; or

(d) any premises used for the manufacture, processing, preparation, packing or serving of products intended for human or animal consumption.

(2) An anti‑fouling paint containing more than 0.1% lead (the proportion of lead for the purposes of this section is calculated as a percentage of the element present in the non‑volatile content of the paint) must not be manufactured, supplied or used.

(3) A paint (other than an anti‑fouling paint) or tinter containing more than 0.009% lead (calculated as a percentage of the element present in the non‑volatile content of the paint) must not be manufactured, supplied or used.

(4) A paint for application to toys must not be manufactured, supplied or used unless it complies with the specification for coating materials contained in Australian/New Zealand Standard AS/NZS ISO 8124.3:2012, *Safety of toys Part 3: Migration of certain elements (ISO 8124‑03:2010, MOD)*, published jointly by, or on behalf of, Standards Australia and Standards New Zealand.

(5) A paint or tinter containing a pesticide other than a fungicide, algaecide, bactericide or antifouling agent must not be manufactured, supplied or used.

67 Definition of *first group paint*

A paint containing a substance mentioned in column 1 of an item in the following table in the proportion (calculated as a percentage of the element present in the non‑volatile content of the paint) specified in column 2 of the item is a ***first group paint***.

| First group paints | | |
| --- | --- | --- |
| Item | Column 1 Substance | Column 2 Proportion |
| 1 | ANTIMONY or antimony compounds other than antimony titanate pigments | more than 5% |
| 2 | BARIUM salts **except** barium sulfate or barium metaborate | more than 5% |
| 3 | CADMIUM or cadmium compounds | more than 0.1% |
| 4 | CHROMIUM as chromates of ammonia, barium, potassium sodium, strontium or zinc | more than 5% |
| 5 | SELENIUM or selenium compounds | more than 0.1% |

68 Definition of *second group paint*

A paint containing a substance mentioned in column 1 of an item in the following table in the proportion specified in column 2 of the item is a ***second group paint***.

| Second group paints | | |
| --- | --- | --- |
| Item | Column 1 Substance | Column 2 Proportion |
| 1 | DICHLOROMETHANE (methylene chloride) | more than 5% by weight |
| 2 | ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates | more than 10% by volume |
| 3 | HEXYLOXYETHANOL | more than 10% by volume |
| 4 | TOLUENE | more than 50% by volume |
| 5 | XYLENE | more than 50% by volume |

Schedule 1—Blank

Note: Schedule 1 is intentionally blank.

Schedule 2—Pharmacy medicines

Note: See section 16, subsection 54(1) and section 58.

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid (CH3COOH) for therapeutic use.

ACETYLCYSTEINE in preparations for oral use **except** when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACONITUM spp. for therapeutic use in adults:

(a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids; or

(b) in preparations for dermal use containing 0.02% or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids.

ALIMEMAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day‑night pack containing alimemazine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

ALOXIPRIN.

AMOROLFINE in preparations for topical use **except** in preparations for the treatment of tinea pedis.

ANTAZOLINE in eye drops.

ASPIRIN **except** when:

(a) included in Schedule 4, 5 or 6; or

(b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than when combined with an effervescent agent, that are:

(i) enclosed in a primary pack that contains 12 or less individually wrapped powders or sachets of granules; and

(ii) compliant with the requirements of the required advisory statements for medicine labels; or

(c) in tablets or capsules containing aspirin as the only therapeutically active constituent other than when combined with an effervescent agent, that are:

(i) either:

(A) packed in blister or strip packing; or

(B) in a container with a child-resistant closure; and

(ii) either:

(A) in a primary pack that contains not more than 25 tablets or capsules, each containing 325 mg or less of aspirin; or

(B) in a primary pack that contains not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; or

(C) in a primary pack that contains not more than 100 tablets or capsules, each containing 100 mg or less of aspirin, and that is labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and

(iii) compliant with the requirements of the required advisory statements for medicine labels.

ASTODRIMER SODIUM when used in a nasal spray.

ATROPA BELLADONNA (belladonna):

(a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or

(b) for oral use:

(i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ATROPINE (excluding atropine methonitrate) for oral use:

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

AZELAIC ACID in dermal preparations.

AZELASTINE:

(a) in preparations for nasal use; or

(b) in topical eye preparations containing 0.05% or less of azelastine.

BECLOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of beclometasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

BENZOCAINE in preparations for topical use other than eye drops:

(a) containing 10% or less of total local anaesthetic substances, **except** in dermal preparations containing 2% or less of total local anaesthetic substances; or

(b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10% or less of benzoyl peroxide **except** in preparations containing 5% or less of benzoyl peroxide.

BENZYDAMINE in preparations for topical use, **except**:

(a) in preparations for dermal use; or

(b) in divided topical oral preparations containing 3 mg or less of benzydamine; or

(c) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL.

BEPHENIUM SALTS.

BIFONAZOLE in preparations for dermal use **except**:

(a) in preparations containing 1% or less of bifonazole for the treatment of the scalp; or

(b) in preparations for the treatment of tinea pedis.

BILASTINE in oral preparations when labelled with a recommended daily dose not exceeding 20 mg bilastine for the treatment of adults and children aged 12 years and over.

BRIMONIDINE in ophthalmic preparations for adult use containing not more than 0.025% of brimonidine.

BROMHEXINE.

BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day‑night pack containing brompheniramine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

BUDESONIDE in aqueous nasal sprays delivering 64 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

CARBETAPENTANE **except** in preparations containing 0.5% or less of carbetapentane.

CARBOCISTEINE.

CETIRIZINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over when:

(a) in a primary pack containing not more than 10 days’ supply; and

(b) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.

CHLOPHEDIANOL.

CHLORBUTANOL for human use in topical preparations containing 5% or less of chlorbutanol **except** in preparations containing 0.5% or less of chlorbutanol.

CHLOROFORM in preparations for therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 0.5% or less of chloroform.

CHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day‑night pack containing chlorphenamine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

CHOLINE SALICYLATE in preparations for oromucosal use.

CICLOPIROX:

(a) in preparations for dermal use containing 2% or less of ciclopirox **except** in preparations for the treatment of tinea pedis; or

(b) in preparations for application to the nails containing 8% or less of ciclopirox.

CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5% or less of total local anaesthetic substances.

CINNAMEDRINE.

CLOTRIMAZOLE for human use in dermal preparations and for application to the nails **except** in preparations for the treatment of tinea pedis.

CREOSOTE derived from wood other than beechwood for human therapeutic use, **except** in preparations containing 10% or less of creosote derived from wood other than beechwood.

DATURA spp. for oral use:

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;

except when separately specified in these Schedules.

DATURA STRAMONIUM (stramonium) for oral use when:

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;

except for smoking or burning.

DATURA TATULA (stramonium) for oral use:

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;

except for smoking or burning.

DELPHINIUM STAPHISAGRIA **except** in preparations containing 0.2% or less of Delphinium staphisagria.

DESLORATADINE in preparations for oral use.

DEXCHLORPHENAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day‑night pack containing dexchlorphenamine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

DEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan.

DIBROMOPROPAMIDINE for ophthalmic use.

DICLOFENAC when:

(a) in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac; or

(b) in preparations for dermal use containing 4% or less of diclofenac **except** in preparations for dermal use containing 2% or less of diclofenac or for the treatment of solar keratosis; or

(c) in transdermal preparations for topical use containing 140 mg or less of diclofenac.

DIMENHYDRINATE in primary packs of 10 doses or less for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.

DIPHENHYDRAMINE in oral preparations:

(a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or

(b) when combined with one or more other therapeutically active substances when:

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day‑night pack containing diphenhydramine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day‑night pack containing doxylamine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

DUBOISIA LEICHHARDTII for oral use:

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

DUBOISIA MYOPOROIDES for oral use:

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ECONAZOLE for human use in dermal preparations **except** in preparations for the treatment of tinea pedis.

ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days’ supply.

ETAFEDRINE.

ETHER for therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 10% or less of ether.

ETHYLMORPHINE when:

(a) compounded with one or more other therapeutically active substances:

(i) in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or

(ii) in undivided preparations containing 0.25% or less of ethylmorphine; and

(b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine.

ETOFENAMATE in preparations for external use.

FAMOTIDINE when sold in the manufacturer’s original pack containing not more than 14 days’ supply.

FELBINAC in preparations for external use.

FEXOFENADINE in preparations for oral use **except** in divided preparations:

(a) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and

(ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine; or

(b) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing 10 dosage units or less and not more than 10 days’ supply; and

(ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or

(c) for the treatment of seasonal allergic rhinitis and children 6 years of age and over when:

(i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and

(ii) labelled with a recommended daily dose not exceeding 60 mg of fexofenadine.

FLUORIDES for human use:

(a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or

(b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a child‑resistant closure:

(i) for therapeutic use when compliant with the requirements of the required advisory statements for medicine labels **except** in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a child‑resistant closure and compliant with the requirements of required advisory statements for medicine labels; or

(ii) for non‑therapeutic use when labelled with warnings to the following effect:

(A) Do not swallow; and

(B) Do not use [this product/insert name of product] in children 6 years of age or less;

**except** in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child‑resistant closure and labelled with warnings to the following effect:

(C) Do not swallow; and

(D) Do not use [this product/insert name of product] in children 6 years of age or less;

**except** in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.

FLURBIPROFEN in preparations for topical oral use when:

(a) in divided preparations containing 10 mg or less of flurbiprofen per dosage unit **except** when:

(i) in a primary pack containing not more than 16 dosage units; and

(ii) labelled only for the treatment of adults and children over 12 years; or

(b) in undivided preparations containing either:

(i) 0.25% or less of flurbiprofen per dose; or

(ii) 10 mg or less of flurbiprofen per dose;

**except** when:

(iii) in a primary pack containing not more than 15 mL; and

(iv) labelled only for the treatment of adults 18 years and over.

FLUTICASONE PROPIONATE (excluding derivatives) in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

FOLIC ACID for human therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.

FOLINIC ACID for human therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.

FORMALDEHYDE (excluding its derivatives) for human therapeutic use **except**:

(a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or

(b) in other preparations containing 0.2% or less of free formaldehyde.

GELSEMIUM SEMPERVIRENS.

GLUTARAL for human therapeutic use.

GUAIFENESIN in a modified release dosage form of 1200 mg or less of guaifenesin with a recommended daily dose of 2400 mg or less when not labelled for the treatment of children under 12 years of age.

HEXACHLOROPHENE in preparations for human use containing 3% or less of hexachlorophene **except**:

(a) in preparations for use on infants, as specified in Schedule 4; or

(b) in preparations for cosmetic use, as specified in Schedule 6; or

(c) in other preparations containing 0.75% or less of hexachlorophene.

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use:

(a) for dermal use in preparations containing 0.5% or less of hydrocortisone, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or

(b) for dermal use in preparations containing 1% or less of hydrocortisone, in packs containing 15 g or less of such preparations, containing an antifungal substance and no other therapeutically active constituent:

(i) for the treatment of tinea (tinea pedis, tinea cruris, tinea corporis) and other fungal skin infections; and

(ii) not labelled for the treatment of children under 12 years of age; or

(c) for rectal use in preparations containing 0.5% or less of hydrocortisone, when combined with a local anaesthetic substance but no other therapeutically active constituent **except** unscheduled astringents:

(i) in undivided preparations in packs of 35 g or less; or

(ii) in packs containing 12 or less suppositories.

HYDROQUINONE (excluding monobenzone and alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2% or less of hydroquinone **except**:

(a) in hair preparations containing 0.3% or less of hydroquinone; or

(b) in cosmetic nail preparations containing 0.02% or less of hydroquinone.

HYOSCINE:

(a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or

(b) for oral use:

(i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.

HYOSCYAMINE:

(a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or

(b) for oral use:

(i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less total solanaceous alkaloids.

HYOSCYAMUS NIGER for oral use:

(a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;

except in a pack containing 0.03 mg or less of total solanaceous alkaloids.

IBUPROFEN in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen, when:

(a) in liquid preparations that are sold in the manufacturer’s original pack containing 8 g or less of ibuprofen; or

(b) in divided immediate release preparations:

(i) each containing 400 mg or less of ibuprofen in a primary pack containing not more than 12 dosage units; and

(ii) that are labelled not for the treatment of children under 12 years; or

(c) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units **except** when:

(i) ibuprofen is the only therapeutically active constituent, other than phenylephrine or when combined with an effervescent agent; and

(ii) packed in blister or strip packaging or in a container with a child-resistant closure; and

(iii) in a primary pack containing not more than 25 dosage units; and

(iv) compliant with the requirements of the required advisory statements for medicine labels; and

(v) not labelled for the treatment of children 6 years or under; and

(vi) if combined with phenylephrine—not labelled for the treatment of children under 12 years.

INDANAZOLINE.

INDOMETACIN in preparations for external use containing 1% or less of indometacin.

IODINE:

(a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or

(b) in preparations for human external therapeutic use containing more than 2.5% of available iodine (excluding salts, derivatives or iodophors);

except in oral preparations for use in prophylaxis and treatment in the event of radioactive iodine exposure under an emergency plan approved by an appropriate authority.

IPRATROPIUM in preparations for nasal use.

IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1% or less of total iron oxides) for human internal use **except**:

(a) when included in Schedule 4; or

(b) when labelled with a recommended daily dose of 24 mg or less of iron:

(i) in undivided preparations supplied in packs each containing 750 mg or less of iron; or

(ii) in divided preparations:

(A) containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or

(B) containing 5 mg or less of iron per dosage unit.

ISOCONAZOLE for human use in dermal preparations.

ISOPROPAMIDE in preparations for dermal use containing 2% or less of isopropamide.

KETOCONAZOLE in preparations for dermal use **except**:

(a) in preparations containing 1% or less of ketoconazole for the treatment of the scalp; or

(b) in preparations for the treatment of tinea pedis.

KETOTIFEN for ophthalmic use in preparations containing 0.025% or less of ketotifen.

LANSOPRAZOLE in oral preparations 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 7 days’ supply.

LEVOCABASTINE in topical eye or nasal preparations.

LEVOCETIRIZINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(a) in a primary pack containing not more than 5 days’ supply; and

(b) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.

LIDOCAINE in preparations for topical use other than eye drops:

(a) containing 10% or less of total local anaesthetic substances, **except**:

(i) in dermal preparations containing 2% or less of total local anaesthetic substances; or

(ii) in aqueous sprays for oromucosal use containing 0.6% or less of total local anaesthetic substances; or

(b) in divided preparations containing 200 mg or less of total local anaesthetic substances, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

LINDANE in preparations for human external therapeutic use containing 2% or less of lindane.

LITHIUM in preparations for dermal use containing 1% or less of lithium **except**:

(a) when present as an excipient at 0.25% or less of lithium; or

(b) in preparations containing 0.01% or less of lithium.

LOBELIA INFLATA **except** for smoking or burning.

LOBELINE **except** in preparations for smoking or burning.

LODOXAMIDE in preparations for ophthalmic use.

LOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less **except** in preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.

LORATADINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis when:

(a) in a primary pack containing 10 dosage units or less when labelled for adults and children 6 years and over; and

(b) labelled with a recommended daily dose not exceeding 10 mg of loratadine.

MACROGOLS in preparations for oral use as a liquid concentrate for laxative use.

MEBENDAZOLE for human therapeutic use.

MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.

MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.

MEPYRAMINE for dermal use.

MERCUROCHROME in preparations for external use containing 2% or less of mercurochrome **except** when included in Schedule 6.

MERCURY for external use in preparations containing 0.5% or less of mercury.

METHOXAMINE in preparations for external use **except** in preparations containing 1% or less of methoxamine.

METHOXYPHENAMINE.

METHYLEPHEDRINE.

MICONAZOLE for human use in dermal preparations and for application to the nails **except** in preparations for the treatment of tinea pedis.

MINOXIDIL in preparations for dermal use containing 5% or less of minoxidil.

MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over.

NAPHAZOLINE.

NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.

NICLOSAMIDE for human therapeutic use.

NIZATIDINE when sold in the manufacturer’s original pack containing not more than 14 days’ supply.

NOSCAPINE.

NYSTATIN in dermal preparations.

OLOPATADINE in preparations for nasal use delivering 600 micrograms or less of olopatadine per dose when the maximum recommended daily dose is no greater than 4,800 micrograms for the treatment of allergic rhinitis or rhinoconjunctivitis for up to 6 months in adults and children 12 years of age and over.

OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 7 days’ supply.

OXETACAINE (oxethazaine) in preparations for internal use.

OXICONAZOLE for dermal use **except** in preparations for the treatment of tinea pedis.

OXYMETAZOLINE.

OXYQUINOLINE and its non‑halogenated derivatives for human therapeutic use, **except** in preparations for external use containing 1% or less of such substances.

PAPAVERINE **except** when included in Schedule 4.

PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 7 days’ supply.

PARACETAMOL for therapeutic use:

(a) in liquid preparations for oral use containing a maximum of 10 g of paracetamol per container; or

(b) when combined with ibuprofen in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided doses in a primary pack containing no more than 12 dosage units per pack; or

(c) in tablets or capsules enclosed in a primary pack containing not more than 100 tablets or capsules; or

(d) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules intended only as a bulk medicine pack and labelled “For dispensing only” and “This pack is not to be supplied to a patient”; or

(e) in individually wrapped powders or sachets of granules enclosed in a primary pack containing not more than 50 wrapped powders or sachets of granules; or

(f) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules intended only as a bulk medicine pack and labelled “For dispensing only” and “This pack is not to be supplied to a patient”; or

(g) in other preparations **except**:

(i) when included in Schedule 3 or 4; or

(ii) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than caffeine, phenylephrine and/or guaifenesin or when combined with effervescent agents) when:

(A) enclosed in a primary pack that contains not more than 10 such powders or sachets of granules;

(B) compliant with the requirements of the required advisory statements for medicine labels;

(C) not labelled for the treatment of children 6 years of age or less; and

(D) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin; or

(iii) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than caffeine, phenylephrine and/or guaifenesin or when combined with effervescent agents) when:

(A) packed in blister or strip packaging or in a container with a child‑resistant closure;

(B) in a primary pack containing not more than 20 tablets or capsules;

(C) compliant with the requirements of the required advisory statements for medicine labels;

(D) not labelled for the treatment of children 6 years of age or less; and

(E) not labelled for the treatment of children under 12 years of age when combined with caffeine, phenylephrine and/or guaifenesin.

PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use **except**:

(a) in oral hygiene preparations containing 0.1% or less of free formaldehyde; or

(b) in other preparations containing 0.2% or less of free formaldehyde.

PHEDRAZINE.

PHENAZONE for human external use.

PHENIRAMINE:

(a) in eye drops; or

(b) when combined with one or more other therapeutically active substances in oral preparations when:

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day‑night pack containing pheniramine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

PHENOL, or any homologue boiling below 220°C, for human therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations for external use containing 1% or less of phenol and in preparations for external use containing 3% or less of cresols and xylenols and other homologues of phenol.

PHENYLEPHRINE **except**:

(a) when included in Schedule 4; or

(b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or

(c) in topical eye or nasal preparations containing 1% or less of phenylephrine.

PHOLCODINE:

(a) in liquid preparations containing 0.5% or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or

(b) when compounded with one or more other therapeutically active substances in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine.

PIPERAZINE for human therapeutic use.

PODOPHYLLOTOXIN in preparations containing 0.5% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.

POTASSIUM CHLORATE for therapeutic use **except** in preparations containing 10% or less of potassium chlorate.

PRILOCAINE in preparations for dermal use containing 10% or less of total local anaesthetic substances.

PROCYCLIDINE in preparations containing 5% or less of procyclidine for dermal use.

PROMETHAZINE in oral preparations:

(a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or

(b) when combined with one or more other therapeutically active substances when:

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day‑night pack containing promethazine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

PROPAMIDINE for ophthalmic use.

PYRANTEL for human therapeutic use.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10% of such substances.

PYRITHIONE ZINC for human therapeutic use, **except** in preparations for the treatment of the scalp containing 2% or less of pyrithione zinc when compliant with the requirements of the required advisory statements for medicine labels.

RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 7 days’ supply.

RANITIDINE in preparations supplied in the manufacturer’s original pack containing not more than 14 days’ supply **except**:

(a) in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 14 dosage units; or

(b) in divided preparations for oral use containing 300 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 7 dosage units.

SALICYLAMIDE **except** when included in Schedule 4.

SELENIUM in preparations for human therapeutic use **except**:

(a) for topical use containing 3.5% or less of selenium sulfide;

(b) when included in Schedule 4; or

(c) for oral use with a recommended daily dose of 150 micrograms or less.

SILVER for therapeutic use **except**:

(a) in solutions for human oral use containing 0.3% or less of silver when compliant with the requirements of the required advisory statements for medicine labels; or

(b) in other preparations containing 1% or less of silver.

SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.

SODIUM NITRITE for therapeutic use (excluding when present as an excipient).

SQUILL **except** in preparations containing 1% or less of squill.

SULCONAZOLE in preparations for dermal use.

TERBINAFINE for dermal use **except** in preparations for the treatment of tinea pedis.

TETRACAINE in preparations for topical use other than eye drops, containing 10% or less of total local anaesthetic substances **except** in dermal preparations containing 2% or less of total local anaesthetic substances.

TETRACHLOROETHYLENE for human therapeutic use.

TETRYZOLINE.

THIABENDAZOLE for human therapeutic use.

TIOCONAZOLE in preparations for dermal use **except** in preparations for the treatment of tinea pedis.

TRAMAZOLINE.

TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day‑night pack containing triprolidine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;

except in preparations for the treatment of children under 2 years of age.

TUAMINOHEPTANE.

TYMAZOLINE.

XYLOMETAZOLINE.

ZINC CHLORIDE for human dermal use **except** in preparations containing 5% or less of zinc chloride.

Schedule 3—Pharmacist only medicines

Note: See sections 16 and 31, subsections 54(2) and 57(1) and section 59.

ADAPALENE in topical preparations containing 0.1% or less of adapalene for the treatment of acne vulgaris in adults and in children over 12 years of age.

ADRENALINE in preparations containing 1% or less of adrenaline **except** in preparations that are not for injection containing 0.02% or less of adrenaline.

ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of alclometasone in packs containing 30 g or less of the preparation.

ALIMEMAZINE:

(a) in solid oral preparations **except** when included in Schedule 2; or

(b) in liquid oral preparations containing 10 mg or less of alimemazine per 5 mL;

except in preparations for the treatment of children under 2 years of age.

AMINOPHYLLINE in liquid oral preparations containing 2% or less of aminophylline.

AMYL NITRITE when in preparations for human therapeutic use and packaged in containers with child‑resistant closures.

ASTODRIMER SODIUM **except**:

(a) when included in Schedule 2; or

(b) in a condom lubricant.

AZATADINE in oral preparations.

BILASTINE in oral preparations when labelled with a recommended daily dose not exceeding 10 mg of bilastine for the treatment of children 6-11 years of age **except** when included in Schedule 2.

BROMPHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

BUCLIZINE in oral preparations.

BUTOCONAZOLE in preparations for vaginal use.

CANNABIDIOL in oral, oromucosal and sublingual preparations included in the Register when:

(a) the cannabidiol is either plant derived or, when synthetic, only contains the (‑)‑CBD enantiomer; and

(b) the cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and

(c) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation and of which tetrahydrocannabinol (THC) can only comprise 1% of the total cannabinoid content; and

(d) the maximum recommended daily dose is 150 mg or less of cannabidiol; and

(e) packed in blister or strip packaging or in a container fitted with a child‑resistant closure; and

(f) in packs containing not more than 30 days’ supply; and

(g) for persons aged 18 years and over.

CELECOXIB in tablets or capsules each containing 200 mg or less of celecoxib, in a primary pack containing not more than 10 dosage units for the short‑term treatment of acute pain due to primary dysmenorrhea or musculoskeletal or soft tissue injuries in adults.

CHLORAMPHENICOL for ophthalmic use only.

CHLORBUTANOL in preparations for human use **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 0.5% or less of chlorbutanol.

CHLORPHENAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

CICLOPIROX in preparations for dermal use and for application to the nails **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of tinea pedis.

CIMETIDINE in a primary pack containing not more than 14 days’ supply.

CLEMASTINE in preparations for oral use.

CLOBETASONE (clobetasone‑17‑butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05% or less of clobetasone in packs containing 30 g or less of the preparation.

CLOTRIMAZOLE in preparations for vaginal use.

CYCLIZINE in divided preparations for oral use in primary packs containing 6 dosage units or less.

CYPROHEPTADINE in oral preparations.

DEXCHLORPHENAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units **except** when included in Schedule 2.

DIHYDROCODEINE when indicated for cough suppression and compounded with one or more other therapeutically active substances:

(a) in divided preparations containing 10 mg or less of dihydrocodeine per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or

(b) in undivided preparations containing 0.25% or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine.

DIIODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.

DIMENHYDRINATE in oral preparations **except** when included in Schedule 2.

DIMETHINDENE in oral preparations.

DIPHENHYDRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1% of the dose of diphenoxylate.

DITHRANOL for therapeutic use.

DOXYLAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

ECONAZOLE in preparations for vaginal use.

ELETRIPTAN for oral use in tablets containing 40 mg or less per tablet and when in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of symptoms.

ERYTHRITYL TETRANITRATE for therapeutic use.

FAMCICLOVIR for oral use, in divided preparations containing a total dose of 1500 mg or less of famciclovir for the treatment of herpes labialis (cold sores).

FLAVOXATE.

FLUCONAZOLE in single‑dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.

FLUORIDES for human topical use:

(a) in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a child‑resistant closure **except** when included in or expressly excluded from Schedule 2; or

(b) in non‑liquid preparations containing 5500 mg/kg or less of fluoride ion **except**:

(i) in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, compliant with the requirements of the required advisory statements for medicine labels; or

(ii) in preparations for non‑therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, labelled with warnings to the following effect:

(A) Do not swallow; and

(B) Do not use [this product/name of product] in children six years of age or less; or

(iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority.

GLUCAGON.

GLYCERYL TRINITRATE:

(a) in preparations for oral use; or

(b) in preparations for rectal use.

GLYCOPYRRONIUM **except** when included in Schedule 4.

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1% or less of hydrocortisone:

(a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or

(b) for dermal use, in packs containing 2 g or less of such preparations, containing no other therapeutically active constituent other than aciclovir (5% w/w or less) in adults and adolescents (12 years of age and older); or

(c) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent **except** unscheduled astringents:

(i) in undivided preparations, in packs of 35 g or less; or

(ii) in packs containing 12 or less suppositories;

except when included in Schedule 2.

HYOSCINE BUTYLBROMIDE in undivided preparations for oral use with a recommended single dose not exceeding 20 mg of hyoscine butylbromide in a pack containing 100 mg or less of hyoscine butylbromide when labelled for adults and children 6 years and over.

IBUPROFEN when:

(a) either:

(i) in divided preparations, each containing 400 mg or less of ibuprofen, in a primary pack containing not more than 50 dosage units; or

(ii) in a modified release dosage form, each containing 600 mg of ibuprofen, in a primary pack containing not more than 32 dosage units; and

(b) labelled:

(i) with a recommended daily dose of 1200 mg or less of ibuprofen; and

(ii) not for the treatment of children under 12 years;

except when:

(c) included in Schedule 2; or

(d) in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided preparations, each containing 200 mg or less of ibuprofen, in a pack containing not more than 100 dosage units when:

(i) ibuprofen is the only therapeutically active constitutent, other than phenylephrine or when combined with an effervescent agent; and

(ii) packed in a blister or strip packaging or in a container with a child-resistant closure; and

(iii) in a primary pack containing not more than 25 dosage units; and

(iv) compliant with the requirements of the required advisory statements for medicine labels; and

(v) not labelled for the treatment of children 6 years or under; and

(vi) when combined with phenylephrine—not labelled for the treatment of children under 12 years.

INOSITOL NICOTINATE.

ISOCONAZOLE in preparations for vaginal use.

ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.

KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.

LANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days’ supply **except** when included in Schedule 2.

LEVONORGESTREL for emergency post‑coital contraception.

MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.

MAGNESIUM SULFATE for human therapeutic use in divided oral preparations **except** when containing 1.5 g or less of magnesium sulfate per recommended daily dose.

MALATHION in preparations for human external use **except** in preparations containing 2% or less of malathion.

MANNITYL HEXANITRATE for therapeutic use.

MELATONIN in:

(a) modified release tablets containing 2 mg or less of melatonin for monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep for adults aged 55 or over, in packs containing not more than 30 tablets; or

(b) immediate release preparations containing 5 mg or less of melatonin for the treatment of jet lag in adults 18 years and over, in a primary pack containing no more than 10 dosage units.

MEPYRAMINE in oral preparations.

METHDILAZINE in oral preparations.

METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.

MICONAZOLE for human use in topical preparations:

(a) for the treatment of oral candidiasis; or

(b) for vaginal use.

MOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.1% or less of mometasone in packs containing 15 g or less.

NALOXONE when used for the treatment of opioid overdose.

NAPROXEN in a modified release dosage form of 600 mg or less of naproxen per dosage unit in packs of 16 or less dosage units when labelled not for the treatment of children under 12 years of age.

NARATRIPTAN when in divided oral preparations containing 2.5 mg or less of naratriptan per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of symptoms.

NICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit **except**:

(a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or

(b) nicotinamide.

NICOTINYL ALCOHOL **except** in preparations containing 100 mg or less of nicotinyl alcohol per dosage unit.

NYSTATIN in preparations for topical use **except** when included in Schedule 2.

OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days’ supply **except** when included in Schedule 2.

ORLISTAT in oral preparations for weight‑control purposes containing 120 mg or less of orlistat per dosage unit.

OXICONAZOLE in preparations for vaginal use.

PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days’ supply **except** when included in Schedule 2.

PARACETAMOL:

(a) when combined with ibuprofen in a primary pack containing 30 dosage units or less **except** when included in Schedule 2; or

(b) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed in a primary pack containing not more than 100 tablets or capsules; or

(c) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed in a primary pack containing more than 100 tablets or capsules intended only as a bulk medicine and labelled “For dispensing only” and “This pack is not to be supplied to a patient”; or

(d) in liquid preparations for oral use **except** when in Schedule 2.

PHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

PODOPHYLLOTOXIN in preparations containing 1% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.

PROMETHAZINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of children under 2 years of age.

PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight‑control purposes) when supplied in a primary pack:

(a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or

(b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).

RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days’ supply **except** when included in Schedule 2.

RIZATRIPTAN when in divided oral preparations containing 5 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of migraine symptoms.

SALBUTAMOL as the only therapeutically active substance:

(a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or

(b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.

SALICYLIC ACID in preparations for dermal use **except** in preparations containing 40% or less of salicylic acid.

SANTONIN.

SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.

SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.

SULFACETAMIDE in preparations for ophthalmic use containing 10% or less of sulfacetamide.

SUMATRIPTAN when in divided oral preparations containing 50 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of symptoms.

TERBUTALINE as the only therapeutically active substance:

(a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or

(b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.

THEOPHYLLINE in liquid oral preparations containing 2% or less of theophylline.

TIOCONAZOLE in preparations for vaginal use.

TRIAMCINOLONE for buccal use in preparations containing 0.1% or less of triamcinolone in a pack of 5 g or less.

TRIPROLIDINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

ULIPRISTAL for emergency post‑coital contraception.

VITAMIN D for human internal therapeutic use in preparations containing 175 micrograms or less of vitamin D per recommended single weekly dose **except** in preparations containing 25 micrograms or less of vitamin D per recommended daily dose.

ZOLMITRIPTAN when in divided oral preparations containing 2.5 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of symptoms.

Schedule 4—Prescription only medicines and prescription animal remedies

Note 1: See sections 16, 28, 31 and 49, subsections 54(2) and 57(1) and section 60.

Note 2: Substances marked # are listed in Appendix D.

ABACAVIR.

ABATACEPT.

ABIRATERONE ACETATE.

ABCIXIMAB.

ABEMACICLIB.

ABROCITINIB.

ACALABRUTINIB.

ACAMPROSATE CALCIUM.

ACARBOSE.

ACEBUTOLOL.

ACEPROMAZINE.

ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.

ACETARSOL.

ACETAZOLAMIDE.

ACETOHEXAMIDE.

ACETYL ISOVALERYLTYLOSIN.

ACETYLCARBROMAL.

ACETYLCHOLINE.

ACETYLCYSTEINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for oral use when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACETYLDIGITOXIN.

ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.

ACETYLSTROPHANTHIDIN.

ACICLOVIR **except** in preparations containing 5% or less of aciclovir for the treatment of herpes labialis in packs containing 10 g or less.

ACIPIMOX.

# ACITRETIN.

ACLIDINIUM BROMIDE.

ACOKANTHERA OUABAIO.

ACOKANTHERA SCHIMPERI.

ACONITUM spp. **except**:

(a) when included in Schedule 2; or

(b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or

(c) in preparations for dermal use in adults containing 0.02% or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids.

ACRIVASTINE.

ADALIMUMAB.

ADAPALENE **except** when included in Schedule 3.

ADEFOVIR.

ADENOSINE for human therapeutic use in preparations for injection.

ADIPHENINE.

ADONIS VERNALIS.

ADRAFINIL.

ADRENALINE in:

(a) topical preparations for the treatment of wounds in humans; or

(b) all other preparations containing adrenaline **except** when included in or expressly excluded from Schedule 3.

ADRENOCORTICAL HORMONES **except** when separately specified in these Schedules.

AFAMELANOTIDE.

AFATINIB DIMALEATE.

AFLIBERCEPT.

AGALSIDASE.

AGLEPRISTONE.

AGOMELATINE.

ALANYLGLUTAMINE.

ALATROFLOXACIN MESILATE.

ALBENDAZOLE **except**:

(a) when included in Schedule 5 or 6; or

(b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals.

ALCLOFENAC.

ALCLOMETASONE **except** when included in Schedule 3.

ALCURONIUM.

ALDESLEUKIN.

ALDOSTERONE.

ALECTINIB.

# ALEFACEPT.

ALEMTUZUMAB.

ALENDRONIC ACID.

ALFACALCIDOL.

ALFUZOSIN.

ALGLUCERASE.

ALGLUCOSIDASE.

ALIMEMAZINE **except** when included in Schedule 2 or 3.

ALIROCUMAB.

ALISKIREN.

ALKYL NITRITES **except** when separately specified in these schedules.

ALLERGENS for therapeutic use.

ALLOPURINOL.

ALLYLESTRENOL.

ALOGLIPTIN.

ALOSETRON.

ALPELISIB.

ALPHA1‑PROTEINASE INHIBITOR (HUMAN).

ALPHADOLONE.

ALPHAXALONE.

ALPRENOLOL.

ALPROSTADIL.

ALSEROXYLON.

ALTEPLASE.

ALTRENOGEST.

ALTRETAMINE (hexamethylmelamine).

AMANTADINE.

AMBENONIUM CHLORIDE.

# AMBRISENTAN.

AMBUCETAMIDE.

AMBUTONIUM BROMIDE.

AMCINONIDE.

AMIFAMPRIDINE.

AMIFOSTINE.

AMIKACIN.

AMILORIDE.

AMINOCAPROIC ACID.

AMINOGLUTETHIMIDE.

5‑AMINOLEVULINIC ACID.

AMINOMETRADINE.

AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.

AMINOPHYLLINE **except** when included in Schedule 3.

AMINOPTERIN.

4‑AMINOPYRIDINE for therapeutic use.

AMINOREX.

AMINOSALICYLIC ACID.

AMIODARONE.

AMIPHENAZOLE.

AMISOMETRADINE.

AMISULPRIDE.

AMITRIPTYLINE.

AMLODIPINE.

AMMI VISNAGA.

AMMONIUM BROMIDE for therapeutic use.

AMOBARBITAL when packed and labelled for injection.

AMODIAQUINE.

AMOROLFINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of tinea pedis.

AMOXAPINE.

AMOXICILLIN.

AMPHOMYCIN.

AMPHOTERICIN B.

AMPICILLIN.

AMPRENAVIR.

AMRINONE.

AMSACRINE.

AMYL NITRITE **except** when included in Schedule 3.

AMYLOCAINE.

# ANABOLIC STEROIDAL AGENTS.

ANAGRELIDE.

ANAKINRA.

ANASTROZOLE.

ANCESTIM.

ANCROD and its immunoglobulin antidote.

ANDEXANET ALFA.

ANECORTAVE.

# ANDROGENIC STEROIDAL AGENTS.

# ANDROISOXAZOLE.

# ANDROSTANOLONE.

# ANDROSTENEDIOL.

# ANDROSTENEDIONE.

ANGIOTENSIN AMIDE.

ANIDULAFUNGIN.

ANIRACETAM.

ANISTREPLASE.

ANTAZOLINE **except** when included in Schedule 2.

ANTIBIOTIC SUBSTANCES **except**:

(a) when separately specified in these Schedules; or

(b) nisin.

ANTIGENS for human therapeutic use **except** when separately specified in this Schedule.

ANTIHISTAMINES **except**:

(a) when included in Schedule 2 or 3; or

(b) when separately specified in this Schedule.

ANTIMONY for therapeutic use **except** when separately specified in these Schedules.

ANTISERA (immunosera) for human use by injection **except** when separately specified in these Schedules.

# AOD‑9604 (CAS No. 221231‑10‑3).

APALUTAMIDE.

APIXABAN.

APOCYNUM spp.

APOMORPHINE.

APRACLONIDINE.

APRAMYCIN.

APREMILAST.

APREPITANT.

APROTININ.

ARBUTIN (BETA) in oral preparations **except** herbal preparations containing 500 mg or less beta‑arbutin per recommended daily dose.

ARECOLINE.

ARIPIPRAZOLE.

ARMODAFINIL.

ARSENIC for human therapeutic use **except** when separately specified in these Schedules.

ARTEMETHER.

ARTICAINE.

ASCIMINIB.

ASENAPINE.

ASFOTASE ALFA.

ASPARAGINASE.

ASPIRIN when:

(a) combined with caffeine, paracetamol or salicylamide; or

(b) combined with any derivative of the substances mentioned in paragraph (a); or

(c) for injection.

ASTEMIZOLE.

ASUNAPREVIR.

# ATAMESTANE.

ATAZANAVIR.

ATENOLOL.

ATEZOLIZUMAB.

ATIPAMEZOLE.

ATOMOXETINE.

ATORVASTATIN.

ATOSIBAN.

ATOVAQUONE.

ATRACURIUM BESILATE.

ATROPA BELLADONNA (belladonna) **except** when included in Schedule 2.

ATROPINE **except** when included in Schedule 2.

ATROPINE METHONITRATE.

AURANOFIN.

AUROTHIOMALATE SODIUM.

AVACOPAN.

AVATROMBOPAG.

AVELUMAB.

AVILAMYCIN **except**:

(a) in animal feed premixes containing 15% or less of avilamycin activity; or

(b) in animal feeds containing 50 mg/kg or less of avilamycin activity.

AVIPTADIL.

AXITINIB.

AVOPARCIN.

AZACITIDINE.

AZACYCLONOL.

AZAPERONE.

AZAPROPAZONE.

AZARIBINE.

AZATADINE **except** when included in Schedule 3.

AZATHIOPRINE.

AZELAIC ACID **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 1% or less of azelaic acid for non‑human use.

AZELASTINE **except** when included in Schedule 2.

AZITHROMYCIN.

AZLOCILLIN.

AZTREONAM.

BACAMPICILLIN.

BACITRACIN.

BACLOFEN.

BALOXAVIR MARBOXIL.

BALSALAZIDE.

BAMBERMYCIN (flavophospholipol) **except**:

(a) when included in Schedule 6; or

(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

BAMBUTEROL.

BAMETHAN.

BAMIPINE.

BARBITURATES **except** when separately specified in these Schedules.

BARICITINIB.

BASILIXIMAB.

BAZEDOXIFENE.

BECAPLERMIN.

BECLAMIDE.

BECLOMETASONE **except** when included in Schedule 2.

BELATACEPT.

BELIMUMAB.

BELUMOSUDIL.

BELZUTIFAN.

BEMEGRIDE.

BENACTYZINE.

BENAZEPRIL.

BENDAMUSTINE.

BENDROFLUAZIDE.

BENETHAMINE PENICILLIN.

BENORYLATE.

BENOXAPROFEN.

BENPERIDOL.

BENRALIZUMAB.

BENSERAZIDE.

BENZATHINE PENICILLIN.

BENZILONIUM.

BENZOCAINE **except**:

(a) when included in Schedule 2; or

(b) in dermal preparations containing 2% or less of total local anaesthetic substances; or

(c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

# BENZODIAZEPINE derivatives **except** when separately specified in these Schedules.

BENZOYL PEROXIDE in preparations for human therapeutic use **except**:

(a) when included in Schedule 2; or

(b) in preparations for external use containing 5% or less of benzoyl peroxide.

BENZPHETAMINE.

BENZTHIAZIDE.

BENZATROPINE.

BENZYDAMINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for dermal use; or

(c) in divided topical oral preparations containing 3 mg or less of benzydamine; or

(d) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL.

BENZYLPENICILLIN.

BEPRIDIL.

BERACTANT.

BESIFLOXACIN.

BETAHISTINE.

BETAMETHASONE.

BETAXOLOL.

BETHANECHOL CHLORIDE.

BETHANIDINE.

BEVACIZUMAB.

BEVANTOLOL.

# BEXAROTENE.

BEZAFIBRATE.

BEZLOTOXUMAB.

BICALUTAMIDE.

BICTEGRAVIR.

BIFONAZOLE **except**:

(a) when included in Schedule 2; or

(b) in preparations for dermal use containing 1% or less of bifonazole for the treatment of the scalp; or

(c) in preparations for dermal use for the treatment of tinea pedis.

BILASTINE **except** when included in Schedule 2 or 3.

BIMATOPROST.

BINIMETINIB.

BIPERIDEN.

BISMUTH COMPOUNDS for cosmetic use, **except**:

(a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5% or less; or

(b) bismuth oxychloride.

BISMUTH COMPOUNDS for human therapeutic use, **except** bismuth formic iodide or bismuth subiodide in dusting powders containing 3% or less of bismuth.

BISOPROLOL.

BIVALIRUDIN.

BLEOMYCIN.

BLINATUMOMAB.

BOCEPREVIR.

# BOLANDIOL.

# BOLASTERONE.

# BOLAZINE.

# BOLDENONE (dehydrotestosterone).

# BOLENOL.

# BOLMANTALATE.

BORON, including boric acid and borax, for human therapeutic use **except**:

(a) in preparations for internal use containing 6 mg or less of boron per recommended daily dose; or

(b) in preparations for dermal use containing 0.35% or less of boron, which are not for paediatric or antifungal use; or

(c) when present as an excipient.

BORTEZOMIB.

# BOSENTAN.

BOSUTINIB.

BOTULINUM TOXINS for human use **except** when separately specified in these Schedules.

# BPC‑157.

BRENTUXIMAB VEDOTIN.

BRETYLIUM TOSILATE.

BREXPIPRAZOLE.

BRIGATINIB.

BRIMONIDINE **except** when included in Schedule 2.

BRINZOLAMIDE.

BRIVARACETAM.

# BROMAZEPAM.

BROMIDES, inorganic, for therapeutic use **except** when separately specified in these Schedules.

BROMOCRIPTINE.

BROMOFORM for therapeutic use.

BROMPHENIRAMINE **except** when included in Schedule 2 or 3.

BROMVALETONE.

BRUGMANSIA spp.

BUCLIZINE **except** when included in Schedule 3.

BUDESONIDE **except** when included in Schedule 2.

BUFEXAMAC.

BULEVIRTIDE.

BUMETANIDE.

BUPHENINE.

BUPIVACAINE **except** when included in Schedule 5.

BUPROPION.

BUSERELIN.

BUSPIRONE.

BUSULPHAN.

BUTACAINE.

BUTAMBEN **except** in dermal preparations containing 2% or less of total local anaesthetic substances.

BUTOCONAZOLE **except** when included in Schedule 3.

BUTRACONAZOLE.

BUTYLCHLORAL HYDRATE.

BUTYL NITRITE.

CABAZITAXEL.

CABERGOLINE.

CABOTEGRAVIR.

CABOZANTINIB.

CADMIUM COMPOUNDS for human therapeutic use.

CAFFEINE for internal therapeutic use **except**:

(a) in divided preparations when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or

(b) in undivided preparations with a concentration of less than 5% of caffeine and when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine.

CALCIFEDIOL for human internal therapeutic use **except** in preparations containing 10 micrograms or less of calcifediol per recommended daily dose.

CALCIPOTRIOL.

CALCITONIN.

CALCITONIN SALMON.

CALCITRIOL.

CALCIUM CARBIMIDE for therapeutic use.

CALCIUM HYDROXYLAPATITE in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

CALCIUM POLYSTYRENE SULPHONATE.

CALOTROPIS GIGANTEA.

CALOTROPIS PROCERA.

# CALUSTERONE.

CAMPHORATED OIL for therapeutic use.

CAMPHOTAMIDE.

CANAGLIFLOZIN.

CANAKINUMAB.

CANDESARTAN CILEXETIL.

CANDICIDIN.

CANINE TICK ANTI‑SERUM.

CANNABIDIOL in preparations for therapeutic use or analytical and scientific research where:

(a) cannabidiol comprises 98% or more of the total cannabinoid content of the preparation; and

(b) any cannabinoids, other than cannabidiol, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation;

except when:

(c) included in Schedule 3; or

(d) in hemp seed oil at a concentration of 75 mg/kg or less.

CANTHARIDIN.

CAPECITABINE.

CAPREOMYCIN.

# CAPROMORELIN.

CAPTODIAME.

CAPTOPRIL.

CAPURIDE.

CARAMIPHEN.

CARBACHOL.

CARBAMAZEPINE.

CARBARYL for human therapeutic use.

CARBAZOCHROME.

CARBENICILLIN.

CARBENOXOLONE for internal use.

CARBETOCIN.

CARBIDOPA.

CARBIMAZOLE.

CARBOCROMEN.

CARBOPLATIN.

CARBOPROST.

CARBROMAL.

CARBUTAMIDE.

CARBUTEROL.

CARFILZOMIB.

CARGLUMIC ACID (*N*‑carbamoyl‑L‑glutamic acid).

CARINDACILLIN.

CARIPRAZINE.

CARISOPRODOL.

CARMUSTINE.

CARNIDAZOLE.

CARPROFEN.

CARVEDILOL.

CASIRIVIMAB.

CASPOFUNGIN.

CATHINE.

CATUMAXOMAB.

CEDAZURIDINE.

CEFACETRILE.

CEFACLOR.

CEFADROXIL.

CEFALEXIN.

CEFALORIDINE.

CEFALOTIN.

CEFAMANDOLE.

CEFAPIRIN.

CEFAZOLIN.

CEFEPIME.

CEFETAMET.

CEFIXIME.

CEFODIZIME.

CEFONICID.

CEFOPERAZONE.

CEFOTAXIME.

CEFOTETAN.

CEFOTIAM.

CEFOVECIN for veterinary use.

CEFOXITIN.

CEFPIROME.

CEFPODOXIME.

CEFQUINOME.

CEFTAROLINE FOSAMIL.

CEFSULODIN.

CEFTAZIDIME.

CEFTIBUTEN.

CEFTIOFUR.

CEFTRIAXONE.

CEFUROXIME.

CELECOXIB **except** when included in Schedule 3.

CELIPROLOL.

CENEGERMIN.

CEPHAELIS ACUMINATA (ipecacuanha) **except** in preparations containing 0.2% or less of emetine.

CEPHAELIS IPECACUANHA **except** in preparations containing 0.2% or less of emetine.

CEPHALONIUM.

CEPHRADINE.

CERITINIB.

CERIVASTATIN.

CERLIPONASE ALFA.

CERTOLIZUMAB PEGOL.

CERULETIDE.

CETIRIZINE **except**

(a) when included in Schedule 2; or

(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over when:

(i) in a primary pack containing not more than 10 days’ supply; and

(ii) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.

CETRORELIX.

CETUXIMAB.

CHENODEOXYCHOLIC ACID.

CHLORAL FORMAMIDE.

CHLORAL HYDRATE **except** in preparations for topical use containing 2% or less of chloral hydrate.

CHLORALOSE **except** when included in Schedule 6.

CHLORAMBUCIL.

CHLORAMPHENICOL **except** when included in Schedule 3.

# CHLORANDROSTENOLONE.

CHLORAZANIL.

CHLORCYCLIZINE.

# CHLORDIAZEPOXIDE.

CHLORMERODRIN.

CHLORMETHIAZOLE.

CHLORMEZANONE.

CHLOROFORM for use in anaesthesia.

# 4‑CHLOROMETHANDIENONE.

2‑(4‑CHLOROPHENYL)‑(1,2,4)TRIAZOLO[5,1‑A]ISOQUINOLINE.

CHLOROQUINE.

CHLOROTHIAZIDE.

CHLOROTRIANISENE.

# CHLOROXYDIENONE.

CHLORPHENAMINE **except** when included in Schedule 2 or 3.

CHLORPHENTERMINE.

CHLORPROMAZINE.

CHLORPROPAMIDE.

CHLORPROTHIXENE.

CHLORQUINALDOL for human topical use.

CHLORTALIDONE.

CHLORTETRACYCLINE **except** when included in Schedule 5.

CHLORZOXAZONE.

CHOLERA VACCINE.

CHOLIC ACID.

CHYMOPAPAIN for human therapeutic use.

CICLACILLIN.

CICLESONIDE.

CICLOPIROX **except**:

(a) when included in Schedule 2 or 3; or

(b) in preparations for the treatment of tinea pedis.

CICLOSPORIN.

CIDOFOVIR.

CILASTATIN.

CILAZAPRIL.

CILGAVIMAB.

CILOSTAZOL.

CIMETIDINE **except** when included in Schedule 3.

CIMICOXIB.

CINACALCET.

CINCHOCAINE **except** when included in Schedule 2.

CINNARIZINE.

CINOXACIN.

CIPROFLOXACIN.

CISAPRIDE.

CISATRACURIUM BESILATE.

CISPLATIN.

CITALOPRAM.

# CJC‑1295 (CAS No. 863288‑34‑0).

CLADRIBINE.

CLANOBUTIN.

CLARITHROMYCIN.

CLASCOTERONE.

CLAVULANIC ACID.

CLEMASTINE **except** when included in Schedule 3.

CLEMIZOLE.

CLENBUTEROL.

CLEVIDIPINE.

CLIDINIUM BROMIDE.

CLINDAMYCIN.

CLIOQUINOL and other halogenated derivatives of oxyquinoline for human topical use **except** when separately specified in this Schedule.

CLOBAZAM.

CLOBETASOL.

CLOBETASONE (clobetasone‑17‑butyrate) **except** when included in Schedule 3.

CLOCORTOLONE.

CLODRONIC ACID (includes sodium clodronate).

CLOFARABINE.

CLOFAZIMINE.

CLOFENAMIDE.

CLOFIBRATE.

# CLOMIFENE.

CLOMIPRAMINE.

CLOMOCYCLINE.

# CLONAZEPAM.

CLONIDINE.

CLOPAMIDE.

CLOPIDOGREL.

CLOPROSTENOL.

# CLORAZEPATE.

CLOREXOLONE.

CLORPRENALINE.

# CLOSTEBOL (4‑chlorotestosterone).

CLOTRIMAZOLE **except**:

(a) when included in Schedule 2, 3 or 6; or

(b) in preparations for dermal use for the treatment of tinea pedis.

CLOXACILLIN.

# CLOZAPINE.

COBALT for human therapeutic use **except** as dicobalt edetate in preparations for the treatment of cyanide poisoning.

COBICISTAT.

COBIMETINIB.

CODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing 30 mg or less of codeine per dosage unit; or

(b) in undivided preparations containing 1% or less of codeine.

CO‑DERGOCRINE.

COLCHICINE.

COLCHICUM AUTUMNALE.

COLESTIPOL.

COLESTYRAMINE for human therapeutic use.

COLFOSCERIL PALMITATE for human therapeutic use.

COLISTIN.

COLLAGEN in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

COLLAGENASE CLOSTRIDIUM HISTOLYTICUM.

COLURACETAM.

CONCIZUMAB.

CONVALLARIA KEISKI.

CONVALLARIA MAJALIS.

COPPER COMPOUNDS for human use **except**:

(a) when separately specified in these Schedules; or

(b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or

(c) in other preparations containing 5% or less of copper compounds.

# CORIFOLLITROPIN ALFA.

CORONILLA spp.

CORTICOSTERONE.

CORTICOTROPHIN.

CORTISONE.

CO‑TRIMOXAZOLE.

COUMARIN for therapeutic use (excluding when present as an excipient).

CRISABOROLE.

CRIZOTINIB.

CROFELEMER.

CUPRIMYXIN.

CURARE.

CYCLANDELATE.

CYCLIZINE **except** when included in Schedule 3.

CYCLOBENZAPRINE.

# CYCLOFENIL.

CYCLOHEXIMIDE.

CYCLOPENTHIAZIDE.

CYCLOPENTOLATE.

CYCLOPHOSPHAMIDE.

CYCLOPROPANE for therapeutic use.

CYCLOSERINE.

CYCLOTHIAZIDE.

CYCRIMINE.

CYMARIN.

CYPROHEPTADINE **except** when included in Schedule 3.

CYPROTERONE.

CYTARABINE.

DABRAFENIB MESILATE.

DABIGATRAN.

DACARBAZINE.

DACLATASVIR.

DACLIZUMAB.

DACTINOMYCIN.

DALFOPRISTIN.

DALTEPARIN (includes dalteparin sodium).

DANAPAROID (includes danaparoid sodium).

# DANAZOL.

DANTHRON for human use.

DANTROLENE.

DAPAGLIFLOZIN.

DAPOXETINE.

DAPSONE.

DAPTOMYCIN.

DARATUMUMAB.

# DARBEPOETIN.

DARIFENACIN.

DAROLUTAMIDE.

DARUNAVIR.

DATURA spp. **except**:

(a) when included in Schedule 2; or

(b) when separately specified in this Schedule.

DASABUVIR.

DASATINIB.

DATURA STRAMONIUM (stramonium) **except**:

(a) when included in Schedule 2; or

(b) for smoking or burning.

DATURA TATULA (stramonium) **except**:

(a) when included in Schedule 2; or

(b) for smoking or burning.

DAUNORUBICIN.

DEANOL for therapeutic use.

DEBRISOQUINE.

DECAMETHONIUM.

DECITABINE.

DEFERASIROX.

DEFERIPRONE.

DEFIBROTIDE.

DEFLAZACORT.

DEGARELIX.

# DEHYDROCHLOROMETHYLTESTOSTERONE.

DEHYDROCORTICOSTERONE.

DELAVIRDINE MESILATE.

DEMBREXINE **except** when included in Schedule 5.

DEMECARIUM.

DEMECLOCYCLINE.

DENGUE VACCINE.

DENOSUMAB.

DEOXYCHOLIC ACID.

DEOXYCORTONE.

DEOXYRIBONUCLEASE **except**:

(a) when separately specified in this Schedule; or

(b) for external use.

DERACOXIB.

DERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT.

DESFERRIOXAMINE.

DESFLURANE.

DESIPRAMINE.

DESIRUDIN.

DESLANOSIDE.

DESLORATADINE **except** when included in Schedule 2.

DESLORELIN.

DESMOPRESSIN (D.D.A.V.P.).

DESOGESTREL.

DESONIDE.

DESOXYMETHASONE.

DESVENLAFAXINE.

DETOMIDINE.

DEUCRAVACITINIB.

DEUTETRABENAZINE.

DEXAMETHASONE.

DEXCHLORPHENAMINE **except** when included in Schedule 2 or 3.

DEXFENFLURAMINE.

DEXMEDETOMIDINE.

DEXTROMETHORPHAN (excluding its stereoisomers) **except** when included in Schedule 2.

# DEXTROPROPOXYPHENE:

(a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or

(b) liquid preparations containing 2.5% or less of dextropropoxyphene.

DEXTRORPHAN (excluding its stereoisomers).

DIAMTHAZOLE.

DIAVERIDINE.

# DIAZEPAM.

DIAZOXIDE.

DIBENZEPIN.

DIBOTERMIN.

DIBROMOPROPAMIDINE for therapeutic use **except** when included in Schedule 2.

DICHLORALPHENAZONE.

DICHLOROPHEN for human therapeutic use.

DICHLORPHENAMIDE.

DICLOFENAC **except**:

(a) when included in Schedule 2 or 3; or

(b) in preparations for dermal use unless:

(i) for the treatment of solar keratosis; or

(ii) containing more than 4% of diclofenac.

DICLOXACILLIN.

DICYCLOMINE.

DIDANOSINE.

DIENESTROL.

DIENOGEST.

DIETHAZINE.

DIETHYLCARBAMAZINE for human therapeutic use.

DIETHYLPROPION.

DIFELIKEFALIN.

DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5% of the dose of difenoxin.

DIFLORASONE.

DIFLOXACIN.

DIFLUCORTOLONE.

DIFLUNISAL.

DIGITALIS LANATA.

DIGITALIS PURPUREA.

DIGITOXIN.

DIGOXIN.

DIGOXIN‑SPECIFIC ANTIBODY FRAGMENT F (Ab).

DIHYDRALAZINE.

DIHYDROCODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or

(b) in undivided preparations with a concentration of not more than 2.5% of dihydrocodeine;

**except** when included in Schedule 3.

DIHYDROERGOTOXINE.

# DIHYDROLONE.

DIHYDROSTREPTOMYCIN.

DIHYDROTACHYSTEROL.

DIIODOHYDROXYQUINOLINE (iodoquinol) **except**:

(a) when included in Schedule 3; or

(b) for human internal use.

DIISOPROPYLAMINE DICHLOROACETATE.

DILTIAZEM.

DIMENHYDRINATE **except** when included in Schedule 2 or 3.

DIMERCAPROL.

# DIMETHANDROSTANOLONE.

# DIMETHAZINE.

DIMETHINDENE **except** when included in Schedule 3.

DIMETHOTHIAZINE.

DIMETHOXANATE.

DIMETHYL FUMARATE.

DIMETHYL SULFOXIDE (excluding dimethyl sulfone) for therapeutic use **except**:

(a) when included in Schedule 6; or

(b) in *in vitro* test kits; or

(c) when used as a flavour component in compliance with the current Therapeutic Goods (Permissible Ingredients) determination for listed medicines.

DIMETRIDAZOLE.

DIMIRACETAM.

2,4‑DINITROCHLOROBENZENE for therapeutic use.

DINITROCRESOLS for therapeutic use **except** when separately specified in these Schedules.

DINITRONAPHTHOLS for therapeutic use **except** when separately specified in these Schedules.

DINITROPHENOLS for therapeutic use.

DINITROTHYMOLS for therapeutic use **except** when separately specified in these Schedules.

# DINOPROST.

# DINOPROSTONE.

DIPERODON.

DIPHEMANIL **except** in preparations for dermal use.

DIPHENHYDRAMINE **except** when included in Schedule 2 or 3.

DIPHENIDOL.

DIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1% of the dose of diphenoxylate **except** when included in Schedule 3.

DIPHENYLPYRALINE.

DIPHTHERIA TOXOID.

DIPIVEFRIN.

DIPYRIDAMOLE.

DIRITHROMYCIN.

DIRLOTAPIDE.

DIROXIMEL FUMARATE.

DISOPHENOL.

DISOPYRAMIDE.

DISTIGMINE.

DISULFIRAM for therapeutic use.

DISULPHAMIDE.

DITHIAZANINE **except** when included in Schedule 6.

DITIOCARB.

DOBUTAMINE.

DOCETAXEL.

DOFETILIDE.

DOLASETRON.

DOLUTEGRAVIR.

DOMPERIDONE.

DONEPEZIL.

DOPAMINE.

DOPEXAMINE.

DORAVIRINE.

DORIPENEM.

DORNASE.

DORZOLAMIDE.

DOSULEPIN.

DOXANTRAZOLE.

DOXAPRAM.

DOXAZOSIN.

DOXEPIN.

DOXORUBICIN.

DOXYCYCLINE.

DOXYLAMINE **except** when included in Schedule 2 or 3.

DRONEDARONE.

DROPERIDOL.

DROSPIRENONE.

# DROSTANOLONE.

DROTRECOGIN.

DUBOISIA LEICHHARDTII **except** when included in Schedule 2.

DUBOISIA MYOPOROIDES **except** when included in Schedule 2.

DULAGLUTIDE.

DULOXETINE.

DUPILUMAB.

DURVALUMAB.

DUTASTERIDE.

DYDROGESTERONE.

ECONAZOLE **except**:

(a) when included in Schedule 2, 3 or 6; or

(b) in preparations for dermal use for the treatment of tinea pedis.

ECOTHIOPATE (includes ecothiopate iodide).

ECTYLUREA.

ECULIZUMAB.

EDARAVONE.

EDETIC ACID for human therapeutic use **except**:

(a) in preparations containing 0.25% or less of edetic acid; or

(b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or

(c) in contact lens preparations.

EDOXUDINE.

EDROPHONIUM.

EFALIZUMAB.

EFAVIRENZ.

EFLORNITHINE.

ELBASVIR.

ELETRIPTAN **except** when included in Schedule 3.

ELEXACAFTOR.

ELOSULFASE ALFA.

ELOTUZUMAB.

ELRANATAMAB.

ELTENAC.

ELTROMBOPAG.

ELUXADOLINE.

ELVITEGRAVIR.

EMEPRONIUM.

EMETINE **except** in preparations containing 0.2% or less of emetine.

EMPAGLIFLOZIN.

EMTRICITABINE.

ENALAPRIL.

ENASIDENIB.

ENCORAFENIB.

# ENESTEBOL.

ENFLURANE for therapeutic use.

ENFORTUMAB VEDOTIN.

ENFUVIRTIDE.

# ENOBOSARM.

ENOXACIN.

ENOXAPARIN.

ENOXIMONE.

ENPROSTIL.

ENROFLOXACIN.

ENTACAPONE.

ENTECAVIR.

ENTRECTINIB.

ENZALUTAMIDE.

EPHEDRA spp. **except** in preparations containing 0.001% or less of ephedrine.

# EPHEDRINE.

EPICILLIN.

EPINASTINE.

EPIRUBICIN.

# EPITIOSTANOL.

EPLERENONE.

# EPOETINS.

EPOPROSTENOL.

EPROSARTAN.

EPTIFIBATIDE.

ERENUMAB.

ERGOMETRINE.

ERGOT.

ERGOTAMINE.

ERGOTOXINE.

ERIBULIN MESILATE.

ERLOTINIB.

ERTAPENEM.

ERTUGLIFLOZIN.

ERYSIMUM spp.

ERYTHROMYCIN.

# ERYTHROPOIETIN.

# ERYTHROPOIETINS **except** when separately specified in these Schedules.

ESCITALOPRAM.

ESLICARBAZEPINE ACETATE.

ESMOLOL.

ESOMEPRAZOLE **except** when included in Schedule 2.

ESTETROL MONOHYDRATE.

ESTRADIOL **except** when included in Schedule 5.

ESTRIOL.

ESTRAMUSTINE.

ESTROGENS **except** when separately specified in these Schedules.

ESTRONE.

ESTROPIPATE (piperazine estrone sulfate).

ETACRYNIC ACID.

ETANERCEPT.

ETHAMBUTOL.

ETHAMIVAN.

ETHCHLORVYNOL.

ETHER for use in anaesthesia.

ETHINAMATE.

ETHINYLESTRADIOL.

ETHIONAMIDE.

# ETHISTERONE.

ETHOGLUCID.

ETHOHEPTAZINE.

ETHOPROPAZINE.

ETHOSUXIMIDE.

ETHOTOIN.

ETHOXZOLAMIDE.

ETHYL CHLORIDE for human therapeutic use.

# ETHYLDIENOLONE.

ETHYLMORPHINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or

(b) in undivided preparations with a concentration of not more than 2.5% of ethylmorphine;

**except** when included in Schedule 2.

# ETHYLESTRENOL.

ETIDOCAINE.

ETIDRONIC ACID (includes etidronate disodium):

(a) for internal use; or

(b) in topical preparations **except** in preparations containing 1% or less of etidronic acid.

ETILEFRIN.

ETIPROSTON.

ETODOLAC.

ETOFENAMATE **except** when included in Schedule 2.

ETONOGESTREL.

ETOPOSIDE.

ETORICOXIB.

ETRANACOGENE DEZAPARVOVEC.

ETRASIMOD.

ETRAVIRINE.

# ETRETINATE.

ETYNODIOL.

EVEROLIMUS.

EXEMESTANE.

EXENATIDE.

EZETIMIBE.

FAMCICLOVIR **except** when included in Schedule 3.

FAMOTIDINE **except** when included in Schedule 2.

FARICIMAB.

FASORACETAM.

FEBUXOSTAT.

FELBINAC **except** when included in Schedule 2.

FELODIPINE.

FELYPRESSIN.

FENBUFEN.

FENCAMFAMIN.

FENCLOFENAC.

FENFLURAMINE.

FENOFIBRATE.

FENOLDOPAM.

FENOPROFEN.

FENOTEROL.

FENPIPRAMIDE.

FENPIPRANE.

FENPROPOREX.

FENPROSTALENE.

FERRIC DERISOMALTOSE.

FEXOFENADINE **except**:

(a) when included in Schedule 2; or

(b) in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and

(ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine; or

(c) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing 10 dosage units or less and not more than 10 days’ supply; and

(ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or

(d) for the treatment of seasonal allergic rhinitis and children 6 years of age and over when:

(i) in a primary pack containing 20 dosage units or less and not more than 10 days’ supply; and

(ii) labelled with a recommended daily dose not exceeding 60 mg of fexofenadine.

FEZOLINETANT.

FIBRINOLYSIN **except** for external use.

# FIBROBLAST GROWTH FACTORS.

FIDAXOMICIN.

FILGOTINIB.

FILGRASTIM.

FINASTERIDE.

FINERENONE.

FINGOLIMOD.

FIROCOXIB.

FLECAINIDE.

FLEROXACIN.

FLOCTAFENINE.

FLORFENICOL.

FLUANISONE.

FLUCLOROLONE.

FLUCLOXACILLIN.

FLUCONAZOLE **except** when included in Schedule 3.

FLUCYTOSINE.

FLUDARABINE.

FLUDROCORTISONE.

FLUFENAMIC ACID.

FLUMAZENIL.

FLUMETASONE.

FLUMETHIAZIDE.

FLUNISOLIDE.

FLUNIXIN MEGLUMINE.

FLUOCINOLONE.

FLUOCINONIDE.

FLUOCORTIN.

FLUOCORTOLONE.

FLUORESCEIN in preparations for injection.

FLUORIDES in preparations for human use **except** when included in or expressly excluded from Schedule 2 or 3.

FLUOROMETHOLONE.

FLUOROURACIL.

FLUOXETINE.

# FLUOXYMESTERONE.

FLUPENTIXOL.

FLUPHENAZINE.

FLUPROSTENOL.

FLURALANER in injectable preparations for use in companion animals.

FLURANDRENOLONE.

# FLURAZEPAM.

FLURBIPROFEN **except** when:

(a) included in Schedule 2; or

(b) in divided preparations for topical oral use that contain 10 mg or less of flurbiprofen per dosage unit and that are:

(i) in a primary pack containing not more than 16 dosage units; and

(ii) labelled only for the treatment of adults and children over 12 years; or

(c) in undivided preparations for topical oral use containing either:

(i) 0.25% or less of flurbiprofen per dose; or

(ii) 10 mg or less of flurbiprofen per dose; and

that are:

(iii) in a primary pack containing not more than 15 Ml; and

(iv) labelled only for the treatment of adults 18 years and over.

FLUROXENE for human therapeutic use.

FLUSPIRILENE.

FLUTAMIDE.

FLUTICASONE **except** when included in Schedule 2.

FLUVASTATIN.

FLUVOXAMINE.

FOLIC ACID in preparations for human use for injection.

FOLINIC ACID in preparations for human use for injection.

FOLLICLE‑STIMULATING HORMONE **except** when separately specified in this Schedule.

# FOLLISTATIN.

# FOLLITROPIN ALFA.

# FOLLITROPIN BETA.

# FOLLITROPIN DELTA.

FOMEPIZOLE.

FOMIVIRSEN.

FONDAPARINUX.

# FORMEBOLONE.

FORMESTANE.

FORMOTEROL

FOSAMPRENAVIR.

FOSAPREPITANT.

FOSCARNET.

FOSFESTROL (diethylstilbestrol diphosphate).

FOSFOMYCIN.

FOSINOPRIL.

FOSNETUPITANT.

FOSPHENYTOIN.

FOSTEMSAVIR.

FOTEMUSTINE.

FRAMYCETIN.

FULVESTRANT.

FURALTADONE.

# FURAZABOL.

FURAZOLIDONE.

FUROSEMIDE (frusemide).

FUSIDIC ACID.

GABAPENTIN.

GALANTAMINE.

GALANTHUS spp.

GALCANEZUMAB.

GALLAMINE.

GALSULFASE.

GANCICLOVIR.

GANIRELIX.

GATIFLOXACIN.

GRAZOPREVIR.

GEFITINIB.

GEMCITABINE.

GEMEPROST.

GEMFIBROZIL.

GEMIFLOXACIN.

GEMTUZUMAB OZOGAMICIN.

GENTAMICIN.

GESTODENE.

GESTONORONE.

# GESTRINONE.

GHRH INJECTABLE PLASMID.

GILTERITINIB.

GITALIN.

GIVOSIRAN.

GLATIRAMER ACETATE.

GLECAPREVIR.

GLIBENCLAMIDE.

GLIBORNURIDE.

GLICLAZIDE.

GLIMEPIRIDE.

GLIPIZIDE.

GLIPTINS **except** when separately specified in these Schedules.

GLISOXEPIDE.

GLOFITAMAB.

GLUTATHIONE for parenteral use.

# GLUTETHIMIDE.

GLYCERYL TRINITRATE **except** when included in Schedule 3.

GLYCOPYRRONIUM.

GLYMIDINE.

GnRH VACCINE.

GOLIMUMAB.

GONADORELIN.

GONADOTROPHIC HORMONES **except** when separately specified in this Schedule.

GOSERELIN.

GRAMICIDIN.

GRANISETRON.

GRAPIPRANT.

GREPAFLOXACIN.

GRISEOFULVIN.

# GROWTH HORMONE RELEASING HORMONES\* (GHRHs).

# GROWTH HORMONE RELEASING PEPTIDES (GHRPs).

# GROWTH HORMONE RELEASING PEPTIDE‑6 (GHRP‑6).

# GROWTH HORMONE SECRETAGOGUES\* (GHSs).

GUAIFENESIN for human therapeutic use **except**:

(a) when included in Schedule 2; or

(b) in oral liquid preparations containing 2% or less of guaifenesin; or

(c) in divided preparations containing 200 mg or less of guaifenesin per dosage unit.

GUANABENZ.

GUANACLINE.

GUANETHIDINE.

GUANFACINE.

GUANIDINE for therapeutic use.

GUSELKUMAB.

HACHIMYCIN.

HAEMATIN.

HAEMOPHILUS INFLUENZAE VACCINE.

HALCINONIDE.

HALOFANTRINE.

HALOFENATE.

HALOFUGINONE in preparations containing 0.1% or less of halofuginone for the treatment of animals.

HALOPERIDOL.

HALOTHANE for therapeutic use.

HEMEROCALLIS (Hemerocallis flava).

HEPARINS for internal use **except** when separately specified in this Schedule.

HEPATITIS A VACCINE.

HEPATITIS B VACCINE.

HETACILLIN.

HEXACHLOROPHENE:

(a) in preparations for use on infants; or

(b) in other preparations **except**:

(i) when included in Schedule 2 or 6; or

(ii) in preparations containing 0.75% or less of hexachlorophene.

HEXAMETHONIUM.

# HEXARELIN.

HEXETIDINE for human internal use.

HEXOBENDINE.

HEXOCYCLIUM.

HEXOPRENALINE.

HEXYL AMINOLEVULINATE (AS HYDROCHLORIDE).

HISTAMINE for therapeutic use **except** in preparations containing 0.5% or less of histamine.

HMG‑CoA REDUCTASE INHIBITORS (including "statins") **except** when separately specified in these Schedules.

HOMATROPINE.

HUMAN CHORIONIC GONADOTROPHIN **except** in pregnancy test kits.

HUMAN PAPILLOMAVIRUS VACCINE.

HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation.

HYDRALAZINE.

HYDRARGAPHEN.

HYDROCHLOROTHIAZIDE.

HYDROCORTISONE:

(a) for human use **except** when included in Schedule 2 or 3; or

(b) for the treatment of animals.

HYDROCYANIC ACID for therapeutic use.

HYDROFLUMETHIAZIDE.

HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use **except**:

(a) when included in Schedule 2; or

(b) in hair preparations containing 0.3% or less of hydroquinone; or

(c) in cosmetic nail preparations containing 0.02% or less of hydroquinone.

HYDROXYCARBAMIDE.

# HYDROXYCHLOROQUINE.

HYDROXYEPHEDRINE.

HYDROXYPHENAMATE.

HYDROXYPROGESTERONE.

# HYDROXYSTENOZOL.

HYDROXYZINE.

HYGROMYCIN.

HYOSCINE **except** when included in Schedule 2.

HYOSCYAMINE **except** when included in Schedule 2.

HYOSCINE BUTYLBROMIDE **except** when included in Schedule 2 or Schedule 3.

HYOSCYAMUS NIGER **except**:

(a) when included in Schedule 2; or

(b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.

HYPOTHALAMIC RELEASING FACTORS **except** when separately specified in this Schedule.

HYPROMELLOSE in preparations for injection.

IBAFLOXACIN for veterinary use.

IBANDRONIC ACID.

IBOGAINE.

IBRITUMOMAB.

IBRUTINIB.

IBUFENAC.

IBUPROFEN **except** when:

(a) included in Schedule 2 or 3; or

(b) in preparations for dermal use; or

(c) in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen in divided preparations, each containing 200 mg or less of ibuprofen, in a pack containing not more than 100 dosage units when:

(i) ibuprofen is the only therapeutically active constituent, other than phenylephrine or when combined with an effervescent agent; and

(ii) packed in blister or strip packaging or in a container with a child-resistant closure; and

(iii) in a primary pack containing not more than 25 dosage units; and

(iv) compliant with the requirements of the required advisory statements for medicine labels; and

(v) not labelled for the treatment of children 6 years and under; and

(vi) if combined with phenylephrine—not labelled for the treatment of children under 12 years.

# IBUTAMOREN.

IBUTEROL.

IBUTILIDE.

ICATIBANT.

IDARUBICIN.

IDARUCIZUMAB.

IDEBENONE.

IDOXURIDINE **except** in preparations containing 0.5% or less of idoxuridine for dermal use.

IDURSULFASE.

IFOSFAMIDE.

ILOPROST.

IMATINIB.

IMDEVIMAB.

IMEPITOIN.

IMIDAPRIL.

IMIGLUCERASE.

IMIPENEM.

IMIPRAMINE.

IMIQUIMOD.

IMLIFIDASE.

IMMUNOGLOBULINS for human parenteral use **except** when separately specified in these Schedules.

INCLISIRAN.

INDACATEROL.

INDAPAMIDE.

INDINAVIR.

INDOMETACIN **except** when included in Schedule 2.

INDOPROFEN.

INDORAMIN.

INFIGRATINIB.

INFLIXIMAB.

INFLUENZA AND CORYZA VACCINES:

(a) for parenteral use; or

(b) for nasal administration.

INGENOL MEBUTATE.

INOTUZUMAB OZOGAMICIN.

INSULIN DEGLUDEC.

INSULIN GLARGINE.

# INSULIN‑LIKE GROWTH FACTOR I.

# INSULIN‑LIKE GROWTH FACTORS **except** when separately specified in this Schedule.

INSULINS.

INTERFERONS.

INTERLEUKINS **except** when separately specified in these Schedules.

IODOTHIOURACIL.

# IPAMORELIN.

IPILIMUMAB.

IPRATROPIUM **except** when included in Schedule 2.

IPRIFLAVONE.

IPRINDOLE.

IPRONIAZID.

IRBESARTAN.

IRINOTECAN.

IRON COMPOUNDS in injectable preparations for human use.

ISAVUCONAZOLE.

ISOAMINILE.

ISOAMYL NITRITE.

ISOBUTYL NITRITE.

ISOCARBOXAZID.

ISOCONAZOLE **except** when included in Schedule 2, 3 or 6.

ISOETARINE.

ISOFLURANE for therapeutic use.

ISOMETHEPTENE.

ISONIAZID.

ISOPRENALINE.

ISOPRINOSINE.

ISOPROPAMIDE **except** when included in Schedule 2.

ISOSORBIDE DINITRATE **except** when included in Schedule 3.

ISOSORBIDE MONONITRATE.

# ISOTRETINOIN.

ISOXICAM.

ISOXSUPRINE.

ISRADIPINE.

ITRACONAZOLE.

IVABRADINE.

IVACAFTOR.

IVERMECTIN:

(a) for human use; or

(b) for the treatment of mange in dogs.

IVOSIDENIB.

IXABEPILONE.

IXAZOMIB.

IXEKIZUMAB.

JAPANESE ENCEPHALITIS VACCINE.

KANAMYCIN.

KETANSERIN **except** in topical veterinary preparations containing 0.5% or less of ketanserin.

# KETAZOLAM.

KETOCONAZOLE **except**:

(a) when included in Schedule 2; or

(b) in preparations for dermal use containing 1% or less of ketoconazole for the treatment of the scalp; or

(c) in preparations for dermal use for the treatment of tinea pedis.

KETOPROFEN **except**:

(a) in preparations for dermal use; or

(b) when included in Schedule 3.

KETOROLAC (includes ketorolac trometamol).

KETOTIFEN **except** when included in Schedule 2.

KHELLIN.

KITASAMYCIN **except**:

(a) when included in Schedule 5; or

(b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.

LABETALOL.

LACIDIPINE.

LACOSAMIDE.

LAMIVUDINE.

LAMOTRIGINE.

LANADELUMAB.

LANATOSIDES.

LANREOTIDE.

LANSOPRAZOLE **except** when included in Schedule 2 or 3.

LANTHANUM for therapeutic use.

LAPATINIB.

LARONIDASE.

LAROPIPRANT.

LAROTRECTINIB.

LATAMOXEF.

LATANOPROST.

LAUDEXIUM.

LAUROMACROGOLS in preparations for injection **except**:

(a) when present as an excipient; or

(b) when separately specified in these Schedules.

LEBRIKIZUMAB.

LECANEMAB.

LEDIPASVIR.

LEFETAMINE.

LEFLUNOMIDE.

LEMBOREXANT.

LENACAPAVIR.

# LENALIDOMIDE.

LENOGRASTIM.

LENVATINIB.

LEPIRUDIN.

LEPTAZOL.

LERCANIDIPINE.

LESINURAD.

LETERMOVIR.

LETROZOLE.

LEUPRORELIN.

LEVALLORPHAN.

LEVAMISOLE:

(a) for human therapeutic use; or

(b) in preparations for the prevention or treatment of heartworm in dogs.

LEVETIRACETAM.

LEVOBUNOLOL.

LEVOBUPIVACAINE.

LEVOCABASTINE **except** when included in Schedule 2.

LEVOCETIRIZINE **except**:

(a) when included in Schedule 2; or

(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing not more than 5 days’ supply; and

(ii) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.

LEVODOPA.

LEVOMEPROMAZINE.

LEVOMILNACIPRAN.

LEVONORGESTREL **except** when included in Schedule 3.

LEVOSIMENDAN.

LIDOCAINE **except**:

(a) when included in Schedules 2 or 5; or

(b) in dermal preparations containing 2% or less of total local anaesthetic substances per dosage unit; or

(c) in lozenges containing 30 mg or less of total anaesthetic substances per dosage unit.

LIDOFLAZINE.

LIFITEGRAST.

LINACLOTIDE.

LINAGLIPTIN.

LINCOMYCIN.

LINDANE for human therapeutic use **except** when included in Schedule 2.

LINEZOLID.

LIOTHYRONINE.

LIPEGFILGRASTIM.

LIRAGLUTIDE.

LISINOPRIL.

LISURIDE.

LITHIUM for therapeutic use **except**:

(a) when included in Schedule 2; or

(b) when present as an excipient in preparations for dermal use containing 0.25% or less of lithium; or

(c) in preparations containing 0.01% or less of lithium.

LIXISENATIDE.

LODOXAMIDE **except** when included in Schedule 2.

LOFEXIDINE.

LOGIPARIN for internal use.

LOMEFLOXACIN.

LOMUSTINE.

LOPERAMIDE **except**:

(a) when included in Schedule 2; or

(b) in divided oral preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.

LOPINAVIR.

# LOPRAZOLAM.

LORACARBEF.

LORATADINE **except**:

(a) when included in Schedule 2; or

(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and over, when:

(i) in a primary pack containing 10 dosage units or less; and

(ii) labelled with a recommended daily dose not exceeding 10 mg of loratadine.

# LORAZEPAM.

LORLATINIB.

# LORMETAZEPAM.

LOSARTAN.

LOTEPREDNOL.

LOXAPINE.

LUMACAFTOR.

LUMEFANTRINE.

LUMIRACOXIB.

LURASIDONE.

LURBINECTEDIN.

LUSPATERCEPT.

# LUTEINISING HORMONE **except** in ovulation test kits.

LYMECYCLINE.

MACITENTAN for human use.

MAFENIDE **except** when included in Schedule 6.

MANDRAGORA OFFICINARUM.

MANNOMUSTINE.

MAPROTILINE.

MARAVIROC.

MARBOFLOXACIN.

MARIBAVIR.

MAROPITANT.

MAVACAMTEN.

MAVACOXIB.

MAZINDOL.

MEASLES VACCINE.

MEBANAZINE.

MEBEVERINE.

MEBHYDROLIN.

# MEBOLAZINE.

MEBUTAMATE.

MECAMYLAMINE.

MECASERMIN.

MECILLINAM.

MECLOCYCLINE.

MECLOFENAMATE.

MECLOFENOXATE.

MECLOZINE **except** when included in Schedule 2.

# MEDAZEPAM.

MEDETOMIDINE.

MEDIGOXIN (methyldigoxin).

MEDROXYPROGESTERONE.

MEDRYSONE.

MEFENAMIC ACID **except** when included in Schedule 2.

MEFENOREX.

MEFLOQUINE.

MEFRUSIDE.

MEGESTROL.

MELAGATRAN.

MELANOTAN II.

MELATONIN for human use **except** when included in Schedule 3.

MELENGESTROL **except** when included in Schedule 6.

MELOXICAM **except** when included in Schedule 6.

MELPHALAN.

MEMANTINE.

MENINGOCOCCAL VACCINE.

MENINGOCOCCAL GROUP B VACCINE.

MENOTROPHIN.

MEPACRINE.

MEPENZOLATE.

MEPHENESIN.

MEPHENTERMINE.

MEPINDOLOL.

# MEPITIOSTANE.

MEPIVACAINE.

MEPROBAMATE.

MEPTAZINOL.

MEPYRAMINE **except** when included in Schedule 2 or 3.

MEQUITAZINE.

MERCAPTAMINE for human therapeutic use.

MERCAPTOMERIN.

MERCAPTOPURINE.

MERCUROCHROME **except** when included in Schedule 2 or 6.

MERCURY for cosmetic or therapeutic use **except**:

(a) when separately specified in these Schedules; or

(b) in a sealed device which prevents access to the mercury.

MEROPENEM.

MERSALYL.

# MESABOLONE.

MESALAZINE.

MESNA.

# MESTANOLONE (androstalone).

# MESTEROLONE.

MESTRANOL.

# METANDIENONE.

METARAMINOL.

# METENOLONE.

METERGOLINE.

METFORMIN.

METHACHOLINE.

METHACYCLINE.

METHALLENESTRIL.

# METHANDRIOL.

METHANTHELINIUM.

METHAZOLAMIDE.

METHDILAZINE **except** when included in Schedule 3.

# METHENOLONE.

METHICILLIN.

METHIMAZOLE.

METHISAZONE.

METHIXENE.

METHOCARBAMOL.

METHOHEXITONE.

METHOIN.

METHOTREXATE.

METHOXAMINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for external use containing 1% or less of methoxamine.

METHOXSALEN.

METHOXYFLURANE.

METHSUXIMIDE.

METHYCLOTHIAZIDE.

METHYL AMINOLEVULINATE.

#METHYLANDROSTANOLONE.

# METHYLCLOSTEBOL.

METHYLDOPA.

METHYLENE BLUE in preparations for injection.

METHYLERGOMETRINE.

METHYLMERCURY for therapeutic use.

METHYLNALTREXONE.

METHYLPENTYNOL.

METHYLPHENOBARBITAL.

METHYLPHENYLPIRACETAM.

METHYLPREDNISOLONE.

METHYLROSANILINIUM CHLORIDE for human use **except** when used as a dermal marker.

METHYL SALICYLATE in preparations for internal therapeutic use.

# METHYLTESTOSTERONE.

METHYLTHIOURACIL.

# METHYLTRIENOLONE.

METHYPRYLONE.

METHYSERGIDE.

METOCLOPRAMIDE **except** when included in Schedule 3.

METOLAZONE.

METOPROLOL.

# METRIBOLONE.

METRIFONATE (trichlorfon) for human therapeutic use.

METRONIDAZOLE.

METYRAPONE.

MEXILETINE.

MEZLOCILLIN.

MIANSERIN.

MIBEFRADIL.

# MIBOLERONE.

MICAFUNGIN.

MICONAZOLE **except**:

(a) when included in Schedule 2, 3 or 6; or

(b) in preparations for dermal use for the treatment of tinea pedis.

# MIDAZOLAM.

MIDOSTAURIN.

MIDODRINE.

MIFEPRISTONE.

MIGALASTAT.

MIGLITOL.

MIGLUSTAT.

MILBEMYCIN OXIME **except** when included in Schedule 5.

MILNACIPRAN.

MILRINONE.

MINOCYCLINE.

MINOXIDIL **except** when included in Schedule 2.

MIRABEGRON.

MIRIKIZUMAB.

MIRTAZAPINE.

MISOPROSTOL.

MITOBRONITOL.

MITOMYCIN.

MITOTANE.

MITOXANTRONE.

MITRATAPIDE.

MIVACURIUM CHLORIDE.

MOBOCERTINIB.

MOCLOBEMIDE.

MODAFINIL.

MOLGRAMOSTIM.

MOLINDONE.

MOLNUPIRAVIR.

MOMETASONE **except** when included in Schedule 2 or Schedule 3.

MONENSIN **except**:

(a) when included in Schedule 5 or 6; or

(b) in animal feeds containing 360 mg/kg or less of antibiotic substances.

MONOBENZONE and alkyl ethers of hydroquinone for human therapeutic use or cosmetic use **except** in cosmetic nail preparations containing 0.02% or less of monobenzone or alkyl ethers of hydroquinone.

MONOCLONAL ANTIBODIES for therapeutic use **except**:

(a) in diagnostic test kits; or

(b) when separately specified in these Schedules.

MONOETHANOLAMINE in preparations for injection.

MONTELUKAST.

MOPERONE.

MORAZONE.

MORICIZINE.

MOTRAZEPAM.

MOTRETINIDE.

MOXIDECTIN in preparations for injection containing 10% or less of moxidectin **except** when included in Schedule 5 or 6.

MOXIFLOXACIN.

MOXONIDINE.

MUMPS VACCINE.

MUPIROCIN.

MURAGLITAZAR.

MUROMONAB.

MUSTINE (nitrogen mustard).

MYCOPHENOLIC ACID (includes mycophenolate mofetil).

NABUMETONE.

NADOLOL.

NADROPARIN.

NAFARELIN.

NAFTIDROFURYL.

NALBUPHINE.

NALIDIXIC ACID.

NALMEFENE.

NALORPHINE.

NALOXEGOL.

NALOXONE **except** when in Schedule 3.

NALTREXONE.

# NANDROLONE.

NAPROXEN **except** when included in Schedule 2 or 3.

NARASIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 100 mg/kg or less of antibiotic substances.

NARATRIPTAN **except** when included in Schedule 3.

NATALIZUMAB.

NATAMYCIN **except** for use as a food additive.

NATEGLINIDE.

NEBACUMAB.

NEBIVOLOL.

NEBRACETAM.

NEDOCROMIL.

NEFAZODONE.

NEFIRACETAM.

NEFOPAM.

NELARABINE.

NELFINAVIR (includes nelfinavir mesilate).

NEOMYCIN.

NEOSTIGMINE.

NEPAFENAC.

NERATINIB.

NERIUM OLEANDER.

NESIRITIDE.

NETILMICIN.

NETUPITANT.

NEVIRAPINE.

NIALAMIDE.

NICARDIPINE.

NICERGOLINE.

NICOFURANOSE.

NICORANDIL.

# NICOTINE in preparations for human use **except**:

(a) in preparations for oromucosal or transdermal administration for human therapeutic use when included in the Register as an aid in withdrawal either from tobacco smoking or nicotine vaping; or

(b) in tobacco prepared and packed for smoking.

NICOTINIC ACID for human therapeutic use **except**:

(a) when separately specified in these Schedules; or

(b) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or

(c) nicotinamide.

NICOUMALONE.

NIFEDIPINE.

NIFENAZONE.

NIKETHAMIDE.

NILOTINIB.

NILUTAMIDE.

NIMESULIDE.

NIMODIPINE.

NIMORAZOLE.

NINTEDANIB.

NIRAPARIB.

NIRIDAZOLE.

NIRMATRELVIR.

NIRSEVIMAB.

NISOLDIPINE.

NITISINONE.

# NITRAZEPAM.

NITRENDIPINE.

NITRIC OXIDE for human therapeutic use.

NITROFURANTOIN.

NITROFURAZONE.

NITROUS OXIDE for therapeutic use.

NITROXOLINE.

NIVOLUMAB.

NIZATIDINE **except** when included in Schedule 2.

NOMEGESTROL.

NOMIFENSINE.

NORADRENALINE.

# 19‑NORANDROSTENEDIOL.

# 19‑NORANDROSTENEDIONE.

# NORANDROSTENOLONE.

# NORBOLETHONE.

# NORCLOSTEBOL.

NORELGESTROMIN.

# NORETHANDROLONE.

NORETHISTERONE.

NORFLOXACIN.

NORGESTREL.

NORIBOGAINE.

NORMAL HUMAN IMMUNOGLOBULIN.

# NORMETHANDRONE.

NORTRIPTYLINE.

NOVOBIOCIN.

NOXIPTYLINE.

NUSINERSEN.

NYSTATIN **except** when included in Schedule 2 or 3.

OBETICHOLIC ACID.

OCLACITINIB.

OCRELIZUMAB.

OCRIPLASMIN.

OCTAMYLAMINE.

OCTATROPINE.

OCTREOTIDE.

OCTYL NITRITE.

OFATUMUMAB.

OFLOXACIN.

OLANZAPINE.

OLAPARIB.

OLARATUMAB.

OLEANDOMYCIN **except**:

(a) when included in Schedule 5; or

(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

OLEANDRIN.

OLIPUDASE ALFA.

OLMESARTAN.

OLODATEROL.

OLOPATADINE **except** when included in Schedule 2.

OLSALAZINE.

OMALIZUMAB.

OMBERACETAM.

OMBITASVIR.

OMEGA‑3‑ACID ETHYL ESTERS (excluding salts and derivatives) for human therapeutic use, for the treatment of post‑myocardial infarction and/or hypertriglyceridaemia.

OMEPRAZOLE **except** when included in Schedule 2 or 3.

ONASEMNOGENE ABEPARVOVEC.

ONDANSETRON.

OPICAPONE.

OPIPRAMOL.

ORBIFLOXACIN.

ORCIPRENALINE.

ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use **except**:

(a) when separately specified in these Schedules; or

(b) in preparations containing 2% or less of malathion for external use.

ORLISTAT **except** when included in Schedule 3.

ORNIDAZOLE.

ORNIPRESSIN.

ORPHENADRINE.

ORTHOPTERIN.

OSELTAMIVIR.

OSILODROSTAT.

OSIMERTINIB.

OUABAIN.

# OVANDROTONE.

# OXABOLONE.

OXACILLIN.

OXALIPLATIN.

# OXANDROLONE.

OXAPROZIN.

# OXAZEPAM.

OXCARBAZEPINE.

OXEDRINE for human internal use **except** in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.

OXETACAINE (oxethazaine) **except** when included in Schedule 2.

OXICONAZOLE **except**:

(a) when included in Schedule 2 or 3; or

(b) in preparations for the treatment of tinea pedis.

OXIRACETAM.

OXITROPIUM.

OXOLAMINE.

OXOLINIC ACID.

OXPRENOLOL.

OXYBUPROCAINE.

OXYBUTYNIN.

# OXYMESTERONE.

# OXYMETHOLONE.

OXYPHENBUTAZONE.

OXYPHENCYCLIMINE.

OXYPHENONIUM.

OXYTETRACYCLINE **except** when included in Schedule 5.

OXYTOCIN.

OZANIMOD.

PACLITAXEL.

PALBOCICLIB.

PALIFERMIN.

PALIPERIDONE.

PALIVIZUMAB.

PALONOSETRON.

PALOVAROTENE.

PAMAQUIN.

PAMIDRONIC ACID (includes pamidronate disodium).

PANCREATIC ENZYMES **except**:

(a) in preparations containing 20,000 BP units or less of lipase activity per dosage unit; or

(b) when separately specified in these Schedules.

PANCURONIUM.

PANITUMUMAB.

PANOBINOSTAT.

PANTOPRAZOLE **except** when included in Schedule 2 or 3.

PAPAVERINE in preparations for injection.

PARACETAMOL:

(a) when combined with aspirin or salicylamide or any derivative of these substances **except** when separately specified in these Schedules; or

(b) when combined with ibuprofen in a primary pack containing more than 30 dosage units; or

(c) in modified release tablets or capsules containing more than 665 mg paracetamol; or

(d) in non‑modified release tablets or capsules containing more than 500 mg paracetamol; or

(e) in individually wrapped powders or sachets of granules each containing more than 1000 mg paracetamol; or

(f) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules **except** in Schedule 2 or Schedule 3; or

(g) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules **except** when included in Schedule 2; or

(h) for injection; or

(i) for the treatment of animals.

PARALDEHYDE.

PARAMETHADIONE.

PARAMETHASONE.

PARECOXIB.

PARICALCITOL.

PARITAPREVIR.

PAROMOMYCIN.

PAROXETINE.

PASIREOTIDE.

PATIROMER SORBITEX CALCIUM.

PATISIRAN.

PAZOPANIB.

PECAZINE.

PEFLOXACIN.

PEGAPTANIB.

PEGASPARGASE.

PEGCETACOPLAN.

PEGFILGRASTIM.

PEGINTERFERON.

PEGVALIASE.

PEGVISOMANT.

PEMBROLIZUMAB.

PEMETREXED.

PEMIGATINIB.

PEMOLINE.

PEMPIDINE.

PENBUTOLOL.

PENCICLOVIR **except** in preparations containing 1% or less of penciclovir for the treatment of *herpes labialis* in packs containing 10 g or less.

PENETHAMATE.

PENICILLAMINE.

PENTAERYTHRITYL TETRANITRATE.

PENTAGASTRIN.

PENTAMETHONIUM.

PENTAMIDINE (includes pentamidine isetionate).

PENTHIENATE.

# PENTOBARBITAL when packed and labelled for injection.

PENTOLINIUM.

PENTOSAN POLYSULFATE SODIUM.

PENTOXIFYLLINE.

PERAMIVIR.

# PERAMPANEL.

PERGOLIDE.

PERHEXILINE.

PERICIAZINE.

PERINDOPRIL.

PERMETHRIN for human therapeutic use **except** in preparations containing 5% or less of permethrin.

PERPHENAZINE.

PERTUSSIS ANTIGEN.

PERTUZUMAB.

PHENACEMIDE.

PHENACETIN for therapeutic use (excluding when present as an excipient).

PHENAGLYCODOL.

PHENAZONE **except** when included in Schedule 2 or 5.

PHENAZOPYRIDINE.

PHENELZINE.

PHENETICILLIN.

PHENFORMIN.

PHENGLUTARIMIDE.

PHENINDIONE.

PHENIRAMINE **except** when included in Schedule 2 or 3.

PHENISATIN.

PHENOBARBITAL.

PHENOL in preparations for injection.

PHENOLPHTHALEIN for human therapeutic use.

PHENOXYBENZAMINE.

PHENOXYMETHYLPENICILLIN.

PHENSUXIMIDE.

# PHENTERMINE.

PHENTHIMENTONIUM.

PHENTOLAMINE.

PHENYLBUTAZONE.

PHENYLEPHRINE:

(a) in preparations for injection; or

(b) in preparations for human ophthalmic use containing 5% or more of phenylephrine.

PHENYLPIRACETAM.

PHENYLPROPANOLAMINE.

PHENYLTOLOXAMINE.

PHENYTOIN.

PHLEUM PRATENSE POLLEN EXTRACT (Timothy‑grass pollen extract).

PHOLCODINE:

(a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of pholcodine;

**except** when included in Schedule 2.

PHOSPHODIESTERASE TYPE 5 INHIBITORS **except**:

(a) when separately specified in these Schedules; or

(b) when present as an unmodified, naturally occurring substance.

PHTHALYLSULFATHIAZOLE.

PHYSOSTIGMINE.

PIBRENTASVIR.

PICROTOXIN.

PILOCARPINE **except** in preparations containing 0.025% or less of pilocarpine.

PIMECROLIMUS.

PIMOBENDAN.

PIMOZIDE.

PINACIDIL.

PINDOLOL.

PIOGLITAZONE.

PIPECURONIUM.

PIPEMIDIC ACID.

PIPENZOLATE.

PIPER METHYSTICUM (kava) in preparations for human use **except** when included on the Register in preparations:

(a) for oral use when present in tablet, capsule or teabag form that is labelled with a recommended maximum daily dose of 250 mg or less of kavalactones and:

(i) the tablet or capsule form contains 125 mg or less of kavalactones per tablet or capsule; or

(ii) the amount of dried whole or peeled rhizome and/or root in the teabag does not exceed 3 g;

and, where containing more than 25 mg of kavalactones per dose, compliant with the requirements of the required advisory statements for medicine labels; or

(b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome and/or root or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome and/or root; or

(c) in dermal preparations.

PIPERACILLIN.

PIPERIDINE.

PIPERIDOLATE.

PIPOBROMAN.

PIPOTHIAZINE.

PIPRADROL.

PIRACETAM.

PIRBUTEROL.

PIRENOXINE (catalin).

PIRENZEPINE.

PIRETANIDE.

PIRFENIDONE.

PIROXICAM **except** in preparations for dermal use.

PIRPROFEN.

PITAVASTATIN.

PITUITARY HORMONES **except** when separately specified in these Schedules.

PIVAMPICILLIN.

PIZOTIFEN.

PLICAMYCIN.

PLITIDEPSIN.

PLERIXAFOR.

PNEUMOCOCCAL VACCINE.

PODOPHYLLOTOXIN for human use:

(a) internally; or

(b) in preparations for the treatment of anogenital warts; or

(c) in other preparations **except** when included in Schedule 2 or 3.

PODOPHYLLUM EMODI (podophyllin) for human use:

(a) internally; or

(b) in preparations for the treatment of anogenital warts; or

(c) in other preparations **except** when included in Schedule 2 or 3.

PODOPHYLLUM PELTATUM (podophyllin) for human use:

(a) internally; or

(b) in preparations for the treatment of anogenital warts; or

(c) in other preparations **except** when included in Schedule 2 or 3.

POLIDEXIDE.

POLIOMYELITIS VACCINE.

POLYACRYLAMIDE in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use; or

(c) for veterinary use.

POLYCAPROLACTONE in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

POLYESTRADIOL.

POLYLACTIC ACID in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

POLYMYXIN.

POLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, **except** when separately specified in these Schedules.

POLYTHIAZIDE.

POMALIDOMIDE.

PONATINIB.

PONESIMOD.

PORACTANT.

POSACONAZOLE.

POTASSIUM BROMIDE for therapeutic use.

POTASSIUM CHLORIDE in oral preparations for human therapeutic use **except**:

(a) when containing less than 550 mg of potassium chloride per dosage unit; or

(b) in preparations for oral rehydration therapy; or

(c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or

(d) in preparations for enteral feeding.

POTASSIUM PERCHLORATE for therapeutic use.

PRACTOLOL.

PRADOFLOXACIN.

PRALATREXATE.

PRALIDOXIME.

PRAMIPEXOLE.

PRAMIRACETAM.

PRAMOCAINE.

# PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE‑2 (GHRP‑2)).

PRALSETINIB.

PRAMPINE.

# PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone).

PRASUGREL.

PRAVASTATIN.

# PRAZEPAM.

PRAZIQUANTEL for human therapeutic use.

PRAZOSIN.

PREDNISOLONE.

PREDNISONE.

PREGABALIN.

PREGNENOLONE.

PRENALTEROL.

PRENYLAMINE.

PRILOCAINE **except** when included in Schedule 2.

PRIMAQUINE.

PRIMIDONE.

PROBENECID.

PROBUCOL.

PROCAINAMIDE.

PROCAINE.

PROCAINE BENZYLPENICILLIN.

PROCARBAZINE.

PROCHLORPERAZINE **except** when included in Schedule 3.

PROCYCLIDINE **except** when included in Schedule 2.

PROGESTERONE **except** when included in Schedule 5.

PROGESTOGENS **except** when separately specified in these Schedules.

PROGLUMIDE.

PROGUANIL.

PROLINTANE.

PROMAZINE.

PROMETHAZINE **except** when included in Schedule 2 or 3.

PROMOXOLANE.

PROPAFENONE.

PROPAMIDINE for therapeutic use **except** when included in Schedule 2.

PROPANIDID.

PROPANTHELINE.

PROPENTOFYLLINE.

# PROPETANDROL.

PROPIONIBACTERIUM ACNES for therapeutic use.

PROPOFOL.

PROPRANOLOL.

PROPYLHEXEDRINE.

PROPYLTHIOURACIL.

PROPYPHENAZONE.

PROQUAZONE.

PROSCILLARIDIN.

PROSTAGLANDINS **except** when separately specified in this Schedule.

PROSTIANOL.

PROTAMINE.

PROTHIONAMIDE.

PROTHIPENDYL.

PROTIRELIN.

PROTOVERATRINES.

PROTRIPTYLINE.

PROXYMETACAINE.

PRUCALOPRIDE.

PSEUDOEPHEDRINE **except** when included in Schedule 3.

PYRAZINAMIDE.

PYRIDINOLCARBAMATE.

PYRIDOSTIGMINE.

PYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use **except**:

(a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with the requirements of the required advisory statements for medicine labels; or

(b) in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose.

PYRIMETHAMINE.

PYROVALERONE.

PYRVINIUM.

# QUAZEPAM.

QUETIAPINE.

QUINAGOLIDE.

QUINAPRIL.

# QUINBOLONE.

QUINETHAZONE.

QUINIDINE.

QUININE for human therapeutic use **except** when the maximum recommended daily dose is 50 mg or less of quinine.

QUINISOCAINE (dimethisoquin).

QUINUPRISTIN.

RABEPRAZOLE **except** when included in Schedule 2 or 3.

RABIES VACCINE.

RACETAMS **except** when separately specified in these Schedules.

RACTOPAMINE **except** when included in Schedule 5.

RALOXIFENE.

RALTEGRAVIR.

RALTITREXED.

RAMIPRIL.

RAMUCIRUMAB.

RANIBIZUMAB.

RANITIDINE **except**:

(a) when included in Schedule 2; or

(b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer’s original pack containing not more than 14 dosage units; or

(c) in divided preparations for oral use containing 300mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 7 dosage units.

RANOLAZINE.

RAPACURONIUM.

RASAGILINE.

RASBURICASE.

RAUWOLFIA SERPENTINA.

RAUWOLFIA VOMITORIA.

RAZOXANE.

REBOXETINE.

RED YEAST RICE for human therapeutic use.

REMDESIVIR.

REGDANVIMAB.

REGORAFENIB.

RELUGOLIX.

REMOXIPRIDE.

REPAGLINIDE.

RESERPINE.

RESLIZUMAB.

RETAPAMULIN.

RETEPLASE.

RETIGABINE.

RIBAVIRIN.

RIBOCICLIB.

RIDAFOROLIMUS.

RIFABUTIN.

RIFAMPICIN.

RIFAMYCIN.

RIFAPENTINE.

RIFAXIMIN.

RILPIVIRINE.

RILUZOLE.

RIMEGEPANT.

RIMEXOLONE.

RIMITEROL.

RIMONABANT.

# RIOCIGUAT.

RIPRETINIB.

RISANKIZUMAB.

RISDIPLAM.

RISEDRONIC ACID.

RISPERIDONE.

RITODRINE.

RITONAVIR.

RITUXIMAB.

RIVAROXABAN.

RIVASTIGMINE.

RIZATRIPTAN **except** when included in Schedule 3.

ROBENACOXIB.

ROCURONIUM.

ROFECOXIB.

ROFLUMILAST.

ROLITETRACYCLINE.

ROLZIRACETAM.

ROMIDEPSIN.

ROMIFIDINE.

ROMIPLOSTIM.

ROMOSOZUMAB.

RONIDAZOLE.

ROPINIROLE.

ROPIVACAINE.

ROSIGLITAZONE.

ROSOXACIN.

ROSUVASTATIN.

ROTIGOTINE.

# ROXIBOLONE.

ROXITHROMYCIN.

RUBELLA VACCINE.

RUBOXISTAURIN.

RUFINAMIDE.

RUPATADINE.

RUXOLITINIB.

SACITUZUMAB GOVITECAN.

SACUBITRIL.

SAFINAMIDE.

SALBUTAMOL **except** when included in Schedule 3.

SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.

SALINOMYCIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 60 mg/kg or less of antibiotic substances.

SALMETEROL.

SAPROPTERIN.

SAQUINAVIR.

SARILUMAB.

SARS‑COV‑2 (COVID‑19) VACCINE.

SAXAGLIPTIN.

SCHOENOCAULON OFFICINALE (sabadilla) **except** in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of Schoenocaulon officinale.

SCOPOLIA CARNIOLICA for therapeutic use.

SEBELIPASE ALFA.

SECUKINUMAB.

# SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM).

SELEGILINE.

SELENIUM:

(a) for human oral use with a recommended daily dose of more than 300 micrograms; or

(b) for the treatment of animals **except**:

(i) when included in Schedule 6 or 7; or

(ii) in solid, slow release bolus preparations containing 300 mg or less of selenium per dosage unit; or

(iii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit; or

(iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or

(v) in feeds containing 1 g/tonne or less of selenium.

SELETRACETAM.

SELEXIPAG.

SELINEXOR.

SELPERCATINIB.

SELUMETINIB.

SEMAGLUTIDE.

SERELAXIN.

SERMORELIN.

SERTINDOLE.

SERTRALINE.

SEVELAMER.

SEVOFLURANE.

SEX HORMONES and all substances having sex hormonal activity **except** when separately specified in these Schedules.

SIBUTRAMINE.

# SILANDRONE.

SILDENAFIL.

SILICONES for intra‑ocular use.

SILODOSIN.

SILTUXIMAB.

SILVER SULFADIAZINE.

SIMEPREVIR.

SIMVASTATIN.

SIPONIMOD.

SIROLIMUS.

SISOMICIN (sisomycin).

SITAGLIPTIN.

# SITAXENTAN.

SODIUM BROMIDE for therapeutic use.

SODIUM CELLULOSE PHOSPHATE for human internal use.

SODIUM CROMOGLYCATE **except** when included in Schedule 2.

SODIUM GLYCEROPHOSPHATE HYDRATE.

SODIUM MORRHUATE in preparations for injection.

SODIUM NITROPRUSSIDE for human therapeutic use.

SODIUM PHENYLBUTYRATE.

SODIUM PHOSPHATE in preparations for oral laxative use.

SODIUM POLYSTYRENE SULPHONATE for human therapeutic use.

SODIUM SALICYLATE in preparations for internal use for the treatment of animals.

SODIUM TETRADECYLSULFATE in preparations for injection.

SODIUM ZIRCONIUM CYCLOSILICATE.

SOFOSBUVIR.

SOLASODINE.

SOLIFENACIN.

SOMAPACITAN.

SOMATOSTATIN.

SOMATOTROPIN EQUINE.

# SOMATROPIN (human growth hormone).

SONIDEGIB.

SONTOQUINE.

SORAFENIB.

SOTALOL.

SOTORASIB.

SOTROVIMAB.

SPARFLOXACIN.

SPARTEINE.

SPECTINOMYCIN.

SPESOLIMAB.

SPIRAMYCIN.

SPIRAPRIL.

SPIRONOLACTONE.

# STANOLONE.

# STANOZOLOL.

STAVUDINE.

# STENABOLIC (SR9009) and other synthetic REV‑ERB agonists.

# STENBOLONE.

STEROID HORMONES **except** when separately specified in these Schedules.

STILBESTROL (diethylstilbestrol).

STIRIPENTOL.

STREPTODORNASE.

STREPTOKINASE.

STREPTOMYCIN.

STRONTIUM RANELATE.

STROPHANTHINS.

STROPHANTHUS spp.

STRYCHNINE in preparations containing 1.5% or less of strychnine for the treatment of animals.

STRYCHNOS spp. **except** in preparations containing 1 mg or less per litre or per kilogram of strychnine.

STYRAMATE.

SUCCIMER.

SUCROFERRIC OXYHYDROXIDE.

SUGAMMADEX.

SULBACTAM.

SULCONAZOLE **except** when included in Schedule 2.

SULFACETAMIDE **except** when included in Schedule 3 or 5.

SULFADIAZINE **except** when included in Schedule 5.

SULFADIMETHOXINE.

SULFADIMIDINE **except** when included in Schedule 5.

SULFADOXINE.

SULFAFURAZOLE.

SULFAGUANIDINE.

SULFAMERAZINE **except** when included in Schedule 5.

SULFAMETHIZOLE.

SULFAMETHOXAZOLE.

SULFAMETHOXYDIAZINE.

SULFAMETHOXYPYRIDAZINE.

SULFAMETROLE.

SULFAMONOMETHOXINE.

SULFAMOXOLE.

SULFAPHENAZOLE.

SULFAPYRIDINE.

SULFAQUINOXALINE.

SULFASALAZINE.

SULFATHIAZOLE **except** when included in Schedule 5.

SULFATROXAZOLE.

SULFINPYRAZONE.

SULFOMYXIN.

SULFONAMIDES **except**:

(a) when separately specified in this Schedule; or

(b) when included in Schedule 3, 5 or 6; or

(c) when packed and labelled solely for use as a herbicide.

SULFONMETHANE (sulfonal) and alkyl sulfonals.

SULINDAC.

SULTAMICILLIN.

SULTHIAME.

SUMATRIPTAN **except** when included in Schedule 3.

SUNIFIRAM.

SUNITINIB.

SUPROFEN.

SUTILAINS.

SUXAMETHONIUM.

SUXETHONIUM.

SUVOREXANT.

TACRINE.

TACROLIMUS.

TADALAFIL.

TAFAMIDIS.

TAFASITAMAB.

TAFENOQUINE SUCCINATE.

TAFLUPROST.

TAGRAXOFUSP.

TALAZOPARIB.

TALIGLUCERASE ALFA.

TALIMOGENE LAHERPAREPVEC.

TAMOXIFEN.

TAMSULOSIN.

TANACETUM VULGARE **except** in preparations containing 0.8% or less of oil of tansy.

TASONERMIN.

TAZAROTENE.

TAZOBACTAM.

# TB‑500.

T‑CELL RECEPTOR ANTIBODY.

TEBENTAFUSP.

TECLISTAMAB.

TEDUGLUTIDE.

TEGAFUR.

TEGASEROD.

TELAPREVIR.

TELITHROMYCIN.

TEICOPLANIN.

TELBIVUDINE.

TELMISARTAN.

TELOTRISTAT ETHYL.

# TEMAZEPAM.

TEMOZOLOMIDE.

TEMSIROLIMUS.

TENECTEPLASE.

TENIPOSIDE.

TENOFOVIR.

TENOXICAM.

TEPOTINIB.

TEPOXALIN.

TERAZOSIN.

TERBINAFINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for dermal use for the treatment of tinea pedis.

TERBUTALINE **except** when included in Schedule 3.

TERFENADINE.

TERIFLUNOMIDE.

# TERIPARATIDE.

TERLIPRESSIN.

TERODILINE.

TEROPTERIN.

# TESTOLACTONE.

# TESTOSTERONE **except** when included in Schedule 6.

TETANUS ANTITOXIN **except** when used for short‑term protection or treatment of tetanus in animals.

TETANUS TOXOID for human use.

TETRABENAZINE.

TETRACAINE **except**:

(a) when included in Schedule 2; or

(b) in dermal preparations containing 2% or less of total local anaesthetic substances.

TETRACOSACTIDE.

TETRACYCLINE **except** when included in Schedule 5.

TETRAETHYLAMMONIUM.

TETROXOPRIM.

TEZACAFTOR.

# THALIDOMIDE.

THENYLDIAMINE.

THEOPHYLLINE **except** when included in Schedule 3.

THEVETIA PERUVIANA.

THEVETIN.

THIACETARSAMIDE in preparations for the prevention or treatment of heartworm in dogs.

THIAMBUTOSINE.

THIAZOSULFONE.

THIETHYLPERAZINE.

THIOACETAZONE.

THIOCARLIDE.

# THIOMESTERONE (tiomesterone).

THIOPENTAL.

THIOPROPAZATE.

THIOPROPERAZINE.

THIORIDAZINE.

THIOSTREPTON.

THIOTEPA.

THIOTHIXENE.

THIOURACIL.

THIOUREA for therapeutic use **except** in preparations containing 0.1% or less of thiourea.

# THYMOSIN BETA 4 (THYMOSIN β4).

THYMOXAMINE (includes thymoxamine hydrochloride).

THYROID **except** when separately specified in this Schedule.

THYROTROPHIN.

THYROXINE (includes thyroxine sodium).

TIAGABINE.

TIAMULIN.

# TIANEPTINE.

TIAPROFENIC ACID.

TIARAMIDE.

TIBOLONE.

TICAGRELOR.

TICARCILLIN.

TICLOPIDINE.

TIEMONIUM.

TIENILIC ACID.

TIGECYCLINE.

TIGILANOL TIGLATE.

TIGLOIDINE.

TILDIPIROSIN.

TILETAMINE.

TILMANOCEPT.

TILMICOSIN.

TILUDRONIC ACID (includes disodium tiludronate).

TIMOLOL.

TINIDAZOLE.

TINZAPARIN (includes tinzaparin sodium).

TIOCONAZOLE **except**:

(a) when included in Schedule 2 or 3; or

(b) in preparations for dermal use for the treatment of tinea pedis.

TIOGUANINE.

TIOTROPIUM.

TIPEPIDINE.

TIPIRACIL.

TIPRANAVIR.

TIRBANIBULIN.

TIRILAZAD.

TIROFIBAN.

TIRZEPATIDE.

TISLELIZUMAB.

TIXAGEVIMAB.

TOBRAMYCIN.

TOCAINIDE.

TOCERANIB.

TOCILIZUMAB.

TOFACITINIB.

TOLAZAMIDE.

TOLAZOLINE.

TOLBUTAMIDE.

TOLCAPONE.

TOLFENAMIC ACID.

TOLMETIN.

TOLONIUM.

TOLPROPAMINE.

TOLRESTAT.

TOLTERODINE.

TOLVAPTAN.

TOPIRAMATE.

TOPOTECAN.

TORASEMIDE.

TOREMIFENE.

TOXOIDS for human parenteral use **except** when separately specified in these Schedules.

TRABECTEDIN.

TRAMADOL.

TRANDOLAPRIL.

TRAMETINIB DIMETHYL SULFOXIDE.

TRANEXAMIC ACID **except** in preparations containing 3% or less of cetyl tranexamate hydrochloride for dermal cosmetic use.

TRANYLCYPROMINE.

TRASTUZUMAB.

TRASTUZUMAB DERUXTECAN.

TRASTUZUMAB EMTANSINE.

TRAVOPROST.

TRAZODONE.

# TRENBOLONE (trienbolone, trienolone) **except** when included in Schedule 5.

TREOSULPHAN.

TREPROSTINIL.

# TRESTOLONE.

TRETAMINE.

# TRETINOIN **except** the ester hydroxypinacolone retinoate in preparations for dermal use containing 0.5% or less of hydroxypinacolone retinoate.

TRIACETYLOLEANDOMYCIN.

TRIAMCINOLONE **except** when included in Schedule 2 or 3.

TRIAMTERENE.

TRIAZIQUONE.

# TRIAZOLAM.

TRICHLORMETHIAZIDE.

TRICHLOROACETIC ACID for human dermal use **except** when in preparations containing 12.5% or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROETHYLENE for therapeutic use.

TRICLOFOS.

TRICYCLAMOL.

TRIDIHEXETHYL.

TRIENTINE.

TRIFAROTENE.

TRIFLUOPERAZINE.

TRIFLUPERIDOL.

TRIFLUPROMAZINE.

TRIFLURIDINE.

TRIHEXYPHENIDYL.

TRILOSTANE.

TRIMETAPHAN.

TRIMETHOPRIM.

TRIMIPRAMINE.

TRIMUSTINE.

TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.

TRIOXYSALEN.

TRIPELENNAMINE.

TRIPROLIDINE **except** when included in Schedule 2 or 3.

TRIPTORELIN.

TROGLITAZONE.

TROLAMINE when in preparations for tattoo removal.

TROMETAMOL in preparations for injection **except** in preparations containing 3% or less of trometamol.

TROPICAMIDE.

TROPISETRON.

TROVAFLOXACIN.

TROXIDONE.

TRYPTOPHAN for human therapeutic use **except** in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan.

TUBERCULIN.

TUBOCURARINE.

TUCATINIB.

TULATHROMYCIN.

TULOBUTEROL.

TYLOSIN.

TYPHOID VACCINE.

ULIPRISTAL **except** when included in Schedule 3.

UMECLIDINIUM.

UNIFIRAM.

UNOPROSTONE.

UPADACITINIB.

URACIL.

URAPIDIL.

URETHANE (excluding its derivatives) for therapeutic use.

# UROFOLLITROPIN.

UROKINASE.

URSODEOXYCHOLIC ACID.

USTEKINUMAB.

VACCINES for human therapeutic use **except** when separately specified in this Schedule.

VACCINES for veterinary live virus **except**:

(a) poultry vaccines; or

(b) pigeon pox vaccine; or

(c) scabby mouth vaccine; or

(d) bovine ephemeral fever vaccine; or

(e) bovine herpesvirus‑1 vaccine.

VACCINES – PLASMID DNA for animal use **except** when separately specified in these Schedules.

VACCINIA VIRUS VACCINE.

# VADADUSTAT.

VALACICLOVIR.

VALDECOXIB.

VALGANCICLOVIR.

VALNOCTAMIDE.

VALPROIC ACID.

VALSARTAN.

VANCOMYCIN.

VANDETANIB.

VARDENAFIL.

VARENICLINE.

VARICELLA VACCINE.

RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN.

VASOPRESSIN.

VECURONIUM.

VEDAPROFEN.

VEDOLIZUMAB.

VELAGLIFLOZIN.

VELAGLUCERASE ALFA.

VELPATASVIR.

VEMURAFENIB.

VENETOCLAX.

VENLAFAXINE.

VERAPAMIL.

VERATRUM spp. **except** when separately specified in this Schedule.

VERICIGUAT.

VERNAKALANT.

VERTEPORFIN.

VIDARABINE.

VIGABATRIN.

VILANTEROL.

VILDAGLIPTIN.

VILOXAZINE.

VINBLASTINE.

VINCAMINE.

VINCRISTINE.

VINDESINE.

VINFLUNINE.

VINORELBINE.

VINYL ETHER for therapeutic use.

VIRGINIAMYCIN **except** when included in Schedule 5.

VISMODEGIB.

VISNADINE.

VITAMIN A for human therapeutic or cosmetic use **except**:

(a) in preparations for topical use containing 1% or less of Vitamin A; or

(b) in preparations for internal use containing 3000 micrograms retinol equivalents or less of Vitamin A per daily dose; or

(c) in preparations for parenteral nutrition replacement.

VITAMIN D for human internal therapeutic use **except**:

(a) in preparations containing 25 micrograms or less of vitamin D per recommended daily dose ; or

(b) when included in Schedule 3.

VORAPAXAR.

VORETIGENE NEPARVOVEC.

VORICONAZOLE.

VORINOSTAT.

VORTIOXETINE.

VOSORITIDE.

VOXILAPREVIR.

WARFARIN for therapeutic use.

XAMOTEROL.

XANTHINOL NICOTINATE.

XIMELAGATRAN.

XIPAMIDE.

XYLAZINE.

YOHIMBINE.

ZAFIRLUKAST.

ZALCITABINE.

ZALEPLON.

ZANAMIVIR.

ZANUBRUTINIB.

ZERANOL **except** when included in Schedule 6.

ZIDOVUDINE.

ZILPATEROL.

ZILUCOPLAN.

ZIMELDINE.

ZINC COMPOUNDS for human internal use **except**:

(a) in preparations with a recommended daily dose of 25 mg or less of zinc; or

(b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the required advisory statements for medicine labels.

ZIPRASIDONE.

ZOLAZEPAM.

ZOLEDRONIC ACID.

ZOLMITRIPTAN **except** when included in Schedule 3.

ZOLPIDEM.

ZONISAMIDE.

ZOPICLONE.

ZOXAZOLAMINE.

ZUCLOPENTHIXOL.

Schedule 5—Caution

Note: See paragraph (e) of the definition of ***designated solvent*** in section 6, paragraph 7(j), sections 16 and 25, subsection 26(2) and sections 42, 46, 47, 49, 55 and 61.

ABAMECTIN

(a) in preparations, for internal use for the treatment of animals, containing 1% or less of abamectin; or

(b) in gel formulations containing 0.05% or less of abamectin in applicators containing 50 mg or less of abamectin.

ABSCISIC ACID.

ACEQUINOCYL.

ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30% of acetic acid (CH3COOH) **except**:

(a) when included in Schedule 2 or 6; or

(b) for therapeutic use.

ACETONE **except** in preparations containing 25% or less of designated solvents.

ACRIFLAVINIUM CHLORIDE in preparations for veterinary use containing 2.5% or less of acriflavinium chloride.

AFOXOLANER in oral divided preparations each containing 150 mg or less of afoxolaner per dosage unit

(a) for the treatment and prevention of flea infestations and control of ticks in dogs; or

(b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with milbemycin oxime.

AKLOMIDE.

ALBENDAZOLE for the treatment of animals, in preparations containing 12.5% or less of albendazole **except** in intraruminal implants each containing 3.85 g or less of albendazole.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination:

(a) in solid orthodontic device cleaning preparations, tHE pH of which as an “in‑use” aqueous solution is more than 11.5; or

(b) in solid automatic dishwashing preparations, tHE pH of which in a 500 g/L aqueous solution or mixture is more than 11.5 but less than or equal to 12.5; or

(c) in other solid preparations, tHE pH of which in a 10 g/L aqueous solution is more than 11.5; or

(d) in liquid or semi‑solid preparations, tHE pH of which is more than 11.5, unless:

(i) in food additive preparations for domestic use; or

(ii) in automatic dish washing preparations for domestic use with A pH of more than 12.5;

**except** when separately specified in these Schedules.

ALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50% or less of alkoxylated fatty alkylamine polymer **except** in preparations containing 20% or less of alkoxylated fatty alkylamine polymer.

ALLETHRIN in preparations containing 10% or less of allethrin **except**:

(a) in insecticidal mats; or

(b) in other preparations containing 1% or less of allethrin.

ALLOXYDIM.

ALPHA‑CYPERMETHRIN:

(a) in aqueous preparations containing 3% or less of alpha‑cypermethrin; or

(b) in other preparations containing 1.5% or less of alpha‑cypermethrin.

AMETRYN.

AMINES for use as curing agents for epoxy resins **except** when separately specified in these Schedules.

AMINOACRIDINE in preparations for veterinary use containing 2.5% or less of aminoacridine.

AMINOCYCLOPYRACHLOR **except** in preparations containing 25% or less of aminocyclopyrachlor.

AMINOPYRALID in preparations containing 22% or less of aminopyralid.

AMISULBROM.

AMITROLE.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5% or less of ammonia **except**:

(a) in preparations for human internal therapeutic use; or

(b) in preparations for inhalation when absorbed in an inert solid material; or

(c) in preparations containing 0.5% or less of free ammonia.

AMMONIUM THIOCYANATE **except** in preparations containing 10% or less of ammonium thiocyanate.

ANHYDRIDES, ORGANIC ACID for use as curing agents for epoxy resins **except** when separately specified in these Schedules.

ANISE OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50% or less of anise oil.

ASPIRIN for the treatment of animals, that is in divided preparations, when:

(a) packed in blister or strip packaging; or

(b) in a container with a child-resistant closure.

ATRAZINE.

AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5% or less of total limonoids, for agricultural use.

AZOXYSTROBIN.

BACILLUS THURINGIENSIS DELTA ENDOTOXIN encapsulated in killed Pseudomonas fluorescens.

BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq. cm.

BASIL OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 5% or less of methyl chavicol.

BEAUVERIA BASSIANA in preparations containing 1 x 108 Colony Forming Units (CFu)/mL or less of Beauveria bassiana.

BENALAXYL.

BENDIOCARB in preparations containing 2% or less of bendiocarb.

BENTAZONE.

BENZALKONIUM CHLORIDE in preparations containing 10% or less of benzalkonium chloride **except** in preparations containing 5% or less of benzalkonium chloride.

BENZOFENAP.

BENZOIC ACID (excluding its salts and derivatives) in preparations for agricultural use **except** preparations containing 1% or less of benzoic acid.

BENZOYL PEROXIDE **except**:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 5% or less of benzoyl peroxide.

BERGAMOT OIL **except**:

(a) when steam distilled or rectified; or

(b) in preparations for internal use; or

(c) in preparations containing 0.4% or less of bergamot oil; or

(d) in soaps or bath or shower gels that are washed off the skin; or

(e) in medicines for human therapeutic use when compliant with the requirements of the required advisory statements for medicine labels; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

BETACYFLUTHRIN:

(a) in aqueous preparations containing 2.5% or less of betacyfluthrin; or

(b) in solid preparations containing 8% or less of betacyfluthrin in a plastic matrix.

BICYCLOPYRONE in preparations containing 20% or less of bicyclopyrone.

BIFLUORIDES (including ammonium, potassium and sodium salts), in preparations containing 0.3% or less of total bifluorides.

BIOALLETHRIN in preparations containing 10% or less of bioallethrin **except** in preparations containing 1% or less of bioallethrin.

BIORESMETHRIN **except** in preparations containing 10% or less of bioresmethrin.

BISPYRIBAC **except** in preparations containing 10% or less of bispyribac.

BIXAFEN.

BORIC ACID **except**:

(a) when included in Schedule 4; or

(b) in cosmetic hand cleaning preparations when labelled with a warning to the following effect:

NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and

if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words:

NOT TO BE USED ON PEELING OR IRRITATED SKIN; or

(c) in cosmetic talc preparations containing 5% or less calculated as boric acid when labelled with a warning to the following effect:

NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and

if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words:

NOT TO BE USED ON PEELING OR IRRITATED SKIN; or

(d) in cosmetic oral hygiene preparations containing 0.1% or less calculated as boric acid when labelled with a warning to the following effect:

NOT TO BE SWALLOWED. NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; or

(e) in other cosmetic preparations containing 3% or less calculated as boric acid when labelled with a warning to the following effect:

NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and

if the concentration of free soluble borates exceeds 1.5% (as boric acid), with the words:

NOT TO BE USED ON PEELING OR IRRITATED SKIN; or

(f) in preparations, other than insect baits, containing 6% or less calculated as boric acid.

BORON TRIFLUORIDE in preparations containing 0.1% or less of boron trifluoride (BF3).

BROFLANILIDE in preparations containing 0.3% or less of broflanilide.

BROMUCONAZOLE in preparations containing 20% or less of bromuconazole.

BUPIVACAINE in aqueous gel preparations containing 0.5% or less of bupivacaine, for the dermal spray‑on administration to the wounds of animals.

BUPROFEZIN **except** in preparations containing 40% or less of buprofezin.

BUTHIDAZOLE.

BUTOXYCARBOXIM in solid preparations containing 10% or less of butoxycarboxim.

BUTRALIN.

BUTROXYDIM.

*n*‑BUTYL ALCOHOL in preparations containing 10% or less of n‑butyl alcohol **except**:

(a) in preparations containing 5% or less of n‑butyl alcohol; or

(b) in preparations for cosmetic or therapeutic use other than spray form.

CAMPHOR as a natural component in essential oils containing 10% or less of camphor **except**:

(a) in medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(c) in rosemary oil, sage oil (Spanish), or lavandin oils; or

(d) in preparations containing 2.5% or less of camphor.

CARBAMIDE PEROXIDE in preparations containing 18% or less of carbamide peroxide **except** in preparations containing 9% or less of carbamide peroxide.

CARBARYL:

(a) in preparations containing 10% or less of carbaryl **except** when included in Schedule 4; or

(b) when impregnated into plastic resin material containing 20% or less of carbaryl.

CASSIA OIL **except**:

(a) in food additives; or

(b) in preparations for dermal use as a rubefacient containing 5% or less of cassia oil; or

(c) in other preparations containing 2% or less of cassia oil.

CHLORFENAC.

CHLORFENAPYR. in preparations containing 0.5% or less of chlorfenapyr.

CHLORFENSON.

CHLORHEXIDINE in preparations containing 3% or less of chlorhexidine **except**:

(a) in preparations containing 1% or less of chlorhexidine; or

(b) when in solid preparations.

CHLORINATING COMPOUNDS containing 20% or less of available chlorine, **except**:

(a) when separately specified in these Schedules; or

(b) sodium hypochlorite preparations with A pH of less than 11.5; or

(c) liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or

(d) liquid preparations containing less than 2% of available chlorine; or

(e) other preparations containing 4% or less of available chlorine.

CHLORNIDINE.

CHLOROCRESOL **except** in preparations containing 3% or less of chlorocresol.

CHLORPROPHAM.

CHLORPYRIFOS:

(a) in aqueous preparations containing 20% or less of microencapsulated chlorpyrifos; or

(b) in controlled release granular preparations containing 10% or less of chlorpyrifos; or

(c) in other preparations containing 5% or less of chlorpyrifos;

except in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORSULFURON.

CHLORTETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or

(b) containing 40% or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

CHLORTHAL‑DIMETHYL.

CINMETHYLIN.

CINNAMON BARK OIL **except**:

(a) in food additives; or

(b) in preparations containing 2% or less of cinnamon bark oil.

CIS‑JASMONE when prepared and packaged as an agricultural chemical **except** when present as a fragrance.

CLETHODIM.

CLIMBAZOLE in preparations containing 40% or less of climbazole **except**:

(a) in leave‑on hair, face and foot cosmetic preparations containing 0.5% or less of climbazole; or

(b) in other preparations (that are not leave‑on cosmetic preparations) containing 2% or less of climbazole.

CLOFENTEZINE.

CLOPYRALID.

CLOQUINTOCET.

CLORSULON.

CLOTHIANIDIN in preparations containing 20% or less of clothianidin **except** in gel preparations dispensed in sealed cartridges containing 1% or less of clothianidin.

CLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil **except** in preparations containing 25% or less of clove oil.

COPPER ACETATE in preparations containing 20% or less of copper acetate **except** in preparations containing 5% or less of copper acetate.

COPPER COMPOUNDS in animal feed additives containing 5% or less of copper **except** in preparations containing 1% or less of copper.

COPPER HYDROXIDE in preparations containing 50% or less of copper hydroxide **except** in preparations containing 12.5% or less of copper hydroxide.

COPPER OXIDES in preparations containing 25% or less of copper oxides **except**:

(a) in preparations for internal use; or

(b) in marine paints; or

(c) in other preparations containing 5% or less of copper oxides.

COPPER OXYCHLORIDE in preparations containing 50% or less of copper oxychloride **except** in preparations containing 12.5% or less of copper oxychloride.

COPPER SULFATE in preparations containing 15% or less of copper sulfate **except**:

(a) in preparations for internal use; or

(b) in other preparations containing 5% or less of copper sulfate.

COUMATETRALYL in rodenticides containing 0.05% or less of coumatetralyl.

4‑CPA.

CYANATRYN.

CYANOACRYLATE ESTERS in contact adhesives **except**:

(a) when labelled with the warning:

KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water; or

(b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters:

(i) labelled with the approved name or trade name of the poison, the quantity and the warning:

Can cause eye injury. Instantly bonds skin; and

enclosed in a primary pack labelled with the warning:

KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water.

CYANTRANILIPROLE.

CYANURIC ACID (excluding its salts and derivatives).

CYAZOFAMID.

CYCLOHEXANONE PEROXIDE.

CYCLOPROTHRIN **except** in preparations containing 10% or less of cycloprothrin.

CYCLOXYDIM.

CYFLUFENAMID.

CYFLUMETOFEN.

CYFLUTHRIN:

(a) in wettable powders containing 10% or less of cyfluthrin; or

(b) in emulsifiable concentrates containing 2% or less of cyfluthrin; or

(c) in emulsions containing 5% or less of cyfluthrin.

CYHALOFOP‑BUTYL.

CYMIAZOLE.

CYPERMETHRIN in preparations containing 10% or less of cypermethrin.

CYPHENOTHRIN in preparations containing 10% or less of cyphenothrin.

CYPROCONAZOLE **except** in preparations containing 10% or less of cyproconazole.

CYPRODINIL.

CYTHIOATE for the treatment of animals:

(a) in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a child‑resistant closure; or

(b) in undivided preparations containing 5% or less of cythioate.

2,4‑D in preparations containing 20% or less of 2,4‑D.

DAMINOZIDE.

2,4‑DB.

DECOQUINATE:

DELTAMETHRIN:

(a) when impregnated in plastic resin strip material containing 4% or less of deltamethrin; or

(b) in aqueous preparations containing 5% or less of deltamethrin when no organic solvent other than a glycol is present; or

(c) in wettable granular preparations containing 25% or less of deltamethrin when packed in child‑resistant packaging each containing 3 g or less of the formulation; or

(d) in water‑dispersible tablets each containing 500 mg or less of deltamethrin in child‑resistant packaging; or

(e) in other preparations containing 0.5% or less of deltamethrin;

except:

(f) in factory prepared mosquito nets containing 1% or less deltamethrin; or

(g) in preparations containing 0.1% or less of deltamethrin.

DEMBREXINE in oral preparations for the treatment of animals.

2,4‑DES.

DIAFENTHIURON.

*N,N*‑DIALLYLDICHLOROACETAMIDE **except** in preparations containing 10% or less of *N,N*‑diallyldichloroacetamide.

DIAZINON in dust preparations containing 2% or less of diazinon.

DICAMBA (including its salts and derivatives) in preparations containing 20% or less of dicamba.

DICHLONE.

*p*‑DICHLOROBENZENE.

DICHLOROISOCYANURIC ACID containing 40% or less of available chlorine, **except** in:

(a) liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or

(b) liquid preparations containing less than 2% of available chlorine; or

(c) other preparations containing 4% or less of available chlorine.

DICHLOROMETHANE (methylene chloride) **except**:

(a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10% or less of dichloromethane; or

(b) in other preparations in pressurised spray packs; or

(c) in paints and tinters containing 5% or less of dichloromethane; or

(d) in preparations for human therapeutic use.

DICHLOROPHEN for the treatment of animals.

DICHLORVOS:

(a) when impregnated in plastic resin strip material containing 20% or less of dichlorvos; or

(b) in sustained release resin pellets containing 20% or less of dichlorvos for the treatment of animals; or

(c) in pressurised spray packs containing 10 g or less of dichlorvos.

DICLOBUTRAZOL.

DICLORAN.

DICOFOL.

DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20% or less of diethanolamine **except** in preparations containing 5% or less of diethanolamine.

DIETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent **except**:

(a) in paints or paint tinters; or

(b) in toothpastes or mouthwashes containing more than 0.25% of diethylene glycol; or

(c) in other preparations containing 2.5% or less of diethylene glycol.

DIETHYLENE GLYCOL MONOBUTYL ETHER **except** in preparations containing 10% or less of diethylene glycol monobutyl ether.

DIETHYLTOLUAMIDE (DEET) **except**:

(a) in medicines for human therapeutic use containing 20% or less of diethyltoluamide, when compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations for human use, other than medicines, containing 20% or less of diethyltoluamide, when labelled with the warning statement:

WARNING: May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time; or

(c) in preparations other than for human use containing 20% or less of diethyltoluamide.

DIFENOCONAZOLE.

DIFLUBENZURON.

DIMETHICODIETHYLBENZALMALONATE **except** when included in preparations containing 10% or less of dimethicodiethylbenzalmalonate.

DIMETHIRIMOL.

DIMETHOMORPH **except** in preparations containing 10% or less of dimethomorph.

DIMETHYLACETAMIDE in preparations containing 20% or less of dimethylacetamide.

DIMETHYLFORMAMIDE in preparations containing 10% or less of dimethylformamide **except** in silicone rubber mastic containing 2% or less of dimethylformamide.

3,7‑DIMETHYL‑2,6‑OCTADIENAL and its isomers in cosmetic and household cleaning preparations **except** in preparations containing 5% or less of 3,7‑dimethyl‑2,6,‑octadienal isomers.

DIMPROPYRIDAZ in preparations containing 13% or less of dimpropyridaz.

DINICONAZOLE.

DINOTEFURAN **except** in preparations containing 1% or less of dinotefuran.

DI‑n‑PROPYL ISOCINCHOMERONATE **except** in preparations containing 25% or less of di‑n‑propyl isocinchomeronate.

DIPHENAMID.

DIRECT RED 254 in preparations containing 30% or less of Direct Red 254 calculated as free acid.

DITHIOPYR.

*N‑(N*‑DODECYL)‑2‑PYRROLIDONE in preparations containing 50% or less of *N*‑(*N*‑dodecyl)‑2‑pyrrolidone or preparations containing 50% or less of a mixture of any two or more of *N*‑(*N*‑dodecyl)‑2‑pyrrolidone, *N*‑methyl‑2‑pyrrolidone or *N*‑(*N*‑octyl)‑2‑pyrrolidone **except** in preparations containing 25% or less of designated solvents.

DORAMECTIN for internal use for the treatment of animals, in preparations containing 2% or less of doramectin.

EMAMECTIN in preparations containing 2% or less of emamectin.

EMODEPSIDE in preparations:

(a) containing 2.5% or less of emodepside for the external treatment of animals; or

(b) containing 30 mg or less of emodepside per dosage unit for the oral treatment of animals.

EPOXICONAZOLE.

EPOXY RESINS, LIQUID.

EPRINOMECTIN in preparations containing 0.5% or less of eprinomectin.

ESBIOTHRIN in preparations containing 10% or less of esbiothrin **except** in pressurised spray packs containing 1% or less of esbiothrin.

ESFENVALERATE in preparations containing 0.1% or less of esfenvalerate.

ESTRADIOL in implant preparations for growth promotion in animals.

1,2‑ETHANEDIAMINE POLYMERWITH (CHLOROMETHYL) OXIRANE AND N‑METHYLMETHANAMINE.

ETHER in preparations containing more than 10% of ether for use in internal combustion engines.

ETHOFUMESATE.

ETHOXYQUIN **except** in preparations containing 10% or less of ethoxyquin.

ETHOXYSULFURON.

ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent **except**:

(a) in paints or paint tinters; or

(b) in toothpastes or mouthwashes containing more than 0.25% of ethylene glycol; or

(c) in other preparations containing 2.5% or less of ethylene glycol.

ETHYL METHACRYLATE (excluding its derivatives) for cosmetic use **except** in preparations containing 1% or less of ethyl methacrylate as residual monomer in a polymer.

ETRIDIAZOLE.

EUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol **except** in preparations containing 25% or less of eugenol.

EXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (Corymbia citriodora), **except** in preparations containing 40% or less of extract of lemon eucalyptus.

FENARIMOL.

FENBENDAZOLE for the treatment of animals.

FENBUCONAZOLE.

FENCHLORAZOLE‑ETHYL.

FENNEL OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of an instrument made under subsection 3(5A) of the Act relating to medicine advisory statements; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 5% or less of methyl chavicol.

FENOPROP.

FENOXAPROP‑ETHYL.

FENOXAPROP‑*p*‑ETHYL.

FENPYRAZAMINE **except** in preparations containing 40% or less of fenpyrazamine.

FENSON.

FENTHION:

(a) in preparations containing 25% or less of fenthion when packed in single‑use containers having a capacity of 2 mL or less; or

(b) in preparations containing 10% or less of fenthion.

FIPRONIL in preparations containing 10% or less of fipronil **except** in preparations containing 0.05% or less of fipronil.

FLAMPROP‑METHYL.

FLAMPROP‑*M*‑METHYL.

FLAZASULFURON.

FLORASULAM.

FLUAZAINDOLIZINE in preparations containing 50% or less fluazaindolizine.

FLUAZURON.

FLUBENDAZOLE for the treatment of animals.

FLUBENDIAMIDE.

FLUCHLORALIN.

FLUDIOXONIL **except** in preparations containing 10% or less of fludioxonil.

FLUMETHRIN:

(a) when impregnated in plastic resin strip material containing 3% or less of flumethrin; or

(b) in oil based preparations containing 1% or less of flumethrin.

FLUMICLORAC PENTYL.

FLUOPYRAM **except** in preparations containing 50% or less of fluopyram.

FLUORIDES in preparations containing 3% or less of fluoride ion **except**:

(a) in preparations for human use; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

FLURALANER **except** when included in Schedule 4.

FLUVALINATE in aqueous preparations containing 25% or less of fluvalinate.

FLUXAPYROXAD.

FORAMSULFURON.

FORMIC ACID (excluding its salts and derivatives) **except** in preparations containing 0.5% or less of formic acid.

FOSPIRATE when impregnated in plastic resin strip material containing 20% or less of fospirate.

FURALAXYL.

FURATHIOCARB in microencapsulated suspensions containing 50% or less of furathiocarb.

GAMMA‑CYHALOTHRIN in aqueous preparations containing 15% or less of microencapsulated gamma‑cyhalothrin.

GLUFOSINATE‑AMMONIUM.

GLUTARAL in preparations containing 5% or less of glutaral **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 0.5% or less of glutaral when labelled with the statements:

(A) IRRITANT; and

(B) Avoid contact with eyes.

GLYPHOSATE.

HALOSULFURON‑METHYL.

HEXACONAZOLE **except** in preparations containing 5% or less of hexaconazole.

HEXAZINONE in preparations containing 25% or less of hexazinone.

HYDRAMETHYLNON in solid baits containing 2% or less of hydramethylnon in welded plastic labyrinths.

HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives), **except**:

(a) toluene and xylene when included in Schedule 6; or

(b) benzene and liquid aromatic hydrocarbons when included in Schedule 7; or

(c) food grade and pharmaceutical grade white mineral oils; or

(d) in solid or semi‑solid preparations; or

(e) in preparations containing 25% or less of designated solvents; or

(f) in preparations packed in pressurised spray packs; or

(g) in adhesives packed in containers each containing 50 g or less of adhesive; or

(h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or

(i) in other preparations when packed in containers with a capacity of 2 mL or less.

HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of hydrochloric acid (HCl) **except**:

(a) in preparations containing 0.5% or less of hydrochloric acid (HCl); or

(b) for therapeutic use.

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1% or less of hydrogen fluoride.

HYDROGEN PEROXIDE (excluding its salts and derivatives):

(a) in hair dye preparations containing 12% or less of hydrogen peroxide **except** in hair dyes containing 6% or less of hydrogen peroxide; or

(b) in other preparations containing 6% (20 volume) or less of hydrogen peroxide **except** in preparations containing 3% (10 volume) or less of hydrogen peroxide.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1% or less of hydrosilicofluoric acid (H2SiF6).

2‑HYDROXYETHYL METHACRYLATE **except**:

(a) when included in dental restorative preparations for therapeutic use; or

(b) in nail preparations when labelled “Avoid contact with skin”; or

(c) in other preparations containing 0.1% or less of 2‑hydroxyethyl methacrylate when labelled “Avoid contact with skin”.

2‑HYDROXYPROPYL METHACRYLATE in nail preparations **except** when labelled “Avoid contact with skin”.

IMAZALIL.

IMAZAMOX **except** in preparations containing 25% or less of imazamox.

IMAZAPIC **except** in preparations containing 25% or less of imazapic.

IMAZAPYR **except** in preparations containing 25% or less of imazapyr.

IMAZETHAPYR **except** in preparations containing 25% or less of imazethapyr.

IMIDACLOPRID in preparations containing 20% or less of imidacloprid **except** in preparations containing 5% or less of imidacloprid.

IMIPROTHRIN in preparations containing 50% or less of imiprothrin **except** in preparations containing 10% or less of imiprothrin.

INDOXACARB (includes the R and S enantiomers) in preparations containing 1% or less of indoxacarb.

3‑IODO‑2‑PROPYNYL BUTYL CARBAMATE (Iodocarb) in preparations containing 10% or less of 3‑iodo‑2‑propynyl butyl carbamate **except**:

(a) in aqueous preparations not for cosmetic use containing 10% or less 3‑iodo‑2‑propynyl butyl carbamate; or

(b) in cosmetic preparations (other than aerosolised preparations) containing 0.1% or less of 3‑iodo‑2‑propynyl butyl carbamate.

IODOSULFURON‑METHYL‑SODIUM.

IPCONAZOLE in preparations containing 2% or less of ipconazole.

IRON COMPOUNDS:

(a) for the treatment of animals (excluding up to 1% of iron oxides when present as an excipient):

(i) in preparations for injection containing 20% or less of iron **except** in preparations containing 0.1% or less of iron; or

(ii) in other preparations containing 4% or less of iron **except**:

(A) in liquid or gel preparations containing 0.1% or less of iron; or

(B) in animal feeds or feed premixes; or

(b) for use as agricultural chemicals **except** in preparations containing 4% or less of iron.

ISOEUGENOL in preparations not intended for skin contact containing 25% or less of isoeugenol **except** in preparations containing 10% or less of isoeugenol.

ISOPHORONE.

ISOXABEN.

ISOXAFLUTOLE.

IVERMECTIN for use in animals:

(a) in preparations for the prophylaxis of heartworm in cats and dogs; or

(b) in intraruminal implants containing 160 mg or less of ivermectin; or

(c) in preparations containing 3.5% or less of ivermectin when packed in child‑resistant packaging or in packaging approved by the relevant registration authority; or

(d) in other preparations containing 2% or less of ivermectin.

KITASAMYCIN in animal feed premixes for growth promotion containing 2% or less of antibiotic substances.

LAMBDA‑CYHALOTHRIN:

(a) in aqueous preparations containing 1% or less of lambda‑ cyhalothrin; or

(b) in aqueous preparations containing 10% or less of microencapsulated lambda‑cyhalothrin.

LASIODIPLODIA PSEUDOTHEOBROMAE **except** when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.

LEMON OIL **except**:

(a) when steam distilled or rectified; or

(b) in preparations for internal use; or

(c) in preparations containing 0.05% or less of lemon oil; or

(d) in soaps or bath or shower gels that are washed off the skin; or

(e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

LEMONGRASS OIL in cosmetic and household cleaning preparations **except** in preparations containing 5% or less of 3,7‑dimethyl‑2,6‑octadienal.

LEVAMISOLE in preparations containing 15% or less of levamisole for the treatment of animals **except**:

(a) when included in Schedule 4; or

(b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LIDOCAINE:

(a) in aqueous gel preparations containing 4.5% or less of lidocaine, for the dermal spray‑on administration to the wounds of animals; or

(b) in injectable preparations containing 2% or less of lidocaine when packaged in a container with a tamper resistant cartridge which can only be dispensed through a rubber ring applicator for tail docking and castration of lambs; or castration of calves.

LIME OIL **except**:

(a) when steam distilled or rectified; or

(b) in preparations for internal use; or

(c) in preparations containing 0.5% or less of lime oil; or

(d) in soaps or bath or shower gels that are washed off the skin; or

(e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

LINDANE in preparations containing 10% or less of lindane **except** when included in Schedule 2 or 4.

LOTILANER.

LUFENURON **except**:

(a) in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or

(b) in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals.

MACROPHOMINA PHASEOLINA **except** when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.

MADURAMICIN in animal feed premixes containing 1% or less of antibiotic substances.

MAGNESIUM CHLORATE **except** in preparations containing 10% or less of magnesium chlorate.

MALACHITE GREEN in preparations for veterinary use containing 10% or less of malachite green.

MALATHION in preparations containing 10% or less of malathion **except**:

(a) for human therapeutic use; or

(b) in dust preparations containing 2% or less of malathion.

MANCOZEB.

MANDESTROBIN **except** in preparations containing 25% or less of mandestrobin.

MANDIPROPAMID.

MARJORAM OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50% or less of marjoram oil.

MCPA:

(a) in preparations containing 25% or less of MCPA (acid); or

(b) in preparations containing 50% or less of the salts and esters of MCPA.

MEBENDAZOLE for the treatment of animals:

(a) in divided preparations each containing 300 mg or less of mebendazole per dosage unit; or

(b) in undivided preparations containing 25% or less of mebendazole.

MECLOFENAMIC ACID for the treatment of animals.

MECOPROP in preparations containing 2% or less of mecoprop.

MEFENPYR‑DIETHYL.

MEFENTRIFLUCONAZOLE **except** in preparations containing 7.5% or less of mefentrifluconazole.

MEPIQUAT.

MERCAPTAMINE in cosmetic preparations containing 6% or less of mercaptamine **except** in preparations containing 1% or less of mercaptamine.

MERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic preparations containing 20% or less of mercaptoacetic acid or its salts (as mercapturic acid), **except** in preparations containing 5% or less of mercaptoacetic acid or its salts (as mercapturic acid)

MESOTRIONE.

METAFLUMIZONE.

METALAXYL in preparations containing 35% or less of metalaxyl.

METALDEHYDE in preparations containing 2% or less of metaldehyde.

METAZACHLOR.

METHABENZTHIAZURON.

METHANOL (excluding its derivatives) in preparations containing 10 % or less of methanol **except:**

(a) when included in Schedule 10; or

(b) in preparations containing 2% or less of methanol; or

(c) when methanol is present only as a denaturant of ethanol.

METHENAMINE in cosmetic preparations, **except** in preparations containing 0.15% or less of methenamine.

METHIOCARB in pelleted preparations containing 2% or less of methiocarb.

METHIOZOLIN.

METHOXYCHLOR.

METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) **except**:

(a) when included in preparations or admixtures; or

(b) when packed in containers having a capacity of more than 5 L.

METHYLATED SPIRIT(S) when packed and labelled as a “biofuel” suitable for use in “spirit burners”.

METHYLENE BLUE in preparations for veterinary use containing 50% or less of methylene blue.

METHYL ETHYL KETONE **except** in preparations containing 25% or less of designated solvents.

METHYL ETHYL KETONE PEROXIDE.

METHYL ISOAMYL KETONE **except** in preparations containing 25% or less of designated solvents.

METHYL ISOBUTYL KETONE **except** in preparations containing 25% or less of designated solvents.

*N*‑METHYL‑2‑PYRROLIDONE:

(a) when packed in single use containers having a capacity of 2 mL or less; or

(b) in preparations containing 50% or less of *N*‑methyl‑2‑pyrrolidone or preparations containing 50% or less of a mixture of any two or more of *N*‑methyl‑2‑pyrrolidone, *N*‑(*N*‑octyl)‑2‑pyrrolidone or *N*‑(*N*‑dodecyl)‑2‑pyrrolidone **except** in preparations containing 25% or less of designated solvents.

METHYL SALICYLATE in preparations containing 25% or less of methyl salicylate **except**:

(a) in preparations for therapeutic use; or

(b) in preparations containing 5% or less of methyl salicylate.

2‑METHYLTHIO‑4‑(2‑METHYLPROP‑2‑YL) AMINO‑6‑CYCLOPROPYLAMINO‑5‑ TRIAZINE.

METIRAM.

METOBROMURON **except** in preparations containing 50% or less of metobromuron.

METOFLUTHRIN:

(a) in impregnated fabric mosquito repellent preparations for use in a vaporiser containing 15 mg or less of metofluthrin per disk; or

(b) when impregnated into a polyethylene slow release matrix containing 250 mg or less of metofluthrin.

METOLACHLOR.

METRAFENONE in preparations containing 50% or less of metrafenone.

MILBEMECTIN in preparations containing 1% or less of milbemectin.

MILBEMYCIN OXIME

(a) for the prophylaxis of heartworm in dogs and cats; or

(b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal nematodes and heartworm in dogs, when combined with afoxolaner, in oral divided preparations each containing 150 mg or less of afoxolaner per dosage unit.

MONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.

MONEPANTEL.

MONOETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20% or less of monoethanolamine **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 5% or less of monoethanolamine.

MORANTEL in preparations containing 25% or less of morantel **except** in preparations containing 10% or less of morantel.

MOXIDECTIN:

(a) in preparations for external use for the treatment of animals other than cats and dogs, containing 0.5% or less of moxidectin; or

(b) in preparations for external use for the treatment of cats and dogs, containing 2.5% or less of moxidectin packed in single dose tubes with a volume of 1 mL or less; or

(c) for internal use for the treatment of animals:

(i) in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or

(ii) in other preparations containing 2% or less of moxidectin.

MYCLOBUTANIL.

NAA **except** in preparations containing 25% or less of NAA.

NALED when impregnated in plastic resin strip material containing 20% or less of naled.

NAPTALAM.

NEOSCYTALIDIUM NOVAEHOLLANDIAE **except** when used as a herbicide in capsule preparations at a concentration of 16 CFU or less per capsule.

NETOBIMIN for the treatment of animals, in preparations containing 12.5% or less of netobimin.

NITRIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of nitric acid (HNO3) **except** in preparations containing 0.5% or less of nitric acid.

NITROSCANATE for the treatment of animals.

NONANOIC ACID:

(a) when used in a pesticide; or

(b) in other preparations **except** in preparations containing 10% or less of nonanoic acid.

NONOXINOL 9 in preparations containing 25% or less of nonoxinol 9 **except**:

(a) when labelled with the statements:

(i) IRRITANT; and

(ii) Avoid contact with eyes; or

(b) in preparations containing 12.5% or less of nonoxinol 9; or

(c) in preparations for human use.

NORBORMIDE.

NUTMEG OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50% or less of nutmeg oil.

*N*‑OCTYL BICYCLOHEPTENE DICARBOXIMIDE **except** in preparations containing 10% or less of *N*‑octyl bicycloheptene dicarboximide.

*N*‑(*N*‑OCTYL)‑2‑PYRROLIDONE in preparations containing 50% or less of:

(a) *N*‑(*N*‑octyl)‑2‑pyrrolidone or preparations containing 50% or less of a mixture of any two or more of *N*‑(*N*‑octyl)‑2‑pyrrolidone, N‑methyl‑2‑pyrrolidone; or

(b) *N*‑(*N*‑dodecyl)‑2‑pyrrolidone **except** in preparations containing 25% or less of designated solvents.

OLEANDOMYCIN in animal feed premixes for growth promotion.

OMETHOATE in pressurised spray packs containing 0.2% or less of omethoate.

ORANGE OIL (BITTER) **except**:

(a) when steam distilled or rectified; or

(b) in preparations for internal use; or

(c) in preparations containing 1.4% or less of orange oil (bitter); or

(d) in soaps or bath or shower gels that are washed off the skin; or

(e) in medicines for human therapeutic use, when compliant with the requirements of the required advisory statements for medicine labels; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

OXADIARGYL.

OXADIXYL.

OXANTEL EMBONATE for the treatment of animals.

OXFENDAZOLE for the treatment of animals.

OXIBENDAZOLE for the treatment of animals.

OXYCARBOXIN.

OXYTETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or

(b) containing 40% or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

OXYTHIOQUINOX.

PACLOBUTRAZOL.

PENCONAZOLE.

PENDIMETHALIN.

PENFLUFEN.

PENTHIOPYRAD **except** in preparations containing 20% or less of penthiopyrad.

PERACETIC ACID in concentrations of 10% or less of peracetic acid.

PERMETHRIN (excluding preparations for human therapeutic use):

(a) in preparations containing 25% or less of permethrin; or

(b) in preparations for external use, for the treatment of dogs, containing 50% or less of permethrin when packed in single use containers having a capacity of 4 mL or less;

except in preparations containing 2% or less of permethrin.

PETROL **except** preparations containing 25% or less of petrol.

PHENAZONE for the external treatment of animals.

PHENISOPHAM.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15% or less of such substances, **except** in preparations containing 1% or less of phenol and in preparations containing 3% or less of cresols and xylenols and other homologues of phenol.

PHENYL METHYL KETONE **except** in preparations containing 25% or less of designated solvents.

*o*‑PHENYLPHENOL **except** in preparations containing 5% or less of *o*‑phenylphenol.

PHOSPHONIC ACID (excluding its salts and derivatives) **except** in preparations containing 10% or less of phosphonic acid (H3PO3).

PHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35% or less of phosphoric acid (H3PO4) **except**:

(a) in preparations containing 15% or less of phosphoric acid (H3PO4); or

(b) in solid or semi‑solid preparations; or

(c) in professional dental kits.

*o*‑PHTHALALDEHYDE in preparations containing 1% or less of *o*‑phthalaldehyde.

PICARIDIN **except** in preparations containing 20% or less of picaridin.

PINE OILS in preparations containing 25% or less of pine oils when packed and labelled as a herbicide.

PINOXADEN in preparations containing 10% or less of pinoxaden.

PIPERAZINE for animal use.

PIRIMICARB in preparations containing 0.5% or less of pirimicarb.

POLIXETONIUM SALTS in preparations containing 60% or less of polixetonium salts **except** in preparations containing 1% or less of polixetonium salts.

POLYETHANOXY (15) TALLOW AMINE.

POLYOXIN D ZINC SALT.

POLY(OXY‑1,2‑ETHANEDIYL), α ‑[2‑[(2‑HYDROXYETHYL)AMINO]‑2‑OXOETHYL]‑ α ‑HYDROXY‑,MONO‑C13‑15‑ALKYL ETHERS.

POTASSIUM CHLORATE **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 10% or less of potassium chlorate.

POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5% or less of potassium hydroxide being:

(a) solid preparations, tHE pH of which in a 10 g/L aqueous solution is more than 11.5; or

(b) liquid or semi‑solid preparations, tHE pH of which is more than 11.5 **except** in food additive preparations for domestic use.

POTASSIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10% or less of potassium metabisulphite.

POTASSIUM NITRITE in preparations containing 1% or less of potassium nitrite **except**:

(a) in preparations containing 0.5% or less of potassium nitrite;

(b) when present as an excipient in preparations for therapeutic use; or

(c) in aerosols.

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5% or less of potassium peroxomonosulfate triple salt being:

(a) solid preparations, tHE pH of which in a 10 g/L aqueous solution is less than 2.5; or

(b) liquid or semi‑solid preparations, tHE pH of which is less than 2.5.

POTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide.

PRALLETHRIN (cis:trans=20:80) in preparations containing 10% or less of prallethrin **except** in insecticidal mats containing 1% or less of prallethrin.

PROFOXYDIM **except** in preparations containing 20% or less of profoxydim.

PROGESTERONE:

(a) in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or

(b) in implant preparations for growth promotion in cattle.

PROHEXADIONE CALCIUM.

PROMETRYN.

PROPAMOCARB.

PROPANIL.

PROPAQUIZAFOP.

PROPICONAZOLE in preparations containing 20% or less of propiconazole.

PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80% or less of propionic acid, **except**:

(a) in preparations containing 30% or less of propionic acid; or

(b) for therapeutic use.

PROPOXUR:

(a) when impregnated in plastic resin strip material containing 10% or less of propoxur; or

(b) in dust preparations containing 3% or less of propoxur; or

(c) in granular sugar‑based fly baits containing 1% or less of propoxur, a dark colouring agent and a separate bittering agent; or

(d) in pressurised spray packs containing 2% or less of propoxur; or

(e) in printed paper sheets for pest control containing 0.5% or less of propoxur and in any case not more than 100 mg of propoxur per sheet.

*n*‑PROPYL ALCOHOL in preparations containing 10% or less of *n*‑propyl alcohol **except**:

(a) in preparations containing 5% or less of *n*‑propyl alcohol; or

(b) in preparations for cosmetic or therapeutic use other than in spray form.

PROPYZAMIDE.

PROTHIOCONAZOLE‑DESCHLORO **except** in preparations containing 0.5% or less of prothioconazole‑deschloro.

PROTHIOCONAZOLE‑TRIAZOLIDINETHIONE **except** in preparations containing 0.5% or less of prothioconazole‑triazolidinethione.

PYMETROZINE.

PYRACLOSTROBIN.

PYRAFLUFEN‑ETHYL.

PYRASULFOTOLE.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids **except**:

(a) in preparations for human therapeutic use; or

(b) in preparations containing 10% or less of such substances.

PYRIDABEN in preparations containing 25% or less of pyridaben.

PYRIFENOX.

PYRITHIOBAC SODIUM.

PYRITHIONE ZINC in paints containing 0.5% or less of pyrithione zinc calculated on the non‑volatile content of the paint **except** in paints containing 0.1% or less of pyrithione zinc calculated on the non‑volatile content of the paint.

PYRIOFENONE in preparations containing 30% or less of pyriofenone.

QUATERNARY AMMONIUM COMPOUNDS in preparations containing 20% or less of quaternary ammonium compounds **except**:

(a) when separately specified in these Schedules; or

(b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or

(c) in preparations containing 5% or less of such quaternary ammonium compounds.

QUINCLORAC.

QUININE in preparations for veterinary use containing 1% or less of quinine.

QUINTOZENE.

QUIZALOFOP‑*p*‑ETHYL in aqueous preparations containing 40% or less of   
quizalofop‑*p*‑ethyl.

RACTOPAMINE in animal feed premixes containing 10% or less of ractopamine.

RESMETHRIN in preparations containing 10% or less of resmethrin.

RIMSULFURON.

ROBENIDINE **except** in preparations containing 20% or less of robenidine.

ROSIN when packaged for use as a soldering flux or in flux‑cored solder.

SAFLUFENACIL in water dispersible granules or a water‑based suspension concentrate.

SALICYLANILIDE.

SAROLANER for veterinary use in divided preparations each containing 120 mg or less of sarolaner per dosage unit.

SEDAXANE.

SELAMECTIN **except** in preparations containing 12% or less of selamectin.

SETHOXYDIM.

SIDURON.

SILICOFLUORIDES in preparations containing 3% or less of fluoride ion **except**:

(a) barium silicofluoride when separately specified in this Schedule; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

SINBIOALLETHRIN in preparations containing 10% or less of sinbioallethrin **except** in preparations containing 1% or less of sinbioallethrin.

SODIUM BROMIDE **except** when included in Schedule 4.

SODIUM CHLORATE **except** in preparations containing 10% or less of sodium chlorate.

SODIUM DIACETATE **except** in preparations containing 60% or less of sodium diacetate.

SODIUM DODECYLBENZENE SULFONATE **except** in preparations containing 30% or less of sodium dodecylbenzene sulfonate.

SODIUM HYDROGEN SULFATE **except** in preparations containing 10% or less of sodium hydrogen sulfate.

SODIUM HYDROSULFITE when packed for domestic use **except** in preparations containing 10% or less of sodium hydrosulfite.

SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5% or less of sodium hydroxide being:

(a) solid preparations, tHE pH of which in a 10 g/L aqueous solution is more than 11.5; or

(b) liquid or semi‑solid preparations, tHE pH of which is more than 11.5 **except** in food additive preparations for domestic use.

SODIUM LAURETH‑6 CARBOXYLATE **except** in preparations containing 1% or less of sodium laureth‑6 carboxylate.

SODIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10% or less of sodium metabisulphite.

SODIUM NITRITE in preparations containing 1% or less of sodium nitrite **except**:

(a) in preparations containing 0.5% or less of sodium nitrite; or

(b) when present as an excipient in preparations for therapeutic use; or

(c) in aerosols.

SODIUM PERCARBONATE (CAS No. 15630‑89‑4) in preparations containing 35% or less of sodium percarbonate **except** in preparations containing 15% or less of sodium percarbonate.

SODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use **except** in preparations containing 10% or less of sodium polystyrene sulphonate.

SODIUM STANNATE **except** in preparations for cosmetic use containing 1% or less of sodium stannate.

SODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide.

SPINETORAM.

SPINOSAD **except** in aqueous suspensions containing 25% or less of spinosad.

SPIROMESIFEN for agricultural use.

STAR ANISE OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50% or less of star anise oil.

STYRENE (excluding its derivatives).

SULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFADIAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFADIMIDINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFAMERAZINE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10% or less of sulfamic acid (H3NO3S).

SULFATHIAZOLE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFOMETURON‑METHYL.

SULFOXAFLOR in preparations containing 25% or less of sulfoxaflor.

SYMPHYTUM spp. (Comfrey) for dermal therapeutic or dermal cosmetic use.

2,3,6‑TBA.

TDE (1,1‑dichloro‑2,2‑bis[4‑chlorophenyl]ethane) in preparations containing 10% or less of TDE.

TEBUCONAZOLE.

TEBUFENOZIDE.

TEFLUTHRIN in preparations containing 2% or less of tefluthrin.

TEMEPHOS:

(a) in liquid preparations containing 10% or less of temephos; or

(b) in powders containing 2% or less of temephos; or

(c) in preparations containing 40% or less of temephos when packed in single use containers having a capacity of 2 mL or less.

TEPRALOXYDIM.

TERBUTRYN.

TETRACHLOROETHYLENE in preparations containing 5% or less of tetrachloroethylene **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of animals; or

(c) when absorbed into an inert solid.

TETRACHLORVINPHOS **except** in animal feeds containing 0.2% or less of tetrachlorvinphos.

TETRACONAZOLE in preparations containing 20% or less of tetraconazole.

TETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or

(b) containing 40% or less of tetracycline when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

TETRAMETHRIN [(R, cis): (R, trans) = 20:80] **except** in pressurised spray packs.

TETRANILIPROLE **except** in preparations containing 20% or less tetraniliprole.

THIABENDAZOLE:

(a) for the treatment of animals; or

(b) when packed and labelled for use as a fungicide **except** in preparations containing 50% or less of thiabendazole.

THIAMETHOXAM in preparations containing 60% or less of thiamethoxam.

THIAZOPYR.

THIFENSULFURON.

THIOBENCARB.

THIODICARB in pelleted preparations containing 1.5% or less of thiodicarb.

THIOPHANATE‑METHYL in preparations containing 25% or less of thiophanate‑methyl.

THYME OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50% or less of thyme oil.

TIGOLANER in preparations containing 10% or less of tigolaner.

TIOCARBAZIL.

TOLCLOFOS‑METHYL.

TOLTRAZURIL.

TOPRAMEZONE

TRALKOXYDIM.

TRENBOLONE in implant preparations for growth promotion in animals.

TRIADIMEFON in wettable powders containing 25% or less of triadimefon.

TRIADIMENOL.

TRI‑ALLATE.

TRIBENURON‑METHYL.

TRICHLOROACETIC ACID, alkali salts of.

1,1,1‑TRICHLOROETHANE **except**:

(a) in preparations packed in pressurised spray packs; or

(b) in preparations containing 25% or less of designated solvents; or

(c) in preparations, other than writing correction fluids or thinners for writing correction fluids in containers having a capacity of 50 mL or less; or

(d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with:

(i) the word “Trichloroethane” written in letters not less than 1 mm in height and in distinct contrast to the background; and

(ii) the expression:

WARNING – DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU;

written in bold face sans serif capital letters not less than 1 mm in height and in distinct contrast to the background.

TRIDIPHANE.

TRIETAZINE.

TRIFLOXYSTROBIN.

TRIFLUDIMOXAZIN **except** in preparations containing 12.5% or less.

TRIFLUMIZOLE.

TRIFLUMURON.

TRIISOPROPANOLAMINE LAURYL ETHER SULFATE **except** in preparations containing 30% or less of triisopropanolamine lauryl ether sulfate when labelled with the statements:

(a) Avoid contact with eyes and skin; and

(b) Wash hands after handling.

TRINEXAPAC‑ETHYL **except**:

(a) when packed in a sealed water‑soluble measure pack; or

(b) in solid preparations containing 25% or less of trinexapac‑ethyl in packs of 50 g or less.

3,6,9‑TRIOXAUNDECANEDIOIC ACID **except** in preparations containing 5% or less of 3,6,9‑trioxaundecanedioic acid, tHE pH of which is 3.5 or greater.

TRITICONAZOLE.

TROLAMINE (excluding its salts and derivatives) **except**:

(a) when in Schedule 4; or

(b) in preparations containing 5% or less of trolamine.

TURPENTINE OIL **except** in preparations containing 25% or less of turpentine oil.

VIRGINIAMYCIN in animal feed additives containing 1% or less of virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less.

VERNOLATE.

WARFARIN in rodent baits containing 0.1% or less of warfarin.

ZINEB.

Schedule 6—Poisons

Note: See section 16, subsection 46(2), section 49, subsection 54(3) and sections 55 and 61.

ABAMECTIN:

(a) in preparations for pesticidal use containing 4% or less of abamectin except when included in Schedule 5; or

(b) in slow‑release plastic matrix ear tags for livestock use containing 1 g or less of abamectin.

ACEPHATE.

ACETAMIPRID **except** in preparations containing 1% or less of acetamiprid.

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid (CH3COOH) **except** when included in Schedule 2.

ACETIC ANHYDRIDE excluding its derivatives.

ACIFLUORFEN.

ACINITRAZOLE **except** in preparations containing 20% or less of acinitrazole.

ACLONIFEN.

ALBENDAZOLE for the treatment of animals **except**:

(a) when included in Schedule 5; or

(b) in intraruminal implants each containing 3.85 g or less of albendazole.

ALDRIN.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for non‑domestic use:

(a) in solid automatic dishwashing preparations, tHE pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or

(b) in liquid or semi‑solid automatic dishwashing preparations, tHE pH of which is more than 12.5.

ALKOXYLATED FATTY ALKYLAMINE POLYMER **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 20% or less of alkoxylated fatty alkylamine polymer.

ALLETHRIN **except**:

(a) when included in Schedule 5; or

(b) in insecticidal mats containing 20% or less of allethrin; or

(c) in other preparations containing 1% or less of allethrin.

ALLYL ESTERS (excluding derivatives) being:

(a) ALLYL CYCLOHEXANEACETATE (CAS No. 4728‑82‑9); or

(b) ALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705‑87‑5); or

(c) ALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142‑19‑8); or

(d) ALLYL HEXANOATE (CAS No. 123‑68‑2); or

(e) ALLYL ISOVALERATE (CAS No. 2835‑39‑4); or

(f) ALLYL NONANOATE (CAS No. 7493‑72‑3); or

(g) ALLYL OCTANOATE (CAS No. 4230‑97‑1); or

(h) ALLYL PHENYLACETATE (CAS No. 1797‑74‑6); or

(i) ALLYL TRIMETHYLHEXANOATE (CAS No. 68132‑80‑9);

in preparations containing 0.1% or less of free allyl alcohol by weight of allyl ester **except** in preparations containing 5% or less of allyl esters with 0.1% or less of free allyl alcohol by weight of allyl esters.

ALPHA‑CYPERMETHRIN:

(a) in aqueous preparations containing 30% or less of alpha‑cypermethrin; or

(b) in other preparations containing 10% or less of alpha‑cypermethrin;

**except** when included in Schedule 5.

AMICARBAZONE.

AMIDITHION.

AMIDOPROPYL BETAINES **except**:

(a) in cosmetic wash‑off preparations containing 30% or less of amidopropyl betaines and, if containing more than 5% of amidopropyl betaines when labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or

(b) in cosmetic leave‑on preparations containing 1.5% or less of amidopropyl betaines; or

(c) in other preparations containing 30% or less of amidopropyl betaines and, if containing more than 5% of amidopropyl betaines, when labelled with warnings to the following effect:

(i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

(ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

2‑AMINO‑6‑CHLORO‑4‑NITROPHENOL in hair dye and eyebrow/eyelash colouring preparations, **except**:

(a) in preparations containing 2% or less of 2‑amino‑6‑chloro‑4‑nitrophenol when applied directly to the hair, or containing 2% or less of 2‑amino‑6‑chloro‑4‑nitrophenol after mixing and when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

(b) in eyelash and eyebrow tinting products containing 1.5% or less of 2‑amino‑6‑chloro‑4‑nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statement:

WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5mm in height.

4‑AMINO‑*m*‑CRESOL in hair dyes and eyebrow/eyelash colouring preparations **except**:

(a) in hair dye preparations containing 1.5% or less of 4‑amino‑m‑cresol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5mm in height; or

(b) in eyelash and eyebrow tinting products containing 1.5% or less of 4‑amino‑*m*‑cresol after mixing for use when the immediate container and primary pack are labelled with the following statement:

WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5mm in height.

2‑AMINO‑5‑ETHYLPHENOL in hair dye preparations **except** in preparations containing 1% or less of 2‑amino‑5‑ethylphenol when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes and eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

4‑AMINO‑2‑HYDROXYTOLUENE in hair dyes and eyebrow/eyelash colouring products **except**:

(a) in hair dye preparations containing 1.5% or less of 4‑amino‑2‑hydroxytoluene after mixing for use when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5mm in height; or

(b) in eyelash and eyebrow tinting products containing 1.5% or less of 4‑amino‑2‑hydroxytoluene after mixing for use when the immediate container and primary pack are labelled with the following statement:

WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals, and when used for eyelash or eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5mm in height.

AMINOCARB in preparations containing 25% or less of aminocarb.

AMINOETHOXYVINYLGLYCINE **except** in preparations containing 15% or less of aminoethoxyvinylglycine.

1‑AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.

4‑AMINO‑3‑NITROPHENOL **except**:

(a) in non‑oxidative hair dye preparations and eyebrow/eyelash colouring products containing 1% or less of 4‑amino‑3‑nitrophenol when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations and eyebrow/eyelash colouring products containing 1% or less of 4‑amino‑3‑nitrophenol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

2,2'‑[(4‑AMINO‑3‑NITROPHENYL)IMINO]BISETHANOL (including its salts) **except**:

(a) in non‑oxidative hair dye preparations containing 2.5% or less of 2,2'‑[(4‑amino‑3‑nitrophenyl)imino]bisethanol after mixing when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations containing 1.25% or less of 2,2'‑[(4‑amino‑3‑nitrophenyl)imino]bisethanol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

*m*‑AMINOPHENOL **except** when used in hair dye and eyebrow/eyelash preparations at a concentration of 1.2% or less of *m*‑aminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

*p*‑ AMINOPHENOL **except** when used in hair dye and eyebrow/eyelash colouring products at a concentration of 1% or less of *p*‑aminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

AMINOPYRALID **except** when included in Schedule 5.

AMITRAZ.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) **except**:

(a) when included in Schedule 5; or

(b) in preparations for human internal therapeutic use; or

(c) in preparations for inhalation when absorbed in an inert solid material; or

(d) in preparations containing 0.5% or less of ammonia.

AMMONIUM COCOYL ISETHIONATE, **except** in cosmetic rinse‑off preparations containing 30% or less of ammonium cocoyl isethionate and, if containing more than 5% of ammonium cocoyl isethionate, when labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER.

AMMONIUM PERSULFATE in hair preparations.

ANILINE (excluding its salts and derivatives) **except** in preparations containing 1% or less of aniline.

ANTIMONY COMPOUNDS **except**:

(a) when included in Schedule 4; or

(b) antimony chloride in polishes; or

(c) antimony titanate pigments in paint; or

(d) in paints or tinters containing 5% or less of antimony calculated on the non‑volatile content of the paint or tinter.

ARBUTIN (ALPHA) **except**:

(a) in preparations for application to the face containing 2% or less alpha‑arbutin with hydroquinone levels of 10mg/kg or less; or

(b) in preparations for application to the body containing 0.5% or less alpha‑arbutin with hydroquinone levels of 10mg/kg or less.

ARBUTIN (BETA) **except**:

(a) when included in Schedule 4; or

(b) oral herbal preparations containing 500 mg or less beta‑arbutin per recommended daily dose; or

(c) in preparations for application to the face containing 7% or less beta‑arbutin with hydroquinone levels of 10mg/kg or less.

ARBUTIN (DEOXY OR OTHER DERIVATIVES).

ARSENIC:

(a) in ant poisons containing 0.4% or less of arsenic; or

(b) in animal feed premixes containing 4% or less of arsenic; or

(c) in preparations for the treatment of animals **except** thiacetarsamide when included in Schedule 4,

**except** when separately specified in this Schedule.

ASPIRIN for the treatment of animals **except** when included in Schedule 4 or 5.

AZACONAZOLE **except** in preparations containing 1% or less of azaconazole.

AZADIRACHTA INDICA (Neem) including its extracts and derivatives **except**:

(a) when included in Schedule 5; or

(b) in preparations for human internal use; or

(c) debitterised neem seed oil; or

(d) in preparations for human dermal therapeutic use containing cold pressed neem seed oil, when in a container fitted with a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(e) in preparations for dermal use containing 1% or less of cold pressed neem seed oil.

AZAMETHIPHOS.

AZOBENZENE.

BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2% or less of antibiotic substances.

BARIUM SALTS **except**:

(a) when included in Schedule 5; or

(b) barium sulfate; or

(c) in paints or tinters containing 5% or less of barium calculated on the non‑volatile content of the paint or tinter.

BASIC BLUE 26 (CAS No. 2580‑56‑5) **except** when used as a colourant in cosmetics not intended to be in contact with mucous membranes.

BASIC ORANGE 31 (2‑[(4‑aminophenyl)azo]‑1,3‑dimethyl‑1H‑imidazolium chloride) **except**:

(a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or

(b) in hair dye preparations containing 1% or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN;

(ii) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

(iii) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

BASIC RED 76 (CAS No. 68391‑30‑0) in non‑oxidative hair dye preparations and eyebrow/eyelash colouring products containing 2% or less of Basic Red 76 and 0.001% or less of free *o‑*anisidine.

BAY OIL except:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations containing 25% or less of bay oil.

BEAUVERIA BASSIANA **except** when included in Schedule 5.

BENDIOCARB:

(a) in wettable powders containing 80% or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb; or

(b) in wettable powders containing 20% or less of bendiocarb and not less than 0.002% of denatonium benzoate when packed in containers or primary packs containing not less than 48 g of bendiocarb and labelled for use as a fly control preparation; or

(c) in insoluble granular preparations containing 5% or less of bendiocarb; or

(d) when impregnated in plastic resin strip material containing 10% or less of bendiocarb;

**except** when included in Schedule 5.

BENQUINOX.

BENSULIDE.

BENZALKONIUM CHLORIDE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5% or less of benzalkonium chloride.

1,2‑BENZENEDIOL.

BENZOVINDIFLUPYR.

6‑BENZYLADENINE **except** in preparations containing 10% or less of 6‑benzyladenine.

BERYLLIUM.

BETACYFLUTHRIN in preparations containing 12.5% or less of betacyfluthrin **except** when included in Schedule 5.

BETA‑CYPERMETHRIN.

BHC (excluding lindane).

BICYCLOPYRONE **except** when included in Schedule 5.

BIFENTHRIN in preparations containing 25% or less of bifenthrin **except** in preparations containing 0.5% or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 3% or less of total bifluorides **except** when included in Schedule 5.

BIOALLETHRIN **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1% or less of bioallethrin.

1,3‑BIS(2,4‑DIAMINOPHENOXY)PROPANE (including its salts) **except** when in hair dye preparations containing 1.2% or less of 1,3‑bis(2,4‑diaminophenoxy)propane after mixing when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

BIS‑ISOBUTYL PEG/PPG‑20/35/AMODIMETICONE COPOLYMER **except** in rinse‑off cosmetic products containing 1% or less of bis‑isobutyl PEG/PPG‑20/35/amodimeticone copolymer when labelled with a warning to the following effect:

IF IN EYES, WASH OUT IMMEDIATELY WITH WATER.

*N*,*N*‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,5‑DIMETHANAMINE **except** in preparations containing 1% or less of *N*,*N*‑bis(phenylmethylene)‑bicyclo‑ (2.2.1)heptane‑2,5‑dimethanamine, or a combination of *N*,*N*‑bis(phenylmethylene)‑bicyclo‑(2.2.1)heptane‑2,5‑dimethanamine and N,N‑bis(phenylmethylene)‑bicyclo‑(2.2.1)heptane‑2,6‑dimethanamine, when labelled with statements to the effect of:

(a) IRRITANT; and

(b) REPEATED EXPOSURE MAY CAUSE SENSITISATION; and

(c) Avoid contact with eyes; and

(d) Avoid contact with skin; and

(e) Wear protective gloves when mixing or using; and

(f) Ensure adequate ventilation when using.

*N,N*‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,6‑DIMETHANAMINE **except** in preparations containing 1% or less of *N*,*N*‑bis(phenylmethylene)‑bicyclo‑(2.2.1)heptane‑2,6‑dimethanamine, or a combination of *N*,*N*‑bis(phenylmethylene)‑bicyclo‑(2.2.1)heptane‑2,5‑dimethanamine and *N*,*N*‑bis(phenylmethylene)‑bicyclo‑(2.2.1)heptane‑2,6‑dimethanamine, when labelled with statements to the effect of:

(a) IRRITANT; and

(b) REPEATED EXPOSURE MAY CAUSE SENSITISATION; and

(c) Avoid contact with eyes; and

(d) Avoid contact with skin; and

(e) Wear protective gloves when mixing or using; and

(f) Ensure adequate ventilation when using.

BITHIONOL for the treatment of animals.

BORON TRIFLUORIDE in preparations containing 1% or less of boron trifluoride (BF3) **except** when included in Schedule 5.

BRODIFACOUM in preparations containing 0.25% or less of brodifacoum.

BROFLANILIDE **except** when included in Schedule 5.

BROMADIOLONE in preparations containing 0.25% or less of bromadiolone.

BROMETHALIN in rodent baits containing 0.01% or less of bromethalin.

BROMOFORM **except** when included in Schedule 4.

BROMOPHOS.

BROMOPHOS‑ETHYL.

BROMOXYNIL.

BROMUCONAZOLE **except** when included in Schedule 5.

BROTIANIDE.

BUNAMIDINE.

BUTACARB.

BUTOXYCARBOXIM **except** when included in Schedule 5.

2‑BUTOXYETHANOL and its acetates **except**:

(a) in plant growth regulator preparations containing 20% or less of such substances; or

(b) in other preparations containing 10% or less of such substances.

2‑BUTOXY‑2'‑THIOCYANODIETHYL ETHER.

*n*‑BUTYL ALCOHOL **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5% or less of n‑butyl alcohol; or

(c) in preparations for cosmetic or therapeutic use other than in spray form.

BUTYRIC ACID in preparations for use as insect lures.

CACODYLIC ACID:

(a) in animal feed premixes containing 4% or less of arsenic; or

(b) in herbicide or defoliant preparations containing 10% or less of cacodylic acid.

CADMIUM COMPOUNDS **except**:

(a) when included in Schedule 4; or

(b) in paints or tinters containing 0.1% or less of cadmium calculated on the non‑volatile content of the paint or tinter.

CADUSAFOS in aqueous preparations containing 20% or less of microencapsulated cadusafos.

CAFFEINE **except**:

(a) when included in Schedule 4; or

(b) in divided preparations for internal human therapeutic use when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or

(c) in undivided preparations for internal human therapeutic use with a concentration of less than 5% of total caffeine and when labelled with a maximum recommended daily dose of no greater than 600 mg of total caffeine; or

(d) in preparations for external use; or

(e) in other preparations with a concentration of less than 5% of caffeine.

CAJUPUT OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations containing 25% or less of cajuput oil; or

(f) in oils containing 25% or less of cajuput oil.

CALCIFEROL in rodent baits containing 0.1% or less of calciferol.

CAMBENDAZOLE.

CAMPHOR **except**:

(a) when included in Schedule 4 or 5; or

(b) when enclosed in an inhaler device which prevents ingestion of its contents; or

(c) in solid or semi‑solid preparations containing 12.5% or less of camphor; or

(d) in liquid preparations containing 2.5% or less of camphor; or

(e) in essential oils when the camphor is present as a natural component of the oil:

(i) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(ii) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(iii) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(A) KEEP OUT OF REACH OF CHILDREN; and

(B) NOT TO BE TAKEN; or

(iv) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:

(A) KEEP OUT OF REACH OF CHILDREN; and

(B) NOT TO BE TAKEN; or

(f) in rosemary oil, sage oil (Spanish), or lavandin oil as such.

CAPTAN.

CARBARYL **except** when included in Schedule 4 or 5.

CARBON DISULFIDE.

CARBAMIDE PEROXIDE **except**:

(a) when included in Schedule 5; or

(b) in other preparations containing 9% or less of carbamide peroxide.

CARBETAMIDE.

CASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for cosmetic use **except** in wash‑off preparations containing 1% or less of castor oil, monomaleate.

CHLORALOSE (alpha‑CHLORALOSE) when packed and labelled for use as a pesticide.

CHLORDANE.

CHLORFENAPYR in preparations containing 36% or less of chlorfenapyr **except** when included in Schedule 5.

CHLORFENETHOL.

CHLORHEXIDINE in preparations containing 7% or less of chlorhexidine **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1% or less of chlorhexidine; or

(c) when in solid preparations.

CHLORINATING COMPOUNDS **except**:

(a) when included in Schedule 5; or

(b) when separately specified in these Schedules; or

(c) sodium hypochlorite preparations with A pH of less than 11.5; or

(d) in liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or

(e) in liquid preparations containing less than 2% of available chlorine; or

(f) in other preparations containing 4% or less of available chlorine.

CHLORMEQUAT.

CHLOROACETAMIDE

(a) in preparations for cosmetic use; or

(b) in preparations for topical therapeutic use; or

(c) in other preparations containing more than 0.3% of chloroacetamide.

2‑CHLORO‑6‑(ETHYLAMINO)‑4‑NITROPHENOL **except**:

(a) in non‑oxidative hair dye preparations containing 3% or less of 2‑chloro‑6‑(ethylamino)‑4‑nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations containing 1.5% or less of 2‑chloro‑6‑(ethylamino)‑4‑nitrophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

CHLOROFORM **except**:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 10% or less of chloroform.

ALPHA‑CHLOROHYDRIN.

CHLOROPHACINONE.

(*E*)‑(*S*)‑1‑(4‑CHLOROPHENYL)‑4,4‑DIMETHYL‑2‑(1H‑1,2,4‑TRIAZOL‑1‑YL)PENT‑1‑EN‑3‑OL (uniconazole‑p) **except** in preparations containing 5% or less of (*E*)‑(*S*)‑1‑(4‑chlorophenyl)‑4,4‑dimethyl‑2‑(1*H*‑1,2,4‑triazol‑1‑yl)pent‑1‑en‑3‑ol.

CHLOROPICRIN in preparations containing 5% or less of chloropicrin.

CHLOROTHALONIL **except** in water‑based paint containing 0.5% or less of chlorothalonil.

2‑CHLORO‑6‑(TRICHLOROMETHYL)‑PYRIDINE.

CHLORPYRIFOS **except**:

(a) when included in Schedule 5; or

(b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORPYRIFOS‑METHYL.

CHLORTHIAMID.

CHROMATES (including dichromates) **except** in paints or tinters containing 5% or less of chromium as the ammonium, barium, calcium, iron, potassium, sodium, strontium or zinc chromate calculated on the non‑volatile content of the paint or tinter.

CHROMIUM TRICHLORIDE HEXAHYDRATE **except** in preparations containing 0.5% or less chromium.

CHROMIUM TRIOXIDE (excluding its salts and derivatives).

CHRYSOIDINE BASE **except** when in Schedule 10.

CINEOLE **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations containing 25% or less of cineole; or

(f) in oils containing 25% or less of cineole; or

(g) in rosemary oil or camphor oil (white).

CINNAMON LEAF OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations containing 25% or less of cinnamon leaf oil.

CLIMBAZOLE **except**:

(a) when included in Schedule 5; or

(b) in leave‑on hair, face and foot cosmetic preparations containing 0.5% or less of climbazole; or

(c) in other preparations (that are not leave‑on cosmetic preparations) containing 2% or less of climbazole.

CLODINAFOP‑PROPARGYL.

CLOMAZONE.

CLOSANTEL.

CLOTHIANIDIN **except**

(a) when included in Schedule 5; or

(b) when in gel preparations dispensed in sealed cartridges containing 1% or less of clothianidin.

CLOTRIMAZOLE for the external treatment of animals.

CLOVE OIL **except**:

(a) when included in Schedule 5; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN;

(e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(f) in preparations containing 25% or less of clove oil.

*N*‑COCO‑1,3‑DIAMINOPROPANE.

COCOYL GLYCINATE in cosmetic preparations **except**:

(a) in leave‑on preparations containing 5% or less of cocoyl glycinate; or

(b) in wash‑off preparations containing 30% or less of cocoyl glycinate and, when containing more than 5% of cocoyl glycinate labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER.

COPPER ACETATE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5% or less of copper acetate.

COPPER COMPOUNDS **except**:

(a) when separately specified in these Schedules; or

(b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or

(c) pigments where the solubility of the copper compound(s) in water is 1 g per litre or less; or

(d) in feed additives containing 1% or less of copper; or

(e) in other preparations containing 5% or less of copper compounds.

COPPER HYDROXIDE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 12.5% or less of copper hydroxide.

COPPER NITRATE in preparations containing copper chloride for the treatment of footrot in sheep.

COPPER OXIDES **except**:

(a) when included in Schedule 5; or

(b) in preparations for internal use; or

(c) in marine paints; or

(d) in other preparations containing 5% or less of copper oxides.

COPPER OXYCHLORIDE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 12.5% of less of copper oxychloride.

COPPER SULFATE **except**:

(a) when included in Schedule 5; or

(b) in preparations for internal use; or

(c) in other preparations containing 5% or less of copper sulfate.

COUMAPHOS:

(a) in slow‑release plastic matrix ear tags for livestock use containing 6 g or less of coumaphos; or

(b) in other preparations containing 5% or less of coumaphos.

COUMATETRALYL in rodenticides containing 1% or less of coumatetralyl **except** when included in Schedule 5.

CREOSOTE derived from wood other than beechwood **except**:

(a) when included in Schedule 2; or

(b) in preparations for human therapeutic use containing 10% or less of creosote derived from wood other than beechwood; or

(c) in other preparations containing 3% or less of phenols and homologues of phenol boiling below 220°C.

CROTOXYPHOS.

CRUFOMATE.

CYANAMIDE.

CYANAZINE.

CYCLANILIDE.

*N*‑CYCLOHEXYLDIAZENIUMDIOXY‑POTASSIUM.

CYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2) when presented in a wipe and when packaged in a container with a child‑resistant closure, with chemical resistant gloves and labelled with the following effect:

(a) DO NOT USE WITHOUT PROTECTIVE GLOVES; and

(b) KEEP OUT OF EYES.

CYFLUTHRIN **except**:

(a) when included in Schedule 5; or

(b) in pressurised spray packs containing 1% or less of cyfluthrin.

CYOMETRINIL.

CYPERMETHRIN **except** when included in Schedule 5.

CYPHENOTHRIN **except** when included in Schedule 5.

CYTHIOATE **except** when included in Schedule 5.

2,4‑D **except** when included in Schedule 5.

DAZOMET.

DELTAMETHRIN:

(a) in aqueous preparations containing 25% or less of deltamethrin, when no organic solvent, other than 10% or less of a glycol, is present; or

(b) in wettable granular preparations containing 25% or less of deltamethrin; or

(c) in water‑dispersible tablets each containing 500 mg or less of deltamethrin; or

(d) in emulsifiable concentrates containing 11% or less of deltamethrin in a solvent containing 40% or less of acetophenone and 45% or less of liquid hydrocarbons; or

(e) in other preparations containing 3% or less of deltamethrin;

**except**:

(f) when included in Schedule 5; or

(g) in factory prepared mosquito nets containing 1% or less of deltamethrin; or

(h) in preparations containing 0.1% or less of deltamethrin.

DERQUANTEL.

1‑DEOXY‑1‑(METHYLAMINO)‑d‑GLUCITOL *N*‑COCO ACYL DERIVATIVES **except**:

(a) in cosmetic rinse‑off preparations containing 8% or less of 1‑deoxy‑1‑(methylamino)‑d‑glucitol N‑coco acyl derivatives when labelled with the following statement:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER, or

(b) in household cleaning preparations, other than those intended to be sprayed, containing 10% or less of 1‑deoxy‑1‑(methylamino)‑d‑glucitol N‑coco acyl derivatives when labelled with the following statement:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER.

2,4‑DIAMINOPHENOXYETHANOL **except** when used in hair dye and eyebrow/eyelash preparations at concentrations of 2% or less of 2,4‑diaminophenoxyethanol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

DIAZINON **except** when included in Schedule 5.

DICAMBA (including its salts and derivatives) **except** when included in Schedule 5.

DICHLOBENIL.

DICHLOFENTHION.

DICHLOFLUANID.

*o*‑DICHLOROBENZENE.

DICHLOROETHYL ETHER.

DICHLOROISOCYANURIC ACID **except**:

(a) when included in Schedule 5; or

(b) in liquid preparations containing not less than 2% but not more than 4% of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products; or

(c) in liquid preparations containing less than 2% of available chlorine; or

(d) in other preparations containing 4% or less of available chlorine.

4,5‑DICHLORO‑2‑N‑OCTYL‑3(2*H*)‑ISOTHIAZOLONE.

DICHLOROPHEN **except**:

(a) when included in Schedule 4 or 5; or

(b) in fabrics other than when:

(i) for human therapeutic use; or

(ii) as part of a registered pesticidal product.

1,2‑DICHLOROPROPANE.

2,4‑DICHLORPROP (including the R and S enantiomers).

DICHLORVOS in preparations containing 50% or less of dichlorvos **except** when included in Schedule 5.

DICLOFOP‑METHYL.

DICYCLANIL **except** in preparations containing 6.5% or less of dicyclanil.

DIDECYLDIMETHYLAMMONIUM SALTS **except** in preparations containing 1% or less of didecyldimethylammonium salts labelled with the statement:

Avoid contact with eyes.

DIELDRIN.

DIETHANOLAMINE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5% or less of diethanolamine.

DIETHYLENE GLYCOL (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in paints or paint tinters; or

(c) in toothpastes or mouthwashes containing more than 0.25% of diethylene glycol; or

(d) in other preparations containing 2.5% or less of diethylene glycol.

DIETHYLENE GLYCOL MONOMETHYL ETHER.

DIFENACOUM in preparations containing 0.25% or less of difenacoum.

DIFENZOQUAT.

DIFETHIALONE in rodent baits containing 0.0025% or less of difethialone.

5,6‑DIHYDROXYINDOLINE.

DIMETHENAMID‑P.

DIMETHIPIN.

DIMETHOATE.

2,6‑DIMETHOXY‑3,5‑PYRIDINEDIAMINE **except** when used in hair dye and eyebrow/eyelash colouring products at a concentration of 0.25% or less of 2,6‑dimethoxy‑3,5‑pyridinediamine after mixing for use when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

DIMETHYLACETAMIDE **except** when included in Schedule 5.

*N*,*N*‑DIMETHYLDECANAMIDE.

DIMETHYLFORMAMIDE **except**:

(a) when included in Schedule 5; or

(b) in silicone rubber mastic containing 2% or less of dimethylformamide.

4,4‑DIMETHYL‑1‑CYCLOHEXENE‑1‑PROPANAL **except**:

(a) in leave‑on cosmetic preparations containing 0.1% or less of 4,4‑dimethyl‑1‑cyclohexene‑1‑propanal; or

(b) in rinse‑off cosmetic preparations containing 0.5% or less of 4,4‑dimethyl‑1‑cyclohexene‑1‑propanal; or

(c) in other preparations containing 1% or less of 4,4‑dimethyl‑1‑cyclohexene‑1‑propanal.

3,7‑DIMETHYL‑2,6‑OCTADIEN‑1‑OL and its isomers **except** in products containing 5% or less 3,7‑dimethyl‑2,6‑octadien‑1‑ol and its isomers.

*N*,*N*‑DIMETHYLOCTANAMIDE.

DIMETHYL SULFOXIDE (excluding dimethyl sulfone):

(a) when not for therapeutic use; or

(b) in cosmetic preparations; or

(c) for the treatment of animals:

(i) when combined with no other therapeutic substance(s); or

(ii) in liquid preparations containing copper salicylate and 1% or less of methyl salicylate as the only other therapeutic substances; or

(iii) in clay poultices containing 2% or less of dimethyl sulfoxide; or

(d) in other preparations **except** when containing 10% or less of dimethyl sulfoxide.

DIMPROPYRIDAZ **except** when included in Schedule 5.

DINITROCRESOLS and their homologues in preparations containing 5% or less of such compounds **except**:

(a) when included in Schedule 4; or

(b) when separately specified in this Schedule.

DINITROPHENOLS and their homologues in preparations containing 5% or less of such compounds **except**:

(a) when included in Schedule 4; or

(b) when separately specified in this Schedule.

DIOXACARB.

DIOXANE **except**:

(a) in preparations for cosmetic or human internal therapeutic use containing 0.001% or less of dioxane; or

(b) in other preparations containing 0.01% or less of dioxane.

DIPHACINONE.

DIQUAT in preparations containing 20% or less of diquat.

DIRECT RED 254 **except** when included in Schedule 5.

DISPERSE YELLOW 3 **except** when in Schedule 10.

DISULFIRAM **except** when included in Schedule 4.

DISULFOTON in granular preparations containing 5% or less of disulfoton.

DITHIANON.

DITHIAZANINE in preparations containing 2% or less of dithiazanine for the treatment of animals.

DIUREDOSAN.

*N*‑(*N*‑DODECYL)‑2‑PYRROLIDONE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25% or less of designated solvents.

DODINE.

DORAMECTIN for external use for the treatment of animals, in preparations containing 2% or less of doramectin.

DSMA in herbicide or defoliant preparations containing 10% or less of DSMA.

ECONAZOLE for the external treatment of animals.

EMAMECTIN in preparations containing 5% or less of emamectin **except** when included in Schedule 5.

EMODEPSIDE for the treatment of animals **except** when included in Schedule 5.

ENDOSULFAN in aqueous preparations containing 33% or less of microencapsulated endosulfan.

ENDOTHAL in preparations containing 20% or less of endothal.

EPRINOMECTIN for internal use in preparations containing 5% or less of eprinomectin **except** when included in Schedule 5.

EPTC.

ESBIOTHRIN **except**:

(a) when included in Schedule 5; or

(b) in pressurised spray packs containing 1% or less of esbiothrin.

ESFENVALERATE **except** when included in Schedule 5.

ETHEPHON (excluding its salts and derivatives).

ETHER **except**:

(a) when included in Schedule 2, 4 or 5; or

(b) in preparations containing 10% or less of ether.

ETHIOFENCARB.

ETHOATE‑METHYL.

ETHOPROPHOS in granular formulations containing 10% or less of ethoprophos and 2% of linseed oil.

ETHYL BROMIDE.

ETHYLENE CHLOROHYDRIN.

ETHYLENE DICHLORIDE.

ETHYLENE GLYCOL (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in paints or paint tinters; or

(c) in toothpastes or mouthwashes containing more than 0.25% of ethylene glycol; or

(d) in other preparations containing 2.5% or less of ethylene glycol.

ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates, **except**:

(a) when separately specified in these Schedules; or

(b) in preparations containing 10% or less of such substances.

ETHYL FORMATE when packed and labelled for use as a fumigant.

ETHYLHEXANEDIOL **except** in preparations containing 5% or less of ethylhexanediol.

2‑ETHYLHEXANOIC ACID and its alkyl esters **except** in preparations containing 5% or less calculated as 2‑ethylhexanoic acid.

ETRIMFOS.

EUCALYPTUS OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations containing 25% or less of eucalyptus oil.

EUGENOL **except**:

(a) when included in Schedule 5; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(f) in preparations containing 25% or less of eugenol.

FAMOXADONE.

FAMPHUR in preparations containing 20% or less of famphur.

FEBANTEL **except**:

(a) in divided preparations containing 1000 mg or less of febantel per dosage unit; or

(b) in undivided preparations containing 10% or less of febantel.

FENAMIPHOS in granular preparations containing 5% or less of fenamiphos.

FENAZAFLOR.

FENBUTATIN OXIDE.

FENCHLORPHOS.

FENITROTHION.

FENOXACRIM in preparations for the treatment of carpets during manufacture.

FENPROPIDIN.

FENPYROXIMATE.

FENTHION in preparations containing 60% or less of fenthion **except** when included in Schedule 5.

FENVALERATE.

FIPRONIL **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 0.05% or less of fipronil.

FLOCOUMAFEN in preparations containing 0.005% or less of flocoumafen.

FLONICAMID.

FLUAZAINDOLIZINE **except** when included in Schedule 5.

FLUAZIFOP‑BUTYL.

FLUAZIFOP‑p‑BUTYL.

FLUAZINAM.

FLUCOFURON in preparations for the treatment of carpets during manufacture.

FLUENSULFONE.

FLUMETHRIN **except** when included in Schedule 5.

FLUMIOXAZIN when contained in water soluble bags individually packed in sealed sachets.

FLUORIDES **except**:

(a) when included in Schedule 5; or

(b) in preparations for human use; or

(c) in preparations containing 15 mg/kg or less of fluoride ion.

FLUPROPANATE.

FLUPYRADIFURONE.

FLUQUINCONAZOLE.

FLUSILAZOL.

FLUTRIAFOL **except** in fertilisers containing 0.5% or less of flutriafol.

FLUVALINATE **except** when included in Schedule 5.

FOMESAFEN SODIUM.

FORMALDEHYDE (excluding its derivatives) in preparations containing 0.05% or more of free formaldehyde **except**:

(a) for human therapeutic use; or

(b) in oral hygiene preparations; or

(c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or

(d) in nail hardener cosmetic preparations containing 0.2% or less of free formaldehyde when labelled with the statement:

PROTECT CUTICLES WITH GREASE OR OIL;

(e) in all other cosmetic preparations; or

(f) in other preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

FORMOTHION.

FOSPIRATE **except** when included in Schedule 5.

FUMAGILLIN.

FURFURAL **except** in preparations containing 0.1% or less of furfural.

GLUTARAL **except**:

(a) when included in Schedule 2 or 5; or

(b) in preparations containing 0.5% or less of glutaral when labelled with the statements:

IRRITANT; and

Avoid contact with eyes.

GLYCERYL THIOGLYCOLLATE in hair waving preparations **except** when labelled with directions for use that include the statement:

Wear protective gloves when using. Keep out of eyes.

GLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and labelled for use as an agricultural chemical **except**:

(a) in cosmetic preparations for salon use only, when labelled in accordance with requirements under applicable jurisdictional Work Health and Safety laws, as amended from time to time; or

(b) in preparations containing 5% or less of glycolic acid; or

(c) in preparations containing 20% or less of glycolic acid with A pH of 3.5 or greater.

GUANIDINE **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 1% or less of guanidine.

GUAZATINE.

HALOXON.

HALOXYFOP.

HC VIOLET 1 **except**:

(a) in non‑oxidative hair dye preparations containing 0.28% or less of HC Violet 1 after mixing when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations containing 0.25% or less of HC Violet 1 after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

HEPTACHLOR.

HEXACHLOROPHENE:

(a) in preparations for the treatment of animals; or

(b) for cosmetic use.

HEXAZINONE **except** when included in Schedule 5.

HEXYLOXYETHANOL **except** in preparations containing 10% or less of hexyloxyethanol.

HYDRAMETHYLNON **except** when included in Schedule 5.

HYDRAZINE.

HYDROCHLORIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations for therapeutic use; or

(c) in preparations containing 0.5% or less of hydrochloric acid (HCl).

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 1% or less of hydrogen fluoride **except** when included in Schedule 5.

HYDROGEN PEROXIDE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in hair dye preparations containing 6% (20 volume) or less of hydrogen peroxide; or

(c) in other preparations containing 3% (10 volume) or less of hydrogen peroxide.

HYDROQUINONE **except**:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 10% or less of hydroquinone.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 1% or less of hydrosilicofluoric acid (H2SiF6) **except** when included in Schedule 5.

HYDROXYETHYL‑3,4‑METHYLENEDIOXYANILINE (including its salts) **except** in oxidative hair dye preparations containing 1.5% or less of hydroxyethyl‑3,4‑methylenedioxyaniline after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

IMIDACLOPRID **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5% or less of imidacloprid.

IMIDOCARB.

IMINOCTADINE TRIALBESILATE.

IMIPROTHRIN **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 10% or less of imiprothrin.

INDAZIFLAM.

INDOXACARB (includes the R and S enantiomers) **except** when included in Schedule 5.

INPYRFLUXAM.

IODINE (excluding its salts, derivatives and iodophors) **except**:

(a) when included in Schedule 2; or

(b) in solid or semi‑solid preparations containing 2.5% or less of available iodine.

IODOPHORS **except** in preparations containing 1.5% or less of available iodine.

3‑IODO‑2‑PROPYNYL BUTYL CARBAMATE (Iodocarb) **except**:

(a) when included in Schedule 5; or

(b) in aqueous preparations not for cosmetic use containing 10% or less of 3‑iodo‑2‑propynyl butyl carbamate (Iodocarb); or

(c) in cosmetic preparations (other than aerosolised preparations) containing 0.1% or less of 3‑iodo‑2‑propynyl butyl carbamate.

IOXYNIL.

IPCONAZOLE **except** when included in Schedule 5.

IRON COMPOUNDS (excluding up to 1% of iron oxides when present as an excipient) for the treatment of animals **except**:

(a) when included in Schedule 5; or

(b) in liquid or gel preparations containing 0.1% or less of iron; or

(c) in animal feeds or feed premixes.

ISOCONAZOLE for the external treatment of animals.

ISOCYANATES, free organic, boiling below 300° C, **except** in:

(a) viscous polyurethane adhesives; or

(b) viscous polyurethane sealants;

containing not more than 0.7% of free organic isocyanates boiling below 300°C.

ISOCYCLOSERAM.

ISOEUGENOL **except**:

(a) when included in Schedule 5; or

(b) in preparations not intended for skin contact containing 10% or less of isoeugenol; or

(c) in preparations intended for skin contact containing 0.02% or less of isoeugenol.

ISOPYRAZAM.

ISOTIANIL.

LAMBDA‑CYHALOTHRIN:

(a) in aqueous preparations containing 25% or less of microencapsulated lambda‑cyhalothrin; or

(b) in emulsifiable granule formulations containing 25% or less lambda‑cyhalothrin; or

(c) in other preparations containing 1.6% or less of lambda‑cyhalothrin;

**except** when included in Schedule 5.

LASALOCID **except** in animal feeds containing 100 mg/kg or less of antibiotic substances.

LAURETH CARBOXYLIC ACIDS (excluding their salts and derivatives) **except**:

(a) in leave‑on preparations containing 1.5% or less of laureth carboxylic acids; or

(b) in wash‑off preparations containing 30% or less of laureth carboxylic acids and, if containing more than 5% of laureth carboxylic acids, when labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or

(c) in other preparations containing 30% or less of laureth carboxylic acids and, if containing more than 5% of laureth carboxylic acids, when labelled with warnings to the following effect:

(i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

(ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

LAURYL ISOQUINOLINIUM BROMIDE.

LAURYL SULFATE SALTS (excluding their derivatives) **except**:

(a) in wash‑off preparations containing 30% or less of lauryl sulfates and, if containing more than 5% of lauryl sulfates, when labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or

(b) in leave‑on preparations containing 1.5% or less of lauryl sulfates; or

(c) in toothpaste and oral hygiene preparations containing 5% or less of lauryl sulfates; or

(d) in other preparations for animal use containing 2% or less of lauryl sulfates; or

(e) in other preparations containing 30% or less of lauryl sulfates and, if containing more than 5% of lauryl sulfates, when labelled with warnings to the following effect:

(i) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

(ii) IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

LEAD COMPOUNDS **except**:

(a) when included in, or expressly excluded from, Schedule 10; or

(b) in preparations for cosmetic use containing 10 mg/kg or less of lead; or

(c) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 25 mg/kg or less of lead; or

(d) in ceramic glazes when labelled with the warning statement:

CAUTION – Harmful if swallowed. Do not use on surfaces which contact food or drink;

written in letters not less than 1.5 mm in height.

LEPTOSPERMUM SCOPARIUM OIL (manuka oil) **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings;

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations containing 25% or less of Leptospermum scoparium oil.

LEVAMISOLE for the treatment of animals **except**:

(a) when included in Schedule 4 or 5; or

(b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LINDANE **except** when included in Schedule 2, 4 or 5.

MAFENIDE when packed and labelled for the treatment of ornamental fish only.

MALATHION **except**:

(a) when included in Schedule 5; or

(b) for human therapeutic use; or

(c) in dust preparations containing 2% or less of malathion.

MCPA **except** when included in Schedule 5.

MCPB.

MEBENDAZOLE for the treatment of animals **except** when included in Schedule 5.

MECOPROP **except** when included in Schedule 5.

MECOPROP‑*P*.

MEFLUIDIDE.

MELALEUCA OIL (tea tree oil) **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(e) in preparations containing 25% or less of melaleuca oil.

MELENGESTROL ACETATE when used as an animal feed additive.

MELOXICAM in:

(a) oral transmucosal preparations containing 1% or less of meloxicam for pre‑surgical treatment and pain management in livestock during routine husbandry procedures; or

(b) injectable vaccines containing bacterial antigens and 1% or less of meloxicam for single use in lambs undergoing husbandry procedures at marking.

MENAZON.

MERCAPTAMINE for cosmetic use **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1% or less of mercaptamine.

MERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic preparations **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5% or less of mercaptoacetic acid or its salts (as mercapturic acid).

2‑MERCAPTOETHANOL in preparations for use as insect lures.

MERCURIC OXIDE for the treatment of animals, in preparations for ocular use.

MERCUROCHROME for the treatment of animals, in preparations for topical use.

METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT for the treatment of animals.

METALAXYL **except** when included in Schedule 5.

METALDEHYDE **except** when included in Schedule 5.

METHACRIFOS in preparations containing 60% or less of methacrifos.

METHAM.

METAMITRON.

METHANOL (excluding its derivatives) **except**:

(a) when included in Schedule 5; or

(b) when included in Schedule 10; or

(c) in preparations containing 2% or less of methanol.

METHIOCARB in preparations containing 20% or less of methiocarb **except** when included in Schedule 5.

METHOMYL in fly‑baits containing 1% or less of methomyl and not less than 0.002% of denatonium benzoate as a bittering agent.

6‑METHOXY‑N2‑METHYL‑2,3‑PYRIDINEDIAMINE **except** when used in oxidative or non‑ oxidative hair dyes at a concentration of 1% or less when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height.

2‑METHOXY‑5‑NITROPHENOL.

METHYLCHLOROISOTHIAZOLINONE **except**:

(a) in rinse‑off cosmetic preparations or therapeutic goods intended for topical rinse‑off application containing 0.0015% or less of methylchloroisothiazolinone and methylisothiazolinone in total; or

(b) in other preparations that are not intended for direct application to the skin containing 0.1% or less of methylchloroisothiazolinone and methylisothiazolinone in total.

METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL in preparations containing 10% or less of methylcyclopentadienyl manganese tricarbonyl when fitted with a child‑resistant closure.

METHYLDIBROMO GLUTARONITRILE **except** when in Schedule 10.

METHYLENE BISTHIOCYANATE **except** in preparations containing 1% or less of methylene bisthiocyanate.

METHYLEUGENOL **except** in preparations containing 1% or less of methyleugenol.

METHYL ETHYL KETONE OXIME **except**:

(a) in viscous silicone adhesives or viscous silicone sealants containing 2.5% or less of methyl ethyl ketone oxime; or

(b) in other preparations containing 1% or less of methyl ethyl ketone oxime.

*p*‑METHYLAMINOPHENOL **except** when used in hair dye and eyebrow/eyelash colouring products at a concentration of 1% or less of *p*‑methylaminophenol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

METHYL ISOTHIOCYANATE.

METHYL METHACRYLATE (excluding its derivatives) **except**:

(a) for cosmetic use; or

(b) in preparations containing 1% or less of methyl methacrylate as residual monomer in a polymer.

METHYL NEODECANAMIDE **except** in liquid preparations containing 2% or less of methyl neodecanamide.

METHYLISOTHIAZOLINONE **except**:

(a) in rinse‑off cosmetic preparations or therapeutic goods intended for topical rinse‑off application containing 0.0015% or less of methylisothiazolinone; or

(b) in other preparations that are not intended for direct application to the skin containing 0.1% or less of methylisothiazolinone

METHYLNORBORNYLPYRIDINE.

*N*‑METHYL‑2‑PYRROLIDONE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25% or less of designated solvents.

2‑METHYLRESORCINOL **except**:

(a) in non‑oxidative hair dye preparations containing 1.8% or less of 2‑methylresorcinol when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations containing 1.8% or less of 2‑methylresorcinol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letter not less than 1.5 mm in height.

METHYLROSANILINIUM CHLORIDE (formerly known as crystal violet CAS No. 548‑62‑9) and the following TRIARYLMETHANE DYES:

(a) Acid Violet 49 (CAS No. 1694‑09‑3);

(b) Ethyl Violet (CAS No. 2390‑59‑2);

(c) Basic Blue 7 (CAS No. 2390‑60‑5);

(d) Methylium, 4‑(dimethylamino)phenylbis4‑(ethylamino)‑3‑methylphenyl‑, acetate (CAS No. 72102‑55‑7);

**except** when included in Schedule 4 or Schedule 10.

METHYL SALICYLATE **except**:

(a) when included in Schedule 5; or

(b) in preparations for therapeutic use; or

(c) in preparations containing 5% or less of methyl salicylate.

METOFLUTHRIN **except** when included in Schedule 5.

METOSULAM.

METRAFENONE **except** when included in Schedule 5.

METRIBUZIN.

MICONAZOLE for the external treatment of animals.

MILBEMECTIN **except** when included in Schedule 5.

MOMFLUOROTHRIN **except** in preparations containing 0.2% or less of momfluorothrin.

MONENSIN:

(a) in animal feed premixes containing 12.5% or less of antibiotic substances; or

(b) in stockfeed supplements, blocks or licks containing 0.75% or less of antibiotic substances.

MONOETHANOLAMINE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 4 or 5; or

(b) in preparations containing 5% or less of monoethanolamine.

MORANTEL **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 10% or less of morantel.

MOXIDECTIN:

(a) in preparations for external use containing 2.5% or less of moxidectin when packed in single dose tubes for the treatment of cats and dogs; or

(b) in preparations for external use containing 2% or less of moxidectin for the treatment of animals; or

(c) in preparations for internal use containing 10% or less of moxidectin for the treatment of sheep or cattle;

**except** when included in Schedule 5.

MSMA in herbicide or defoliant preparations containing 10% or less of MSMA.

NALED **except** when included in Schedule 5.

NAPHTHALENE (excluding its derivatives) **except** in liquid hydrocarbons.

1,5‑NAPHTHALENEDIOL **except**:

(a) in non‑oxidative hair dye preparations containing 1% or less of 1,5‑naphthalenediol when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations containing 1% or less of 1,5‑naphthalenediol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

2,7‑NAPHTHALENEDIOL **except**:

(a) in non‑oxidative hair dye preparations containing 1% or less of 2,7‑naphthalenediol when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations containing 1% or less of 2,7‑naphthalenediol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

1‑NAPHTHOL **except** in hair dye preparations containing 1% or less of 1‑naphthol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

NAPHTHALOPHOS in preparations containing 80% or less of naphthalophos.

NARASIN in animal feed premixes containing 12% or less of narasin.

NETOBIMIN for the treatment of animals **except** when included in Schedule 5.

NICKEL SULFATE.

NIMIDANE in preparations containing 25% or less of nimidane.

NITENPYRAM **except** in divided preparations containing 100 mg or less of nitenpyram.

NITRIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 0.5% or less of nitric acid (HNO3).

NITROBENZENE **except**:

(a) in solid or semi‑solid polishes; or

(b) in soaps containing 1% or less of nitrobenzene; or

(c) in other preparations containing 0.1% or less of nitrobenzene.

3‑NITRO‑*p*‑HYDROXYETHYLAMINOPHENOL **except**

(a) in non‑oxidative hair dye preparations containing 1.85% or less of 3‑nitro‑*p*‑hydroxyethylaminophenol after mixing when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height; or

(b) in oxidative hair dye preparations containing 3% or less of 3‑nitro‑*p*‑hydroxyethylaminophenol after mixing under oxidative conditions when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

NITROPHENOLS, ortho, meta and para, **except** when separately specified in these Schedules.

NITROPRUSSIDES in preparations containing 2.5% or less of nitroprussides **except** when included in Schedule 4.

NITROUS OXIDE **except** when included in Schedule 4.

NITROXYNIL.

NONOXINOL 9 **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25% or less of nonoxinol 9 when labelled with the statements:

(i) IRRITANT; and

(ii) Avoid contact with eyes; or

(c) in preparations containing 12.5% or less of nonoxinol 9; or

(d) in preparations for human use.

1‑OCTEN‑3‑OL **except** in preparations containing 5% or less of 1‑octen‑3‑ol.

OCTHILINONE **except** in paints, jointing compounds and sealants containing 1% or less of octhilinone calculated on the non‑volatile content.

*N*‑(*N*‑OCTYL)‑2‑PYRROLIDONE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25% or less of designated solvents.

OLAQUINDOX **except** in preparations containing 10% or less of olaquindox.

*N*‑OLEYL‑1,3‑DIAMINOPROPANE.

OMETHOATE in preparations containing 30% or less of omethoate **except** when included in Schedule 5.

OXADIAZON.

OXALIC ACID **except**

(a) in dental care preparations, including mouthwashes, containing 3% or less of soluble salts of oxalic acid; or

(b) its insoluble salts.

OXYCLOZANIDE.

PAECILOMYCES LILACINUS STRAIN 251.

PARAFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05% or more of free formaldehyde **except**:

(a) for human therapeutic use; or

(b) in oral hygiene preparations; or

(c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or

(d) in nail hardener cosmetic preparations containing 0.2% or less of free formaldehyde when labelled with the statement:

PROTECT CUTICLES WITH GREASE OR OIL; or

(e) in all other cosmetic preparations; or

(f) in other preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

PARATHION‑METHYL in aqueous preparations containing 45% or less of microencapsulated parathion‑methyl.

PARBENDAZOLE.

PEBULATE.

PENNYROYAL OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(c) in preparations containing 4% or less of **d**‑pulegone.

PENTACHLOROPHENOL in preparations containing 1.5% or less of pentachlorophenol.

PERACETIC ACID **except** when included in Schedule 5.

PERFLUIDONE.

PERMANGANATES **except** potassium permanganate in aqueous solutions containing 1% or less of potassium permanganate.

PERMETHRIN **except**:

(a) when included in Schedule 4 or 5; or

(b) in preparations for human therapeutic use containing 5% or less of permethrin; or

(c) in preparations containing 2% or less of permethrin.

2‑PHENOXYETHANOL **except**:

(a) in cosmetic preparations containing 1% or less of 2‑phenoxyethanol; or

(b) in other preparations containing 15% or less of 2‑phenoxyethanol.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, **except**:

(a) when separately specified in these Schedules; or

(b) in preparations containing 1% or less of phenols, and in preparations containing 3% or less of cresols and xylenols and other homologues of phenol.

PHENOTHIAZINE (excluding its derivatives) **except** in preparations containing 10% or less of phenothiazine.

PHENOXYMETHYL OXIRANE.

PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives not elsewhere specified in these Schedules:

(a) in preparations packed and labelled for photographic purposes; or

(b) in preparations packed and labelled for testing water **except** tablets containing 10 mg or less of diethyl‑para‑phenylenediamine or dimethyl‑para‑phenylenediamine in opaque strip packaging provided the directions for use include the statement, “Do not discard testing solutions into the pool”; or

(c) in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING ‒ This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height; or

(d) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

WARNING ‒ This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height.

PHENYL METHYL PYRAZOLONE **except** when used in hair dye and eyebrow/eyelash preparations at a concentration of 0.25% or less after mixing for use when the immediate container and primary pack are labelled with warning statements to the following effect:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use.

written in letters not less than 1.5 mm in height.

PHOSALONE.

PHOSMET.

PHOSPHORIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 15% or less of phosphoric acid (H3PO4); or

(c) in solid or semi‑solid preparations; or

(d) in professional dental kits.

PHOXIM.

*o*‑PHTHALALDEHYDE **except** when included in Schedule 5.

PICRAMIC ACID including its salts (excluding other derivatives) **except** when used in hair dye products at a concentration of 0.6% or less of picramic acid after mixing for use when the immediate container and primary pack are labelled with the following statements:

(a) KEEP OUT OF REACH OF CHILDREN; and

(b) WARNING ‒ This product contains ingredients which may cause skin allergy to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height.

PINDONE.

PINE OILs when packed and labelled as a herbicide **except** when included in Schedule 5.

PINOXADEN **except** when included in Schedule 5.

PIPEROPHOS.

PIRIMICARB **except** when included in Schedule 5.

PIRIMIPHOS‑ETHYL.

PIRIMIPHOS‑METHYL.

POLIHEXANIDE **except**:

(a) in cosmetic preparations containing 0.3% or less of polihexanide; or

(b) when packed and labelled for therapeutic use; or

(c) in other preparations containing 5% or less of polihexanide.

POLIXETONIUM SALTS **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1% or less of polixetonium salts.

POTASSIUM AZELOYL DIGLYCINATE **except** in preparations for cosmetic use containing 1% or less of potassium azeloyl diglycinate.

POTASSIUM BROMATE **except** in preparations containing 0.5% or less of potassium bromate.

POTASSIUM CYANATE.

POTASSIUM HYDROXIDE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5 or Schedule 10; or

(b) in preparations containing 5% or less of potassium hydroxide being:

(i) solid preparations, tHE pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(ii) liquid or semi‑solid preparations, tHE pH of which is 11.5 or less.

POTASSIUM NITRITE in preparations containing 40% or less of potassium nitrite **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 0.5% or less of potassium nitrite; or

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2% or less of potassium nitrite.

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT **except**:

(a) when included in Schedule 5; or

(b) in solid orthodontic device cleaning preparations, tHE pH of which as an “in‑use” aqueous solution is 2.5 or more, but not more than 11.5; or

(c) in preparations containing 5% or less of potassium peroxomonosulfate triple salt being:

(i) solid preparations, tHE pH of which in a 10 g/L aqueous solution is 2.5 or more; or

(ii) liquid or semi‑solid preparations, tHE pH of which is 2.5 or more.

POTASSIUM PERSULFATE in hair preparations.

PRALLETHRIN (cis:trans=20:80) **except**:

(a) when included in Schedule 5; or

(b) in insecticidal mats containing 1% or less of prallethrin.

PROCHLORAZ.

PROFENOFOS.

PROMACYL.

PROPACHLOR.

PROPARGITE.

PROPETAMPHOS.

PROPICONAZOLE **except** when included in Schedule 5.

PROPINEB.

PROPIONIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 30% or less of propionic acid; or

(c) for therapeutic use.

PROPOXUR **except** when included in Schedule 5.

*n*‑PROPYL ALCOHOL **except:**

(a) when included in Schedule 5; or

(b) in preparations containing 5% or less of *n*‑propyl alcohol; or

(c) in preparations for cosmetic or therapeutic use other than in spray form.

PROQUINAZID.

PROSULFOCARB.

PROSULFURON.

PROTHIOFOS.

**d**‑PULEGONE **except** in preparations containing 4% or less of d‑pulegone.

PYRACLOFOS.

PYRAZOPHOS.

PYRIDABEN **except** when included in Schedule 5.

PYRIDALYL.

PYRIDATE.

PYRIPROLE.

PYRITHIONE COPPER.

PYRITHIONE ZINC **except**:

(a) when included in Schedule 2 or 5; or

(b) for human use in preparations for the treatment of the scalp containing 2% or less of pyrithione zinc when compliant with the requirements of the required advisory statements for medicine labels; or

(c) in semi‑solid hair preparations for animal use; or

(d) in shampoos for animal use containing 2% or less of pyrithione zinc when labelled with the statements “Keep out of eyes” and “If in eyes rinse well with water”; or

(e) when immobilised in solid preparations containing 0.5% or less of pyrithione zinc; or

(f) in paints, jointing materials or sealants containing 0.1% or less of pyrithione zinc calculated on the non‑volatile content.

PYRIOFENONE **except** when included in Schedule 5.

PYROXASULFONE.

PYROXSULAM.

QUATERNARY AMMONIUM COMPOUNDS **except**:

(a) when separately specified in these Schedules; or

(b) when included in Schedule 5; or

(c) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or

(d) in preparations containing 5% or less of such quaternary ammonium compounds.

QUININE in cosmetic preparations **except**:

(a) in rinse‑off hair preparations containing 0.5% or less of quinine calculated as free base; or

(b) in leave‑on hair preparations containing 0.2% or less of quinine calculated as free base.

QUINOLINE and its salts (excluding other derivatives).

QUIZALOFOP ETHYL.

QUIZALOFOP‑*p*‑ETHYL **except** when included in Schedule 5.

QUIZALOFOP‑*p*‑TEFURYL.

RESCALURE for agricultural use **except** when enclosed in a vapour releasing device which in normal use prevents access to its contents.

RESMETHRIN **except** when included in Schedule 5.

RESORCINOL **except**:

(a) in preparations for human therapeutic use; or

(b) in oxidative hair dye preparations containing 1.25% or less of resorcinol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height; or

(c) in oxidative eyelash and eyebrow dye preparations containing 1.25% or less of resorcinol after mixing for use when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height; or

(d) in hair lotions/shampoo products containing 0.5% or less of resorcinol when the immediate container and primary pack are labelled with the following statement:

WARNING – This product contains ingredients which may cause skin sensitisation to certain individuals;

written in letters not less than 1.5 mm in height.

ROTENONE **except** in solid or semi‑solid preparations containing 2% or less of rotenone.

SAFROLE **except**:

(a) for internal use; or

(b) in other preparations containing 1% or less of safrole.

SAGE OIL (Dalmatian) **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) NOT TO BE TAKEN; or

(c) in preparations containing 4% or less of thujone.

SALINOMYCIN in animal feed premixes containing 12% or less of antibiotic substances.

SAROLANER **except** when included in Schedule 5.

SASSAFRAS OIL **except**:

(a) for internal use; or

(b) in other preparations containing 1% or less of safrole.

SELENIUM:

(a) in preparations containing 2.5% or less of selenium when packed and labelled:

(i) for the blueing of gun barrels; or

(ii) for photographic purposes; or

(iii) for the colouring of lead or lead alloys; or

b) in coated granules containing 1% or less of selenium for application to pasture **except** in fertilisers containing 200 g/tonne or less of selenium; or

(c) for the treatment of animals:

(i) in a drench, injection, paste, stocklick, vaccine or horse feed supplement containing 0.5% or less of selenium; or

(ii) in animal feed premixes containing 2% or less of selenium for the preparation of feeds containing 1 g/tonne or less of selenium; or

(iii) in controlled release bolus preparations containing 25 mg or less of selenium with a release rate not greater than 0.25 mg/day; or

(iv) as barium selenate in preparations for injection containing 5% or less of selenium.

SEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5% or less of antibiotic substances.

SILICOFLUORIDES **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

SILVER NITRATE **except**:

(a) when included in or expressly excluded from Schedule 2; or

(b) in preparations containing 1% or less of silver.

SINBIOALLETHRIN **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1% or less of sinbioallethrin.

SODIUM ALUMINATE (excluding its salts and derivatives) **except**:

(a) in solid preparations, tHE pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(b) in liquid preparations, tHE pH of which is 11.5 or less.

SODIUM BROMATE **except** in preparations containing 0.5% or less of sodium bromate.

SODIUM HYDROXIDE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5 or Schedule 10; or

(b) in preparations containing 5% or less of sodium hydroxide being:

(i) solid preparations, tHE pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(ii) liquid or semi‑solid preparations, tHE pH of which is 11.5 or less.

SODIUM NITRITE:

(a) in preparations containing 15% or less of sodium nitrite **except**:

(i) when included in Schedule 2 or 5; or

(ii) in preparations containing 0.5% or less of sodium nitrite; or

(iii) when present as an excipient in preparations for therapeutic use; or

(iv) in aerosols containing 2% or less of sodium nitrite; or

(b) for use in closed‑loop water treatment systems (products).

SODIUM PERCARBONATE (CAS No. 15630‑89‑4) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 15% or less of sodium percarbonate.

SODIUM PERSULFATE:

(a) in hair preparations; or

(b) in products for the treatment of water for swimming pools and spas.

SODIUM SULFIDE in preparations for use as insect lures.

SPIROPIDION.

SPIROTETRAMAT.

SPIROXAMINE.

SULCOFURON in preparations for the treatment of carpets during manufacture.

SULFAMIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5.

SULFLURAMID.

SULFOXAFLOR **except** when included in Schedule 5.

SULFURIC ACID (excluding its salts and derivatives) **except**:

(a) in fire extinguishers; or

(b) in preparations containing 0.5% or less of sulfuric acid (H2SO4).

SULFURYL FLUORIDE.

SULPROFOS.

2,4,5‑T.

*N*‑TALLOW ALKYL‑1,3‑PROPANEDIAMINE DIACETATE and TALLOW ALKYLAMINE ACETATES.

TAR ACIDS distilling within the range 230‑290°C inclusive.

TCMTB (2‑[thiocyanomethylthio]benzothiazole).

TDE (1,1‑dichloro‑2,2‑bis[4‑chlorophenyl]ethane) **except** when included in Schedule 5.

TEBUFENPYRAD.

TEBUTHIURON.

TEMEPHOS **except** when in Schedule 5.

TERBUTHYLAZINE **except** in preparations containing 5% or less of terbuthylazine.

TERPENES, CHLORINATED.

TESTOSTERONE in implant preparations for use in animals.

TETRACHLOROETHYLENE **except**:

(a) when included in Schedule 2 or 5; or

(b) in preparations containing 6% or less of tetrachloroethylene when absorbed into an inert solid; or

(c) in preparations for the treatment of animals.

TETRACONAZOLE **except** when included in Schedule 5.

TETRADIFON.

TETRAHYDROFURFURYL ALCOHOL (excluding its derivatives).

2,2',6,6'‑TETRAISOPROPYL‑DIPHENYL‑CARBODIIMIDE in amitraz formulations containing 2% or less of 2,2',6,6'‑tetraisopropyl‑diphenyl‑carbodiimide.

TETRAMISOLE in preparations for the treatment of animals.

THIACLOPRID.

THIAMETHOXAM **except** when included in Schedule 5.

THIAZAFLURON.

THIODICARB **except** when included in Schedule 5.

THIOMETON.

THIOPHANATE‑METHYL **except** when included in Schedule 5.

THIOUREA AND ALKYL THIOUREAS **except**:

(a) when separately specified in these Schedules; or

(b) for therapeutic use.

THIRAM **except** in paint containing 0.5% or less of thiram.

THUJONE **except** in preparations containing 4% or less of thujone.

THYMOL when packed and labelled for use as a pesticide.

TIGOLANER **except** when in Schedule 5.

TOLUENE (excluding its derivatives) **except** in preparations containing 50% or less of toluene or toluene and xylene.

TOLUENEDIAMINES not elsewhere specified in these Schedules:

(a) in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:

(i) KEEP OUT OF REACH OF CHILDREN; and

(ii) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

written in letters not less than 1.5 mm in height; or

(b) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

WARNING – This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use;

written in letters not less than 1.5 mm in height; or

(c) in nail polish preparations containing 2,5‑toluenediamine **except** when labelled “avoid contact with skin”.

TOLYLFLUANID.

TRANSFLUTHRIN **except**:

(a) in preparations containing 1% or less of transfluthrin; or

(b) in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per cartridge.

TRIADIMEFON **except**:

(a) when included in Schedule 5; or

(b) in fertilisers containing 5 g/kg or less of triadimefon.

TRICHLORFON **except** metrifonate included in Schedule 4.

TRICHLOROACETIC ACID **except**:

(a) when included in Schedule 4 or 5; or

(b) in human dermal preparations containing 12.5% or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROETHYLENE **except** when included in Schedule 4.

TRICHLOROPHENOL.

TRICLABENDAZOLE **except** in preparations containing 20% or less of triclabendazole.

TRICLOPYR.

TRICLOSAN in cosmetic preparations for human use containing more than 0.3% of triclosan.

TRIDEMORPH.

TRIETHYL PHOSPHATE.

TRIFLUOROMETHANESULFONIC ACID.

TRINITROPHENOL (excluding its derivatives) **except**:

(a) in preparations for human therapeutic use; or

(b) in preparations containing 5% or less of trinitrophenol.

TRISODIUM NITRILOTRIACETATE **except** in preparations containing 20% or less of trisodium nitrilotriacetate.

VAMIDOTHION.

VINYL ACETATE MONOMER (excluding its derivatives) **except**:

(a) in preparations for therapeutic use; or

(b) in cosmetic preparations containing 0.01% or less of vinyl acetate as residual monomer in a polymer; or

(c) in other preparations containing 1% or less of vinyl acetate.

WARFARIN **except** when included in Schedule 4 or 5.

XYLENE (excluding its derivatives) **except** in preparations containing 50% or less of xylene or xylene and toluene.

ZERANOL in ear implants for use as a growth promotant in steer cattle.

ZETA‑CYPERMETHRIN in preparations containing 10% or less of zeta‑cypermethrin.

ZINC BORATE (excluding its derivatives) for use as an agricultural chemical.

ZINC CHLORIDE **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 5% or less of zinc chloride.

ZINC para‑PHENOLSULFONATE **except** in preparations containing 5% or less of zinc para‑phenolsulfonate.

ZINC LACTATE in toothpaste **except** in toothpaste preparations containing 2.5% or less of zinc lactate and labelled with the statement:

Not recommended for children under twelve years of age.

ZINC SULFATE **except**:

(a) when included in or expressly excluded from Schedule 4; or

(b) in other preparations containing 5% or less of zinc sulfate.

ZIRAM in granular preparations.

Schedule 7—Dangerous poisons

Note: See section 16, subsection 54(4) and sections 55, 56, 62 and 65.

ABAMECTIN **except** when included in Schedule 5 or 6.

ACIBENZOLAR‑*S*‑METHYL.

ACRIFLAVINIUM CHLORIDE for veterinary use **except** when in Schedule 5.

ACROLEIN.

ACRYLONITRILE.

ALACHLOR.

ALDICARB.

ALDOXYCARB.

ALLYL ALCOHOL **except**:

(a) in preparations containing 5% or less of allyl esters with 0.1% or less of free allyl alcohol by weight of allyl ester; or

(b) when separately specified in these Schedules.

ALPHA‑CYPERMETHRIN **except** when included in Schedule 5 or 6.

AMINOACRIDINE for veterinary use **except** when included in Schedule 5.

AMINOCARB **except** when included in Schedule 6.

2‑AMINO‑5‑METHYLPHENOL **except** when included in Schedule 10.

4‑AMINOPROPIOPHENONE.

4‑AMINOPYRIDINE **except** when included in Schedule 4.

AMITON.

ARPRINOCID.

ARSENIC **except**:

(a) when separately specified in this Schedule; or

(b) when included in Schedule 4 or 6; or

(c) as selenium arsenide in photocopier drums; or

(d) as 10,10'‑oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of arsenic; or

(e) as 10,10'‑oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded and moulded articles containing 160 mg/kg or less of arsenic other than when included in articles:

(i) in contact with foodstuffs, animal feeds or potable water; or

(ii) of clothing and footwear in contact with the skin; or

(iii) used as infant wear; or

(iv) intended for use as packaging materials; or

(f) in animal feeds containing 75 g/tonne or less of arsenic; or

(g) in paints containing 0.1% or less of arsenic calculated on the non‑volatile content of the paint.

AZAFENIDIN.

AZINPHOS‑ETHYL.

AZINPHOS‑METHYL.

AZOCYCLOTIN.

AZO DYES that are derivatives by diazotisation of any of the following substances:

(a) *p*‑aminoazobenzene (CAS No. 60‑09‑3);

(b) *o*‑aminoazotoluene (CAS No. 97‑56‑3);

(c) *o*‑anisidine (CAS No. 90‑04‑0);

(d) *p*‑chloroaniline (CAS No. 106‑47‑8);

(e) 4‑chloro‑*o*‑toluidine (CAS No. 95‑69‑2);

(f) 2,4‑diaminoanisole (CAS No. 615‑05‑4);

(g) 6‑methoxy‑*m*‑toluidine (p‑cresidine) (CAS No. 120‑71‑8);

(h) 4,4‑methylenedianiline (CAS No. 101‑77‑9);

(i) 2‑naphthylamine (CAS No. 91‑59‑8);

(j) 5‑nitro‑*o*‑toluidine (CAS No. 99‑55‑8);

(k) 2,4‑toluenediamine (CAS No. 95‑80‑7);

(l) *o*‑toluidine (CAS No. 95‑53‑4);

(m) 2,4,5‑trimethylaniline (CAS No. 137‑17‑7);

**except** for BASIC RED 76 (CAS No. 68391‑30‑0) when included in Schedule 6.

BENDIOCARB **except** when included in Schedule 5 or 6.

BENOMYL **except** in paints containing 0.5% or less of benomyl.

BENZENE (excluding its derivatives) **except**:

(a) preparations containing 15 mL/L or less of benzene; or

(b) petrol containing 50 mL/L or less of benzene.

BENZIDINE‑BASED AZO DYES being:

(a) 2,2'‑[[1,1'‑biphenyl]‑4,4'‑diylbis(azo)]bis[*N*‑(4‑chlorophenyl)‑3‑oxobutanamide] (CAS No. 94249‑03‑3); or

(b) Acid Red 85 (Acid Fast Red A): 1,3‑Naphthalenedisulfonic acid, 7‑hydroxy‑8‑[[4'‑[[4‑[[(4‑methylphenyl)sulfonyl]oxy]phenyl]azo][1,1'‑biphenyl]‑4‑yl]azo]‑, disodium salt (CAS No. 3567‑65‑5); or

(c) C.I Acid Black 29: (CAS No. 12217‑14‑0); or

(d) C.I. Direct Orange 1: (CAS No. 54579‑28‑1); or

(e) Direct Black 38: 2,7‑Naphthalenedisulfonic acid, 4‑amino‑3‑[[4'‑[(2,4‑diaminophenyl)azo][1,1'‑biphenyl]‑4‑yl]azo]‑5‑hydroxy‑6‑(phenylazo)‑, disodium salt (CAS No. 1937‑37‑7); or

(f) Direct Blue 2: 2,7‑Naphthalenedisulfonic acid, 5‑amino‑3‑[[4'‑[(7‑amino‑1‑hydroxy‑3‑sulfo‑2‑naphthalenyl)azo][1,1'‑biphenyl]‑4‑yl]azo]‑4‑hydroxy‑, trisodium salt (CAS No. 2429‑73‑4); or

(g) Direct Blue 6: 2,7‑Naphthalenedisulfonic acid, 3,3'‑[[1,1'‑biphenyl]‑4,4'‑diylbis(azo)]bis[5‑amino‑4‑hydroxy‑, tetrasodium salt (CAS No. 2602‑46‑2); or

(h) Direct Brown 2: 5‑[[4'‑[(7‑amino‑1‑hydroxy‑3‑sulfo‑2‑naphthalenyl)azo][1,1'‑biphenyl]‑4‑yl]azo]‑2‑hydroxy‑ benzoic acid disodium salt (CAS No. 2429‑82‑5); or

(i) Direct Brown 95: Cuprate(2‑), [5‑[[4'‑[[2,6‑dihydroxy‑3‑[(2‑hydroxy‑5‑sulfophenyl)azo]phenyl]azo][1,1'‑biphenyl]‑4‑yl]azo]‑2‑hydroxybenzoato(4‑)]‑, disodium salt (CAS No. 16071‑86‑6); or

(j) Direct Green 1: 2,7‑Naphthalenedisulfonic acid, 4‑amino‑5‑hydroxy‑3‑[[4'‑[(4‑hydroxyphenyl)azo][1,1'‑biphenyl]‑4‑yl]azo]‑6‑(phenylazo)‑, disodium salt (CAS No. 3626‑28‑6); or

(k) Direct Green 6: 2,7‑Naphthalenedisulfonic acid, 4‑amino‑5‑hydroxy‑6‑[[4'‑[(4‑hydroxyphenyl)azo][1,1'‑biphenyl]‑4‑yl]azo]‑3‑[(4‑nitrophenyl)azo]‑, disodium salt (CAS No. 4335‑09‑5); or

(l) Direct Red 28 (Congo Red): 1‑Naphthalenesulfonic acid, 3,3'‑[[1,1'‑biphenyl]‑4,4'‑diylbis(azo)]bis[4‑amino‑, disodium salt (CAS No. 573‑58‑0); or

(m) Direct Red 37: 1,3‑Naphthalenedisulfonic acid, 8‑[[4'‑[(4‑ethoxyphenyl)azo][1,1'‑biphenyl]‑4‑yl]azo]‑7‑hydroxy‑, disodium salt (CAS No. 3530‑19‑6).

BENZIDINE‑CONGENER (3,3'‑disubstituted) AZO DYES.

BETACYFLUTHRIN **except** when included in Schedule 5 or 6.

BIFENTHRIN **except**:

(a) when included in Schedule 6; or

(b) in preparations containing 0.5% or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) **except** when included in Schedule 5 or 6.

BORON TRIFLUORIDE **except** when included in Schedule 5 or 6.

BRODIFACOUM **except** when included in Schedule 6.

BROMADIOLONE **except** when included in Schedule 6.

BROMETHALIN **except** when included in Schedule 6.

BROMINE (excluding its salts and derivatives).

BRUCINE **except** in alcohol containing 0.02% or less of brucine as a denaturant.

CACODYLIC ACID **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 75 g/tonne or less of arsenic.

CADUSAFOS **except** when included in Schedule 6.

CALCIFEROL for use as a rodenticide **except** when included in Schedule 6.

CAPTAFOL.

CARBADOX.

CARBENDAZIM **except** in paints, jointing compounds and sealants containing 0.1% or less of carbendazim.

CARBOFURAN.

CARBON TETRACHLORIDE **except** in chlorinated rubber based paint containing 1% or less of carbon tetrachloride.

CARBONYL SULFIDE when packed and labelled for use as a fumigant.

CARBOPHENOTHION.

CARBOSULFAN.

CHLORDECONE.

CHLORDIMEFORM.

CHLORFENAPYR **except** when included in Schedule 5 or 6.

CHLORFENVINPHOS.

CHLORINE (excluding its salts and derivatives).

CHLORHEXIDINE **except**:

(a) when included in Schedule 5 or 6; or

(b) in preparations containing 1% or less of chlorhexidine; or

(c) in solid preparations.

CHLOROMETHIURON.

5‑CHLORO‑3‑METHYL‑4‑NITROPYRAZOLE.

4‑CHLORO‑*o*‑TOLUIDINE.

CHLOROPICRIN **except** when included in Schedule 6.

CHLORTHIOPHOS.

COLECALCIFEROL for use as a rodenticide.

COUMAPHOS **except** when included in Schedule 6.

COUMATETRALYL **except** when included in Schedule 5 or 6.

CREOSOTE derived from coal.

CREOSOTE derived from beechwood.

CYANIDES, metallic **except**:

(a) ferricyanides; or

(b) ferrocyanides; or

(c) when separately specified in these Schedules.

CYANOGEN.

CYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2) **except** when included in Schedule 6.

CYHALOTHRIn (aRS,1R,cis,Z):(aRS,1S,cis,Z) = 50:50.

CYHEXATIN.

DELTAMETHRIN **except**:

(a) when included in Schedule 5 or 6; or

(b) in factory prepared mosquito nets containing 1% or less of deltamethrin; or

(c) in preparations containing 0.1% or less of deltamethrin.

DEMETON.

DEMETON‑*O*‑METHYL.

DEMETON‑*S*‑METHYL.

DIALIFOS.

4,4‑DIAMINODIPHENYLMETHANE (Methylene dianiline).

1,2‑DIBROMO‑3‑CHLOROPROPANE.

1,3‑DICHLOROPROPENE **except** in biocidal preparations containing 0.3% or less of 1,3‑dichloropropene.

DICHLORVOS **except** when included in Schedule 5 or 6.

DICROTOPHOS.

DIFENACOUM **except** when included in Schedule 6.

DIFETHIALONE **except** when included in Schedule 6.

DIMEFOX.

4‑DIMETHYLAMINOAZOBENZENE (*N*,*N*‑dimethyl‑4‑[phenylazo]‑benzenamine).

DIMETHYL SULFATE.

DIMETILAN.

DINITROCRESOLS **except** when included in Schedule 4 or 6.

DINITROPHENOLS **except** when included in Schedule 4, 6 or 10.

DINOCAP.

DINOSEB.

DIQUAT **except** when included in Schedule 6.

DISULFOTON **except** when included in Schedule 6.

DORAMECTIN **except** when included in Schedule 5 or 6.

DSMA **except** when included in Schedule 6.

EMAMECTIN **except** when included in Schedule 5 or 6.

ENDOSULFAN **except** when included in Schedule 6.

ENDOTHAL **except** when included in Schedule 6.

ENDRIN.

EPICHLOROHYDRIN.

EPIDERMAL GROWTH FACTOR **except** in preparations for human therapeutic use.

EPRINOMECTIN **except** when included in Schedule 5 or 6.

ETACONAZOLE.

ETHALFLURALIN.

ETHION.

ETHOPROPHOS **except** when included in Schedule 6.

2‑ETHOXYETHANOL and its acetates **except** in preparations containing 0.5% or less of 2‑ethoxyethanol.

ETHYLENE DIBROMIDE.

ETHYLENE OXIDE.

FAMPHUR **except** when included in Schedule 6.

FENAMIPHOS **except** when included in Schedule 6.

FENOXACRIM **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

FENSULFOTHION.

FENTHION **except** when included in Schedule 5 or 6.

FENTHION‑ETHYL.

FLOCOUMAFEN **except** when included in Schedule 6.

FLUCOFURON **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

FLUCYTHRINATE.

FLUMIOXAZIN **except** when included in Schedule 6.

FLUOROACETAMIDE.

FLUOROACETIC ACID.

FOLPET.

FORMETANATE.

FOSTHIAZATE.

FURATHIOCARB **except** when included in Schedule 5.

GAMMA‑CYHALOTHRIN **except** when included in Schedule 5.

HALOFUGINONE **except** when included in Schedule 4.

HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS.

HCB.

HYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any fraction of which boils above 350°C **except**:

(a) when in solid polymers; or

(b) when containing 1% or less of total polycyclic aromatic compounds as measured by IP 346; or

(c) when having a Mutagenicity Index of zero as measured by ASTM E1687‑95.

HYDROCYANIC ACID **except**:

(a) when included in Schedule 4; or

(b) its salts and derivatives other than cyanides separately specified in this Schedule.

HYDROFLUORIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5 or 6.

HYDROGEN SULFIDE.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5 or 6.

IODOMETHANE.

ISOCARBOPHOS.

ISOFENPHOS.

ISOPROTURON.

IVERMECTIN **except** when included in Schedule 4 or 5.

LAMBDA‑CYHALOTHRIN **except** when included in Schedule 5 or 6.

LEPTOPHOS.

LITHIUM PERFLUOROOCTANE SULFONATE **except** in sealed bait stations containing 1% or less of lithium perfluorooctane sulfonate.

MADURAMICIN **except**:

(a) when included in Schedule 5; or

(b) in animal feeds containing 5 mg/kg or less of antibiotic substances.

MALACHITE GREEN for veterinary use **except** when included in Schedule 5.

MAZIDOX.

MECARBAM.

2‑METHOXYETHANOL and its acetates **except** in preparations containing 0.5% or less of 2‑methoxyethanol.

MERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes.

MERCURY **except**:

(a) when separately specified in this Schedule; or

(b) when included in Schedule 2, 4 or 6; or

(c) in preparations containing 0.01% or less of mercury in organic form as a preservative; or

(d) mercury (metallic) in scientific instruments; or

(e) dental amalgams; or

(f) in a sealed device, for therapeutic use, which prevents access to the mercury.

METHACRIFOS **except** when included in Schedule 6.

METHAMIDOPHOS.

METHAPYRILENE.

METHAZOLE.

METHIDATHION.

METHIOCARB **except** when included in Schedule 5 or 6.

METHOMYL **except** when included in Schedule 6.

METHOXYETHYLMERCURIC ACETATE.

METHOXYETHYLMERCURIC CHLORIDE.

METHYL BROMIDE.

METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL **except**:

(a) when included in Schedule 6; or

(b) when used in laboratory analysis; or

(c) when packed for industrial use in containers with a nominal capacity of 100 L or more.

4,4'‑METHYLENEBIS[2‑CHLOROANILINE] (MOCA).

METHYLENE BLUE for veterinary use **except** when included in Schedules 4 or 5.

MEVINPHOS.

MIPAFOX.

MIREX.

MOLINATE.

MONOCROTOPHOS.

MOXIDECTIN **except** when included in Schedule 4, 5 or 6.

MSMA **except** when included in Schedule 6.

NAPHTHALOPHOS **except** when included in Schedule 6.

NICOTINE **except**:

(a) when included in Schedule 4; or

(b) in preparations for oromucosal or transdermal administration for human therapeutic use when included in the Register as an aid in withdrawal either from tobacco smoking or nicotine vaping; or

(c) in tobacco prepared and packed for smoking.

NIMIDANE **except** when included in Schedule 6.

NITROFEN.

NITROPRUSSIDES **except** when included in Schedule 4 or 6.

2‑NITROTOLUENE.

OMETHOATE **except** when included in Schedule 5 or 6.

OXAMYL.

OXYDEMETON METHYL.

PARAQUAT.

PARATHION.

PARATHION‑METHYL **except** when included in Schedule 6.

PENTACHLOROPHENOL **except** when included in Schedule 6.

PHENYLMERCURIC ACETATE **except** in preparations containing 0.01% or less of mercury as a preservative.

PHORATE.

PHOSFOLAN.

PHOSPHIDES, METALLIC.

PHOSPHINE.

PHOSPHORUS, YELLOW (excluding its salts and derivatives).

POTASSIUM NITRITE **except**:

(a) when included in Schedule 5 or 6; or

(b) in preparations containing 0.5% or less of potassium nitrite; or

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2% or less of potassium nitrite.

PROCYMIDONE.

PROPYLENE OXIDE.

PYRINURON.

QUININE for veterinary use **except** when included in Schedule 5.

SAFLUFENACIL **except** when included in Schedule 5.

SCHRADAN.

SELENIUM **except**:

(a) when included in Schedule 6; or

(b) as selenium arsenide in photocopier drums; or

(c) in preparations for therapeutic use other than:

(i) drench concentrates containing 2.5% or less of selenium; or

(ii) pour‑on preparations containing 0.5% or less of selenium; or

(d) in paints or tinters containing 0.1% or less of selenium calculated on the non‑volatile content of the paint or tinter; or

(e) in fertilisers containing 200 g/tonne or less of selenium.

SEMDURAMICIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 25 mg/kg or less of antibiotic substances.

SODIUM NITRITE **except**:

(a) when included in Schedule 2, 5 or 6; or

(b) in preparations containing 0.5% or less of sodium nitrite; or

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2% or less of sodium nitrite.

STRYCHNINE **except** when included in Schedule 4.

SULCOFURON **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

SULFENTRAZONE.

SULFOTEP.

TEFLUTHRIN **except** when included in Schedule 5.

TEPP.

TERBUFOS.

TETRACHLOROETHANE.

2,2',6,6'‑TETRAISOPROPYL‑DIPHENYL‑CARBODIIMIDE **except** when included in Schedule 6.

THALLIUM.

THIOFANOX.

TIN ORGANIC COMPOUNDS, being dialkyl, trialkyl and triphenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl **except**:

(a) when separately specified in this Schedule; or

(b) in plastics; or

(c) in semi‑solid sealants, adhesives or elastomers containing 1% or less of the dialkyl, trialkyl or triphenyl tin component; or

(d) in paint containing 1% or less of such compounds calculated as tin in the non‑volatile content of the paint.

*o*‑TOLIDINE **except** in solid‑state diagnostic therapeutic reagents.

TRIAMIPHOS.

TRIAZBUTIL.

TRIBUFOS (S,S,S‑tributylphosphorotrithioate).

VINCLOZOLIN.

VINYL CHLORIDE.

ZETA‑CYPERMETHRIN **except** when included in Schedule 6.

ZIRAM **except** when included in Schedule 6.

Schedule 8—Controlled drugs

Note 1: See paragraph 7(b), sections 16, 17, 28, 31, 50 and subsection 57(1).

Note 2: Substances marked # are listed in Appendix D.

ACETYLDIHYDROCODEINE.

ACETYLMETHADOL.

ACETYLMORPHINES.

ALFENTANIL.

ALPHACETYLMETHADOL.

ALPHAPRODINE.

# ALPRAZOLAM.

AMFETAMINE.

AMOBARBITAL **except** when included in Schedule 4.

ANILERIDINE.

BENZYLMORPHINE.

BEZITRAMIDE.

BUPRENORPHINE.

BUTOBARBITAL.

BUTORPHANOL.

# CANNABIS (including seeds, extracts, resins and the plant, and any part of the plant) when prepared or packed for human therapeutic use, when:

(a) cultivated or produced, or in products manufactured[[1]](#footnote-1), in accordance with the *Narcotic Drugs Act 1967*; and/or

(b) for use in products manufactured in accordance with the *Narcotic Drugs Act 1967*; and/or

(c) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Act; and/or

(d) in therapeutic goods supplied in accordance with the Act;

**except**:

(e) when it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the Therapeutic *Goods Regulations 1990* applies; or

(f) when separately specified in the NABIXIMOLS entry in this Schedule; or

(g) when captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3; or

(h) hemp seed oil containing 75 mg/kg or less of cannabidiol and 10 mg/kg or less of tetrahydrocannabinols.

CARFENTANYL.

COCAINE.

CODEINE **except** when included in Schedule 4.

CODEINE‑*N*‑OXIDE.

CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids).

4‑CYANO‑1‑METHYL‑4‑PHENYLPIPERIDINE (Pethidine intermediate A).

CYCLOBARBITAL.

DEXAMFETAMINE.

DEXTROMORAMIDE.

# DEXTROPROPOXYPHENE **except** when included in Schedule 4.

DIFENOXIN **except** when included in Schedule 4.

DIHYDROCODEINE **except** when included in Schedule 3 or 4.

DIHYDROMORPHINE.

# *N, α* ‑DIMETHYL‑3,4‑(METHYLENEDIOXY)PHENYLETHYLAMINE \*(MDMA) in preparations for human therapeutic use for the treatment of post-traumatic stress disorder.

DIPHENOXYLATE **except** when included in Schedule 3 or 4.

DIPIPANONE.

# DRONABINOL (delta‑9‑tetrahydrocannabinol) when prepared and packed for therapeutic use.

DROTEBANOL.

ESKETAMINE.

ETHYLAMFETAMINE.

ETHYLMORPHINE **except** when included in Schedule 2 or 4.

FENTANYL.

# FLUNITRAZEPAM.

HYDROCODONE.

HYDROMORPHINOL.

HYDROMORPHONE.

KETAMINE.

LEVAMFETAMINE.

LEVOMETHAMFETAMINE.

LEVOMORAMIDE.

LEVORPHANOL (excluding its stereoisomers).

LISDEXAMFETAMINE.

METHADONE.

METAMFETAMINE.

METHYLDIHYDROMORPHINE.

METHYLPHENIDATE.

1‑METHYL‑4‑PHENYLPIPERIDINE‑4‑CARBOXYLIC ACID (Pethidine intermediate C).

MORPHINE.

MORPHINE METHOBROMIDE.

MORPHINE‑N‑OXIDE.

NABILONE.

# NABIXIMOLS (botanical extract of *Cannabis sativa* which includes the following cannabinoids: tetrahydrocannabinols, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acids, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinols and cannabidiol (in approximately equal proportions) comprise not less than 90% of the total cannabinoid content) in a buccal spray for human therapeutic use.

NORCODEINE.

NORMETHADONE.

OPIUM **except** the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4.

OXYCODONE.

OXYMORPHONE.

PENTAZOCINE.

# PENTOBARBITAL **except** when included in Schedule 4.

PETHIDINE.

PHENDIMETRAZINE.

PHENMETRAZINE.

PHENOPERIDINE.

4‑PHENYLPIPERIDINE‑4‑CARBOXYLIC ACID ETHYL ESTER (Pethidine intermediate B).

PHOLCODINE **except** when included in Schedule 2 or 4.

PIRITRAMIDE.

PROPIRAM.

# PSILOCYBINE in preparations for human therapeutic use for the treatment of treatment‑resistant depression.

RACEMORAMIDE.

REMIFENTANIL.

SECBUTOBARBITAL.

SECOBARBITAL.

# SODIUM OXYBATE for human therapeutic use.

SUFENTANIL.

TAPENTADOL.

# TETRAHYDROCANNABINOLS when extracted from cannabis for human therapeutic use, when:

(a) included in products manufactured in accordance with the *Narcotic Drugs Act 1967*; and/or

(b) imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Act; and/or

(c) in therapeutic goods supplied in accordance with the Act;

**except** when:

(d) it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the *Therapeutic Goods Regulations 1990* applies; or

(e) separately specified in the NABIXIMOLS entry in this Schedule; or

(f) captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3; or

(g) in hemp seed oil at a concentration of 10 mg/kg or less.

THEBACON.

THEBAINE.

TILIDINE.

Schedule 9—Prohibited substances

Note 1: See paragraph 7(b) and subsection 57(2).

Note 2: Trivial or unofficial names are marked \*.

ACETORPHINE.

ACETYL‑ALPHA‑METHYLFENTANYL.

ALKOXYAMFETAMINES and substituted alkoxyamfetamines **except** when separately specified in these Schedules.

ALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines **except** when separately specified in these Schedules.

ALKYLTHIOAMFETAMINES and substituted alkylthioamfetamines **except** when separately specified in these Schedules.

ALLYLPRODINE.

ALPHAMEPRODINE.

ALPHA‑METHYLFENTANYL.

ALPHA‑METHYLTHIOFENTANYL.

ALPHAMETHADOL.

ALPHA‑PYRROLIDINOVALEROPHENONE \*(ALPHA‑PVP).

2‑AMINO‑1‑(2,5‑DIMETHOXY‑4‑METHYL)PHENYLPROPANE \*(STP or DOM).

5‑(2‑AMINOPROPYL)INDAN and substituted 5‑(2‑aminopropyl)indans **except** when separately specified in these Schedules.

BENZETHIDINE.

BENZOYLINDOLES **except** when separately specified in these Schedules.

BENZYLPIPERAZINE \*(BZP).

BETACETYLMETHADOL.

BETA‑HYDROXYFENTANYL.

BETA‑HYDROXY‑3‑METHYLFENTANYL.

BETAMEPRODINE.

BETAMETHADOL.

BETAPRODINE.

1‑(8‑BROMOBENZO[1,2‑B;4,5‑B]DIFURAN‑4‑YL)‑2‑AMINOPROPANE \*(Bromo‑Dragonfly).

4‑BROMO‑2,5‑DIMETHOXYPHENETHYLAMINE \*(BDMPEA).

BUFOTENINE.

BUTONITAZENE.

CANNABIS (including seeds, extracts, resins, and the plant and any part of the plant when packed or prepared), **except**:

(a) when separately specified in these Schedules; or

(b) processed hemp fibre containing 0.1% or less of tetrahydrocannabinols and hemp fibre products manufactured from such fibre; or

(c) hemp seed oil containing 75 mg/kg or less of cannabidiol and 10 mg/kg or less of tetrahydrocannabinols.

CATHINONES **except** when separately specified in these Schedules.

CLONAZOLAM.

CLONITAZENE.

COCA LEAF.

CODOXIME.

4‑CYANO‑2‑DIMETHYLAMINO‑4,4'‑DIPHENYLBUTANE.

CYCLOHEXYLPHENOLS **except**:

(a) when separately specified in these Schedules; or

(b) in preparations containing 0.5% or less of cyclohexylphenols.

DESCHLOROETIZOLAM.

DESOMORPHINE.

*N*,*N‑*DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES **except** when separately specified in these Schedules.

*N*,*N*‑DIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES except when separately specified in these Schedules.

DIAMPROMIDE.

DIBENZOPYRANS **except** when separately specified in these Schedules.

3,4‑DICHLORO‑N‑[(1R,2R)‑2‑(DIMETHYLAMINO)CYCLOHEXYL]*‑N*‑METHYLBENZAMIDE (U‑47700).

3,4‑DICHLORO‑N‑{[1‑ (DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE \*(AH‑7921).

DICLAZEPAM.

DIETHYLTHIAMBUTENE.

*N,N*‑DIETHYLTRYPTAMINE \*(DET).

2,5‑DIHYDRO‑2‑(1‑METHYL‑1‑PHENYLETHYL)‑5‑PENTYL‑1H‑PYRIDO[4,3‑B]INDOL‑1‑ONE (SGT‑151).

DIMENOXADOL.

DIMEPHEPTANOL.

2,5‑DIMETHOXYAMFETAMINE \*(DMA).

2,5‑DIMETHOXY‑4‑BROMOAMFETAMINE \*(DOB).

2,5‑DIMETHOXY‑4‑ETHYL‑*a*‑AMFETAMINE \*(DOET).

2,5‑DIMETHOXY‑4‑ETHYLTHIOPHENETHYLAMINE \*(2C‑T‑2).

2,5‑DIMETHOXY‑4‑IODOPHENETHYLAMINE \*(2C‑I).

2,5‑DIMETHOXY‑4‑(*N*)‑PROPYLTHIOPHENETHYLAMINE \*(2C‑T‑7).

3‑(2‑DIMETHYLAMINOETHYL)‑4‑HYDROXYINDOLE \*(PSILOCINE or PSILOTSIN).

3‑(1,2‑DIMETHYLHEPTYL)‑1‑HYDROXY‑7,8,9,10‑TETRAHYDRO‑6,6,9‑ TRIMETHYL‑6H‑DIBENZO (b,d) PYRAN \*(DMHP).

*N, α* ‑DIMETHYL‑3,4‑(METHYLENEDIOXY)PHENYLETHYLAMINE \*(MDMA) **except** when included in Schedule 8.

*N*,*N*‑DIMETHYLAMFETAMINE (Dimetamfetamine).

DIMETHYLTHIAMBUTENE.

*N*,*N*‑DIMETHYLTRYPTAMINE \*(DMT).

DIOXAPHETYL BUTYRATE.

ECGONINE.

*N*‑ETHYL‑α‑METHYL‑3,4‑(METHYLENEDIOXY)PHENETHYLAMINE \*(*N*‑ETHYL MDA).

ETHYLMETHYLTHIAMBUTENE.

ETICYCLIDINE \*(PCE).

ETODESNITAZENE.

ETONITAZENE.

ETONITAZEPIPNE.

ETONITAZEPYNE.

ETORPHINE.

ETOXERIDINE.

FENETYLLINE.

4‑FLUORO‑*N*‑METHYLAMFETAMINE.

FLUBROMAZEPAM.

FLUBROMAZOLAM.

FLUNITAZENE.

1‑(5‑FLUOROPENTYL)‑3‑(2‑IODOBENZOYL)INDOLE \*(AM‑694).

FURETHIDINE.

HARMALA ALKALOIDS **except** in herbs, or preparations, for therapeutic use:

(a) containing 0.1% or less of harmala alkaloids; or

(b) in divided preparations containing 2 mg or less of harmala alkaloids per recommended daily dose.

HEROIN.

3‑HEXYL‑1‑HYDROXY‑7,8,9,10‑TETRAHYDRO‑6,6,9‑TRIMETHYL‑6H‑DIBENZO (b,d) PYRAN \*(PARAHEXYL).

4‑HYDROXYBUTANOIC ACID and its salts **except** for sodium oxybate when in Schedule 8. \*(GAMMA HYDROXYBUTYRATE (GHB)).

2‑[(1*R*,3*S*)‑3‑HYDROXYCYCLOHEXYL]‑5‑(2‑METHYLNONAN‑2‑YL)PHENOL \*(Cannabicyclohexanol or CP 47,497 C8 homologue).

2‑[(1*R*,3*S*)‑3‑HYDROXYCYCLOHEXYL]‑5‑(2‑METHYLOCTAN‑2‑YL)PHENOL \*(CP 47,497).

HYDROXYPETHIDINE.

IBOTENIC ACID.

ISOMETHADONE.

ISOTONITAZENE.

KETOBEMIDONE.

LEVOMETHORPHAN (excluding its stereoisomers).

LEVOPHENACYLMORPHAN.

LYSERGIC ACID.

LYSERGIDE.

MECLONAZEPAM.

MECLOQUALONE.

METAZOCINE.

METHAQUALONE.

METHCATHINONE.

5‑METHOXY‑ α –METHYLTRYPTAMINE \*(5‑MeO‑AMT).

5‑METHOXY‑3,4‑METHYLENEDIOXYAMFETAMINE \*(MMDA).

4‑METHOXY‑ α –METHYLPHENYLETHYLAMINE \*(PMA).

2‑(2‑METHOXYPHENYL)‑1‑(1‑PENTYLINDOL‑3‑YL)ETHANONE \*(JWH‑250).

METHYL (2*S*, 4a*R*, 6a*R*, 7*R*, 9*S*, 10a*S*, 10b*R*)‑9‑ACETOXY‑6a,10b‑DIMETHYL‑4,10‑DIOXO‑DODECAHYDRO‑2‑(3‑FURYL)‑2H‑NAPHTHO[2,1‑c]PYRAN‑7‑CARBOXYLATE \*(SALVINORIN A).

4‑METHYLAMINOREX.

METHYLDESORPHINE.

3,4‑METHYLENEDIOXYAMFETAMINE \*(MDA).

3,4‑METHYLENEDIOXYPYROVALERONE \*(MDPV).

3‑METHYLFENTANYL.

4‑METHYLMETHCATHINONE \*(MEPHEDRONE).

*N*‑ α ‑[METHYL‑3,4‑(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE \*(*N*‑HYDROXY MDA).

*N*‑METHYL‑1‑(3,4‑METHYLENEDIOXYPHENYL)‑2‑BUTANAMINE \*(MBDB).

2‑METHYL‑3‑MORPHOLINO‑1, 1‑DIPHENYLPROPANE CARBOXYLIC ACID (Moramide intermediate).

METHYLONE \*(MDMC).

1‑METHYL‑4‑PHENYL‑4‑PIPERIDINOL PROPIONATE \*(MPPP).

4‑METHYLTHIOAMFETAMINE.

3‑METHYLTHIOFENTANYL.

METODESNITAZENE.

METONITAZENE.

METOPON.

MITRAGYNA SPECIOSA.

MITRAGYNINE.

MORPHERIDINE.

(1‑(2‑MORPHOLIN‑4‑YLETHYL)INDOL‑3‑YL)‑NAPTHALEN‑1‑YLMETHANONE \*(JWH‑200).

MUSCIMOL.

MYROPHINE.

NAPHTHOYLINDOLES **except** when separately specified in these Schedules.

NAPHTHYLMETHYLINDOLES **except** when separately specified in these Schedules.

NAPHTHOYLPYRROLES **except** when separately specified in these Schedules.

NAPHTHYLMETHYLINDENES **except** when separately specified in these Schedules.

NAPHTHALEN‑1‑YL‑(1‑BUTYLINDOL‑3‑YL)METHANONE \*(JWH‑073).

NICOCODINE.

NICODICODINE.

NICOMORPHINE.

NIFOXIPAM.

NORACYMETHADOL.

NORLEVORPHANOL.

NORMORPHINE.

NORPIPANONE.

PARA‑FLUOROFENTANYL.

1‑PENTYL‑3‑(4‑METHYL‑1‑NAPTHOYL)INDOLE. \*(JWH‑122).

1‑PENTYL‑3‑(1‑NAPHTHOYL)INDOLE \*(JWH‑018).

PHENADOXONE.

PHENAMPROMIDE.

PHENAZOCINE.

PHENCYCLIDINE \*(PCP).

PHENIBUT.

*N*‑PHENETHYL‑4‑PIPERIDONE.

PHENOMORPHAN.

PHENYLACETYLINDOLES **except** when separately specified in these Schedules.

1‑PHENYLETHYL‑4‑PHENYL‑4‑PIPERIDINOL ACETATE \*(PEPAP).

PIMINODINE.

PROHEPTAZINE.

PROPERIDINE.

PROTONITAZENE.

PSILOCYBINE **except** when included in Schedule 8.

PYRAZOLAM.

RACEMETHORPHAN.

RACEMORPHAN.

ROLICYCLIDINE \*(PHP or PCPY).

SALVIA DIVINORUM.

SYNTHETIC CANNABINOMIMETICS **except** when separately specified in these Schedules.

TENOCYCLIDINE \*(TCP).

TETRAHYDROCANNABINOLS and their alkyl homologues, **except**:

(a) when included in Schedule 4 or Schedule 8; or

(b) processed hemp fibre containing 0.1% or less of tetrahydrocannabinols, and hemp fibre products manufactured from such fibre; or

(c) in hemp seed oil at a concentration of 10 mg/kg or less.

THIOFENTANYL.

1‑(3‑TRIFLUOROMETHYLPHENYL)PIPERAZINE \*(TFMPP).

TRIMEPERIDINE.

3,4,5‑TRIMETHOXY‑ α –METHYLPHENYLETHYLAMINE \*(TMA).

3,4,5‑TRIMETHOXYPHENETHYLAMINE (mescaline) and other substances structurally derived from methoxy‑phenylethylamine **except**:

(a) methoxyphenamine; or

(b) when separately specified in this Schedule.

1‑(3,4,5‑TRIMETHOXYPHENYL)‑2‑AMINOBUTANE.

Schedule 10—Substances of such danger to health as to warrant prohibition of supply and use

Note 1: See subsection 57(2) and section 63.

Note 2: Schedule 10 contains substances previously included in Appendix C.

ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.

ACORUS CALAMUS (calamus) for human therapeutic use.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use:

(a) in liquid or semi‑solid food additive preparations, tHE pH of which is more than 11.5; or

(b) in solid automatic dishwashing preparations, tHE pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or

(c) in liquid or semi‑solid automatic dishwashing preparations, tHE pH of which is more than 12.5.

ALKYLAMINES WITH STIMULANT PROPERTIES **except** when separately specified in these schedules.

2‑AMINO‑5‑METHYLPHENOL in preparations for cosmetic use.

AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use**.**

AMYGDALIN for therapeutic use.

ANCHUSA OFFICINALIS for therapeutic use.

*o*‑ANISIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows **except** in preparations containing 0.001% or less of *o*‑anisidine.

APRONAL for therapeutic use.

ARISTOLOCHIA spp. for therapeutic use.

ARISTOLOCHIC ACID(S) for human therapeutic use.

ASARUM spp. containing aristolochic acid(s) for human therapeutic use.

AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use **except** “debitterised neem seed oil”.

BASIC ORANGE 31 (2‑[(4‑aminophenyl)azo]‑1,3‑dimethyl‑1H‑imidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows.

1,2‑BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).

1,3‑BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including tattooing).

BITHIONOL for human therapeutic use.

BORAGO OFFICINALIS (Borage) for therapeutic use **except** the fixed oil derived from the seeds of Borago officinalis.

BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.

BUCLOSAMIDE for therapeutic use.

BUNIODYL SODIUM for therapeutic use.

1,4‑BUTANEDIOL (excluding its derivatives) in non‑polymerised form in preparations for domestic use.

BUTYL BENZYL PHTHALATE for cosmetic use.

CACALIA spp. for therapeutic use.

CARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 18% of carbamide peroxide **except** in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.

CARDARINE.

CHRYSOIDINE BASE in preparations for use in hair dyes.

CINCHOPHEN and its derivatives for therapeutic use.

CLIOQUINOL and other halogenated derivatives of oxyquinoline for human internal use **except** or when being used solely for experimental purposes in humans and where such use:

(a) is in accordance with:

(i) an approval granted under paragraph 19(1)(b) of the Act, including any conditions specified in the notice of approval; and

(ii) any conditions specified in the *Therapeutic Goods Regulations 1990* for the purposes of subsection 19(1A) of the Act; and

(iii) any conditions specified in the *Therapeutic Goods Regulations 1990* for the purposes of subsection 19(4A) of the Act; or

(b) is in accordance with the requirements of item 3 of Schedule 5A to the *Therapeutic Goods* Regulations 1*990*.

COAL TAR for cosmetic use other than in therapeutic goods.

CONIUM MACULATUM (coniine) for therapeutic use.

COTARNINE for therapeutic use.

CROTALARIA spp. for therapeutic use.

CROTON TIGLIUM for therapeutic use.

CYNOGLOSSUM spp. for therapeutic use.

DIBUTYL PHTHALATE for cosmetic use.

DICOPHANE (DDT) for therapeutic use.

DIETHYLENE GLYCOL for use in toothpastes or mouthwashes **except** in preparations containing 0.25% or less of diethylene glycol.

DIETHYLENE GLYCOL MONOMETHYL ETHER for cosmetic use.

DIETHYLHEXYL PHTHALATE for cosmetic use.

DIETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use **except** in preparations containing 0.5% or less of diethylphthalate.

5,6‑DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2% of 5,6‑dihydroxyindoline.

DIIODOHYDROXYQUINOLINE (iodoquinol) for human internal use.

DIISOBUTYL PHTHALATE for cosmetic use.

1,3‑DIMETHYLAMYLAMINE (DMAA).

1,3‑DIMETHYLBUTYLAMINE (DMBA) **except** when separately specified in these schedules.

1‑(1,1‑DIMETHYLETHYL)‑2‑METHOXY‑4‑METHYL‑3,5‑DINITROBENZENE (musk ambrette).

1,5‑DIMETHYLHEXYLAMINE (DMHA) **except** when separately specified in these schedules.

DI(METHYLOXYETHYL) PHTHALATE for cosmetic use.

1,4‑DIMETHYLPENTYLAMINE (DMPA).

DIMETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use **except** in preparations containing 0.5% or less of dimethylphthalate.

2,4‑DINITROPHENOL for human use.

DISPERSE YELLOW 3 for use in hair dyes.

DULCIN for therapeutic use.

ETHYLENE GLYCOL for use in toothpastes or mouthwashes **except** in preparations containing 0.25% or less of ethylene glycol.

EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.

FARFUGIUM JAPONICUM for therapeutic use.

FORMALDEHYDE (excluding its derivatives):

(a) in oral hygiene preparations containing more than 0.1% of free formaldehyde; or

(b) in aerosol sprays for cosmetic use containing 0.005% or more of free formaldehyde; or

(c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or

(d) in all other cosmetic preparations containing 0.05% or more of free formaldehyde **except** in preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

GAMMA BUTYROLACTONE (excluding its derivatives) in non‑polymerised form in preparations for domestic and cosmetic use.

HELIOTROPIUM spp. for therapeutic use.

HYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 6% (20 volume) of hydrogen peroxide **except** in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.

ISOPROPYL NITRITE.

JUNIPERUS SABINE [savin(e)] for therapeutic use.

KAMBO.

LEAD COMPOUNDS:

(a) in anti‑fouling paints **except** in preparations containing 0.1% or less of lead calculated on the non‑volatile content of the paint; or

(b) in paints (other than anti‑fouling paints), tinters, inks or ink additives **except** in preparations containing 0.009% or less of lead calculated on the non‑volatile content of the paint, tinter, ink or ink additive; or

(c) for human therapeutic use except in preparations containing 10 mg/kg or less of lead.

LIGULARIA DENTATA for therapeutic use.

MELIA AZEDARACH including its extracts and derivatives.

METHANOL in hand sanitiser preparations containing more than 5% methanol.

METHYLDIBROMO GLUTARONITRILE in preparations intended to be in contact with the skin, including cosmetic use.

METHYL METHACRYLATE for cosmetic use **except** in preparations containing 1% or less of methyl methacrylate as residual monomer in a polymer.

METHYLROSANILINIUM CHLORIDE (formerly known as crystal violet) and the following TRIARYLMETHANE DYES – for use in hair dyes:

(a) Acid Violet 49; or

(b) Ethyl Violet; or

(c) Basic Blue 7; or

(d) Basic Blue 26 (CI 44045).

NAPHTHALENE (excluding derivatives) in preparations in block, ball, disc, pellet or flake form for domestic use **except** when enclosed in a device which, in normal use, prevents removal or ingestion of its contents.

OXYPHENISATIN for therapeutic use.

PARAFORMALDEHYDE (excluding its derivatives):

(a) in oral hygiene preparations containing more than 0.1% of free formaldehyde; or

(b) in aerosol sprays for cosmetic use containing 0.005% or more of free formaldehyde; or

(c) in nail hardener cosmetic preparations containing 5% or more of free formaldehyde; or

(d) in all other cosmetic preparations containing 0.05% or more of free formaldehyde **except** in preparations containing 0.2% or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

PETASITES spp. for therapeutic use.

PHENPROMETHAMINE.

PHENYLENEDIAMINES, including alkylated, arylated, halogenated and nitro derivatives, in preparations for skin colouration, tattooing and dyeing of eyelashes or eyebrows **except** when included in Schedule 6.

POTASSIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi‑solid food additive preparations, for domestic use, tHE pH of which is more than 11.5.

*n*‑PROPYL NITRITE.

PTERIDIUM spp. for therapeutic use.

PULMONARIA spp. for therapeutic use.

SAFROLE for internal therapeutic use **except** in preparations containing 0.1% or less of safrole.

SANGUINARIA CANADENSIS (bloodroot) in preparations for human use **except** in preparations containing 0.01% or less of SANGUINARINE.

SENECIO spp. for therapeutic use.

SILICONES for injection or implantation **except** when included in Schedule 4.

SODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi‑solid food additive preparations, for domestic use, tHE pH of which is more than 11.5.

SYMPHYTUM spp. (Comfrey) in preparations for human or animal use **except** when in Schedule 5.

2,4‑TOLUENEDIAMINE in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows.

TOLUENEDIAMINES in preparations for skin colouration (including tattooing) and dyeing of eyelashes or eyebrows **except** when included in Schedule 6.

*o*‑TOLUIDINE (excluding derivatives) in preparations for skin colouration (including tattooing) and dyeing of hair, eyelashes or eyebrows **except** in preparations containing 0.001% or less of *o*‑toluidine.

1,1,1‑TRICHLOROETHANE in pressurised spray packs for therapeutic use.

TRICHODESMA AFRICANA for therapeutic use.

TRIPARANOL for therapeutic use.

TUSSILAGO FARFARA for therapeutic use.

Appendix A—General exemptions

Note: See paragraph 11(a).

1 Exempt preparations and products

The following table specifies preparations and products for the purposes of paragraph 11(a).

| Exempt preparations and products | |
| --- | --- |
| Item | Column 1 Preparation or product |
| 1 | ALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that are not agricultural chemical products or veterinary chemical products |
| 2 | BACTERIAL CULTURE MEDIA containing antibiotics |
| 3 | CERAMICS |
| 4 | CHEMISTRY SETS for toy and educational use, when complying with the requirements of Australian Standard AS 8124.4‑2003, *Safety of toys,* Part 4: *Experimental sets for chemistry and related activities* |
| 5 | COPPER COMPOUNDS in paints |
| 6 | DEXTRANS, GELATIN ‑ SUCCINYLATED & ETHERIFIED STARCHES used as plasma substitutes/blood volume expanders |
| 7 | ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS |
| 8 | ELECTRONIC COMPONENTS |
| 9 | ENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging |
| 10 | EXPLOSIVES |
| 11 | FOOD **except**:  (a) food additives before incorporation into food; or  (b) when used as a means of administering a poison for therapeutic use |
| 12 | FRITTED GLAZING OR ENAMELLING PREPARATIONS in which the poison is confined as a non‑migratory component of glassy solid flakes or granules |
| 13 | GLASS (including CRYSTAL WARE) |
| 14 | GLAZED POTTERY |
| 15 | HUMAN BLOOD PRODUCTS including:  (a) whole blood;  (b) blood components including red cells, white cells, platelets and plasma (including cryoprecipitate); and  (c) the following plasma‑derived therapeutic proteins; and their equivalent recombinant alternatives:  (i) albumin;  (ii) anticoagulation complex;  (iii) C1 esterase inhibitors;  (iv) clotting factors;  (v) fibrinogen;  (vi) protein C;  (vii) prothrombin complex concentrate (PCC);  (viii) thrombin |
| 16 | IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001% or less of a poison included in Schedules 1 to 8 |
| 17 | INTRAOCULAR VISCOELASTIC PRODUCTS |
| 18 | LUBRICANTS in preparations that provide a lubricating action between machinery parts, **except** soluble oils and solvent‑deposited lubricating agents |
| 19 | MATCHES |
| 20 | MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS |
| 21 | MEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to the *Therapeutic Goods (Medical Devices) Regulation 2002*, **except** the following:  (a) injectable tissue reconstructive, augmentation and restoration materials, including collagen;  (b) medical devices which include anticoagulants;  (c) artificial tears;  (d) urinary catheters;  (e) intra‑articular fluids |
| 22 | MOTOR, HEATING or FURNACE FUELS **except** the following:  (a) when the contrary intention appears in any Schedule;  (b) when containing methanol;  (c) toy or hobby fuels; or  (d) petrol or kerosene when packed in containers having a capacity of 20 L or less |
| 23 | NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION |
| 24 | PAPER **except**:  (a) when prepared for pesticidal use; or  (b) when containing a poison included in Schedule 8 or 9 |
| 25 | PHOTOGRAPHIC PAPER or FILM |
| 26 | PIGMENTS when immobilised in a polymer |
| 27 | PORCELAIN |
| 28 | PRINTING INKS or INK ADDITIVES **except**:  (a) when containing a pesticide; or  (b) preparations containing more than 0.009% of lead calculated on the non‑volatile content of the ink or ink additive |
| 29 | RADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use |
| 30 | RADIOISOTOPES for therapeutic use |
| 31 | SEEDS treated with seed protectants |
| 32 | SINGLE‑USE TUBES for the estimation of alcohol content of breath |
| 33 | TERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the relevant registration authority, and laminated between impervious sheeting |
| 34 | TIMBER or WALLBOARD |
| 35 | TREATMENT LAYERS OF COATED METAL ARTICLES **except** articles intended for use in the collection of drinking water when not compliant with the health and safety requirements of the Australian Standard AS 4020:2018, *Testing of products for use in contact with drinking water* |
| 36 | VITREOUS ENAMELS |
| 37 | WRITING CORRECTION PENS which do not allow ingestion of the contents and which contain no scheduled poison other than designated solvents included in Schedule 5 |

Appendix B—Substances considered not to require control by scheduling

Note: See paragraph 11(b).

1 Reasons for including substances in the table in clause 3

For the purposes of the table in clause 3, the letter specified in column 1 of an item of the following table represents the reason specified in column 2 of the item.

| Reasons for including substances in the table in clause 3 | | |
| --- | --- | --- |
| Item | Column 1 Letter | Column 2 Reason |
| 1 | a | Low Toxicity |
| 2 | b | Use pattern restricts hazard |
| 3 | c | Presentation/packaging restricts hazard |
| 4 | d | Industrial use only |

2 Areas of use in relation to substances included in the table in clause 3

For the purposes of the table in clause 3, the number specified in column 1 of an item of the following table represents the area, sub‑area or sub‑sub‑area of use specified in column 2, 3 or 4 (as applicable) of the item.

| Areas of use in relation to substances included in the table in clause 3 | | | | |
| --- | --- | --- | --- | --- |
| Item | Column 1 Number | Column 2 Area | Column 3 Sub‑area | Column 4 Sub‑sub‑area |
| 1 | 1 | Agriculture |  |  |
| 2 | 1.1 |  | Herbicide |  |
| 3 | 1.2 |  | Insecticide |  |
| 4 | 1.2.1 |  |  | Insecticide for codling moth |
| 5 | 1.2.2 |  |  | Termiticide |
| 6 | 1.3 |  | Fungicide |  |
| 7 | 1.3.1 |  |  | On seed fungicide |
| 8 | 1.4 |  | Bird Repellent |  |
| 9 | 1.5 |  | Fertiliser |  |
| 10 | 1.6 |  | Plant Growth Regulator |  |
| 11 | 1.7 |  | Insect Pheromone |  |
| 12 | 1.8 |  | Mushroom Bactericide |  |
| 13 | 1.9 |  | Acaricide |  |
| 14 | 1.10 |  | Biological control agent |  |
| 15 | 1.11 |  | Adjuvant in agricultural products |  |
| 16 | 2 | Veterinary |  |  |
| 17 | 2.1 |  | For animal use |  |
| 18 | 2.2 |  | Treatment of mastitis in cows |  |
| 19 | 2.3 |  | Coccidiostat |  |
| 20 | 2.4 |  | Feed additive |  |
| 21 | 2.5 |  | Antiseptic |  |
| 22 | 2.6 |  | Scabicide |  |
| 23 | 2.7 |  | Anthelmintic |  |
| 24 | 2.8 |  | Vitamin/Mineral |  |
| 25 | 2.9 |  | Growth Promotant |  |
| 26 | 2.10 |  | Ectoparasiticide |  |
| 27 | 3 | Domestic |  |  |
| 28 | 3.1 |  | Aromatherapy |  |
| 29 | 3.2 |  | Food additive |  |
| 30 | 3.3 |  | Cosmetic |  |
| 31 | 3.4 |  | Human use |  |
| 32 | 3.5 |  | Miticide |  |
| 33 | 4 | Industrial |  |  |
| 34 | 4.1 |  | Water treatment |  |
| 35 | 4.2 |  | Biological control agent |  |
| 36 | 5 | Environmental |  |  |
| 37 | 5.1 |  | Mosquito control |  |
| 38 | 6 | Human therapeutic use |  |  |
| 39 | 6.1 |  | Diagnostic agent |  |
| 40 | 6.2 |  | Medical device |  |
| 41 | 6.3 |  | Antiseptic |  |
| 42 | 6.4 |  | Sunscreen |  |
| 43 | 6.5 |  | External use |  |
| 44 | 6.6 |  | Laxative |  |
| 45 | 6.7 |  | Antiseborrheic |  |
| 46 | 6.8 |  | Cytoprotective |  |
| 47 | 6.9 |  | Vitamin/Mineral |  |
| 48 | 6.10 |  | Eye Drops |  |
| 49 | 7 | General |  |  |
| 50 | 7.1 |  | Any use |  |
| 51 | 7.2 |  | Excipient |  |
| 52 | 7.3 |  | Synergist |  |
| 53 | 7.4 |  | Flux |  |
| 54 | 7.5 |  | Pesticide |  |
| 55 | 7.6 |  | Insect repellent |  |
| 56 | 7.7 |  | Solvent |  |
| 57 | 7.8 |  | Disinfectant |  |
| 58 | 7.9 |  | Preservative |  |
| 59 | 7.10 |  | Antioxidant |  |
| 60 | 7.11 |  | Resin activator/accelerant |  |
| 61 | 7.12 |  | Sweetener artificial |  |
| 62 | 7.13 |  | Food additive |  |

3 Substances exempt in certain uses

For the purposes of paragraph 11(b), the following table specifies:

(a) substances; and

(b) areas, sub‑areas and sub‑sub‑areas of use in relation to those substances.

Note: Columns 3 and 4 of the table are included for information only.

| Substances exempt in certain uses | | | | |
| --- | --- | --- | --- | --- |
| Item | Column 1 Substance | Column 2 Area, sub‑area or sub‑sub‑area of use | Column 3 Reason for inclusion | Column 4 Date of inclusion |
| 1 | 4‑[4‑(ACETYLOXY)PHENYL]‑2‑BUTANONE | 1.7 | b | Feb 2005 |
| 2 | AFIDOPYROPEN | 1.2 | b | Jun 2018 |
| 3 | ALCOHOL, DEHYDRATED | 6 | b | Aug 2000 |
| 4 | ALUM | 7.1 | a | May 1997 |
| 5 | ALUMINIUM AMMONIUM SULFATE | 7.1 | a | May 1997 |
| 6 | ALUMINIUM POTASSIUM SULFATE | 7.1 | a | May 1997 |
| 7 | ALUMINIUM SILICATE | 7.1 | a | Nov 1974 |
| 8 | ALUMINIUM tris (ETHYLPHOSPHONATE) | 1 | a | Aug 1986 |
| 9 | AMETOCTRADIN | 1.3 | a | May 2012 |
| 10 | AMMONIUM PHOSPHATE | 7.1 | a | Nov 1974 |
| 11 | AMMONIUM THIOSULPHATE | 7.1 | a | Nov 1974 |
| 12 | AMPROLIUM | 2.3 | a | Jun 1969 |
| 13 | AMYL ACETATE | 7.1 | a | Nov 1974 |
| 14 | α ‑AMYLASE derived from *Aspergillus niger* | 2.4 | a | Feb 2005 |
| 15 | AMYL CINNAMALDEHYDE | 3.3 | a, b | Feb 2017 |
| 16 | ANDROSTENEDIONE ALBUMEN CONJUGATE WITH DEA DEXTRAN ADJUNCT | 2.1 | a | Jun 2004 |
| 17 | ASPARTIC ACID | 6 | a | ‑ |
| 18 | ASULAM | 1 | a | May 1986 |
| 19 | *AUREOBASIDIUM PULLULANS* (strains DSM14940 and DSM14941) | 1.3 | a | Oct 2017 |
| 20 | AZIMSULFURON | 1.1 | a | Jun 2003 |
| 21 | *BACILLUS AMYLOLIQUEFACIENS* | 1.3 | a | Jun 2018 |
| 22 | *BACILLUS SPHAERICUS*, STRAIN 2362 | 5.1 | a | Feb 2003 |
| 23 | *BACILLUS THURINGIENSIS* | 5.1 | a | May 1992 |
| 24 | *BACILLUS THURINGIENSIS* (excluding endotoxin) | 2.10 | a | Jun 2003 |
| 25 | *BACILLUS TOYOI* | 2.9 | a | Aug 1980 |
| 26 | *BACULOVIRUS CYDIA POMONELLA* | 1.2 | a | Jun 2006 |
| 27 | BENFLURALIN | 1.1 | a | ‑ |
| 28 | BENSULFURON‑METHYL | 1 | a | Aug 1987 |
| 29 | BENTONITE | 7.1 | a | Jun 2002 |
| 30 | BENZYL BENZOATE | 1.2 | a | Aug 1989 |
| 31 | BETAINE HYDROCHLORIDE | 7.1 | a | Nov 1974 |
| 32 | BIFENAZATE | 1.9 | a | Oct 2002 |
| 33 | BISMUTH SUBNITRATE | 2.1 | b, c | Nov 1999 |
| 34 | BISTRIFLURON | 1.2.2 | a | Feb 2014 |
| 35 | BIURET | 2.4 | a | Nov 1974 |
| 36 | BIXLOZONE | 1.1 | a | Feb 2020 |
| 37 | BLAD (banda de Lupinus albus doce) | 1.3 | a | Feb 2016 |
| 38 | BOSCALID | 1.3 | a | June 2003 |
| 39 | BOVINE SOMATOTROPHIN | 2 | a | May 1992 |
| 40 | BROMACIL | 1 | a | Aug 1987 |
| 41 | BROMOPROPYLATE | 1 | a | Nov 1994 |
| 42 | BUPIRIMATE | 1 | a | Nov 1990 |
| 43 | BUTAFENACIL | 1 | a | May 2000 |
| 44 | BUTOXYPOLYPROPYLENE GLYCOL | 7.7 | a | Nov 1974 |
| 45 | n‑BUTYL BUTYRATE | 7.1 | a | ‑ |
| 46 | n‑BUTYL LACTATE | 7.1 | a | ‑ |
| 47 | CARBOXIN | 1 | a | Aug 1987 |
| 48 | CARFENTRAZONE‑ETHYL | 1 | a | Aug 1998 |
| 49 | CELLULASE derived from *Aspergillus niger* | 2.4 | a | Feb 2005 |
| 50 | CETYL ALCOHOL | 7.1 | a | Nov 1974 |
| 51 | CHAMOMILE OIL | 3.1 | a | Feb 2000 |
| 52 | CHINA CLAY | 1.2 | a | Sep 2008 |
| 53 | CHLORANTRANILIPROLE | 1.2 | a | Sep 2008 |
| 54 | CHLORFLUAZURON | 1.2.2 | a | Oct 2005 |
| 55 | CHLORFLURENOL | 1.6 | a | Feb 1974 |
| 56 | CHLORIDAZON | 1 | a | May 1988 |
| 57 | CHLOROXYLENOLS | 7.8 | a | Feb 1975 |
| 58 | CITRONELLA OIL | 7.1 | a | Feb 2000 |
| 59 | CLARY SAGE OIL | 7.1 | a | Feb 2000 |
| 60 | CLITORIA TERNATEA EXTRACT | 1.2 | a | Feb 2016 |
| 61 | CLOPIDOL | 2.3 | d | Nov 1974 |
| 62 | COBALT NAPHTHENATE | 7.1 | d | ‑ |
| 63 | CROSPOVIDONE | 2 | a | Aug 1996 |
| 64 | *CULICINOMYCES CLAVOSPORUS* | 5.1 | a | Nov 1982 |
| 65 | CYCLAMIC ACID | 7.1 | a | Nov 1971 |
| 66 | CYCLANILIPROLE | 1.2 | a | Oct 2016 |
| 67 | CYCLOBUTRIFLURAM | 1.3, 1.3.1 | a | Oct 2022 |
| 68 | CYCLOHEXANE | 7.7 | a | Nov 1974 |
| 69 | CYCLOHEXANOL ACETATE | 7.7 | a | ‑ |
| 70 | *CYPRINID HERPESVIRUS‑3* | 1.10 | a | Oct 2018 |
| 71 | CYROMAZINE | 2 | a | Nov 1980 |
| 72 | DICLAZURIL | 2.3 | a | Nov 2001 |
| 73 | DIETHYL CARBONATE | 7.1 | a | ‑ |
| 74 | DIFLUFENICAN | 1 | a | Feb 1987 |
| 75 | DIKEGULAC‑SODIUM | 1.6 | a | Mar 1980 |
| 76 | DIMETHYL ETHER | 4 | d | Nov 1988 |
| 77 | DIMETICONE | 7.1 | a | ‑ |
| 78 | DIPHENYLAMINE | 1 | a | Feb 1988 |
| 79 | DIPROPYLENE GLYCOL MONOMETHYL ETHER | 4 | a | Nov 1987 |
| 80 | DISODIUM MANGANESE EDTA | 2.1 | a | Feb 2022 |
| 81 | DIURON | 1 | a | Nov 1987 |
| 82 | DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE) | 7.1 | a | Feb 1970 |
| 83 | 2,2‑DPA | 1 | a | Nov 1989 |
| 84 | DROMETRIZOLE TRISILOXANE | 6.4 | a | Oct 2003 |
| 85 | *DUDDINGTONIA FLAGRANS*, STRAIN IAH 1297 | 2.7 | a | Feb 2018 |
| 86 | EPSIPRANTEL | 2 | a | Nov 1991 |
| 87 | ETHAMETSULFURON‑METHYL | 1.1 | a | Nov 2000 |
| 88 | ETHOPABATE | 2.3 | d | Jun 1969 |
| 89 | ETHYL ACETATE | 7.1 | a | Nov 1974 |
| 90 | ETHYL ALCOHOL | 7.1 | a | Nov 1974 |
| 91 | ETHYLBUTYLACETYL AMINOPROPRIONATE | 3.4 | a | Aug 2000 |
| 92 | ETHYL BUTYRATE | 7.1 | a | ‑ |
| 93 | ETHYL LACTATE | 7.1 | a | ‑ |
| 94 | ETOFENPROX | 1.2 | a | Jun 2018 |
| 95 | ETOXAZOLE | 1.2 | a | Oct 2003 |
| 96 | *EUBACTERIUM sp. strain DSM11798* | 2.4 | a | Sep 2013 |
| 97 | FENFURAM | 1.3.1 | a | May 1977 |
| 98 | FENHEXAMID | 1 | a | Feb 1999 |
| 99 | FENOXYCARB | 1 | a | Feb 1988 |
| 100 | FLORPYRAUXIFEN‑BENZYL | 1, 1.1 | a | Feb 2018 |
| 101 | FLORYLPICOXAMID | 1.3 | a | Feb 2021 |
| 102 | FLUFENOXURON | 1 | a | Feb 1997 |
| 103 | FLUMETSULAM | 1 | a | Feb 1992 |
| 104 | FLUOMETURON | 1 | a | Aug 1989 |
| 105 | FLUOPICOLIDE | 1.3 | a | Oct 2016 |
| 106 | FLUOXAPIPROLIN | 1.3 | a | Feb 2022 |
| 107 | FLUTOLANIL | 1.3 | a | Nov 2001 |
| 108 | FLUROXYPYR | 1 | a, c | May 1986 |
| 109 | FORCHLORFENURON | 1.6 | a | Feb 2005 |
| 110 | FULLERS EARTH | 7.1 | a | Nov 1974 |
| 111 | FUNGAL PROTEASE derived from *Aspergillus niger* | 2.4 | a | Feb 2005 |
| 112 | GERANIUM OIL | 7.1 | a | Feb 2000 |
| 113 | GIBBERELLIC ACID | 1.6 | a | Nov 1974 |
| 114 | α‑GLUCANASE derived from *Aspergillus niger* | 2.4 | a | Feb 2005 |
| 115 | HALAUXIFEN METHYL | 1, 1.1 | a | Oct 2014 |
| 116 | HELIONAL | 7 | a | Feb 2023 |
| 117 | HEXAFLURON | 1 | a | Nov 1988 |
| 118 | HEXYL ACETATE | 7.7 | a | ‑ |
| 119 | HEXYL CINNAMALDEHYDE | 3.3 | a, b | Feb 2017 |
| 120 | HEXYTHIAZOX | 1 | a | Feb 1988 |
| 121 | HUMAN OSTEOGENIC PROTEIN‑1 (OP‑1) | 6.2 | b | Aug 2001 |
| 122 | HYDROPRENE | 1 | a | Feb 1988 |
| 123 | HYDROXYPROPYL CELLULOSE | 7.1 | a | Nov 1982 |
| 124 | ICODEXTRIN | 6 | b | Nov 2000 |
| 125 | INDOLE‑3‑ACETIC ACID | 1.6 | b | Feb 1985 |
| 126 | IPFLUFENOQUIN | 1.3, 1.3.1 | a | Sep 2022 |
| 127 | ISOPRENE ALCOHOL | 7.1 | a | ‑ |
| 128 | IPRODIONE | 1 | a | Feb 1997 |
| 129 | ISETHIONATE, as mixed ammonium and ethanolamine salts of 2‑hydroxyethanesulfonic acid | 1.11 | a, b | Jun 2016 |
| 130 | ISOFETAMID | 1.3 | a | Feb 2018 |
| 131 | ISOSTEARYL ALCOHOL ETHOXYLATE | 5.1 | a | Nov 1999 |
| 132 | KAOLIN | 7.1 | a | Nov 1974 |
| 133 | KINETIN | 1.6 | a | Feb 2022 |
| 134 | KRESOXIM‑METHYL | 1 | a | Aug 1999 |
| 135 | KUNZEA OIL | 7.1 | a | Feb 2000 |
| 136 | LAURIC ACID | 7.1 | a | Oct 2005 |
| 137 | LAURYL ALCOHOL (1‑DODECANOL) | 7.1 | a | Nov 1974 |
| 138 | LAVANDIN OIL | 7.1 | a | Feb 2000 |
| 139 | LAVENDER OIL | 7.1 | a | Feb 2000 |
| 140 | LEAD METALLIC | 7.1 | a | ‑ |
| 141 | LEPIDOPTEROUS SEX PHEROMONES | 1 | a | Nov 1990 |
| 142 | LIMONENE (DIPENTENE) | 7.1 | a | Jun 2002 |
| 143 | LINOLEIC ACID | 7.1 | a | Oct 2005 |
| 144 | LINSEED FATTY ACIDS | 2.1 | a | Aug 1990 |
| 145 | LINURON | 1 | a | Feb 1990 |
| 146 | LIQUORICE, DEGLYCYRRHISINISED | 7.1 | a | May 1999 |
| 147 | MAGNESIUM HYDROXIDE | 7.1 | a | Jun 2021 |
| 148 | MALEIC HYDRAZIDE | 1 | a | Nov 1992 |
| 149 | MANGANESE DIOXIDE | 1 | b | May 1999 |
| 150 | *MEGASPHAERA ELSDENII strain 41125* | 2.4 | a | Sep 2013 |
| 151 | MESOSULFURON‑METHYL | 1.1 | a | Feb 2002 |
| 152 | *METARHIZIUM ANISOPLIAE* | 4.2 | b | Feb 2000 |
| 153 | *METARHIZIUM ANISOPLIAE* | 1.10 | a | Jun 2003 |
| 154 | METCAMIFEN | 1.1 | a | Feb 2020 |
| 155 | METHOPRENE | 1 | a | Aug 1987 |
| 156 | METHOXYFENOZIDE | 1 | a | Nov 2000 |
| 157 | METHYL ACETATE | 7.7 | a | ‑ |
| 158 | METHYL BENZOQUATE | 2.3 | d | Nov 1974 |
| 159 | 1‑METHYLCYCLOPROPENE | 1.6 | a | Jun 2003 |
| 160 | METHYL *p*‑HYDROXYBENZOATE | 7.9 | a | Nov 1974 |
| 161 | METSULFURONMETHYL | 1.1 | a | Nov 1985 |
| 162 | MYRISTIC ACID | 7.1 | a | Oct 2005 |
| 163 | NAPROPAMIDE | 1 | a | Aug 1987 |
| 164 | NAPTHYL ACETAMIDE | 1.6 | a | Nov 1974 |
| 165 | NEROLI OIL | 7.1 | a | Feb 2000 |
| 166 | NICARBAZIN | 2.3 | d | Jun 1969 |
| 167 | NISIN | 3.2 | a | Jun 2003 |
| 168 | NORFLURAZON | 1.1 | a | Nov 1983 |
| 169 | NOVALURON | 1 | a | Nov 2000 |
| 170 | NUCLEAR POLYHEDROSIS VIRUS of *Helicoverpa armigera* occlusion bodies | 1.2 | a | Feb 2004 |
| 171 | OCTYL ALCOHOLS | 7.1 | a | Nov 1974 |
| 172 | OLEIC ACID | 7.1 | a | Oct 2005 |
| 173 | ORANGE OIL, SWEET | 7.1 | a | Aug 2000 |
| 174 | OXABETRINIL | 1 | a | Feb 1987 |
| 175 | OXATHIAPIPROLIN | 1.3 | a | Jun 2016 |
| 176 | OXYFLUORFEN | 1 | a | May 2001 |
| 177 | PALMAROSA OIL | 7.1 | a | Feb 2000 |
| 178 | PALMITIC ACID | 7.1 | a | Oct 2005 |
| 179 | PATCHOULI OIL | 7.1 | a | Feb 2000 |
| 180 | PECTINASE derived from *Aspergillus niger* | 2.4 | a | Feb 2005 |
| 181 | PEGBOVIGRASTIM | 2.1 | a | Jun 2017 |
| 182 | PENCYCURON | 1 | a | Aug 1994 |
| 183 | PENTADECANOIC ACID | 7.1 | a | Oct 2005 |
| 184 | PEPPERMINT OIL | 7.1 | a | Feb 2000 |
| 185 | PHENMEDIPHAM | 1.1 | a | May 1989 |
| 186 | **D**‑PHENOTHRIN | 7.5, 1.2 | a | Feb 1982 |
| 187 | PHYTASE | 2.4 | a | Feb 1996 |
| 188 | PICLORAM | 1 | a | Aug 1987 |
| 189 | PICOLINAFEN | 1 | a | May 2000 |
| 190 | PIMELIC ACID | 7.1 | a | Oct 2005 |
| 191 | PIPERONYL BUTOXIDE | 7.5 | a | Aug 1991 |
| 192 | POLOXALENE | 7.1 | a | Nov 1974 |
| 193 | POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE (PolyDADMAC) | 4.1 | a | Nov 1997 |
| 194 | POLYHEDROSIS VIRUS of *Helico zea* occlusion bodies | 1 | a | Nov 1996 |
| 195 | POLY (GNRF) OVALBUMIN | 2 | a | Feb 1990 |
| 196 | POLYSORBATE 20 | 1 | a | May 2001 |
| 197 | PORCINE SOMATOTROPHIN | 2 | c | Nov 1991 |
| 198 | POTASSIUM SORBATE | 1.3 | a | Oct 2004 |
| 199 | POTASSIUM BICARBONATE | 1 | a | Jun 2004 |
| 200 | PROPYL ACETATES | 7.1 | a | ‑ |
| 201 | PROPYLENE GLYCOL | 7.1 | a | Nov 1974 |
| 202 | 2‑PROPYLENE GLYCOL 1‑MONOMETHYL ETHER | 4 | a | Nov 1987 |
| 203 | PROTHIOCONAZOLE | 1.3.1 | a | Jun 2005 |
| 204 | *PSEUDOMONAS FLUORESCENS* | 1.8 | a | May 1985 |
| 205 | PYDIFLUMETOFEN | 1.3 | a | Feb 2018 |
| 206 | PYRIMETHANIL | 1 | a | Feb 1996 |
| 207 | PYRIPROXYFEN | 1 | a | Aug 1994 |
| 208 | QUASSIA | 6, 2.1 | d | Nov 1974 |
| 209 | QUINOXYFEN | 1.3 | a | Nov 2001 |
| 210 | *RHIZOBIUM RHIZOGENES* | 1 | b | Nov 1989 |
| 211 | ROSEMARY OIL | 7.1 | a | Feb 2000 |
| 212 | SAGE OIL (Spanish) | 7.1 | a | Feb 2000 |
| 213 | SANDALWOOD OIL | 7.1 | a | Feb 2000 |
| 214 | SEAWEED & UNFRACTIONED SEAWEED EXTRACTS | 1.5 | d | Feb 1985 |
| 215 | SILVER OXIDE | 7.14 | b | Jun 2018 |
| 216 | SIMAZINE | 1.1 | a | Nov 1987 |
| 217 | SODIUM BICARBONATE | 1 | a | Jun 2004 |
| 218 | SODIUM PROPIONATE | 1.3 | a | Oct 2004 |
| 219 | STERIC ACID | 7.1 | a | Oct 2005 |
| 220 | STREPTOMYCES LYDICUS WYEC 108 | 1.3 | a | Oct 2016 |
| 221 | SUCRALFATE | 6.8 | a | Aug 1982 |
| 222 | SULESOMAB | 6.1 | b | Jun 2002 |
| 223 | SULFOSULFURON | 1 | a | Feb 1998 |
| 224 | SULPHATED POLYSACCHARIDES | 7.1 | a | ‑ |
| 225 | TANNIC ACID | 7.1 | a | Dec 1965 |
| 226 | TANNIC ACID/BENZYL ALCOHOL PRODUCT | 7.1 | a | Nov 1993 |
| 227 | TERBACIL | 1 | a | Aug 1987 |
| 228 | THAUMATIN | 3.2 | a | Nov 1990 |
| 229 | THIDIAZURON | 1 | a | Nov 1989 |
| 230 | TIAFENACIL | 1 | a | June 2019 |
| 231 | TRIASULFURON | 1 | a | Feb 1988 |
| 232 | TRICHODERMA HARZIANUM | 1 | a | May 1996 |
| 233 | (*Z*)‑9‑TRICOSENE | 1 | a | Aug 1991 |
| 234 | TRIETHYLENE GLYCOL | 7.1 | a | Nov 1974 |
| 235 | TRIFLOXYSULFURON | 1.1 | a | Feb 2002 |
| 236 | TRIFLURALIN | 1 | a | Aug 1990 |
| 237 | TRIFORINE | 1 | a | Aug 1987 |
| 238 | ULOCLADIUM OUDEMANSII | 1.10 | a | Oct 2003 |
| 239 | UREA | 7.1 | a | Nov 1974 |
| 240 | 13C‑UREA | 6.1 | a | May 2001 |
| 241 | VETIVER OIL | 7.1 | a | Feb 2000 |
| 242 | VINYL ETHER | 6 | b | Nov 1987 |
| 243 | VITAMIN K | 6.9, 2.8 | a | Jul 1963 |
| 244 | XANTHOPHYLL (lutein) | 7.1 | a | Nov 1974 |
| 245 | XYLANASE derived from *Aspergillus niger* | 2.4 | a | Feb 2005 |
| 246 | YLANG YLANG OIL | 7.1 | a | Feb 2000 |
| 247 | ZINC NAPHTHENATE | 1.3 | a | ‑ |

Appendix C—Blank

Note 1: Appendix C is intentionally blank.

Note 2: Appendix C previously included poisons now included in Schedule 10.

Appendix D—Additional controls on possession or supply of poisons included in Schedule 4 or 8

Note: See section 64.

1 Poisons available for human use only from or on the prescription or order of an authorised medical practitioner

A poison specified in the following table may be supplied for human use only by, on the prescription or order of, an authorised medical practitioner.

| Item | Poison |
| --- | --- |
| 1 | CANNABIS for human use |
| 2 | CLOMIFENE for human use |
| 3 | CLOZAPINE for human use |
| 4 | CORIFOLLITROPIN ALFA (recombinant follicle stimulant) for human use |
| 5 | CYCLOFENIL for human use |
| 6 | DINOPROST for human use |
| 7 | DINOPROSTONE for human use |
| 8 | FOLLITROPIN ALFA (recombinant human follicle‑stimulating hormone) for human use |
| 9 | FOLLITROPIN BETA (recombinant human follicle‑stimulating hormone) for human use |
| 10 | FOLLITROPIN DELTA (recombinant human follicle‑stimulating hormone) for human use |
| 11 | LUTEINISING HORMONE for human use |
| 12 | NABIXIMOLS for human use |
| 13 | SODIUM OXYBATE for human use |
| 14 | TETRAHYDROCANNABINOLS for human use |
| 15 | TERIPARATIDE for human use |
| 16 | UROFOLLITROPIN (human follicle‑stimulating hormone) for human use |

2 Poisons available for human use only from or on the prescription or order of a specialist physician or a dermatologist

A poison specified in the following table may be supplied for human use:

(a) only by, or on the prescription or order of, a specialist physician or a dermatologist; and

(b) if the person to whom the poison is to be supplied is a woman of child‑bearing age—only if the specialist physician or dermatologist has:

(i) ensured that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(ii) if the poison is acitretin or etretinate—advised the patient to avoid becoming pregnant during or for a period of 36 months after completion of treatment; and

(iii) if the poison is bexarotene, isotretinoin or thalidomide—advised the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.

| Item | Poison |
| --- | --- |
| 1 | ACITRETIN for human use |
| 2 | BEXAROTENE for human use |
| 3 | ETRETINATE for human use |
| 4 | ISOTRETINOIN for human oral use |
| 5 | THALIDOMIDE for human use |

3 Poisons available only from or on the prescription or order of a medical practitioner approved or authorised under section 19 of the Act

A poison specified in the following table may be supplied only by, or on the prescription or order of, a medical practitioner for whom an approval or authority under section 19 of the Act that covers the poison is in force.

| Item | Poison |
| --- | --- |
| 1 | DRONABINOL (delta‑9‑tetrahydrocannabinol) |

4 Poisons available only from or on the order of a specialist physician

A poison specified in the following table may be supplied:

(a) only by, or on the prescription or order of, a specialist physician; and

(b) if the person to whom the poison is to be supplied is a woman of child‑bearing age—only if the specialist physician has:

(i) ensured that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(ii) advised the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.

| Item | Poison |
| --- | --- |
| 1 | LENALIDOMIDE |
| 2 | POMALIDOMIDE |
| 3 | RIOCIGUAT for human use |
| 4 | TRETINOIN for human oral use |

5 Poisons for which possession without authority is illegal

The following table specifies poisons that must not be possessed by a person without authority (for example, possession other than in accordance with a legal prescription).

| Item | Poison |
| --- | --- |
| 1 | ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule 4 |
| 2 | ANDROGENIC STEROIDAL AGENTS, including those separately specified in Schedule 4 |
| 3 | AOD‑9604 (CAS No. 221231‑10‑3) |
| 4 | BENZODIAZEPINE DERIVATIVES, including those separately specified in Schedule 4 and Schedule 8 |
| 5 | BPC‑157 |
| 6 | CAPROMORELIN |
| 7 | CJC‑1295 (CAS No. 863288‑34‑0) |
| 8 | DARBEPOETIN |
| 9 | DEXTROPROPOXYPHENE |
| 10 | *N, α* -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE \*(MDMA) |
| 11 | EPHEDRINE |
| 12 | EPOETINS |
| 13 | ERYTHROPOIETIN |
| 14 | ERYTHROPOIETINS **except** when separately specified in this Appendix |
| 15 | FIBROBLAST GROWTH FACTORS |
| 16 | FOLLISTATIN |
| 17 | GLUTETHIMIDE |
| 18 | GROWTH HORMONE RELEASING HORMONES (GHRHs) including those separately specified in Schedule 4 |
| 19 | GROWTH HORMONE RELEASING PEPTIDES (GHRPs) including those separately specified in Schedule 4 |
| 20 | GROWTH HORMONE RELEASING PEPTIDE‑6 (GHRP‑6) |
| 21 | GROWTH HORMONE SECRETAGOGUES including those separately specified in Schedule 4 |
| 22 | HEXARELIN |
| 23 | IBUTAMOREN |
| 24 | INSULIN‑LIKE GROWTH FACTORS |
| 25 | IPAMORELIN |
| 26 | NICOTINE |
| 27 | PERAMPANEL for human use |
| 28 | PHENTERMINE |
| 29 | PRALMORELIN ((GROWTH HORMONE RELEASING PEPTIDE‑2) (GHRP‑2)) |
| 30 | PSILOCYBINE |
| 31 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM), including those separately specified in Schedule 4 |
| 32 | SOMATROPIN (human growth hormone) |
| 33 | STENABOLIC (SR9009) and other synthetic REV‑ERB agonists |
| 34 | TB‑500 |
| 35 | THYMOSIN BETA 4 (THYMOSIN β4) |
| 36 | TIANEPTINE |
| 37 | VADADUSTAT |

6 Poisons available for human use only from or on the prescription or order of a specialist physician

A poison specified in the following table may be supplied for human use:

(a) only by, or on the prescription or order of, a specialist physician; and

(b) if the person to whom the poison is to be supplied is a woman of child‑bearing age—only if the specialist physician has:

(i) ensured that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(ii) advised the patient to avoid becoming pregnant during and for a period of 3 months after completion of treatment.

| Item | Poison |
| --- | --- |
| 1 | AMBRISENTAN for human use |
| 2 | BOSENTAN for human use |
| 3 | ENZALUTAMIDE for human use |
| 4 | MACITENTAN for human use |
| 5 | SITAXENTAN for human use |

7 Poisons available for human use only from or on the prescription or order of a dermatologist

A poison specified in the following table may be supplied for human use only by, or on the prescription or order of, a dermatologist.

| Item | Poison |
| --- | --- |
| 1 | ALEFACEPT for human use |

8 Poisons available for initial treatment of a patient only if authorised by certain health practitioners

HYDROXYCHLOROQUINE may be supplied, for human use, for the initial treatment of a patient only if that treatment is authorised by:

(a) a medical practitioner registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist in any of the following specialties or fields of specialty practice:

(i) dermatology;

(ii) emergency medicine;

(iii) intensive care medicine;

(iv) paediatrics and child health;

(v) physician; or

(b) a dental practitioner registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist in the specialty of oral medicine.

9 Poisons which must be stored in a locked container to prevent unauthorised access

The following table specifies poisons that must be stored in a locked container to prevent unauthorised access.

| Item | Poison |
| --- | --- |
| 1 | PENTOBARBITAL in injectable preparations |

10 Poisons available only when prescribed or authorised in certain circumstances

*N, α* -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE \*(MDMA) in preparations for human use may be supplied only for the treatment of post-traumatic stress disorder:

(a) if MDMA is prescribed, or its supply is authorised, by a medical practitioner:

(i) registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist psychiatrist; and

(ii) for whom an authority under subsection 19(5) of the Act that covers MDMA is in force; or

(b) for use in a clinical trial that is approved by, or notified to, the Secretary under the Act.

PSILOCYBINE in preparations for human use may be supplied only for the treatment of treatment-resistant depression:

(a) if psilocybine is prescribed, or its supply is authorised, by a medical practitioner:

(i) registered under State or Territory legislation that forms part of the Health Practitioner Regulation National Law as a specialist psychiatrist; and

(ii) for whom an authority under subsection 19(5) of the Act that covers psilocybine is in force; or

(b) for use in a clinical trial that is approved by, or notified to, the Secretary under the Act.

Appendix E—First aid instructions for poisons

Note: See section 31.

1 Standard statements for first aid instructions

For the purposes of the table in clause 3, the statement code specified in column 2 of an item of the following table represents:

(a) the statement specified in column 3 of the item; or

(b) a different statement that has the same intent as the statement specified in column 3 of the item.

| Standard statements for first aid instructions | | | |
| --- | --- | --- | --- |
| Item | Column 1 Category | Column 2 Statement code | Column 3 Statement |
| 1 | Basic | A | For advice, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor (at once). |
| 2 | Basic | Z | First aid is not generally required. If in doubt, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor. |
| 3 | General | G1 | Urgent hospital treatment is likely to be needed.  (Note ‑ the words “at once” to be added to instruction A). |
| 4 | General | G2 | If swallowed, give activated charcoal if instructed.  (Note ‑ the words “at once” to be added to instruction A). |
| 5 | General | G3 | If swallowed, do NOT induce vomiting. |
| 6 | General | G4 | Immediately give a glass of water. |
| 7 | General | G5 | Avoid giving milk or oils. |
| 8 | General | G6 | If sprayed in mouth, rinse mouth with water. |
| 9 | Eyes | E1 | If in eyes wash out immediately with water. |
| 10 | Eyes | E2 | If in eyes, hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor, or for at least 15 minutes. |
| 11 | Respiratory system | R1 | If inhaled, remove from contaminated area. Apply artificial respiration if not breathing. |
| 12 | Respiratory system | R2 | If swallowed or inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Do not give direct mouth‑to‑mouth resuscitation. To protect rescuer, use air‑viva, oxy‑viva or one‑way mask. Resuscitate in a well‑ventilated area. |
| 13 | Skin | S1 | If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. |
| 14 | Skin | S2 | If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor. |
| 15 | Skin | S3 | If on skin, remove any contaminated clothing, wash skin thoroughly with soap and water, then methylated spirit if available. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor. |
| 16 | Skin | S4 | If on skin, immediately remove any contaminated clothing, wash skin with methylated spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor. |
| 17 | Skin | S5 | If skin contact occurs, immediately remove contaminated clothing. Flush skin under running water for 15 minutes. Then apply calcium gluconate gel. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766). |
| 18 | Special Purpose | SP1 | If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor at once. Remove any contaminated clothing and wash skin thoroughly. If swallowed, activated charcoal may be advised. Give atropine if instructed. |

2 Poisons information centre contact information in statements

A statement required for a poison that includes a reference to a Poisons Information Centre must include:

(a) the telephone number that is appropriate to the country or countries in which the poison is to be supplied; and

(b) immediately following the reference to a Poisons Information Centre:

(i) the national telephone number for the Poisons Information Centre in Australia (13 11 26); or

(ii) the telephone number for another poisons information centre:

(A) that is attended by adequately trained staff for 24 hour emergency poisons information; and

(B) calls to which are logged and submitted for incorporation into the official collection of poisoning data.

Note: For subparagraph (b)(ii), in 2022 the Poisons Information Centre telephone number in New Zealand was 0800 764 766.

3 First aid instructions for poisons

(1) For the purposes of subsection 31(1), and subject to subclause (2), the statement represented by each statement code specified in column 2 of an item of the following table is required for the poison specified in column 1 of the item.

(2) A statement required for a poison must:

(a) be modified for its use in relation to that poison as appropriate for the poison (for example if the poison is combined with other substances (whether toxic or non‑toxic) or is in a particular physical form or presentation); and

(b) if the statement refers to a Poisons Information Centre—comply with clause 2.

| Poisons that must be labelled with first aid instructions | | |
| --- | --- | --- |
| Item | Column 1 Poison | Column 2 Statement code |
| 1 | ACETIC ACID | A, G3, E2, S1 |
| 2 | ACETIC ANHYDRIDE | A, G3, E2, S1 |
| 3 | ACETONE | A, G3 |
| 4 | ACROLEIN | A, G1, G2, G3, E2, R2, S2 |
| 5 | ALKALINE SALTS | A, G3, E2, S1 |
| 6 | ALKYL NITRITES | A |
| 7 | AMIDOPROPYL BETAINES—in cosmetic wash‑off preparations when included in Schedule 6 | E1 |
| 8 | AMIDOPROPYL BETAINES—in other preparations when included in Schedule 6 | E1, S1 |
| 9 | AMINES for use as curing agents | A, G3, E1, S1 |
| 10 | 2‑AMINO‑6‑CHLORO‑4‑NITROPHENOL | A, E1 |
| 11 | 4‑AMINO‑*m*‑CRESOL | A, E1 |
| 12 | 2‑AMINO‑5‑ETHYLPHENOL | A |
| 13 | 4‑AMINO‑2‑HYDROXYTOLUENE | A, E1 |
| 14 | 4‑AMINO‑3‑NITROPHENOL | A |
| 15 | 2,2'‑[(4‑AMINO‑3‑NITROPHENYL)IMINO]BISETHANOL | E1 |
| 16 | *m*‑AMINOPHENOL | A, S1 |
| 17 | *p*‑AMINOPHENOL | A, S1 |
| 18 | 4‑AMINOPYRIDINE | A, G1, G2, E1, S1 |
| 19 | AMMONIA—5% or less | A |
| 20 | AMMONIA—above 5% | A, G3, E1, R1, S1 |
| 21 | AMMONIUM COCOYL ISETHIONATE | E1 |
| 22 | AMMONIUM PERSULFATE | A, G3, E2 |
| 23 | AMMONIUM THIOCYANATE | A |
| 24 | AMYL NITRITE | A |
| 25 | ANHYDRIDES, organic acid, for use as curing agents for epoxy resins | A, G3, E1, S1 |
| 26 | ANILINE | A, E2, R1, S1 |
| 27 | ANISE OIL | A, G3 |
| 28 | ANITMONY CHLORIDE | A, E2, S2 |
| 29 | ANTIMONY COMPOUNDS, **except** antimony chloride | A |
| 30 | ARBUTIN when included in Schedule 6 | A, G2, G3, E2, R2, S1 |
| 31 | AZADIRACHTA INDICA (neem) including its extracts and derivatives when included in Schedule 6 | A, E1 |
| 32 | AZO DYES (derivatives by diazotisation) | A |
| 33 | BARIUM SALTS, **except** barium sulfate | A |
| 34 | BASIC RED 76 | A |
| 35 | BASIL OIL | A, G3 |
| 36 | BAY OIL | A, G3 |
| 37 | BENZALKONIUM CHLORIDE—when included in Schedule 5 | A, G3, E2 |
| 38 | BENZALKONIUM CHLORIDE—when included in Schedule 6 | A, G3, E2, S1 |
| 39 | BENZENE | A, G3, E1, R1, S1 |
| 40 | 1,2‑BENZENEDIOL (Catechol) | A, E1, S1 |
| 41 | BENZOYL PEROXIDE—above 20% | A, E2, S1 |
| 42 | BENZOYL PEROXIDE—above 10% up to 20% | A, E1 |
| 43 | BENZOYL PEROXIDE—10% or less | A |
| 44 | BERGAMOT OIL | A, G3 |
| 45 | BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 5 | A |
| 46 | BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 6 or 7 | A, G3, E2, S5 |
| 47 | 1,3‑BIS(2,4‑DIAMINOPHENOXY)PROPANE | E1, S1 |
| 48 | BIS‑ISOBUTYL PEG/PPG‑20/35/AMODIMETICONE COPOLYMER | A, E1 |
| 49 | BORAX | A |
| 50 | BORIC ACID | A |
| 51 | BORON TRIFLUORIDE—when included in Schedule 5 | A |
| 52 | BORON TRIFLUORIDE—when included in Schedule 6 or 7 | A, G3, E2, S5 |
| 53 | BROMOFORM | A, G3, E2, R1, S2 |
| 54 | BRUCINE | A, G1, G2, G3, R2 |
| 55 | 2‑BUTOXYETHANOL and its acetates | A, E2, S1 |
| 56 | n‑BUTYL ALCOHOL | A, E1, S1 |
| 57 | BUTYL NITRITE | A |
| 58 | CADMIUM COMPOUNDS | A |
| 59 | CAJUPUT OIL | A, G3 |
| 60 | CAMPHOR | A, G1, G3, G5 |
| 61 | CARBAMIDE PEROXIDE—more than 9% up to 60% | A, G3, E2, S1 |
| 62 | CARBAMIDE PEROXIDE—more than 60% | A, G1, G3, G4, E2, S1 |
| 63 | CARBON DISULFIDE | A, G3, E2, R1, S2 |
| 64 | CARBON TETRACHLORIDE | A, G3, E1, R1, S1 |
| 65 | CASSIA OIL | A, G3 |
| 66 | CHLORINATING COMPOUNDS, **except** when separately specified—containing above 4% and below 10% of available chlorine | A, G3, E1, S1 |
| 67 | CHLORINATING COMPOUNDS, **except** when separately specified—containing 10% or more of available chlorine | A, G3, E2, S1 |
| 68 | CHLORIDE (gas) | A, E1, R1 |
| 69 | CHLOROACETAMIDE | A |
| 70 | CHLOROCRESOL | A, G3, E2, S2 |
| 71 | 2‑CHLORO‑6‑(ETHYLAMINO)‑4‑NITROPHENOL | A, S1 |
| 72 | CHLOROFORM | A, G3, E1, R1, S1 |
| 73 | CHROMATES | A, G3, E2, S1 |
| 74 | CHROMIUM TRIOXIDE | A, G3, E2, S1 |
| 75 | CHRYSOIDINE BASE | A, S1, E1 |
| 76 | CINEOLE | A, G1, G3 |
| 77 | CINNAMON BARK OIL | A, G3 |
| 78 | CINNAMON LEAF OIL | A, G3 |
| 79 | CLIMBAZOLE | A |
| 80 | CLOVE OIL | A, G1, G3, E2 |
| 81 | COCOYL GLYCINATE | E1 |
| 82 | COPPER SULFATE | A, G3, E2, S1 |
| 83 | CREOSOTE | A, G3, E2, S1 |
| 84 | CRESOLS | A, G3, E2, S3 |
| 85 | CRESOLS in pressurised spray packs | A, G6, E1, S1 |
| 86 | CYANIDES | A, G1, E1, R2 |
| 87 | CYANOACRYLIC ACID ESTERS | A |
| 88 | CYANURIC ACID | A |
| 89 | CYCLOHEXANONE PEROXIDE | A, G3, E2, S1 |
| 90 | CYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2) | A, E2, S1 |
| 91 | CYCTEAMINE | E1 |
| 92 | 1‑DEOXY‑1‑(METHYLAMINO)‑d‑GLUCITOL N‑COCO ACYL DERIVATIVES | E1 |
| 93 | 2,4‑DIAMINOPHENOXYETHANOL | A, E2, S1 |
| 94 | *o*‑DICHLOROBENZENE | A, G3, E1, S1 |
| 95 | para‑DICHLOROBENZENE (PDB) | A |
| 96 | DICHLOROETHYL ETHER | A, G3, E1, R1, S1 |
| 97 | DICHLOROISOCYANURATES | A, G3, E1, S1 |
| 98 | DICHLOROMETHANE (methylene chloride) | A, G3, G5, E1, R1, S1 |
| 99 | DICHLOROMETHANE (methylene chloride)—in pressurised spray packs | A, G6, S1 |
| 100 | DICHROMATES | A, G1, G3, E2, S1 |
| 101 | DIDECYLDIMETHYLAMMONIUM SALTS | A, G3 |
| 102 | DIESEL (distillate) | A, G3 |
| 103 | DIETHANOLAMINE—when included in Schedule 5 | A, G3 |
| 104 | DIETHANOLAMINE—when included in Schedule 6 | A, G3, E2, S1 |
| 105 | DIETHYLENE GLYCOL MONOBUTYL ETHER | A, E1, S1 |
| 106 | 5,6‑DIHYDROXYINDOLINE | E1 |
| 107 | DIMETHYLFORMAMIDE—less than 75% | A |
| 108 | DIMETHYLFORMAMIDE—75% or more | A, E1, R1, S1 |
| 109 | 4,4‑DIMETHYL‑1‑CYCLOHEXENE‑1‑PROPANAL | A, E2 |
| 110 | 3,7‑DIMETHYL‑2,6‑OCTADIEN‑1‑OL | A, E1, S1 |
| 111 | DIMETHYL SULFOXIDE | A, G3, E1, S1 |
| 112 | DINITROCRESOLS | A, G1, E1, S1 |
| 113 | DINITROPHENOLS | A, G1, E1, S1 |
| 114 | DIOXANE | A, G3, E1, R1, S1 |
| 115 | DISPERSE YELLOW 3 | A, S1 |
| 116 | DISTILLATE | A, G3 |
| 117 | *N*‑(*N*‑DODECYL)‑2‑PYRROLIDONE—when included in Schedule 5 | A, G3, E1 |
| 118 | *N*‑(*N*‑DODECYL)‑2‑PYRROLIDONE—when included in Schedule 6 | A, G3, E2, S1 |
| 119 | EPOXY RESINS liquid | A, G3, E2, S1 |
| 120 | Essential oils containing CAMPHOR as natural component unless otherwise specified | A, G3 |
| 121 | ETHER | A, G3, E1, R1 |
| 122 | ETHYL BROMIDE | A, E2, S1, R1 |
| 123 | ETHYLENE GLYCOL | A |
| 124 | ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates, **except** when separately specified | A, G3, E2, S1 |
| 125 | ETHYLENE OXIDE | A, E2, R1 |
| 126 | ETHYLHEXANEDIOL | A, E2 |
| 127 | 2‑ETHYLHEXANOIC ACID | A |
| 128 | EUCALYPTUS OIL | A, G1, G3 |
| 129 | EUGENOL | A, G1, G3, E2 |
| 130 | FENNEL OIL | A, G3 |
| 131 | FLUORIDES **except** when separately specified—when included in Schedule 5 | A |
| 132 | FLUORIDES **except** when separately specified—when included in Schedule 6 | A, G1, G3, E2, S1 |
| 133 | FORMALDEHYDE (see also paraformaldehyde) | A, G3, E2, R1, S1 |
| 134 | FORMIC ACID | A, G3, E2, S1 |
| 135 | FURFURAL | A, E1, S1 |
| 136 | GLUTARAL—below 5% | A, G3, E1 |
| 137 | GLUTARAL—5% or more | A, G3, E2, S1 |
| 138 | GLYCOLIC ACID | A, G3, E2 |
| 139 | GUANIDINE when included in Schedule 6 | A, G3, E2, S1 |
| 140 | HC VIOLET 1 | E1 |
| 141 | HEXACHLOROPHENE when included in Schedule 6 | A |
| 142 | HEXYLOXYETHANOL | A, G3, E2, S1 |
| 143 | HYDRAZINE | A, G1, G3, E2, R1, S1 |
| 144 | HYDROCARBONS, liquid | A, G3 |
| 145 | HYDROCHLORIC ACID | A, G3, E2, S1 |
| 146 | HYDROCHLORIC ACID—when included in Schedule 5 | A, G3 |
| 147 | HYDROFLUORIC ACID and admixtures that generate hydrofluoric acid—when included in Schedule 5 | A |
| 148 | HYDROFLUORIC ACID and admixtures that generate hydrofluoric acid—when included in Schedule 6 or 7 | A, G3, E2, S5 |
| 149 | HYDROGEN PEROXIDE—more than 3% up to 20% | A, G3, E2, S1 |
| 150 | HYDROGEN PEROXIDE—more than 20% | A, G1, G3, G4, E2, S1 |
| 151 | HYDROQUINONE—when included in Schedule 2 | A |
| 152 | HYDROQUINONE—when included in Schedule 4 or 6 | A, G2, G3, E2, R2, S1 |
| 153 | HYDROSILICOFLUORIC ACID—when included in Schedule 5 | A |
| 154 | HYDROSILICOFLUORIC ACID—when included in Schedule 6 or 7 | A, G3, E2, S5 |
| 155 | 2‑HYDROXYETHYL METHACRYLATE | A, E1, S1 |
| 156 | HYDROXYETHYL‑3,4‑METHYLENEDIOXYANILINE | E1, S1 |
| 157 | IODINE (excluding salts, derivatives and iodophors)—2.5% or more for human external use | A, E2 |
| 158 | IODINE (excluding salts, derivatives and iodophors)—2.5% or more for other uses | A, E2, S1 |
| 159 | IODINE (excluding salts, derivatives and iodophors)—below 2.5% | A |
| 160 | IODOPHORS | A |
| 161 | ISOAMYL NITRITE | A |
| 162 | ISOBUTYL NITRITE | A |
| 163 | ISOCYANATES, free organic | A, E2, S1 |
| 164 | ISOEUGENOL | A, E1, S1 |
| 165 | ISOPHORONE | A, G3, E2, S1 |
| 166 | KEROSENE | A, G3 |
| 167 | LAURETH CARBOXYLIC ACIDS—leave‑on or wash‑off preparations above 5% | E1 |
| 168 | LAURETH CARBOXYLIC ACIDS—other preparations above 5% | E1, S1 |
| 169 | LAURYL ISOQUINOLINIUM BROMIDE | A, E1 |
| 170 | LEAD COMPOUNDS—in hair cosmetics | A |
| 171 | LEAD COMPOUNDS—in other preparations | A, S1 |
| 172 | LEMON OIL | A, G3 |
| 173 | LEPTOSPERMUM SCOPARIUM OIL (manuka oil) | A, G1, G3 |
| 174 | LIME OIL | A, G3 |
| 175 | MAGNESIUM CHLORATE | A |
| 176 | MALATHION at 20% or less | A |
| 177 | MARJORAM OIL | A, G3 |
| 178 | MELALEUCA OIL | A, G1, G3 |
| 179 | MERCAPTOACETIC ACID | A, E1 |
| 180 | MERCURIC CHLORIDE—for external therapeutic use | A |
| 181 | MERCURIC CHLORIDE—for other uses | A, G1, G3, E2, R2, S1 |
| 182 | MERCURIC IODIDE | A, G1, G3, E2, R2, S1 |
| 183 | MERCURIC NITRATE | A, G1, G3, E2, R2, S1 |
| 184 | MERCURIC OXIDE | A, G1, G3 |
| 185 | MERCURIC POTASSIUM IODIDE | A, G1, G3, E2, R2, S1 |
| 186 | MERCURIC THIOCYANATE | A, G1, G3, E2, R2, S1 |
| 187 | MERCUROCHROME | A |
| 188 | MERCUROUS CHLORIDE | A |
| 189 | MERCURY—metallic | A |
| 190 | MERCURY—organic compounds | A, S1 |
| 191 | MERCURY—organic compounds in preparations for human external use | A |
| 192 | METALDEHYDE | A, E1, S1 |
| 193 | METHANOL—above 10% | A, G3 |
| 194 | METHANOL—10% or less | A |
| 195 | METHYLATED SPIRIT(S) | A, G3 |
| 196 | METHYLATED SPIRIT(S)—when packed and labelled as a “biofuel” suitable for use in “spirit burners” | A, G3 |
| 197 | METHYL ETHYL KETONE | A, G3 |
| 198 | METHYL ETHYL KETONE OXIME | A, E1, S1 |
| 199 | METHYL ETHYL KETONE PEROXIDE | A, G3, E2, S1 |
| 200 | METHYLEUGENOL | A |
| 201 | METHYL ISOAMYL KETONE | A, G3 |
| 202 | METHYL ISOBUTYL KETONE | A, G3 |
| 203 | N‑METHYL‑2‑PYRROLIDONE—when included in Schedule 5 | A, G3, E1 |
| 204 | N‑METHYL‑2‑PYRROLIDONE—when included in Schedule 6 | A, G3, E2 |
| 205 | 2‑METHYLRESORCINOL | A, E1 |
| 206 | METHYL SALICYLATE LIQUID when included in Schedule 5 or 6 | A, G3, E1 |
| 207 | MONOETHANOLAMINE—when included in Schedule 5 | A, G3, E1 |
| 208 | MONOETHANOLAMINE—when included in Schedule 6 | A, G3, E2, S1 |
| 209 | 1,5‑NAPHTHALENEDIOL | A, E1, S1 |
| 210 | 2,7‑NAPHTHALENEDIOL | A, E1, S1 |
| 211 | NAPHTHALENE | A, G1, G3 |
| 212 | 1‑NAPHTHOL | A, E1, S1 |
| 213 | NITRIC ACID | A, G3, E2, S1 |
| 214 | NITROBENZENE | A, G3, E1, S1 |
| 215 | 3‑NITRO‑*p*‑HYDROXYETHYLAMINOPHENOL | E1 |
| 216 | NITROPHENOL | A, G3, E2, S1 |
| 217 | NITROPRUSSIDES—in aerosols | A, G6, R1 |
| 218 | NITROPRUSSIDES—in other preparations | A, G3 |
| 219 | NITROUS OXIDE | A |
| 220 | NONOXINOL 9 | A, E2 |
| 221 | NUTMEG OIL | A, G3 |
| 222 | OCTHILINONE | A, G3, E2, S1 |
| 223 | OCTYL NITRITE | A |
| 224 | *N*‑(*N*‑OCTYL)‑2‑PYRROLIDONE—when included in Schedule 5 | A, G3, E1 |
| 225 | *N*‑(*N*‑OCTYL)‑2‑PYRROLIDONE—when included in Schedule 6 | A, G3, E2 |
| 226 | ORANGE OIL (bitter) | A, G3 |
| 227 | OXALIC ACID | A, G3, E2, S1 |
| 228 | PARAFORMALDEHYDE | A, G3, E2, R1, S1 |
| 229 | PENNYROYAL OIL | A, G3 |
| 230 | PERACETIC ACID—when included in Schedule 5 | A, G3, E1, S1 |
| 231 | PERACETIC ACID—when included in Schedule 6 | A, G3, E2, S1 |
| 232 | PETROL | A, G3, R1 |
| 233 | 2‑PHENOXYETHANOL | A, E1 |
| 234 | PHENOL when included in Schedule 6 | A, E1 |
| 235 | PHENOLS—25% and less | A, G3, E2, S3 |
| 236 | PHENOLS—above 25% | A, G3, E2, S4 |
| 237 | PHENOLS—in pressurised spray packs | A, E1 |
| 238 | PHENOXYMETHYL OXIRANE | A, E1 |
| 239 | PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in hair dyes | A, E1 |
| 240 | PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in preparations other than hair dyes | A, G1, G3, E1, S1 |
| 241 | PHENYL METHYL KETONE as such, or in preparations of similar viscosity | A, G3, E1 |
| 242 | PHENYL METHYL PYRAZOLONE | A, S1 |
| 243 | *N*,*N*‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,5‑DIMETHANAMINE | A, E2, S1 |
| 244 | *N*,*N*‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,6‑DIMETHANAMINE | A, E2, S1 |
| 245 | *o*‑PHENYLPHENOL | A, G3, E2, S1 |
| 246 | *o*‑PHENYLPHENOL—in pressurised spray packs | A, G6, E2, S1 |
| 247 | PHOSPHONIC ACID | A, G3, E2, S1 |
| 248 | PHOSPHONIC ACID—neutralised to pH 6 (approx) | A |
| 249 | PHOSPHONIC ACID—in spray packs | A, E2, S1 |
| 250 | PHOSPHORIC ACID | A, G3, E2, S1 |
| 251 | PHOSPHORUS, YELLOW | A, G1, G3, E2, R2, S2 |
| 252 | *o*‑PHTHALALDEHYDE—when included in Schedule 5 | A, E1 |
| 253 | *o*‑PHTHALALDEHYDE—when included in Schedule 6 | A, G3, E2, S1 |
| 254 | PICRAMIC ACID including its salts (excluding other derivatives) | A, E1 |
| 255 | PICRIC ACID | A, G1, G3, E2, R1, S1 |
| 256 | POLIHEXANIDE | E1 |
| 257 | POLYETHANOXY (15) TALLOW AMINE | A, E2, S1 |
| 258 | POLY(OXY‑1,2‑ETHANEDIYL), Α ‑[2‑[(2‑HYDROXYETHYL)AMINO]‑2‑OXOETHYL]‑  Α ‑HYDROXY‑,MONO‑C13‑15‑ALKYL ETHERS | A, E1 |
| 259 | POTASSIUM BROMATE | A |
| 260 | POTASSIUM CHLORATE | A |
| 261 | POTASSIUM CYANATE | A, E1, S1 |
| 262 | POTASSIUM HYDROXIDE | A, G3, E2, S1 |
| 263 | POTASSIUM METABISULPHITE | A |
| 264 | POTASSIUM NITRITE—when included in Schedule 7 | A, G1, G3 |
| 265 | POTASSIUM NITRITE—when included in Schedule 5 or 6 | A, G3 |
| 266 | POTASSIUM PEROXOMONOSULFATE TRIPLE SALT—when included in Schedule 5 | A, G3, E1 |
| 267 | POTASSIUM PEROXOMONOSULFATE TRIPLE SALT—when included in Schedule 6 | A, G3, E2, S1 |
| 268 | POTASSIUM PERSULFATE | A, G3, E2 |
| 269 | POTASSIUM SULFIDE | A, G3, E2, S1 |
| 270 | PROPIONIC ACID | A, G3, E1, S1 |
| 271 | n‑PROPYL ALCOHOL | A, E1 |
| 272 | **D**‑PULEGONE | A, G3 |
| 273 | PYRITHIONE ZINC | A, E1 |
| 274 | QUATERNARY AMMONIUM COMPOUNDS **except** when separately specified—above 20% | A, G3, E2 |
| 275 | QUATERNARY AMMONIUM COMPOUNDS **except** when separately specified—20% and below | A, E2 |
| 276 | QUATERNARY AMMONIUM COMPOUNDS **except** when separately specified—in pressurised spray packs | A, E2, G6 |
| 277 | QUINOLINE | A, E1, S1 |
| 278 | RESORCINOL | A, E2, S1 |
| 279 | SAFROLE | A, G1, G3 |
| 280 | SAGE OIL (Dalmatian) | A, G3 |
| 281 | SASSAFRAS OIL | A, G1, G3 |
| 282 | SELENIUM COMPOUNDS | A, G1, E1, S1 |
| 283 | SILICOFLUORIDES—when included in Schedule 5 | A |
| 284 | SILICOFLUORIDES—when included in Schedule 6 | A, G1, G3, E2, S1 |
| 285 | SILVER SALTS | A, E2 |
| 286 | SODIUM ALUMINATE | A, G3, E2, S1 |
| 287 | SODIUM BROMATE | A, G1 |
| 288 | SODIUM CHLORATE | A |
| 289 | SODIUM DIACETATE | A, G3, E2, S1 |
| 290 | SODIUM DICHLOROISOCYANURATE | A, G3, E1, S1 |
| 291 | SODIUM DODECYLBENZENE SULFONATE | A, G3, E2, S1 |
| 292 | SODIUM HYDROGEN SULFATE | A, G3, E1, S1 |
| 293 | SODIUMHYDROSULFITE | A, G3, E2, S1 |
| 294 | SODIUM HYDROXIDE | A, G3, E2, S1 |
| 295 | SODIUM LAURETH‑6 CARBOXYLATE | A |
| 296 | LAURYL SULFATE SALTS—leave‑on or wash‑off preparations above 5% | E1 |
| 297 | LAURYL SULFATE SALTS—other preparations above 5% | E1, S1 |
| 298 | SODIUM METABISULPHITE | A, G3 |
| 299 | SODIUM NITRITE—when included in Schedule 7 | A, G1, G3 |
| 300 | SODIUM NITRITE—when included in Schedule 5 or 6 | A, G3 |
| 301 | SODIUM PERCARBONATE—when included in Schedule 5 | A, G3, S1 |
| 302 | SODIUM PERCARBONATE—when included in Schedule 6 | A, G3, E2, S1 |
| 303 | SODIUM PERSULFATE | A, G3, E2 |
| 304 | SODIUM STANNATE | A, E1 |
| 305 | SODIUM SULFIDE | A, G3, E2, S1 |
| 306 | SODIUM TRICHLOROACETATE | A |
| 307 | STRYCHNINE | A, G1, G2, G3, R2 |
| 308 | STYRENE | A, G3, S1, E1 |
| 309 | SULCOFURON | A |
| 310 | SULFAMIC ACID | A, G3, E2, S1 |
| 311 | SULFURIC ACID | A, G3, E2, S1 |
| 312 | TERPENES, chlorinated | A, G3 |
| 313 | TETRACHLOROETHANE | A, G3, E1, R1, S1 |
| 314 | TETRACHLOROETHYLENE | A, G3, E2, R1, S1 |
| 315 | THIOUREA | A |
| 316 | THUJONE | A, G3 |
| 317 | THYME OIL | A, G3 |
| 318 | *o*‑TOLIDINE | A |
| 319 | TOLUENE—above 75% | A, G3, E1, R1, S1 |
| 320 | TOLUENE—75% and below | A, G3 |
| 321 | TOLUENE—in pressurised spray packs | A |
| 322 | TOLUENEDIAMINES—in hair dyes | A, E1 |
| 323 | TOLUENEDIAMINES—in other preparations | A, G1, G3, E1, S1 |
| 324 | TRICHLOROACETIC ACID | A, G3, E2, S1 |
| 325 | TRICHLOROACETIC ACID ALKALI SALTS | A |
| 326 | 1,1,1‑TRICHLOROETHANE | A, G3, E1, R1, S1 |
| 327 | TRICHLOROETHYLENE | A, G3, E1, R1, S1 |
| 328 | TRICHLOROISOCYANURIC ACID | A, G3, E1, S1 |
| 329 | TRIETHYL PHOSPHATE | A, E1 |
| 330 | TRIFLUOROMETHANESULFONIC ACID | A, G3, E2 |
| 331 | TRIISOPROPANOLAMINE LAURYL ETHER SULFATE | A, E1, S1 |
| 332 | TROLAMINE | A, G3, E1, S1 |
| 333 | TURPENTINE (mineral) | A, G3 |
| 334 | TURPENTINE OIL (vegetable) | A, G3, E2 |
| 335 | VINYL ACETATE MONOMER | A, R1 |
| 336 | WHITE SPIRIT | A, G3 |
| 337 | XYLENE—above 75% | A, G3, E1, R1, S1 |
| 338 | XYLENE—75% and below | A, G3 |
| 339 | XYLENE—in pressurised spray packs | A, G6, E1, S1 |
| 340 | XYLENOLS in pressurised spray packs | A, E1 |
| 341 | ZINC CHLORIDE | A, G3, E2, S1 |
| 342 | ZINC SULFATE | A, G3, E2, S1 |

Appendix F—Warning statements and general safety directions for poisons

Note: See sections 29 and 30, subsection 33(2) and section 42.

1 Warning statements

For the purposes of the table in clause 4 of this Appendix and the table in clause 2 of Appendix L, the item number of an item of the following table represents the warning statement specified in column 1 of the item.

Note: See section 30.

| Warning statements | |
| --- | --- |
| Item | Column 1  Warning statement |
| 1 | Highly corrosive. |
| 2 | Corrosive. |
| 3 | Corrosive liquid. |
| 4 | Strongly alkaline. |
| 5 | Irritant. |
| 6 | May cause cancer. |
| 7 | WARNING – Causes birth defects. |
| 8 | WARNING – May be fatal to children. |
| 9 | Can be fatal to children if sucked or swallowed. |
| 10 | May produce severe burns. |
| 11 | WARNING – Vapour may be harmful. |
| 12 | Vapour is harmful to health on prolonged exposure. |
| 13 | May be fatal if inhaled, swallowed or absorbed through skin. |
| 14 | Dust will irritate and burn eyes, nose and skin. |
| 15 | Liquid will cause burns. |
| 16 | Forms dangerous gas near radiators or naked flames. |
| 17 | Contact with eyes even for short periods can cause blindness. |
| 18 | Product will irritate the eyes, nose, throat and skin. |
| 19 | WARNING – Skin contact may be dangerous. Take every precaution to avoid contact – wash off after spillage and after use. |
| 20 | May give off dangerous gas if mixed with other products. |
| 21 | WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye. |
| 22 | Highly reactive oxidising chlorine compound. |
| 23 | May cause fire or explosion. |
| 24 | For external washing only. Rinse skin thoroughly after use. |
| 25 | Do not use on broken skin. Wash hands thoroughly after use. |
| 26 | (Powder) (and) (concentrated solutions) are dangerous if swallowed. |
| 27 | Not for therapeutic use. |
| 28 | (Over) (Repeated) exposure may cause sensitisation. |
| 29 | If congestion persists, consult your doctor or pharmacist. |
| 30 | WARNING – Do not use on face or on anal or genital areas. |
| 31 | WARNING – Do not use on face or on anal or genital areas except on doctor’s advice. |
| 32 | This preparation should be part of an overall treatment plan regularly assessed with your doctor. |
| 33 | Do not take for periods longer than four weeks except on medical advice. |
| 34 | WARNING – This medication may be dangerous when used in large amounts or for a long time (period). |
| 35 | CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful.  or  CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged or excessive use without medical supervision could be harmful. |
| 36 | For use under medical supervision only. |
| 37 | Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever. |
| 38 | CAUTION – Do not use for children under 2 years unless a doctor has told you to. |
| 39 | This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol. |
| 40 | This medication may cause drowsiness and may increase the effects of alcohol. If affected do not drive a motor vehicle or operate machinery. |
| 41 | Do not give to children under 12 years of age. Do not use beyond 48 hours or in pregnancy or lactation except on doctor’s advice. |
| 42 | WARNING – Overuse may stain the skin or mouth. |
| 43 | Use of this product is not necessary in areas supplied with fluoridated water. |
| 44 | WARNING – May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time. |
| 45 | WARNING – If a pigmented spot or mole has recently become darker, changed colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor immediately. Do not use on children. Do not use near the eyes. Mild irritation may occur; stop use if it becomes severe. If fading is not evident in three months, seek doctor’s advice. |
| 46 | WARNING – Contains (name of substance) which causes birth defects in laboratory animals. Women of child bearing age should avoid contact with (name of substance). |
| 47 | WARNING – This product contains (name of substance) which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed. |
| 48 | WARNING – This product forms cyhexatin which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed. |
| 49 | WARNING – Do not mix with other medication except on veterinarian’s advice. |
| 50 | Unless adequately fired, utensils glazed with this preparation must not be used as containers for food or beverages; to do so may cause lead poisoning. |
| 51 | Irritant to skin, eyes, mucous membranes and upper respiratory tract. |
| 52 | Breathing vapour or spray mist is harmful and may cause an asthma‑like reaction. |
| 53 | CAUTION – (Name of substance) should not be used by pregnant women. |
| 54 | Seek medical advice before first course of treatment. |
| 55 | Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling, irritation, redness or peeling occurs, discontinue use. If these persist, consult a physician. Avoid excessive exposure to sunlight and other sources of ultra violet light. |
| 56 | WARNING – Can cause elevated blood pressure and interact adversely with other medication. |
| 57 | Not to be applied to infants under 12 months of age unless on doctor’s advice. |
| 58 | Highly reactive oxidising bromine and chlorine compound. |
| 59 | May cause allergy. |
| 60 | Do not mix with detergents or other chemicals. |
| 61 | WARNING ‑ Can react with other medicines. Ask your doctor or pharmacist before taking. |
| 62 | Do not use if pregnant. |
| 63 | See a doctor if you are pregnant or diabetic. |
| 64 | See a doctor (or) (dentist) if no better after (Insert number of days as per approved Product Information) days. |
| 65 | If getting better, keep using for (Insert number of days as per approved Product Information) days. |
| 66 | See a doctor if problem returns. |
| 67 | Do not use if pregnant or likely to become pregnant. |
| 68 | If symptoms persist beyond 5 days consult a doctor (or) (dentist). |
| 69 | If symptoms recur within two weeks of completing the course, consult a doctor. |
| 70 | Use only under medical supervision if you are taking other medicines. |
| 71 | Do not use during the last three months of pregnancy. |
| 72 | Do not use in the eyes. |
| 73 | Do not use for acne. |
| 74 | Do not use under waterproof bandages unless a doctor has told you to. |
| 75 | Do not use for more than 7 days unless a doctor has told you to. |
| 76 | Do not become pregnant during use or within (Insert number of months as per approved Product Information) month(s) of stopping treatment. |
| 77 | WARNING ‑ May cause birth defects. |
| 78 | Attacks skin and eyes. |
| 79 | Will irritate eyes. |
| 80 | WARNING: Do not attempt to refill burner while it is in use or still warm; it could lead to serious burn injury. |
| 81 | (Intentionally blank) |
| 82 | (Intentionally blank) |
| 83 | This paint is dangerous to health, even when dry.  For industrial use only.  Do not use on toys or furniture.  Do not use on, in or around the home. |
| 84 | Breathing the vapour is dangerous.  Provide adequate ventilation during application.  Do not use in the presence of a naked flame.  Do not smoke. |
| 85 | This paint contains lead and is dangerous to health, even when dry.  For industrial use only.  Do not use on toys or furniture.  Do not use for painting any building or fixed structure.  Do not use where contact with food or drinking water is possible. |
| 86 | This tinter contains lead.  Do not add to any paint which is for application to any toy, furniture, building (interior or exterior), fixed structure or to anything which may contact food or drinking water. |
| 87 | (Insert brand name) remains in the body for many months after treatment has stopped. Do not become pregnant or father a child before consulting your doctor. |
| 88 | This product is not recommended for dyeing eyelashes or eyebrows. To do so may be injurious to the eye. |
| 89 | Application to skin may increase sensitivity to sunlight. |
| 90 | This preparation is to aid sleep. Drowsiness may continue the following day. If affected do not drive or operate machinery. Avoid alcohol. |
| 91 | CAUTION – Total iodine intake may exceed recommended level when taking this preparation. |
| 92 | WARNING – Contains iodine ‑ do not take when pregnant except on physician’s advice. |
| 93 | Causes severe burns, which are not likely to be immediately painful or visible. |
| 94 | WARNING – Contains nitrite. Substitution for table or cooking salt may be dangerous, particularly for young children. |
| 95 | CAUTION – Do not use for children under 12 years unless a doctor has told you to. |
| 96 | CAUTION – This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor. |
| 97 | Adults: Keep to the recommended dose. Don’t take this medicine for longer than a few days at a time unless advised to by a doctor. |
| 98 | Children and adolescents: Keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor. |
| 99 | If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 13 11 26; New Zealand 0800 764 766) or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage. |
| 100 | Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist. |
| 101 | Don’t use [this product/name of the product]:  If you have a stomach ulcer.  In the last 3 months of pregnancy. [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.]  If you are allergic to (name of substance) or anti‑inflammatory medicines. |
| 102 | Unless a doctor has told you to, don’t use [this product/name of the product]:  For more than a few days at a time.  With other medicines containing aspirin or other anti‑inflammatory medicines.  If you have asthma.  In children under 12 years of age.  In children 12‑16 years of age with or recovering from chicken pox, influenza or fever.  If you are pregnant. |
| 103 | See a doctor before taking [this product/name of the product] for thinning the blood or for your heart. [This statement may be omitted in products for inhibition of platelet aggregation or with additional active ingredients.] |
| 104 | Unless a doctor has told you to, don’t use [this product/name of the product]:  For more than a few days at a time.  With other medicines containing (name of substance) or other anti‑inflammatory medicines.  If you have asthma.  If you are pregnant. [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.] |
| 105 | Do not use on the bedding or clothing of infants or in the bedrooms of children 3 years of age or less. |
| 106 | Contains formaldehyde. |
| 107 | Not recommended for children under twelve years of age. |
| 108 | Breathing of solder fumes is harmful and may cause asthma or sensitisation. |
| 109 | See your healthcare provider if you consider that you may be at risk of a Sexually Transmitted Infection (STI). |
| 110 | See a doctor if you plan to become pregnant, or are breastfeeding or plan to breastfeed. |
| 111 | Do not use if breastfeeding or planning to breastfeed. |
| 112 | WARNING – May cause irreversible nerve damage if inhaled. |

2 Safety directions—general

For the purposes of the table in clause 4, the item number of an item of the following table represents the safety direction specified in column 1 of the item.

Note: See section 29.

| Safety directions | |
| --- | --- |
| Item | Column 1 Safety direction |
| 1 | Avoid contact with eyes. |
| 2 | Attacks eyes ‑ protect eyes when using. |
| 3 | Wear eye protection when mixing or using. |
| 4 | Avoid contact with skin. |
| 5 | Wear protective gloves when mixing or using. |
| 6 | Wash hands after use. |
| 7 | Wash hands thoroughly after use. |
| 8 | Avoid breathing dust (or) vapour (or) spray mist. |
| 9 | Use only in well ventilated area. |
| 10 | Ensure adequate ventilation when using. |
| 11 | No smoking. |
| 12 | Do not allow product to come into contact with other chemicals, especially acids. |
| 13 | Do not allow product to come into contact with combustible materials such as paper, fabric, sawdust or kerosene. |
| 14 | Do not allow to get damp. |
| 15 | Store under cover in a dry, clean, cool, well ventilated place away from sunlight. |
| 16 | Store and transport in an upright container. |
| 17 | Do not mix with other chemicals. |
| 18 | Do not mix with different types of chlorinating chemicals. |
| 19 | Use clean containers for dispensing. |
| 20 | Mix with water only. |
| 21 | Do not add water to product ‑ add product to water, but in case of fire drench with water. |
| 22 | In case of spillage flush with large quantities of water. |
| 23 | Keep away from heat, sparks and naked flames. |
| 24 | Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other mucous membranes. |
| 25 | Avoid contact with food. |
| 26 | Avoid contact with clothing. |
| 27 | Wear a positive‑pressure air‑supplied full‑face respirator whilst spraying and until spray mist has been effectively dispersed. |
| 28 | Do not mix with hot water. |
| 29 | Obtain a supply of calcium gluconate gel. |
| 30 | (Intentionally blank) |
| 31 | Do not use on broken skin. |
| 32 | Do not use under occlusive dressing. |
| 33 | Mix strictly according to instructions. |
| 34 | May cause fire if it comes into contact with other chemicals, paper or other flammable materials. |
| 35 | Wash gloves thoroughly, immediately after use. |
| 36 | Protect cuticles with grease or oil. |
| 37 | Avoid breathing solder fumes. |
| 38 | Do not intentionally inhale contents. |

3 Poisons information centre contact information in statements

A statement required for a poison that includes a reference to a Poisons Information Centre must include:

(a) the telephone number that is appropriate to the country or countries in which the poison is to be supplied; and

(b) immediately following the reference to a Poisons Information Centre:

(i) the national telephone number for the Poisons Information Centre in Australia (13 11 26); or

(ii) the telephone number for another poisons information centre:

(A) that is attended by adequately trained staff for 24 hour emergency poisons information; and

(B) calls to which are logged and submitted for incorporation into the official collection of poisoning data.

Note: For subparagraph (b)(ii), in 2022 the Poisons Information Centre telephone number in New Zealand was 0800 764 766.

4 Poisons that must be labelled with warning statements and safety directions

(1) For the purposes of subsections 29(1) and 30(1), and subject to subclauses (2) and (3), the following are required for a poison specified in column 1 of an item of the following table:

(a) the warning statement represented by each item number specified in column 2 of the item;

(b) the safety direction represented by each item number specified in column 3 of the item.

(2) A warning statement or safety direction required for a poison must:

(a) be completed or modified for its use in relation to that poison if the statement or direction indicates that such completion is required or such modification is appropriate; and

(b) if the statement includes a reference to a Poisons Information Centre—comply with clause 3.

Note: For paragraph (a), for example:

(a) a statement or direction may require completion by including the name of the poison; and

(b) a statement or direction may indicate that modification is appropriate by including different options for the text, or by stating that certain text is not needed in certain circumstances.

(3) If more than one statement or direction is required for a poison, the statements and directions may be combined to form simple sentences (if appropriate).

| Poisons that must be labelled with warning statements and safety directions | | | |
| --- | --- | --- | --- |
| Item | Column 1 Poison | Column 2 Warning statement item number | Column 3 Safety direction item number |
| 1 | ACETIC ACID in concentrations of 80% or more **except** when included in Schedule 2 | 2 | 1, 4, 8 |
| 2 | ACETIC ANHYDRIDE | 2 | 1, 4, 8 |
| 3 | ACETONE in concentrations greater than 75% |  | 1, 4, 8 |
| 4 | ACITRETIN—for oral use | 7, 62, 76 |  |
| 5 | ACITRETIN—for topical use | 62, 77 |  |
| 6 | ADAPALENE for topical use | 62, 77 |  |
| 7 | ALCLOMETASONE when included in Schedule 3 | 38, 72, 73, 74, 75 |  |
| 8 | ALKALINE SALTS | 4 | 1, 4 |
| 9 | AMBRISENTAN | 7, 62, 76 |  |
| 10 | AMINES used as curing agents for epoxy resins |  | 1, 3, 4, 5, 8 |
| 11 | 2‑AMINO‑6‑CHLORO‑4‑NITROPHENOL | 28 |  |
| 12 | 4‑AMINO‑*m*‑CRESOL | 28 |  |
| 13 | 2‑AMINO‑5‑ETHYLPHENOL | 21 |  |
| 14 | 4‑AMINO‑2‑HYDROXYTOLUENE | 28 |  |
| 15 | 4‑AMINO‑3‑NITROPHENOL | 28 |  |
| 16 | 2,2'‑[(4‑AMINO‑3‑NITROPHENYL)IMINO] BISETHANOL | 28 |  |
| 17 | *m*‑AMINOPHENOL | 28 | 4, 8 |
| 18 | *p*‑AMINOPHENOL | 28 |  |
| 19 | AMMONIA/AMMONIUM HYDROXIDE in concentrations greater than 20% ammonia **except** in smelling salts | 4 | 1, 4, 8 |
| 20 | AMMONIUM PERSULFATE | 5, 21, 25 | 1, 5, 23, 33, 34 |
| 21 | ANHYDRIDES, organic acid, for use as curing agents for epoxy resins |  | 1, 3, 4, 5, 8 |
| 22 | ANILINE | 13 | 1, 4, 8 |
| 23 | ANTIHISTAMINES not separately specified in this Appendix **except** the following:  (a) dermal, ocular, parenteral and paediatric preparations;  (b) oral preparations of astemizole, azelastine, bilastine, cetirizine, desloratadine, fexofenadine, loratadine, or terfenadine;  (c) nasal preparations of azelastine or olopatadine;  (d) preparations for the treatment of animals | 39 or 40 |  |
| 24 | ARBUTIN when included in Schedule 6 | 45 | 1, 4 |
| 25 | AROMATIC EXTRACT OILS |  | 1, 3, 4, 5, 6 |
| 26 | ASPIRIN—for inhibition of platelet aggregation | 36 |  |
| 27 | ASPIRIN—in sustained release preparations containing 650 mg or more of aspirin | 36 |  |
| 28 | ASPIRIN—in other preparations | 101, 102, 103 |  |
| 29 | ASTEMIZOLE | 61 |  |
| 30 | ASTODRIMER SODIUM—for the treatment and relief of bacterial vaginosis | 63, 64, 69, 75, 109, 110 |  |
| 31 | ASTODRIMER SODIUM—for the prevention of recurrent bacterial vaginosis | 63, 75, 109, 110 |  |
| 32 | AZADIRACHTA INDICA including its extracts and derivatives when included in Schedule 6 | 67 |  |
| 33 | AZOCYCLOTIN | 48 |  |
| 34 | AZO DYES (derivatives by diazotisation) | 6 | 5 |
| 35 | BASIC RED 76 |  | 5 |
| 36 | BENOMYL | 46 |  |
| 37 | BENZENE | 12 | 1, 4, 9 |
| 38 | 1,2‑BENZENEDIOL (Catechol) | 51, 59 | 1, 4, 8 |
| 39 | BENZOYL PEROXIDE—when included in Schedule 2 | 55 |  |
| 40 | BENZOYL PEROXIDE—when included in Schedule 5 |  | 1, 4, 8 |
| 41 | BERGAMOT OIL | 89 |  |
| 42 | BERYLLIUM |  | 1, 4, 8 |
| 43 | BEXAROTENE—for human use | 7, 62, 76 |  |
| 44 | BEXAROTENE—for topical use | 62, 77 |  |
| 45 | BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 5 | 1, 4 |  |
| 46 | BIFLUORIDES (including ammonium, potassium and sodium salts)—when included in Schedule 6 or 7 | 1, 17, 93 | 1, 3, 4, 5, 8, 29, 35 |
| 47 | 1,3‑BIS(2,4‑DIAMINOPHENOXY)PROPANE | 28, 79 | 1 |
| 48 | BIS‑ISOBUTYL PEG/PPG‑20/35/AMODIMETICONE COPOLYMER |  | 1 |
| 49 | BITHIONOL for the treatment of animals |  | 1, 4, 8 |
| 50 | BORIC ACID when used in Schedule 5 | 25, 26 |  |
| 51 | BORON TRIFLUORIDE (including mixtures that generate boron trifluoride)—when included in Schedule 5 | 2 | 1, 4 |
| 52 | BORON TRIFLUORIDE (including mixtures that generate boron trifluoride)—when included in Schedule 6 or 7 | 1, 17, 93 | 1, 3, 4, 5, 8, 29, 35 |
| 53 | BOSENTAN | 7, 62, 76 |  |
| 54 | BROMOFORM | 1, 4, 8 |  |
| 55 | 2‑BUTOXY‑2'‑THIOCYANODIETHYL ETHER |  | 1, 4, 8 |
| 56 | 2‑BUTOXYETHANOL and its acetates |  | 1, 4, 8 |
| 57 | n‑BUTYL ALCOHOL | 5 | 2, 4, 8 |
| 58 | CAMPHOR—in block, ball, disc, pellet or flake form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents | 9 |  |
| 59 | CAMPHOR—in other forms | 9 | 1 |
| 60 | CANNABIDIOL when included in Schedule 3 | 67, 111 |  |
| 61 | CARBAMIDE PEROXIDE—more than 9% up to 30% | 5 | 1 |
| 62 | CARBAMIDE PEROXIDE—more than 30% up to 60% | 5 | 2 |
| 63 | CARBAMIDE PEROXIDE—more than 60% | 2 | 2, 4 |
| 64 | CARBON DISULFIDE | 12 | 1, 4, 8, 9, 23 |
| 65 | CARBON TETRACHLORIDE | 12 | 1, 4, 8, 9 |
| 66 | CASSIA OIL |  | 4 |
| 67 | CHLORINATING COMPOUNDS—in household cleaning or bleaching preparations | 20 |  |
| 68 | CHLORINATING COMPOUNDS—in preparations containing less than 10% of available chlorine | 11 | 1, 4, 10 |
| 69 | CHLORINATING COMPOUNDS—in liquid preparations containing 10% or more of available chlorine | 3, 18 | 1, 4, 6, 8, 10, 15, 16, 17, 18, 19, 20, 22, 26 |
| 70 | CHLORINATING COMPOUNDS—in dry preparations containing 10% or more of available chlorine | 10, 18, 22, 23 | 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26 |
| 71 | CHLORINATING COMPOUNDS—in dry preparations containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code | 10, 18, 22 | 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,  22, 26 |
| 72 | CHLORINATING COMPOUNDS—in compressed block or tablets containing 10% or more of available chlorine **except** in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid | 10, 22, 23 | 12, 13, 14, 15, 17, 18, 19, 21 |
| 73 | CHLORINATING COMPOUNDS—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code **except** in preparations for use in toilet cisterns only, containing 15 g or less of trichloroisocyanuric acid | 10, 22 | 12, 13, 14, 15, 17, 18, 19, 21 |
| 74 | CHLOROACETAMIDE | 28 | 4 |
| 75 | 2‑CHLORO‑6‑(ETHYLAMINO)‑4‑NITROPHENOL | 28 | 4 |
| 76 | CHLOROFORM when included in Schedule 6 |  | 1, 4, 8 |
| 77 | alpha‑CHLOROHYDRIN | 13, 51 | 1, 4, 8, 9 |
| 78 | CHROMATES (including dichromates) of alkali metals or ammonia |  | 1, 4, 8 |
| 79 | CHROMIUM TRIOXIDE | 2, 14, 15, 23 | 1, 4, 8, 13 |
| 80 | CIMETIDINE when included in Schedule 3 | 70, 96 |  |
| 81 | CINNAMON BARK OIL |  | 4 |
| 82 | CLOBETASONE when included in Schedule 3 | 72, 73, 74, 75, 95 |  |
| 83 | CLOTRIMAZOLE in vaginal preparations when included in Schedule 3 | 54, 63, 64, 66 |  |
| 84 | CLOVE OIL |  | 1 |
| 85 | CYANIDES when included in Schedule 7 | 13 | 4, 8 |
| 86 | CYANURIC ACID |  | 1, 4, 8 |
| 87 | CYCLOHEXANONE PEROXIDE |  | 1, 4, 8 |
| 88 | CYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2) | 2, 10, 78 | 1, 4, 5, 35 |
| 89 | CYCTEAMINE |  | 1 |
| 90 | 1‑DEOXY‑1‑(METHYLAMINO)‑d‑GLUCITOL *N*‑COCO ACYL DERIVATIVES | 79 | 1 |
| 91 | 4,4‑DIAMINODIPHENYLMETHANE (methylene dianiline) |  | 1, 4, 8 |
| 92 | 2,4‑DIAMINOPHENOXYETHANOL | 28, 79 | 1, 4 |
| 93 | *o*‑DICHLOROBENZENE |  | 1, 4, 8 |
| 94 | para‑DICHLOROBENZENE |  | 1, 4 |
| 95 | DICHLOROETHYLENE |  | 1, 4, 8 |
| 96 | DICHLOEOETHYL ETHER |  | 1, 4, 8 |
| 97 | DICHLOROISOCYANURATES—in household cleaning or bleaching preparations | 20 |  |
| 98 | DICHLOROISOCYANURATES—in preparations containing less than 10% of available chlorine | 11 | 1, 4, 10 |
| 99 | DICHLOROISOCYANURATES—in liquid preparations containing 10% or more of available chlorine | 3, 18 | 1, 4, 6, 8, 10,  15, 16, 17, 18, 19, 20, 22, 26 |
| 100 | DICHLOROISOCYANURATES—in dry preparations containing 10% or more of available chlorine | 10, 18, 22, 23 | 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26 |
| 101 | DICHLOROISOCYANURATES—in dry preparations containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code | 10, 18, 22 | 1, 4, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26 |
| 102 | DICHLOROISOCYANURATES—in anti‑bacterial tablets containing 2.5 g or less of sodium dichloroisocyanurate | 60 |  |
| 103 | DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine **except** in preparations containing 21 g or less of sodium dichloroisocyanurate for use in toilet cisterns only | 10, 22, 23 | 12, 13, 14, 15, 17, 18, 19, 21 |
| 104 | DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code **except** in preparations containing 21 g less of sodium dichloroisocyanurate for use in toilet cisterns only | 10, 22 | 12, 13, 14, 15, 17, 18, 19, 21 |
| 105 | DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during storage | 10, 22, 23 | 12, 13, 14, 15, 17, 18, 21 |
| 106 | DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during use | 5 | 1, 4, 7, 12 |
| 107 | DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during storage | 10, 22 | 12, 13, 14, 15, 17, 18, 21 |
| 108 | DICHLOROISOCYANURATES—in other compressed blocks or tablets containing 10% or more of available chlorine certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Dangerous Goods Code in preparations containing 5 g or less of sodium dichloroisocyanurate for use in toilet bowls only—during use | 5 | 1, 4, 7, 12 |
| 109 | DICHLOROMETHANE (methylene chloride)—in paint or lacquer removers | 12, 16 | 1, 4, 8, 11 |
| 110 | DICHLOROMETHANE (methylene chloride)—other than in paint or lacquer removers |  | 1, 4, 8, 25 |
| 111 | DICLOFENAC | 101, 104 |  |
| 112 | DIENESTROL | 67 |  |
| 113 | DIETHANOLAMINE—when included in Schedule 5 | 5 | 1, 4 |
| 114 | DIETHANOLAMINE—when included in Schedule 6 | 2, 11, 18 | 1, 4, 8 |
| 115 | DIETHYLTOLUAMIDE for human use | 44 |  |
| 116 | DIETHYLENE GLYCOL MONOBUTYL ETHER | 5 | 1, 4, 8, 9 |
| 117 | 5,6‑DIHYDROXYINDOLINE | 21, 28 |  |
| 118 | 2,6‑DIMETHOXY‑3,5‑PYRIDINEDIAMINE | 28 |  |
| 119 | DIMETHYLFORMAMIDE |  | 1, 4, 8 |
| 120 | 4,4‑DIMETHYL‑1‑CYCLOHEXENE‑1‑PROPANAL | 5, 28 | 1, 2 |
| 121 | 3,7‑DIMETHYL‑2,6‑OCTADIEN‑1‑OL | 5 | 1, 4 |
| 122 | DIMETHYL SULFATE | 2 | 1, 4, 8 |
| 123 | DIMETHYL SULFOXIDE—when not packed and labelled for therapeutic use | 27 | 1, 4, 5, 8 |
| 124 | DIMETHYL SULFOXIDE—when packed and labelled for the treatment of animals | 49 | 1, 4, 5, 8 |
| 125 | DINITROCRESOLS (and their homologues) **except** when for therapeutic use |  | 1, 4, 8 |
| 126 | DINITROPHENOLS (and their homologues) **except** when for therapeutic use |  | 1, 4, 8 |
| 127 | DINOCAP | 47 |  |
| 128 | DIOXANE |  | 1, 4, 8 |
| 129 | DIPHENOXYLATE when included in Schedule 3 | 39 or 40, 41 |  |
| 130 | DISPERSE YELLOW 3 | 28 | 4 |
| 131 | ECONAZOLE in vaginal preparations when included in Schedule 3 | 54, 63, 64, 66 |  |
| 132 | ENZALUTAMIDE | 7, 67, 87 |  |
| 133 | EPHEDRINE in nasal preparations for topical use | 29 |  |
| 134 | EPICHLOROHYDRIN | 2 | 1, 4, 8 |
| 135 | EPOXY RESINS, liquid |  | 1, 3, 4, 5, 8 |
| 136 | ETHER when included in Schedule 5 or 6 |  | 1, 4, 8 |
| 137 | 2‑ETHOXYETHANOL | 77 | 1, 4, 8 |
| 138 | ETHOXYETHYLMERCURIC CHLORIDE |  | 1, 4 |
| 139 | ETHYL BROMIDE |  | 1, 4, 8 |
| 140 | ETHYLENE CHLOROHYDRIN |  | 1, 4, 8 |
| 141 | ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates **except** when separately specified |  | 1, 4, 8 |
| 142 | ETHYLENE OXIDE |  | 1, 4, 8 |
| 143 | ETHYLHEXANEDIOL | 79 | 1 |
| 144 | 2‑ETHYLHEXANOIC ACID | 53 |  |
| 145 | ETHYLMERCURIC CHLORIDE |  | 1, 4 |
| 146 | ETHYL METHACRYLATE | 28 | 4, 9, 23 |
| 147 | ETRETINATE | 7, 62, 76 |  |
| 148 | EUGENOL |  | 1 |
| 149 | FAMOTIDINE when included in Schedule 2 | 96 |  |
| 150 | FENTEROL in metered aerosols | 32 |  |
| 151 | FLUCONAZOLE in oral preparations when included in Schedule 3 | 64 |  |
| 152 | FLUORIDES (including silicofluorides) when included in Schedule 5 or 6 **except** when separately specified |  | 1, 4 |
| 153 | FORMALDEHYDE—in nail hardener cosmetics | 106 | 1, 4, 8, 36 |
| 154 | FORMALDEHYDE—in other preparations | 106 | 1, 4, 8 |
| 155 | FORMIC ACID |  | 1, 4, 8 |
| 156 | FURFURAL | 5 | 1, 4 |
| 157 | Glazing preparations containing LEAD COMPOUNDS | 50 |  |
| 158 | GLUTARAL **except** when included in Schedule 2—25% or less | 5, 59 | 1, 4, 5 |
| 159 | GLUTARAL **except** when included in Schedule 2—more than 25% | 3, 59 | 1, 4, 5, 8 |
| 160 | GLYCOLIC ACID | 79 | 1, 5, 6, 31 |
| 161 | HC VIOLET 1 | 28 |  |
| 162 | HEXACHLOROPHENE in preparations for skin cleansing purposes containing 3% or less of hexachlorophene | 24 |  |
| 163 | HEXYLOXYETHANOL | 2 | 1, 4, 8 |
| 164 | HYDRAZINE |  | 1, 4, 8 |
| 165 | HYDROCHLORIC ACID—30% or less of HCl |  | 1, 4 |
| 166 | HYDROCHLORIC ACID—more than 30% of HCl |  | 1, 4, 8 |
| 167 | HYDROCORTISONE—for dermal use when included in Schedule 2 or 3 | 38, 72, 73, 74, 75 |  |
| 168 | HYDROCORTISONE—for topical rectal use when included in Schedule 2 or 3 | 38, 75 |  |
| 169 | HYDROCYANIC ACID when included in Schedule 7 | 13 | 4, 8 |
| 170 | HYDROFLUORIC ACID (including mixtures that generate hydrofluoric acid)—when included in Schedule 5 | 2 | 1, 4 |
| 171 | HYDROFLUORIC ACID (including mixtures that generate hydrofluoric acid)—when included in Schedule 6 or 7 | 1, 17, 93 | 1, 3, 4, 5, 8, 29, 35 |
| 172 | HYDROGEN PEROXIDE—more than 3% up to 10% | 5 | 1 |
| 173 | HYDROGEN PEROXIDE—more than 10% up to 20% | 5 | 2 |
| 174 | HYDROGEN PEROXIDE—more than 20% | 2 | 2, 4 |
| 175 | HYDROQUINONE—when included in Schedule 2 | 45 |  |
| 176 | HYDROQUINONE—**except** when included in Schedule 2 or 4 |  | 1, 4 |
| 177 | HYDROSILICOFLUORIC ACID (including mixtures that generate hydrosilicofluoric acid)—when included in Schedule 5 | 2 | 1, 4 |
| 178 | HYDROSILICOFLUORIC ACID (including mixtures that generate hydrosilicofluoric acid)—when included in Schedule 6 or 7 | 1, 17, 93 | 1, 3, 4, 5, 8, 29, 35 |
| 179 | 2‑HYDROXYETHYL METHACRYLATE | 28 | 4 |
| 180 | HYDROXYETHYL‑3,4‑METHYLENEDIOXYANILINE | 28 |  |
| 181 | IBUPROFEN | 101, 104 |  |
| 182 | IODINE—more than 20% |  | 1, 4, 8 |
| 183 | IODINE—in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose | 91, 92 |  |
| 184 | IPRATROPIUM BROMIDE in metered aerosols | 32 |  |
| 185 | ISOCYANATES (free organic)—when in paint | 28, 52 | 1, 5, 8, 10, 27 |
| 186 | ISOCYANATES (free organic)—other than in paint | 28, 52 | 1, 4, 8 |
| 187 | ISOEUGENOL | 19, 28, 79 | 1, 4 |
| 188 | ISOPRENALINE in metered aerosols | 32 |  |
| 189 | ISOTRETINOIN—for human oral use | 7, 62, 76 |  |
| 190 | ISOTRETINOIN—for topical use | 62, 77 |  |
| 191 | LEAD COMPOUNDS—in hair cosmetics | 25 |  |
| 192 | LEAD COMPOUNDS—when included in Schedule 6 preparations that are not hair cosmetics |  | 1, 4, 8 |
| 193 | LEFLUNOMIDE | 7, 62, 87 |  |
| 194 | LEMON OIL | 89 |  |
| 195 | LENALIDOMIDE | 7, 62, 76 |  |
| 196 | LEVOCABASTINE—in eye or nasal preparations containing 0.5 mg/mL or less of levocabastine | 62 |  |
| 197 | LEVOCABASTINE—in other preparations | 62 and either 39 or 40 |  |
| 198 | LIME OIL | 89 |  |
| 199 | LOPERAMIDE when included in Schedule 2 | 41 |  |
| 200 | MAGNESIUM CHLORATE |  | 1, 4 |
| 201 | MEFENAMIC ACID | 101, 104 |  |
| 202 | MERCAPTOACETIC ACID | 5, 28 | 1, 31 |
| 203 | MERCURIC THIOCYANATE |  | 1, 4 |
| 204 | METACRESOLSULPHONIC ACID and formaldehyde condensation product for the treatment of animals |  | 1, 4 |
| 205 | METHANOL **except** in methylated spirit |  | 1, 4, 8 |
| 206 | METHOXAMINE in nasal preparations for topical use | 29 |  |
| 207 | 2‑METHOXYETHANOL | 77 | 1, 4, 8 |
| 208 | METHYLATED SPIRIT(S) when packed and labelled as a “biofuel” suitable for use in “spirit burners” | 80 |  |
| 209 | *p*‑METHYLAMINOPHENOL | 28 |  |
| 210 | METHYL CHLORIDE |  | 1, 4, 8 |
| 211 | METHYL ETHYL KETONE | 5 | 1, 4, 8 |
| 212 | METHYL ETHYL KETONE OXIME | 5, 28 | 1, 4 |
| 213 | METHYL ETHYL KETONE PEROXIDE | 2 | 2, 3, 4, 6 |
| 214 | METHYL ISOAMYL KETONE |  | 1, 4, 8 |
| 215 | METHYL ISOBUTYL KETONE |  | 1, 4, 8 |
| 216 | METHYL ISOTHIOCYANATE | 5, 12 | 1, 4, 8 |
| 217 | METHYL METHACRYLATE | 28 | 4, 9, 23 |
| 218 | METHYLCHLOROISOTHIAZOLINONE | 28 |  |
| 219 | METHYLDIBROMO GLUTARONITRILE | 28 | 1, 4, 7 |
| 220 | METHYLENE BISTHIOCYANATE |  | 1, 4 |
| 221 | METHYLEUGENOL |  | 1, 6 |
| 222 | METHYLISOTHIAZOLINONE | 28 |  |
| 223 | METHYLNORBORNYLPYRIDINE | 59 |  |
| 224 | 2‑METHYLRESORCINOL |  | 1 |
| 225 | 1‑(BETA‑METHYL SULPHONAMIDOETHYL)‑ 2‑AMINO‑3‑N,N‑DIETHYLAMINOBENZENE |  | 1, 4, 8 |
| 226 | MICONAZOLE in vaginal preparations when included in Schedule 3 | 54, 63, 64, 66 |  |
| 227 | MISOPROSTOL | 53 |  |
| 228 | MONOETHANOLAMINE when included in Schedule 5 | 5 | 1, 4 |
| 229 | MONOETHANOLAMINE when included in Schedule 6 | 2, 11, 18 | 1, 4, 8 |
| 230 | NAPHAZOLINE in nasal preparations for topical use | 29 |  |
| 231 | NAPHTHALENE—in block, ball, disc, pellet or flake form, enclosed in a device which, in normal use, prevents removal or ingestion of its contents | 9, 105 |  |
| 232 | NAPHTHALENE—in other forms | 9, 105 | 1 |
| 233 | 1,5‑NAPHTHALENEDIOL | 28 | 1 |
| 234 | 2,7‑NAPHTHALENEDIOL | 28 | 1, 3 |
| 235 | 1‑NAPHTHOL | 28 | 1 |
| 236 | NAPROXEN | 101, 104 |  |
| 237 | NICOTINE **except** when in tobacco |  | 1, 4 |
| 238 | NITRIC ACID—75% or less HNO3 | 2 | 1, 4 |
| 239 | NITRIC ACID—more than 75% HNO3 | 2 | 1, 4, 8 |
| 240 | NITROBENZENE |  | 1, 4, 8 |
| 241 | 3‑NITRO‑*p*‑HYDROXYETHYLAMINOPHENOL | 28 |  |
| 242 | NITROPHENOLS |  | 1, 4 |
| 243 | NITROPRUSSIDES in aerosols | 84 | 8 |
| 244 | NITROUS OXIDE | 112 | 38 |
| 245 | NIZATIDINE when included in Schedule 2 | 96 |  |
| 246 | NORADRENALINE in metered aerosols | 32 |  |
| 247 | NYSTATIN in vaginal preparations when included in Schedule 3 | 54, 63, 64, 65, 66 |  |
| 248 | ORANGE OIL (bitter) | 89 |  |
| 249 | ORCIPRENALINE in metered aerosols | 32 |  |
| 250 | OXALATES, metallic |  | 4, 8 |
| 251 | OXALIC ACID | 2 | 4, 8 |
| 252 | OXYMETAZOLINE in nasal preparations for topical use | 29 |  |
| 253 | OXYQUINOLINE (including salts and derivatives) when prepared for internal use | 33 |  |
| 254 | PAINT—first group paints | 83 |  |
| 255 | PAINT—second group paints | 84 |  |
| 256 | PALOVAROTENE | 7, 62, 76, 111 |  |
| 257 | PARACETAMOL | 97 and/or 98, 99, 100 |  |
| 258 | PENTACHLOROPHENOL |  | 1, 4, 8 |
| 259 | PERACETIC ACID | 2 | 1, 4, 8 |
| 260 | PERMANGANATES | 2 | 24 |
| 261 | 2‑PHENOXYETHANOL | 5 | 1 |
| 262 | PHENOL and any other homologue of phenol |  | 1, 4 |
| 263 | PHENOL when included in Schedule 6 | 3, 51 | 2, 4, 8 |
| 264 | PHENOLS |  | 5 |
| 265 | PHENOXYMETHYL OXIRANE | 12, 28, 51 | 1, 3, 4, 5, 7, 8, 9 |
| 266 | PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in hair dyes | 21 |  |
| 267 | PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives—in preparations other than hair dyes | 28 | 1, 4, 8 |
| 268 | PHENYL METHYL PYRAZOLONE | 28 | 4 |
| 269 | PHENYLEPHRINE in nasal preparations for topical use | 29 |  |
| 270 | POMALIDOMIDE | 7, 62, 76 |  |
| 271 | *N*,*N*‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,5‑DIMETHANAMINE | 5, 28 | 1, 4, 5, 10 |
| 272 | *o*‑PHENYLPHENOL **except** when in antiseptics |  | 1, 4 |
| 273 | PHENYLPROPANOLAMINE | 56 |  |
| 274 | PHENYTOIN in pastes for the treatment of horses | 9 |  |
| 275 | PHOSPHONIC ACID |  | 1, 4 |
| 276 | PHOSPHORIC ACID |  | 1, 4 |
| 277 | PHOSPHORUS (yellow) | 2 | 1, 4 |
| 278 | *o*‑PHTHALALDEHYDE—when included in Schedule 5 | 51, 52, 59 | 1, 4, 5, 8, 10 |
| 279 | *o*‑PHTHALALDEHYDE—when included in Schedule 6 | 51, 52, 59 | 2, 4, 5, 8, 10 |
| 280 | PICRAMIC ACID including its salts (excluding other derivatives) | 28 | 5 |
| 281 | PICRIC ACID (more than 20%) |  | 1, 4 |
| 282 | PODOPHYLLIN—in preparations specifically for use on anal or genital area | 36 |  |
| 283 | PODOPHYLLIN—in other liquid preparations when included in Schedule 2 or 3 | 31 |  |
| 284 | PODOPHYLLIN—in other solid or semi‑solid preparations when included in Schedule 2 | 30 |  |
| 285 | PODOPHYLLOTOXIN—in preparations specifically for use on anal or genital area | 36 |  |
| 286 | PODOPHYLLOTOXIN—in other liquid preparations when included in Schedule 2 or 3 | 31 |  |
| 287 | PODOPHYLLOTOXIN—in other solid or semi‑solid preparations when included in Schedule 2 | 30 |  |
| 288 | POLIHEXANIDE | 28 | 1, 4, 8 |
| 289 | POLYETHANOXY (15) TALLOW AMINE |  | 1, 4 |
| 290 | POLY(OXY‑1,2‑ETHANEDIYL), *Α* ‑[2‑[(2‑HYDROXYETHYL)AMINO] ‑2‑OXOETHYL]‑ Α ‑HYDROXY‑,MONO‑C13‑15 ‑ALKYL ETHERS | 5, 88 | 1, 5 |
| 291 | POTASSIUM HYDROXIDE—in preparations containing 0.5% or less of potassium hydroxide | 5 | 1, 4, 6 |
| 292 | POTASSIUM HYDROXIDE—in solid preparations containing more than 0.5% of potassium hydroxide | 2, 10, 78 | 3, 5, 28 |
| 293 | POTASSIUM HYDROXIDE—in liquid preparations containing more than 0.5% of potassium hydroxide | 2, 10, 78 | 3, 5 |
| 294 | POTASSIUM PERSULFATE | 5, 21, 25 | 1, 5, 23, 33, 34 |
| 295 | POTASSIUM SULFIDE | 2 | 1, 4 |
| 296 | PROPIONIC ACID when included in Schedule 6 | 2 | 1, 4 |
| 297 | n‑PROPYL ALCOHOL | 5 | 1, 9 |
| 298 | QUININE | 28 |  |
| 299 | QUINOLINE | 79 | 1, 4 |
| 300 | RANITIDINE when included in Schedule 2 | 96 |  |
| 301 | RESORCINOL | 19, 28, 79 | 1, 3, 4 |
| 302 | ROSIN | 108 | 37 |
| 303 | SAFROLE—in preparations for therapeutic use |  | 1 |
| 304 | SAFROLE—other than for therapeutic use |  | 1, 4 |
| 305 | SALBUTAMOL in metered aerosols or in dry powder formulations | 32 |  |
| 306 | SALICYLAMIDE | 34 or 35 |  |
| 307 | SASSAFRAS OIL—in preparations for therapeutic use |  | 1 |
| 308 | SASSAFRAS OIL—other than for therapeutic use |  | 1, 4 |
| 309 | SELENIUM COMPOUNDS **except** when for therapeutic use (human or animal) |  | 1, 4, 8 |
| 310 | SILVER in smoking deterrents | 42 |  |
| 311 | SITAXENTAN | 7, 62, 76 |  |
| 312 | SODIUM ALUMINATE | 2 | 1, 4 |
| 313 | SODIUM CHLORATE |  | 1, 4 |
| 314 | SODIUM DODECYLBENZENE SULFONATE | 79 | 1 |
| 315 | SODIUM FLUORIDE in preparations for human ingestion when included in Schedule 2 | 43 |  |
| 316 | SODIUM HYDROGEN SULFATE |  | 1, 4, 8 |
| 317 | SODIUM HYDROSULFITE (more than 50%) | 5, 26 | 1, 4, 8 |
| 318 | SODIUM HYDROXIDE—in preparations containing 0.5% or less of sodium hydroxide | 5 | 1, 4, 6 |
| 319 | SODIUM HYDROXIDE—in solid preparations containing more than 0.5% of sodium hydroxide | 2, 10, 78 | 3, 5, 28 |
| 320 | SODIUM HYDROXIDE—in liquid preparations containing more than 0.5% of sodium hydroxide | 2, 10, 78 | 3, 5 |
| 321 | SODIUM LAURETH‑6 CARBOXYLATE | 79 | 1 |
| 322 | SODIUM METABISULPHITE (more than 50%) | 5, 26 | 1, 4 |
| 323 | SODIUM NITRITE in pickling or curing salts | 94 |  |
| 324 | SODIUM PERSULFATE | 5, 21, 25 | 1, 5, 23, 33, 34 |
| 325 | SODIUM SULFIDE | 2 | 1, 4 |
| 326 | STYRENE |  | 1, 4, 8 |
| 327 | SULFAMIC ACID | 2 | 1, 4 |
| 328 | SULFURIC ACID | 2 | 1, 4 |
| 329 | SYMPHYTUM SPP. (Comfrey) when included in Schedule 5 |  | 31, 32 |
| 330 | TAZAROTENE for topical use | 77, 62 |  |
| 331 | TERBUTALINE in metered aerosols or in dry powder formulations | 32 |  |
| 332 | TERFENADINE |  | 61 |
| 333 | TERIFLUNOMIDE | 7, 62, 87 |  |
| 334 | TERPENES, chlorinated |  | 1, 4, 8 |
| 335 | TETRACHLOROETHANE | 12 | 8 |
| 336 | TETRACHLOROETHYLENE when included in Schedule 5 or 6 | 12, 16 | 1, 4, 8, 11 |
| 337 | TETRYZOLINE in nasal preparations for topical use | 29 |  |
| 338 | THALIDOMIDE | 7, 62, 76 |  |
| 339 | THIOUREA |  | 1, 4 |
| 340 | TOLUENE |  | 1, 4, 8 |
| 341 | TOLUENEDIAMINES—in hair dyes | 21 |  |
| 342 | TOLUENEDIAMINES—in preparations other than hair dyes |  | 1, 4, 8 |
| 343 | TRAMAZOLINE in nasal preparations for topical use | 29 |  |
| 344 | TRETINOIN—for human oral use | 7, 62, 76 |  |
| 345 | TRETINOIN—for topical use | 62, 77 |  |
| 346 | TRIAMCINOLONE when in topical preparations for the treatment of mouth ulcers | 64 or 68 |  |
| 347 | TRICHLOROACETIC ACID **except** when for therapeutic use | 2 | 1, 4 |
| 348 | 1,1,1‑TRICHLOROETHANE |  | 8, 9 |
| 349 | TRICHLOROETHYLENE **except** when for therapeutic use | 12 | 1, 4, 5, 8, 9 |
| 350 | TRICHLOROPHENOL |  | 1, 4, 8 |
| 351 | TRIETHYL PHOSPHATE |  | 1, 4, 8 |
| 352 | TRIFLUOROMETHANESULFONIC ACID—more than 10% | 1, 17 | 1, 4, 8 |
| 353 | TRIFLUOROMETHANESULFONIC ACID—10% or less |  | 1, 4, 8 |
| 354 | TRIISOPROPANOLAMINE LAURYL ETHER SULFATE |  | 1, 4, 6 |
| 355 | 3,6,9‑TRIOXAUNDECANEDIOIC ACID | 5 | 1 |
| 356 | TROLAMINE | 5 | 1, 4 |
| 357 | TYMAZOLINE in nasal preparations for topical use | 29 |  |
| 358 | VINCLOZOLIN | 46 |  |
| 359 | VINYL ACETATE MONOMER | 11 | 8, 9 |
| 360 | XYLENE |  | 1, 4, 8 |
| 361 | XYLOMETAZOLINE in nasal preparations for topical use | 29 |  |
| 362 | ZINC CHLORIDE |  | 1, 4 |
| 363 | ZINC LACTATE | 107 |  |
| 364 | ZINC SULFATE when included in Schedule 6 |  | 1, 4 |

Appendix G—Dilute preparations

Note: See paragraph 11(c).

1 Substances exempt at or below certain concentrations

For the purposes of paragraph 11(c), the following table specifies:

(a) substances; and

(b) concentrations in relation to those substances.

| Substances and concentrations | | |
| --- | --- | --- |
| Item | Column 1 Substance | Column 2 Concentration (quantity per litre or kilogram) |
| 1 | ACETYLCHOLINE | 1 mg |
| 2 | ALDOSTERONE | 10 micrograms |
| 3 | ANTIMONY COMPOUNDS | 1 mg |
| 4 | APOMORPHINE | 1 mg |
| 5 | ARSENIC | 1 mg |
| 6 | ATROPA BELLADONNA (belladonna) | 300 micrograms |
| 7 | ATROPINE | 300 micrograms |
| 8 | CANTHARIDIN | 10 micrograms |
| 9 | CHLORINE | 5 mg |
| 10 | CROTON TIGLIUM (croton oil) | 1 mg |
| 11 | EPIDERMAL GROWTH FACTOR | 2 mg |
| 12 | ERYSIMUM spp. | 1 mg |
| 13 | ESTRADIOL | 10 micrograms |
| 14 | ESTRONE | 100 micrograms |
| 15 | FOLLICLE‑STIMULATING HORMONE | 100 micrograms |
| 16 | GELSEMIUM SEMPERVIRENS | 1 mg |
| 17 | GLUCAGON | 100 micrograms |
| 18 | GLYCERYL TRINITRATE | 100 micrograms |
| 19 | GROWTH HORMONE | 10 micrograms |
| 20 | HALOPERIDOL | 1 mg |
| 21 | HYDROCYANIC ACID | 1 microgram |
| 22 | HYOSCINE | 300 micrograms |
| 23 | HYOSCYAMINE | 300 micrograms |
| 24 | HYOSCYAMUS NIGER | 300 micrograms |
| 25 | HYPOTHALAMIC RELEASING FACTORS | 10 micrograms |
| 26 | INDOMETACIN | 1 mg |
| 27 | MERCURY | 1 mg |
| 28 | METHYLMERCURY | 300 micrograms |
| 29 | NAPHTHALENE | 1 mg |
| 30 | NERIUM OLEANDER | 1 mg |
| 31 | OXYTOCIN | 1 microgram |
| 32 | PHOSPHORUS | 1 mg |
| 33 | PODOPHYLLUM RESIN (podophyllin) | 1 mg |
| 34 | PROGESTERONE | 1 mg |
| 35 | PROPRANOLOL | 1 mg |
| 36 | SELENIUM | 100 micrograms |
| 37 | STROPHANTHUS spp. | 1 mg |
| 38 | STRYCHNINE | 1 mg |
| 39 | TESTOSTERONE | 1 mg |
| 40 | THYROXINE | 10 micrograms |

Appendix H—Schedule 3 medicines permitted to be advertised

Note: See paragraph 57(1)(a).

1 Schedule 3 medicines permitted to be advertised

The following table specifies poisons for the purposes of paragraph 57(1)(a).

| Schedule 3 medicines permitted to be advertised | |
| --- | --- |
| Item | Column 1 Poison |
| 1 | ADAPALENE |
| 2 | ADRENALINE |
| 3 | ASTODRIMER SODIUM—for the treatment and relief of bacterial vaginosis and for the prevention of recurrent bacterial vaginosis |
| 4 | BILASTINE |
| 5 | BUTOCONAZOLE |
| 6 | CELECOXIB |
| 7 | CICLOPIROX |
| 8 | CLOBETASONE |
| 9 | CLOTRIMAZOLE |
| 10 | DICLOFENAC |
| 11 | DIMENHYDRINATE—for the prevention and relief of motion sickness |
| 12 | DIPHENOXYLATE |
| 13 | ECONAZOLE |
| 14 | ELETRIPTAN |
| 15 | ESOMEPRAZOLE |
| 16 | FAMCICLOVIR |
| 17 | FLUCONAZOLE |
| 18 | FLUORIDES |
| 19 | GLUCAGON |
| 20 | GLYCERYL TRINITRATE |
| 21 | HYDROCORTISONE |
| 22 | HYOSCINE BUTYLBROMIDE |
| 23 | IBUPROFEN |
| 24 | ISOCONAZOLE |
| 25 | KETOPROFEN |
| 26 | LANSOPRAZOLE |
| 27 | LEVONORGESTREL |
| 28 | MELATONIN |
| 29 | MICONAZOLE |
| 30 | NALOXONE |
| 31 | NAPROXEN |
| 32 | NARATRIPTAN |
| 33 | NYSTATIN |
| 34 | OMEPRAZOLE |
| 35 | OXICONAZOLE |
| 36 | PANTOPRAZOLE |
| 37 | PARACETAMOL |
| 38 | PODOPHYLLOTOXIN |
| 39 | PODOPHYLLUM EMODI (podophyllin) |
| 40 | PODOPHYLLUM PELTATUM (podophyllin) |
| 41 | RABEPRAZOLE |
| 42 | RIZATRIPTAN |
| 43 | SALICYLIC ACID |
| 44 | SUMATRIPTAN |
| 45 | TIOCONAZOLE |
| 46 | TRIAMCINOLONE |
| 47 | ULIPRISTAL—for emergency post‑coital contraception |
| 48 | VITAMIN D |
| 49 | ZOLMITRIPTAN |

Appendix I—Blank

Note 1: Appendix I is intentionally blank.

Note 2: Appendix I previously included poisons now dealt with in Division 9 of Part 2.

Appendix J—Conditions for availability and use of certain poisons included in Schedule 7

Note: See subsection 62(6).

1 Conditions for supply of certain poisons included in Schedule 7

For the purposes of subsection 62(6), a poison included in Schedule 7 that is specified in column 1 of an item of the following table may be supplied:

(a) only to a person who is appropriately authorised or licensed under the law of the jurisdiction where the person will receive the poison; and

(b) if “a” appears in column 2 of the item—only for analytical or research purposes; and

(c) if “p” appears in column 2 of the item—only to a person who is authorised or licensed, under the law of the jurisdiction where the person will receive the poison, to possess and use the poison.

| Conditions for supply of certain poisons included in Schedule 7 | | |
| --- | --- | --- |
| Item | Column 1 Poison | Column 2 Condition |
| 1 | ABAMECTIN |  |
| 2 | ACIBENZOLAR‑S‑METHYL |  |
| 3 | ACROLEIN |  |
| 4 | ACRYLONITRILE |  |
| 5 | ALACHLOR | a |
| 6 | ALLYL ALCOHOL |  |
| 7 | 4‑AMINOPROPIOPHENONE | p |
| 8 | 4‑AMINOPYRIDINE |  |
| 9 | ARPRINOCID | a |
| 10 | ARSENIC | p |
| 11 | AZOCYCLOTIN | a |
| 12 | BENZENE |  |
| 13 | BIFLUORIDE |  |
| 14 | BORON TRIFLUORIDE |  |
| 15 | BRODIFACOUM |  |
| 16 | BROMADIOLONE |  |
| 17 | BROMINE |  |
| 18 | BRUCINE |  |
| 19 | CALCIFEROL |  |
| 20 | CARBADOX |  |
| 21 | CARBON TETRACHLORIDE |  |
| 22 | CARBONYL SULFIDE |  |
| 23 | CHLORDECONE | a |
| 24 | CHLORDIMEFORM | a |
| 25 | CHLORINE |  |
| 26 | CHLOROMETHIURON | a |
| 27 | CHLOROPICRIN |  |
| 28 | 4‑CHLORO‑*o*‑TOLUIDINE | a |
| 29 | COLECALCIFEROL |  |
| 30 | COUMATETRALYL |  |
| 31 | CYANOGEN |  |
| 32 | CYHEXATIN | a |
| 33 | 4,4‑DIAMINODIPHENYLMETHANE |  |
| 34 | 1,2‑DIBROMO‑3‑CHLOROPROPANE | a |
| 35 | 1,3‑DICHLOROPROPENE |  |
| 36 | DIFENACOUM |  |
| 37 | 4‑DIMETHYLAMINOAZOBENZENE | a |
| 38 | DINITROCRESOLS | a |
| 39 | DINITROPHENOLS | a |
| 40 | DINOSEB | a |
| 41 | EPICHLOROHYDRIN |  |
| 42 | EPIDERMAL GROWTH FACTOR |  |
| 43 | ETACONAZOLE | a |
| 44 | ETHYLENE DIBROMIDE | a |
| 45 | ETHYLENE OXIDE |  |
| 46 | FLUOROACETAMIDE | p |
| 47 | FLUOROACETIC ACID | p |
| 48 | FOLPET |  |
| 49 | HALOFUGINONE |  |
| 50 | HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS | a |
| 51 | HCB | a |
| 52 | HYDROCYANIC ACID AND CYANIDES | p |
| 53 | HYDROFLUORIC ACID |  |
| 54 | HYDROSILICOFLUORIC ACID |  |
| 55 | IODOMETHANE |  |
| 56 | MADURAMICIN |  |
| 57 | MERCURY |  |
| 58 | METHACRIFOS |  |
| 59 | METHOXYETHYLMERCURIC ACETATE | a |
| 60 | METHOXYETHYLMERCURIC CHLORIDE |  |
| 61 | METHYL BROMIDE |  |
| 62 | 4,4'‑METHYLENEBIS[2‑CHLOROANILINE] |  |
| 63 | MIREX | a |
| 64 | MOLINATE |  |
| 65 | NICOTINE **except** when in tobacco |  |
| 66 | NITROFEN | a |
| 67 | PHENYLMERCURIC ACETATE |  |
| 68 | PHOSPHIDE, metallic |  |
| 69 | PHOSPHINE |  |
| 70 | PROPYLENE OXIDE |  |
| 71 | PYRINURON | a |
| 72 | STRYCHNINE | p |
| 73 | SULCOFURON | a |
| 74 | TETRACHLOROETHANE |  |
| 75 | 2,2',6,6'‑TETRAISOPROPYL‑DIPHENYL‑CARBODIIMIDE |  |
| 76 | THALLIUM | p |
| 77 | *o*‑TOLIDINE |  |
| 78 | VINYL CHLORIDE |  |

Appendix K—Human medicines required to be labelled with a sedation warning

Note: See subsection 33(2).

1 Human medicines required to be labelled with a sedation warning

The following table specifies poisons for the purposes of subsection 33(2).

| Human medicines required to be labelled with a sedation warning | |
| --- | --- |
| Item | Column 1 Poison |
| 1 | ALIMEMAZINE |
| 2 | ALPRAZOLAM |
| 3 | AMISULPRIDE |
| 4 | AMITRIPTYLINE |
| 5 | AMOBARBITAL |
| 6 | ARIPIPRAZOLE |
| 7 | ASENAPINE |
| 8 | AZATADINE |
| 9 | BACLOFEN |
| 10 | BENZATROPINE |
| 11 | BREXPIPRAZOLE |
| 12 | BRIVARACETAM |
| 13 | BROMAZEPAM |
| 14 | BROMPHENIRAMINE |
| 15 | BUCLIZINE |
| 16 | BUPRENORPHINE |
| 17 | BUTOBARBITAL |
| 18 | CANNABIS **except** cannabidiol when included in Schedule 3 or 4 |
| 19 | CETIRIZINE |
| 20 | CHLORAL HYDRATE |
| 21 | CHLORDIAZEPOXIDE |
| 22 | CHLORMETHIAZOLE |
| 23 | CHLORPHENAMINE |
| 24 | CHLORPROMAZINE |
| 25 | CLEMASTINE |
| 26 | CLOMIPRAMINE |
| 27 | CLONAZEPAM |
| 28 | CLONIDINE |
| 29 | CLORAZEPATE |
| 30 | CLOZAPINE |
| 31 | CODEINE. |
| 32 | CYCLIZINE |
| 33 | CYCLOBARBITAL |
| 34 | CYCLOSERINE |
| 35 | CYPROHEPTADINE |
| 36 | DANTROLENE |
| 37 | DESIPRAMINE |
| 38 | DEUTETRABENAZINE. |
| 39 | DEXCHLORPHENAMINE |
| 40 | DEXTROMORAMIDE |
| 41 | DEXTROPROPOXYPHENE |
| 42 | DIAZEPAM |
| 43 | DIFELIKEFALIN |
| 44 | DIFENOXIN |
| 45 | DIHYDROCODEINE |
| 46 | DIMENHYDRINATE |
| 47 | DIMETHINDENE |
| 48 | DIPHENHYDRAMINE |
| 49 | DIPHENOXYLATE |
| 50 | DIPHENYLPYRALINE |
| 51 | DOSULEPIN |
| 52 | DOXEPIN |
| 53 | DOXYLAMINE |
| 54 | DRONABINOL (delta‑9‑TETRAHYDROCANNABINOL) |
| 55 | DROPERIDOL |
| 56 | DULOXETINE |
| 57 | ESKETAMINE |
| 58 | ETHYLMORPHINE |
| 59 | FENFLURAMINE |
| 60 | FENTANYL |
| 61 | FLUNITRAZEPAM |
| 62 | FLUPENTIXOL |
| 63 | FLUPHENAZINE |
| 64 | FLURAZEPAM |
| 65 | GABAPENTIN |
| 66 | GEMCITABINE |
| 67 | GLUTETHIMIDE |
| 68 | GUANFACINE |
| 69 | HALOPERIDOL |
| 70 | HYDROCODONE |
| 71 | HYDROMORPHONE |
| 72 | HYDROXYZINE |
| 73 | IMIPRAMINE |
| 74 | LAMOTRIGINE |
| 75 | LEMBOREXANT. |
| 76 | LEVETIRACETAM |
| 77 | LEVOCABASTINE |
| 78 | LEVOCETIRIZINE |
| 79 | LORAZEPAM |
| 80 | LURASIDONE. |
| 81 | MAZINDOL |
| 82 | MEBHYDROLIN |
| 83 | MECLOZINE |
| 84 | MEDAZEPAM |
| 85 | MEPROBAMATE |
| 86 | MEPYRAMINE |
| 87 | MERCAPTAMINE |
| 88 | METHADONE |
| 89 | METHDILAZINE |
| 90 | METHOCARBAMOL |
| 91 | METHYLPHENOBARBITAL |
| 92 | MIANSERIN |
| 93 | MIDAZOLAM |
| 94 | MIRTAZAPINE |
| 95 | MORPHINE |
| 96 | NABIXIMOLS. |
| 97 | NALBUPHINE |
| 98 | NITRAZEPAM |
| 99 | NORMETHADONE |
| 100 | NORTRIPTYLINE |
| 101 | OLANZAPINE |
| 102 | OPIUM in any form **except** the alkaloids noscapine and papaverine |
| 103 | OXAZEPAM |
| 104 | OXYCODONE |
| 105 | PALIPERIDONE |
| 106 | PAPAVERETUM |
| 107 | PENTAZOCINE |
| 108 | PENTOBARBITAL |
| 109 | PERAMPANEL |
| 110 | PERICIAZINE |
| 111 | PERPHENAZINE |
| 112 | PETHIDINE |
| 113 | PHENELZINE |
| 114 | PHENIRAMINE |
| 115 | PHENOBARBITAL |
| 116 | PHENOPERIDINE |
| 117 | PHENYLTOLOXAMINE |
| 118 | PHOLCODINE |
| 119 | PIMOZIDE |
| 120 | PIZOTIFEN |
| 121 | PRAZEPAM |
| 122 | PREGABALIN |
| 123 | PROCHLORPERAZINE |
| 124 | PROMAZINE |
| 125 | PROMETHAZINE |
| 126 | PROTRIPTYLINE |
| 127 | QUETIAPINE |
| 128 | RETIGABINE |
| 129 | RISPERIDONE |
| 130 | ROTIGOTINE |
| 131 | RUFINAMIDE |
| 132 | RUPATADINE |
| 133 | SAFINAMIDE |
| 134 | SECBUTOBARBITAL |
| 135 | SECOBARBITAL |
| 136 | SELETRACETAM |
| 137 | SODIUM OXYBATE |
| 138 | STIRIPENTOL |
| 139 | SUVOREXANT |
| 140 | TAPENTADOL |
| 141 | TEMAZEPAM |
| 142 | TETRAHYDROCANNABINOLS **except** cannabidiol when included in Schedule 3 or 4 |
| 143 | THENYLDIAMINE |
| 144 | THIETHYLPERAZINE |
| 145 | THIOPROPAZATE |
| 146 | THIORIDAZINE |
| 147 | THIOTHIXENE |
| 148 | TRABECTEDIN |
| 149 | TRAMADOL |
| 150 | TRANYLCYPROMINE |
| 151 | TRIFLUOPERAZINE |
| 152 | TRIMIPRAMINE |
| 153 | TRIPROLIDINE |
| 154 | ZIPRASIDONE |
| 155 | ZOLPIDEM |
| 156 | ZONISAMIDE |
| 157 | ZOPICLONE |

Appendix L—Requirements for dispensing labels for medicines

Note: See subsection 33(1) and paragraph 40(b).

1 General

(1) This clause sets out requirements for the purposes of paragraph 40(b).

(2) All details, words and other required information on a label on a container of a substance for therapeutic use must be in the English language in letters at least 1.5 mm in height.

(3) All symbols, numbers and words on a label must be in durable characters.

(4) The label on a container of a substance for therapeutic use must contain the following details:

(a) the name, address and telephone number of the dispenser supplying the substance;

(b) the approved name of the substance and/or its proprietary name (unless it is a preparation compounded in accordance with the dispenser’s own formula);

(c) adequate directions for use;

(d) the strength and form of the substance;

(e) the total quantity of the goods in the container;

(f) the words “KEEP OUT OF REACH OF CHILDREN” in red on a white background;

(g) if the substance is intended for external use only, the word “POISON”, or the words “FOR EXTERNAL USE ONLY”, in red on a white background;

(h) if the substance is a medicine for human use, the name of the person for whom it was dispensed; and

(i) if the substance is a veterinary chemical, the species of animal, the name of the animal’s owner and the words “FOR ANIMAL TREATMENT ONLY”.

(5) The label on a container of a medicine for human use, or a veterinary chemical, that is supplied on prescription must also include:

(a) the prescription reference number; and

(b) the date on which the prescription was supplied (unless that date is clear from the prescription reference number); and

(c) the directions for use set out in the prescription.

2 Additional warning statements for certain human medicines

(1) For the purposes of subsection 33(1), and subject to subclause (2), the warning statement represented by each item number specified in column 2 of an item of the following table is required for the poison specified in column 1 of the item.

Note: For the warning statements represented by the item numbers, see clause 1 of Appendix F.

(2) If more than one statement or direction is required for a poison, the statements and directions may be combined to form simple sentences (if appropriate).

| Additional warning statements for certain human medicines | | |
| --- | --- | --- |
| Item | Column 1 Poison | Column 2 Warning statement item number |
| 1 | ACITRETIN—for oral use | 7, 62, 76 |
| 2 | ACITRETIN—for topical use | 62, 77 |
| 3 | ADAPALENE—for oral use | 7, 62, 76 |
| 4 | ADAPALENE—for topical use | 62, 77 |
| 5 | AMBRISENTAN | 7, 62, 76 |
| 6 | BELUMOSUDIL | 62, 77 |
| 7 | BEXAROTENE—for oral use | 7, 62, 76 |
| 8 | BEXAROTENE—for topical use | 62, 77 |
| 9 | BOSENTAN | 7, 62, 76 |
| 10 | DIENESTROL | 67 |
| 11 | ETRETINATE—for oral use | 7, 62, 76 |
| 12 | ETRETINATE—for topical use | 62, 77 |
| 13 | ENZALUTAMIDE | 7, 67, 87 |
| 14 | FARICIMAB | 76 |
| 15 | FINERENONE | 67, 111 |
| 16 | FINGOLIMOD | 76 |
| 17 | ISAVUCONAZOLE | 53 |
| 18 | ISOTRETINOIN—for oral use | 7, 62, 76 |
| 19 | ISOTRETINOIN—for topical use | 62, 77 |
| 20 | LEFLUNOMIDE | 7, 62, 87 |
| 21 | LENALIDOMIDE—for oral use | 7, 62, 76 |
| 22 | LENALIDOMIDE—for topical use | 62, 77 |
| 23 | LEVOCABASTINE | 62 |
| 24 | MACITENTAN | 7, 62, 76 |
| 25 | MISOPROSTOL | 53 |
| 26 | PALOVAROTENE | 7, 62, 76, 111 |
| 27 | PLITIDEPSIN | 7, 62, 63, 76, 87 |
| 28 | POMALIDOMIDE | 7, 62, 76 |
| 29 | PONESIMOD | 76 |
| 30 | RIOCIGUAT | 7, 62, 76 |
| 31 | RUFINAMIDE | 62, 76, 77 |
| 32 | SAFINAMIDE | 62, 76, 77 |
| 33 | SELINEXOR | 62 and 77 |
| 34 | SELUMETINIB. | 76 |
| 35 | SITAXENTAN | 7, 62, 76 |
| 36 | TERIFLUOMIDE | 7, 62, 87 |
| 37 | THALIDOMIDE—for oral use | 7, 62, 76 |
| 38 | THALIDOMIDE—for topical use | 62, 77 |
| 39 | TIRZEPATIDE | 67 |
| 40 | TRASTUZUMAB DERUXTECAN | 62, 77 |
| 41 | TRETINOIN—for oral use | 7, 62, 76 |
| 42 | TRETINOIN—for topical use | 62, 77 |

Appendix M—Additional controls or supply requirements for poisons included in Schedule 3 to allow them to be provided by a pharmacist

Note: Appendix M is intentionally blank. It is reserved for future use.

Index

**A**

**ABACAVIR**

Schedule 4

**ABAMECTIN**

Schedule 7  
Schedule 6  
Schedule 5  
Appendix J, clause 1

**ABATACEPT**

Schedule 4

**ABCIXIMAB**

Schedule 4

**ABEMACICLIB**

Schedule 4

**ABIRATERONE ACETATE**

Schedule 4

**ABROCITINIB**

Schedule 4

**ABRUS PRECATORIUS**cross reference: JEQUIRITY

Schedule 10

**ABSCISIC ACID**

Schedule 5

**ACALABRUTINIB**

Schedule 4

**ACAMPROSATE CALCIUM**

Schedule 4

**ACARBOSE**

Schedule 4

**ACEBUTOLOL**

Schedule 4

**ACEPHATE**

Schedule 6

**ACEPROMAZINE**

Schedule 4

**ACEQUINOCYL**

Schedule 5

**ACETAMIPRID**

Schedule 6

**ACETANILIDE**cross reference: ALKYL ACETANILIDES

Schedule 4

**ACETARSOL**

Schedule 4

**ACETAZOLAMIDE**

Schedule 4

**ACETIC ACID**

Schedule 6  
Schedule 5  
Schedule 2  
Appendix E, clause 3  
Appendix F, clause 4

**ACETIC ANHYDRIDE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**ACETOHEXAMIDE**

Schedule 4

**ACETONE**cross reference: DESIGNATED SOLVENT

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**ACETORPHINE**

cross reference: CAS No. 25333-77-1

Schedule 9

**ACETYL‑ALPHA‑METHYLFENTANYL**

cross reference: CAS No. 101860-00-8

Schedule 9

**ACETYLCARBROMAL**

Schedule 4

**ACETYLCHOLINE**

Schedule 4  
Appendix G, clause 1

**ACETYLCYSTEINE**

Schedule 4  
Schedule 2

**ACETYLDIGITOXIN**

Schedule 4

**ACETYLDIHYDROCODEINE**

Schedule 8

**ACETYL ISOVALERYLTYLOSIN**

Schedule 4

**ACETYLMETHADOL**

Schedule 8

**ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE**

Schedule 4

**ACETYLMORPHINES**

Schedule 8

**4‑[4‑(ACETYLOXY)PHENYL]‑2‑BUTANONE**

Appendix B, clause 3

**ACETYLSTROPHANTHIDIN**

Schedule 4

**ACIBENZOLAR‑S‑METHYL**

Schedule 7  
Appendix J, clause 1

**ACICLOVIR**

Schedule 4

**ACIFLUORFEN**

Schedule 6

**ACINITRAZOLE**

Schedule 6

**ACIPIMOX**

Schedule 4

**ACITRETIN**

Schedule 4  
Appendix D, clause 2  
Appendix F, clause 4  
Appendix L, clause 2

**ACLIDINIUM BROMIDE**

Schedule 4

**ACLONIFEN**

Schedule 6

**ACOKANTHERA OUABAIO**

Schedule 4

**ACOKANTHERA SCHIMPERI**

Schedule 4

**ACONITUM spp.**

Schedule 4  
Schedule 2

**ACORUS CALAMUS**cross reference: CALAMUS

Schedule 10

**ACRIFLAVINE**cross reference:ACRIFLAVINIUM CHLORIDE

**ACRIFLAVINUM CHLORIDE**

Schedule 7  
Schedule 5

**ACRIVASTINE**

Schedule 4

**ACROLEIN**

Schedule 7  
Appendix E, clause 3  
Appendix F, clause 4

**ACRYLONITRILE**

Schedule 7  
Appendix J, clause 1

**ADALIMUMAB**

Schedule 4

**ADAPALENE**

Schedule 4  
Schedule 3  
Appendix F, clause 4  
Appendix H, clause 1  
Appendix L, clause 2

**ADEFOVIR**

Schedule 4

**ADENOSINE**

Schedule 4

**ADIPHENINE**

Schedule 4

**ADONIS VERNALIS**

Schedule 4

**ADRAFINIL**

Schedule 4

**ADRENALINE**

Schedule 4Schedule 3

Appendix H, clause 1

**ADRENOCORTICAL HORMONES**

Schedule 4

**AFAMELANOTIDE**cross reference: MELANOCYTE STIMULATING HORMONE, MELANOTAN I

Schedule 4

**AFATINIB DIMALEATE**

Schedule 4

**AFIDOPYROPEN**

Appendix B, clause 3

**AFLIBERCEPT**

Schedule 4

**AFOXOLANER**

Schedule 5

**AGALSIDASE**

Schedule 4

**AGLEPRISTONE**

Schedule 4

**AGOMELATINE**

Schedule 4

**AKLOMIDE**

Schedule 5

**ALACHLOR**

Schedule 7  
Appendix J, clause 1

**ALANYLGLUTAMINE**

Schedule 4

**ALATROFLOXACIN MESILATE**cross reference: ALATROFLOXACIN MESYLATE

Schedule 4

**ALBENDAZOLE**

Schedule 6  
Schedule 5  
Schedule 4

**ALCLOFENAC**

Schedule 4

**ALCLOMETASONE**

Schedule 4  
Schedule 3  
Appendix F, clause 4

**ALCOHOL, DEHYDRATED**

Appendix B, clause 3

**ALCURONIUM**

Schedule 4

**ALDESLEUKIN**

Schedule 4

**ALDICARB**

Schedule 7

**ALDOSTERONE**

Schedule 4  
Appendix G, clause 1

**ALDOXYCARB**

Schedule 7

**ALDRIN**

Schedule 6

**ALECTINIB**

Schedule 4

**ALEFACEPT**

Schedule 4  
Appendix D, clause 7

**ALEMTUZUMAB**

Schedule 4

**ALENDRONIC ACID**

Schedule 4

**ALFACALCIDOL**

Schedule 4

**ALFENTANIL**

Schedule 8

**ALFUZOSIN**

Schedule 4

**ALGICIDES**

Appendix A, clause 1

**ALGLUCERASE**

Schedule 4

**ALGLUCOSIDASE**

Schedule 4

**ALIMEMAZINE**cross reference: TRIMEPRAZINE

Schedule 4  
Schedule 3  
Schedule 2  
Appendix K, clause 1

**ALIROCUMAB**

Schedule 4

**ALISKIREN**

Schedule 4

**ALKALINE SALTS**cross reference: LYE WATER, POTASSIUM CARBONATE. POTASSIUM PHOSPHATE, POTASSIUM SALTS, POTASSIUM SILICATE, SODIUM CARBONATE, SODIUM SALTS, SODIUM SILICATE(S)

Schedule 10  
Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**ALKOXYAMFETAMINES**cross reference: ALKOXYAMPHETAMINES

Schedule 9

**ALKOXYLATED FATTY ALKYLAMINE POLYMER**

Schedule 6  
Schedule 5

**ALKOXYPHENYLETHYLAMINES**

Schedule 9

**ALKYLAMINES WITH STIMULANT PROPERTIES**cross reference: 1,3‑DIMETHYLBUTYLAMINE, DMBA, OCTODRINE, 1‑AMINOISOHEPTANE, DMHA, 1,5‑DIMETHYLHEXYLAMINE, 4‑METHYLHEXANE‑2‑AMINE, 1,3‑DIMETHYLAMYLAMINE, DMAA, 4‑AMINO‑2‑METHYLPENTANE CITRATE (AMP CITRATE), 1,4‑DIMETHYLPENTYLAMINE, DMPA, 1,4‑DIMETHYLAMYLAMINE, DMAA.

Schedule 10

**ALKYL NITRITES**

Schedule 4  
Appendix E, clause 3

**ALKYLTHIOAMFETAMINES**cross reference: ALKYLTHIOAMPHETAMINES

Schedule 9

**ALLERGENS**

Schedule 4

**ALLETHRIN**

Schedule 6  
Schedule 5

**ALLOPURINOL**

Schedule 4

**ALLOXYDIM**

Schedule 5

**ALLYL ALCOHOL**

Schedule 7  
Appendix J, clause 1

**ALLYL CYCLOHEXANEACETATE** (CAS No. 4728‑82‑9)

Schedule 6

**ALLYL CYCLOHEXANEPROPIONATE** (CAS No. 2705‑87‑5)

Schedule 6

**ALLYL ESTERS** (excluding derivatives)

Schedule 6

**ALLYLESTRENOL**cross reference: ALLYLOESTRENOL

Schedule 4

**ALLYL HEPTANOATE/ALLYL HEPTYLATE** (CAS No. 142‑19‑8)

Schedule 6

**ALLYL HEXANOATE** (CAS No. 123‑68‑2)

Schedule 6

**ALLYL ISOVALERATE** (CAS No. 2835‑39‑4)

Schedule 6

**ALLYL NONANOATE** (CAS No. 7493‑72‑3)

Schedule 6

**ALLYL OCTANOATE** (CAS No. 4230‑97‑1)

Schedule 6

**ALLYLOESTRENOL**cross reference: ALLYLESTRENOL

**ALLYL PHENYLACETATE** (CAS No. 1797‑74‑6)

Schedule 6

**ALLYLPRODINE**

cross reference: CAS No. 25384-17-2

Schedule 9

**ALLYL TRIMETHYLHEXANOATE (CAS No. 68132‑80‑9)**

Schedule 6

**ALOGLIPTIN**

Schedule 4

**ALOSETRON**

Schedule 4

**ALOXIPRIN**

Schedule 2

**ALPELISIB**

Schedule 4

**ALPHACETYLMETHADOL**

Schedule 8

**ALPHA‑CHLOROHYDRIN**

Schedule 6  
Appendix F, clause 4

**ALPHA‑CYPERMETHRIN**

Schedule 7  
Schedule 6  
Schedule 5

**ALPHADOLONE**

Schedule 4

**ALPHAMEPRODINE**

cross reference: CAS No. 468-51-9

Schedule 9

**ALPHAMETHADOL**

cross reference: CAS No. 17199-54-1

Schedule 9

**ALPHA‑METHYLFENTANYL**

cross reference: CAS No. 79704-88-4

Schedule 9

**ALPHA‑METHYLTHIOFENTANYL**

cross reference: CAS No. 103963-66-2

Schedule 9

**ALPHAPRODINE**

Schedule 8

**ALPHA‑PYRROLIDINOVALEROPHENONE \*(ALPHA‑PVP).**

cross reference: CAS No. 14530-33-7

Schedule 9

**ALPHA1‑PROTEINASE INHIBITOR (HUMAN)**

Schedule 4

**ALPHAXALONE**

Schedule 4

**ALPRAZOLAM**

Schedule 8  
Appendix D, clause 5 (Benzodiazepine derivatives)  
Appendix K, clause 1

**ALPRENOLOL**

Schedule 4

**ALPROSTADIL**

Schedule 4

**ALSEROXYLON**

Schedule 4

**ALTEPLASE**

Schedule 4

**ALTRENOGEST**

Schedule 4

**ALTRETAMINE**cross reference: HEXAMETHYLMELAMINE

Schedule 4

**ALUM**

Appendix B, clause 3

**ALUMINIUM AMMONIUM SULFATE**

Appendix B, clause 3

**ALUMINIUM POTASSIUM SULFATE**

Appendix B, clause 3

**ALUMINIUM SILICATE**

Appendix B, clause 3

**ALUMINIUM tris (ETHYLPHOSPHONATE)**

Appendix B, clause 3

**AMANTADINE**

Schedule 4

**AMBENONIUM CHLORIDE**

Schedule 4

**AMBRISENTAN**

Schedule 4  
Appendix D, clause 6  
Appendix F, clause 4  
Appendix L, clause 2

**AMBUCETAMIDE**

Schedule 4

**AMBUTONIUM BROMIDE**

Schedule 4

**AMCINONIDE**

Schedule 4

**AMETOCTRADIN**

Appendix B, clause 3

**AMETRYN**

Schedule 5

**AMICARBAZONE**

Schedule 6

**AMIDITHION**

Schedule 6

**AMIDOPROPYL BETAINES**

Schedule 6  
Appendix E, clause 3

**AMIFAMPRIDINE**

Schedule 4

**AMIFOSTINE**

Schedule 4

**AMIKACIN**

Schedule 4

**AMILORIDE**

Schedule 4

**AMINACRINE**cross reference: AMINOACRIDINE

**AMINES**cross reference: CURING AGENTS FOR EPOXY RESINS

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**AMINOACRIDINE**cross reference: AMINACRINE

Schedule 7  
Schedule 5

**AMINOCAPROIC ACID**

Schedule 4

**AMINOCARB**

Schedule 7  
Schedule 6

**2‑AMINO‑6‑CHLORO‑4‑NITROPHENOL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**4‑AMINO‑m‑CRESOL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**5‑AMINO‑o‑CRESOL**cross reference: 4‑AMINO‑2‑HYDROXYTOLUENE

**AMINOCYCLOPYRACHLOR**

Schedule 5

**2‑AMINO‑1‑(2,5‑DIMETHOXY‑4‑METHYL)PHENYLPROPANE**cross reference: DOM, STP (CAS No. 15588-95-1), DOM HYDROCHLORIDE (CAS No. 15589-00-1)

Schedule 9

**AMINOETHOXYVINYLGLYCINE**

Schedule 6

**2‑AMINO‑5‑ETHYLPHENOL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**AMINOGLUTETHIMIDE**

Schedule 4

**4‑AMINO‑2‑HYDROXYTOLUENE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**5‑AMINOLEVULINIC ACID**

Schedule 4

**1‑AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE**

Schedule 6

**2‑[(4‑AMINO‑2‑METHYL‑5‑NITROPHENYL)AMINO]‑ETHANOL**cross reference: HC VIOLET 1

**2‑AMINO‑5‑METHYLPHENOL**

cross reference: CAS No. 2835-98-5

Schedule 10  
Schedule 7

**AMINOMETRADINE**

Schedule 4

**4‑AMINO‑3‑NITROPHENOL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**2,2'‑[(4‑AMINO‑3‑NITROPHENYL)IMINO]BISETHANOL**cross reference: HC RED 13

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**AMINOPHENAZONE**cross reference: AMIDOPYRINE (CAS No. 58-15-1), AMINOPHENAZONE HYDROCHLORIDE (CAS No. 6170-29-2)

Schedule 10  
Schedule 4

**m‑AMINOPHENOL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**p‑AMINOPHENOL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**AMINOPHYLLINE**

Schedule 4Schedule 3

**4‑AMINOPROPIOPHENONE**cross reference: PARA‑AMINOPROPIOPHENONE (PAPP)

Schedule 7  
Appendix J, clause 1

**5‑(2‑AMINOPROPYL)INDAN**

cross reference: CAS No. 13396-94-6

Schedule 9

**AMINOPTERIN**

Schedule 4

**AMINOPYRALID**

Schedule 6  
Schedule 5

**4‑AMINOPYRIDINE**cross reference: FAMPRIDINE

Schedule 7  
Schedule 4Appendix E, clause 3  
Appendix J, clause 1

**AMINOREX**

Schedule 4

**AMINOSALICYLIC ACID**

Schedule 4

**AMIODARONE**

Schedule 4

**AMIPHENAZOLE**

Schedule 4

**AMISOMETRADINE**

Schedule 4

**AMISULBROM**

Schedule 5

**AMISULPRIDE**

Schedule 4  
Appendix K, clause 1

**AMITON**

Schedule 7

**AMITRAZ**

Schedule 6

**AMITRIPTYLINE**

Schedule 4  
Appendix K, clause 1

**AMITROLE**

Schedule 5

**AMLODIPINE**

Schedule 4

**AMMI VISNAGA**

Schedule 4

**AMMONIA**cross reference: AMMONIUM HYDROXIDE, CHROMATES

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**AMMONIUM BROMIDE**

Schedule 4

**AMMONIUM COCOYL ISETHIONATE**

Schedule 6  
Appendix E, clause 3

**AMMONIUM PERSULFATE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**AMMONIUM PHOSPHATE**

Appendix B, clause 3

**AMMONIUM THIOCYANATE**

Schedule 5  
Appendix E, clause 3

**AMMONIUM THIOSULPHATE**

Appendix B, clause 3

**AMOBARBITAL**

Schedule 8  
Schedule 4  
Appendix K, clause 1

**AMODIAQUINE**

Schedule 4

**AMOROLFINE**

Schedule 4Schedule 2

**AMOXAPINE**

Schedule 4

**AMOXICILLIN**

Schedule 4

**AMOXYCILLIN**cross reference: AMOXICILLIN

**AMFETAMINE**cross reference: AMPHETAMINE

Schedule 8

**AMPHOMYCIN**

Schedule 4

**AMPHOTERICIN**cross reference: AMPHOTERICIN B

**AMPHOTERICIN B**

Schedule 4

**AMPICILLIN**

Schedule 4

**AMPRENAVIR**

Schedule 4

**AMPROLIUM**

Appendix B, clause 3

**AMRINONE**

Schedule 4

**AMSACRINE**

Schedule 4

**AMYGDALIN**cross reference: CAS No. 29883-15-6, APRICOT KERNELS

Schedule 10

**AMYL ACETATE**

Appendix B, clause 3

**AMYL NITRITE**

Schedule 4  
Schedule 3  
Appendix E, clause 3

**α‑AMYLASE derived from Aspergillus niger**

Appendix B, clause 3

**AMYL CINNAMALDEHYDE**

Appendix B, clause 3

**AMYLOBARBITAL**cross reference: AMOBARBITAL

**AMYLOBARBITONE**cross reference: AMOBARBITAL

**AMYLOCAINE**

Schedule 4

**ANABOLIC STEROIDAL AGENTS**cross reference: ANDROSTERONE, STEROIDAL AGENTS

Schedule 4Appendix D, clause 5

**ANAGRELIDE**

Schedule 4

**ANAKINRA**

Schedule 4

**ANASTROZOLE**

Schedule 4

**ANCESTIM**

Schedule 4

**ANCHUSA OFFICINALIS**

Schedule 10

**ANCROD**

Schedule 4

**ANDEXANET ALFA**

Schedule 4

**ANDROGENIC STEROIDAL AGENTS**cross reference: STEROIDAL AGENTS

Schedule 4Appendix D, clause 5

**ANDROISOXAZOLE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**ANDROSTANOLONE**

Schedule 4

**ANDROSTENEDIOL**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**ANDROSTENEDIONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**ANDROSTENEDIONE ALBUMEN**

Appendix B, clause 3

**ANECORTAVE**

Schedule 4

**ANGIOTENSIN AMIDE**

Schedule 4

**ANHYDRIDES, ORGANIC ACID**cross reference: CURING AGENTS FOR EPOXY RESINS

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**ANIDULAFUNGIN**

Schedule 4

**ANILERIDINE**

Schedule 8

**ANILINE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**ANIRACETAM**cross reference: RACETAMS

Schedule 4

**ANISE OIL**

Schedule 5  
Appendix E, clause 3, Part 4

*o***‑ANISIDINE**

cross reference: CAS No. 90-04-0, *o*-ANISIDINE HYDROCHLORIDE (CAS No. 134-29-2)

Schedule 10

**ANISTREPLASE**

Schedule 4

**ANTAZOLINE**

Schedule 4  
Schedule 2

**ANTIBIOTIC SUBSTANCES**cross reference: NISIN

Schedule 4

**ANTIGENS**

Schedule 4

**ANTIHISTAMINES**cross reference: ASTEMIZOLE, AZELASTINE, BILASTINE, CETIRIZINE, DESLORATADINE, FEXOFENADINE, LORATADINE, OLOPATADINE, TERFENADINE

Schedule 4  
Appendix F, clause 4

**ANTIMONY**cross reference: ANTIMONY COMPOUNDS, ANTIMONY CHLORIDE, ANTIMONY TITANATE

Schedule 6  
Schedule 4  
Appendix E, clause 3  
Appendix G, clause 1

**ANTISERA**cross reference: IMMUNOSERA

Schedule 4

**AOD‑9604** (CAS No. 221231‑10‑3)

Schedule 4  
Appendix D, clause 5

**APALUTAMIDE**

Schedule 4

**APIXABAN**

Schedule 4

**APOCYNUM spp.**

Schedule 4

**APOMORPHINE**

Schedule 4Appendix G, clause 1

**APRACLONIDINE**

Schedule 4

**APRAMYCIN**

Schedule 4

**APREMILAST**

Schedule 4

**APREPITANT**

Schedule 4

**APRICOT KERNELS**

cross reference: AMYGDALIN, HYDROCYANIC ACID

**APRONAL**

cross reference: ALLYLISOPROPYLACETYLUREA (CAS No. 528-92-7)

Schedule 10

**APROTININ**

Schedule 4

**ARBUTIN (ALPHA)**

cross reference: ARBUTIN (BETA); ARBUTIN (DEOXY OR OTHER DERIVATIVES)

Schedule 6

Appendix E, clause 3

Appendix F, clause 4

**ARBUTIN (BETA)**

cross reference: ARBUTIN (ALPHA); ARBUTIN (DEOXY OR OTHER DERIVATIVES)

Schedule 6

Schedule 4

Appendix E, clause 3

Appendix F, clause 4

**ARBUTIN (DEOXY OR OTHER DERIVATIVES)**

cross reference: ARBUTIN (ALPHA); ARBUTIN (BETA)

Schedule 6

Appendix E, clause 3

Appendix F, clause 4

**ARECOLINE**

Schedule 4

**ARIPIPRAZOLE**

Schedule 4Appendix K, clause 1

**ARISTOLOCHIA spp.**

Schedule 10

**ARISTOLOCHIC ACID(S)**cross reference: ASARUM spp, BRAGANTIA(CAS No. 313-67-7)

Schedule 10

**ARPRINOCID**

Schedule 7  
Appendix J, clause 1

**ARMODAFINIL**

Schedule 4

**ARSENIC**cross reference: ARSENIC TRIOXIDE, CACODYLIC ACID, TERMITE BARRIERS, COPPER‑CHROME‑ARSENIC, SELENIUM ARSENIDE, THIACETARSAMIDE

Schedule 7  
Schedule 6  
Schedule 4  
Appendix G, clause 1  
Appendix J, clause 1

**ARTEMETHER**

Schedule 4

**ARTICAINE**

Schedule 4

**ASARUM spp**

Schedule 10

**ASCIMINIB**

Schedule 4

**ASENAPINE**

Schedule 4  
Appendix K, clause 1

**ASFOTASE ALFA**

Schedule 4

**ASPARAGINASE**

cross reference: CRISANTASPASE

Schedule 4

**ASPARTIC ACID**

Appendix B, clause 3

**ASPIRIN**cross reference: CAFFEINE, PARACETAMOL, SALICYLAMIDE

Schedule 6  
Schedule 5  
Schedule 4  
Schedule 2  
Appendix F, clause 4

**ASTEMIZOLE**

Schedule 4  
Appendix F, clause 4

**ASTODRIMER SODIUM**

Schedule 3

Schedule 2

Appendix F, clause 4

Appendix H, clause 1

**ASULAM**

Appendix B, clause 3

**ASUNAPREVIR**

Schedule 4

**ATAMESTANE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**ATAZANAVIR**

Schedule 4

**ATENOLOL**

Schedule 4

**ATEZOLIZUMAB**

Schedule 4

**ATIPAMEZOLE**

Schedule 4

**ATOMOXETINE**

Schedule 4

**ATORVASTATIN**

Schedule 4

**ATOSIBAN**

Schedule 4

**ATOVAQUONE**

Schedule 4

**ATRACURIUM BESILATE**cross reference: ATRACURIUM BESYLATE

Schedule 4

**ATRAZINE**

Schedule 5

**ATROPA BELLADONNA**cross reference: BELLADONNA

Schedule 4  
Schedule 2  
Appendix G, clause 1

**ATROPINE**

Schedule 4  
Schedule 2  
Appendix G, clause 1

**ATROPINE METHONITRATE**

Schedule 4

**AURANOFIN**

Schedule 4

**AUREOBASIDIUM PULLULANS (Strains DSM14940 and DSM14941)**

Appendix B

**AUROTHIOMALATE SODIUM**

Schedule 4

**AVACOPAN**

Schedule 4

**AVATROMBOPAG**

Schedule 4

**AVELUMAB**

Schedule 4

**AVILAMYCIN**

Schedule 4

**AVIPTADIL**

Schedule 4

**AVOPARCIN**

Schedule 4

**AXITINIB**

Schedule 4

**AZACITIDINE**

Schedule 4

**AZACONAZOLE**

Schedule 6

**AZACYCLONOL**

Schedule 4

**AZADIRACHTA INDICA**cross reference: DEBITTERISED NEEM SEED OIL, NEEM

Schedule 10  
Schedule 6

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**AZADIRACHTA INDICA EXTRACTS**

Schedule 5

**AZAFENIDIN**

Schedule 7

**AZAMETHIPHOS**

Schedule 6

**AZAPERONE**

Schedule 4

**AZAPROPAZONE**

Schedule 4

**AZARIBINE**

Schedule 4

**AZATADINE**

Appendix K, clause 1

**AZATADINE**

Schedule 4  
Schedule 3

**AZATHIOPRINE**

Schedule 4

**AZELAIC ACID**

Schedule 4  
Schedule 2

**AZELASTINE**

Schedule 4  
Schedule 2

**AZIMSULFURON**

Appendix B, clause 3

**AZINPHOS‑ETHYL**

Schedule 7

**AZINPHOS‑METHYL**

Schedule 7

**AZITHROMYCIN**

Schedule 4

**AZLOCILLIN**

Schedule 4

**AZOBENZENE**

Schedule 6

**AZOCYCLOTIN**

Schedule 7  
Appendix F, clause 4  
Appendix J, clause 1

**AZO DYES (derivatives by diazotisation)**

Schedule 7  
Appendix E, clause 3  
Appendix F, clause 4

**AZOXYSTROBIN**

Schedule 5

**AZTREONAM**

Schedule 4

**B**

**BACAMPICILLIN**

Schedule 4

**BACILLUS AMYLOLIQUEFACIENS**  
cross reference: BACILLUS SUBTILIS, STRAIN QST 713; BACILLUS AMYLOLIQUEFACIENS, STRAIN QST 713; BACILLUS AMYLOLIQUEFACIENS, STRAIN MBI 600

Appendix B, clause 3

**BACILLUS SPHAERICUS, STRAIN 2362**

Appendix B, clause 3

**BACILLUS SUBTILIS, STRAIN QST 713**  
cross reference: BACILLUS AMYLOLIQUEFACIENS, STRAIN QST 713

**BACILLUS THURINGIENSIS**cross reference: ENDOTOXIN

Appendix B, clause 3

**BACILLUS THURINGIENSIS DELTA ENDOTOXIN**

Schedule 5

**BACILLUS TOYOI**

Appendix B, clause 3

**BACITRACIN**

Schedule 4

**BACLOFEN**

Schedule 4  
Appendix K, clause 1

**BACTERIAL CULTURE MEDIA**cross reference: ANTIBIOTIC SUBSTANCES

Appendix A, clause 1

**BACTERICIDES**

Appendix A, clause 1

**BACULOVIRUS CYDIA POMONELLA**

Appendix B, clause 3

**BALOXAVIR MARBOXIL**

Schedule 4

**BALSALAZIDE**

Schedule 4

**BAMBERMYCIN**cross reference: FLAVOPHOSPHOLIPOL

Schedule 6  
Schedule 4

**BAMBUTEROL**

Schedule 4

**BAMETHAN**

Schedule 4

**BAMIPINE**

Schedule 4

**BARBITURATES**

Schedule 4

**BARICITINIB**

Schedule 4

**BARIUM SALTS**cross reference: BARIUM METABORATE, BARIUM SULFATE

Schedule 6  
Appendix E, clause 3

**BARIUM SILICOFLUORIDE**

Schedule 5

**BASIC BLUE 26**

Schedule 10  
Schedule 6

**BASIC ORANGE 31**cross reference: 2‑[(4‑AMINOPHENYL)AZO]‑1,3‑DIMETHYL‑1H‑IMIDAZOLIUM, CHLORIDE (CAS No. 97404-02-9)

Schedule 10  
Schedule 6

**BASIC RED 76** (CAS No. 68391‑30‑0)  
cross reference: [7‑HYDROXY‑8‑[(2‑ METHOXYPHENYL)AZO]‑2‑NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391‑30‑0)

Schedule 7  
Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**BASIL OIL**cross reference: METHYL CHAVICOL

Schedule 5  
Appendix E, clause 3

**BASILIXIMAB**

Schedule 4

**BATTERIES**

Appendix A, clause 1

**BAY OIL**

Schedule 6  
Appendix E, clause 3

**BAZEDOXIFENE**

Schedule 4

**BEAUVERIA BASSIANA**

Schedule 6  
Schedule 5

**BECAPLERMIN**

Schedule 4

**BECLAMIDE**

Schedule 4

**BECLOMETASONE**cross reference: BECLOMETHASONE

Schedule 4  
Schedule 2

**BECLOMETHASONE**cross reference: BECLOMETASONE

**BELATACEPT**

Schedule 4

**BELIMUMAB**

Schedule 4

**BELUMOSUDIL**

Schedule 4

Appendix L, clause 2

**BELZUTIFAN**

Schedule 4

**BEMEGRIDE**

Schedule 4

**BENACTYZINE**

Schedule 4

**BENALAXYL**

Schedule 5

**BENAZEPRIL**

Schedule 4

**BENDAMUSTINE**

Schedule 4

**BENDIOCARB**cross reference: DENATONIUM BENZOATE

Schedule 7  
Schedule 6  
Schedule 5

**BENDROFLUAZIDE**

Schedule 4

**BENETHAMINE PENICILLIN**

Schedule 4

**BENFLURALIN**

Appendix B, clause 3

**BENOMYL**

Schedule 7  
Appendix F, clause 4

**BENORYLATE**

Schedule 4

**BENOXAPROFEN**

Schedule 4

**BENPERIDOL**

Schedule 4

**BENQUINOX**

Schedule 6

**BENRALIZUMAB**

Schedule 4

**BENSERAZIDE**

Schedule 4

**BENSULFURON‑METHYL**

Appendix B, clause 3

**BENSULIDE**

Schedule 6

**BENTAZONE**

Schedule 5

**BENTONITE**

Appendix B, clause 3

**BENZALKONIUM CHLORIDE**

Schedule 6  
Schedule 5  
Appendix E, clause 3

**BENZATHINE PENICILLIN**

Schedule 4

**BENZENE**

cross reference: LIQUID HYDROCARBONS  
Schedule 7  
Appendix E, clause 3  
Appendix F, clause 4  
Appendix J, clause 1

**1,2‑BENZENEDIAMINE**

cross reference: CAS No. 95-54-5, 1,2-BENZENEDIAMINE DIHYDROCHLORIDE (CAS No. 615-28-1)

Schedule 10

**1,3‑BENZENEDIAMINE**

cross reference: CAS No. 108-45-2

Schedule 10

**1,2‑BENZENEDIOL**cross reference: CATECHOL

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**BENZETHIDINE**

cross reference: CAS No. 3691-78-9

Schedule 9

**BENZHEXOL**cross reference: TRIHEXYPHENIDYL

**BENZIDINE‑CONGENER (3,3'‑disubstituted) AZO DYES**

Schedule 7

**BENZIDINE‑BASED AZO DYES**

Schedule 7

**BENZILONIUM**

Schedule 4

**BENZOCAINE**

Schedule 4  
Schedule 2

**BENZODIAZEPINE DERIVATIVES**

Schedule 4  
Appendix D, clause 5

**BENZOFENAP**

Schedule 5

**BENZOIC ACID**

Schedule 5

**BENZOVINDIFLUPYR**

Schedule 6

**BENZOYL PEROXIDE**

Schedule 5  
Schedule 4  
Schedule 2  
Appendix E, clause 3  
Appendix F, clause 4

**BENZOYLINDOLES**

Schedule 9

**BENZPHETAMINE**

Schedule 4

**BENZTHIAZIDE**

Schedule 4

**BENZATROPINE**cross reference: BENZITROPINE

Schedule 4  
Appendix K, clause 1

**BENZYDAMINE**

Schedule 4  
Schedule 2

**6‑BENZYLADENINE**

Schedule 6

**BENZYL BENZOATE**

Appendix B, clause 3

**BENZYLMORPHINE**

Schedule 8

**BENZYLPENICILLIN**

Schedule 4

**BENZYLPIPERAZINE**cross reference: BZP (CAS No. 2759-28-6), BENZYLPIPERAZINE TARTRATE (CAS No. 10510-56-2), BENZYLPIPERAZINE DIHYDROCHLORIDE (CAS No. 5321-63-1)

Schedule 9

**BEPHENIUM SALTS**

Schedule 2

**BEPRIDIL**

Schedule 4

**BERACTANT**

Schedule 4

**BERGAMOT OIL**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**BERYLLIUM**

Schedule 6  
Appendix F, clause 4

**BESIFLOXACIN**

Schedule 4

**BETACETYLMETHADOL**

cross reference: CAS No. 17199-59-6

Schedule 9

**BETACYFLUTHRIN**

Schedule 7  
Schedule 6  
Schedule 5

**BETA‑CYPERMETHRIN**

Schedule 6

**BETA‑PHENYL‑GAMMA‑AMINOBUTYRIC ACID**cross reference: PHENIBUT

**BETAHISTINE**

Schedule 4

**BETA‑HYDROXY‑3‑METHYLFENTANYL**

cross reference: CAS No. 78995-14-9

Schedule 9

**BETA‑HYDROXYFENTANYL**

cross reference: CAS No. 78995-10-5

Schedule 9

**BETAINE HYDROCHLORIDE**

Appendix B, clause 3

**BETAMEPRODINE**

cross reference: CAS No. 468-50-8

Schedule 9

**BETAMETHADOL**

cross reference: CAS No. 17199-55-2

Schedule 9

**BETAMETHASONE**

Schedule 4

**1‑(BETA‑METHYL SULPHONAMIDOETHYL)‑ 2‑AMINO‑3**

Appendix F, clause 4

**BETAPRODINE**

cross reference: CAS No. 468-59-7

Schedule 9

**BETAXOLOL**

Schedule 4

**BETHANECHOL CHLORIDE**

Schedule 4

**BETHANIDINE**

Schedule 4

**BEVACIZUMAB**

Schedule 4

**BEVANTOLOL**

Schedule 4

**BEXAROTENE**

Schedule 4  
Appendix D, clause 2  
Appendix F, clause 4  
Appendix L, clause 2

**BEZAFIBRATE**

Schedule 4

**BEZITRAMIDE**

Schedule 8

**BEZLOTOXUMAB**

Schedule 4

**BHC**

Schedule 6

**BICALUTAMIDE**

Schedule 4

**BICTEGRAVIR**

Schedule 4

**BICYCLOPYRONE**

Schedule 6  
Schedule 5

**BIFENAZATE**

Appendix B, clause 3

**BIFENTHRIN**

Schedule 7  
Schedule 6

**BIFLUORIDES**cross reference: AMMONIUM BIFLUORIDE, AMMONIUM SALTS, POTASSIUM SALTS, SODIUM SALTS

Schedule 7  
Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4  
Appendix J, clause 1

**BIFONAZOLE**

Schedule 4  
Schedule 2

**BILASTINE**

Schedule 4  
Schedule 3

Schedule 2  
Appendix H, clause 1

**BIMATOPROST**

Schedule 4

**BINIMETINIB**

Schedule 4

**BIOALLETHRIN**

Schedule 6  
Schedule 5

**BIORESMETHRIN**

Schedule 5

**BIPERIDEN**

Schedule 4

**1,3‑BIS(2,4‑DIAMINOPHENOXY)PROPANE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**BIS‑ISOBUTYL PEG/PPG‑20/35/AMODIMETICONE COPOLYMER**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**BISMUTH COMPOUNDS**cross reference: BISMUTH CITRATE, BISMUTH FORMIC IODIDE, BISMUTH OXYCHLORIDE, BISMUTH SUBIODIDE

Schedule 4

**BISMUTH SUBNITRATE**

Appendix B, clause 3

**BISOPROLOL**

Schedule 4

***N*,*N*‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,5‑DIMETHANAMINE**cross reference: *N,N*‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,6‑DIMETHANAMINE

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

***N,N*‑BIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,6‑DIMETHANAMINE**cross reference: *N,N*‑bIS(PHENYLMETHYLENE)‑BICYCLO‑(2.2.1)HEPTANE‑2,6‑DIMETHANAMINE

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**BISPYRIBAC**

Schedule 5

**BISTRIFLURON**

Appendix B, clause 3

**BITHIONOL**

cross reference: CAS No. 97-18-7

Schedule 10  
Schedule 6  
Appendix F, clause 4

**BIURET**

Appendix B, clause 3

**BIVALIRUDIN**

Schedule 4

**BIXAFEN**

Schedule 5

**BIXLOZONE**

Appendix B, clause 3

**BLAD (banda de Lupinus albus doce)**

Appendix B, clause 3

**BLEOMYCIN**

Schedule 4

**BLINATUMOMAB**

Schedule 4

**BOCEPREVIR**

Schedule 4

**BOLANDIOL**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**BOLASTERONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**BOLAZINE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**BOLDENONE**cross reference: DEHYDROTESTOSTERONE

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**BOLENOL**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**BOLMANTALATE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**BORAGO OFFICINALIS**cross reference: BORAGE

Schedule 10

**BORIC ACID**cross reference: BORAX, SODIUM BORATE, POTASSIUM BORATE, MEA‑BORATE, MIPA‑BORATE

Schedule 5

Schedule 4  
Appendix E, clause 3  
Appendix F, clause 4

**BORON**cross reference: BORATES, BORAX, BORIC ACID, BORON COMPOUNDS

Schedule 4

**BORON TRIFLUORIDE**

Schedule 7  
Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4  
Appendix J, clause 1

**BORTEZOMIB**

Schedule 4

**BOSCALID**

Appendix B, clause 3

**BOSENTAN**

Schedule 4  
Appendix D, clause 6  
Appendix F, clause 4  
Appendix L, clause 2

**BOSUTINIB**

Schedule 4

**BOTULINUM TOXINS**

Schedule 4

**BOVINE SOMATOTROPHIN**

Appendix B, clause 3

**BPC‑157**

Schedule 4

Appendix D, clause 5

**BRAGANTIA spp**

Schedule 10

**BRENTUXIMAB VEDOTIN**

Schedule 4

**BRETYLIUM TOSILATE**

Schedule 4

**BRETYLIUM TOSYLATE**

cross reference: BRETYLIUM TOSILATE

**BREXPIPRAZOLE**

Schedule 4  
Appendix K, clause 1

**BRIGATINIB**

Schedule 4

**BRIMONIDINE**

Schedule 4  
Schedule 2

**BRINZOLAMIDE**

Schedule 4

**BRIVARACETAM**

cross reference: RACETAMS

Schedule 4  
Appendix K, clause 1

**BRODIFACOUM**

Schedule 7  
Schedule 6  
Appendix J, clause 1

**BROFLANILIDE**

Schedule 6   
Schedule 5

**BROMACIL**

Appendix B, clause 3

**BROMADIOLONE**

Schedule 7  
Schedule 6

Appendix J, clause 1

**BROMAZEPAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)  
Appendix K, clause 1

**BROMETHALIN**

Schedule 7  
Schedule 6

**BROMHEXINE**

Schedule 2

**BROMIDES**

Schedule 4

**BROMINE**

Schedule 7  
Appendix J, clause 1

**1‑(8‑BROMOBENZO[1,2‑B;4,5‑B]DIFURAN‑4‑YL)‑2‑AMINOPROPANE**cross reference: BROMO‑DRAGONFLY (CAS No. 502759-67-3)

Schedule 9

**BROMOCRIPTINE**

Schedule 4

**4‑BROMO‑2,5‑DIMETHOXYPHENETHYLAMINE**cross reference: BDMPEA (CAS No. 66142-81-2)

Schedule 9

**BROMOFORM**

Schedule 6  
Schedule 4  
Appendix E, clause 3  
Appendix F, clause 4

**BROMOPHOS**

Schedule 6

**BROMOPHOS‑ETHYL**

Schedule 6

**BROMOPROPYLATE**

Appendix B, clause 3

**BROMOXYNIL**

Schedule 6

**BROMPHENIRAMINE**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix K, clause 1

**BROMUCONAZOLE**

Schedule 6

Schedule 5

**BROMVALETONE**

Schedule 4

**BROTIANIDE**

Schedule 6

**BRUCINE**

Schedule 7  
Appendix E, clause 3  
Appendix J, clause 1

**BRUGMANSIA** spp.

Schedule 4

**BUCLIZINE**

Schedule 4  
Schedule 3

Appendix K, clause 1

**BUCLOSAMIDE**

cross reference: CAS No. 575-74-6

Schedule 10

**BUDESONIDE**

Schedule 4  
Schedule 2

**BUFEXAMAC**

Schedule 4

**BUFOTENINE**

cross reference: CAS No. 487-93-4

Schedule 9

**BULEVIRTIDE**

Schedule 4

**BUMETANIDE**

Schedule 4

**BUNAMIDINE**

Schedule 6

**BUNIODYL SODIUM**

cross reference: CAS No. 1923-76-8, BUNIODYL BASE (CAS No. 1233-53-0)

Schedule 10

**BUPHENINE**

Schedule 4

**BUPIRIMATE**

Appendix B, clause 3

**BUPIVACAINE**

Schedule 5  
Schedule 4

**BUPRENORPHINE**

Schedule 8  
Appendix K, clause 1

**BUPROFEZIN**

Schedule 5

**BUPROPION**cross reference: AMFEBUTAMONE

Schedule 4

**BUSERELIN**

Schedule 4

**BUSPIRONE**

Schedule 4

**BUSULPHAN**

Schedule 4

**BUTACAINE**

Schedule 4

**BUTACARB**

Schedule 6

**BUTAFENACIL**

Appendix B, clause 3

**BUTAMBEN**  
cross reference: BUTYL AMINOBENZOATE

Schedule 4

**1,4‑BUTANEDIOL**

cross reference: CAS No. 110-63-4

Schedule 10

**BUTHIDAZOLE**

Schedule 5

**BUTOBARBITAL**

Schedule 8  
Appendix K, clause 1

**BUTOBARBITONE**cross reference: BUTOBARBITAL

**BUTOCONAZOLE**

Schedule 4  
Schedule 3  
Appendix H, clause 1

**BUTONITAZENE**

cross reference: CAS No. 95810-54-1

Schedule 9

**BUTORPHANOL**

Schedule 8

**BUTOXYCARBOXIM**

Schedule 6  
Schedule 5

**2‑BUTOXYETHANOL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**BUTOXYPOLYPROPYLENE GLYCOL**

Appendix B, clause 3

**2‑BUTOXY‑2**'**‑THIOCYANODIETHYL ETHER**

Schedule 6  
Appendix F, clause 4

**BUTRACONAZOLE**

Schedule 4

**BUTRALIN**

Schedule 5

**BUTROXYDIM**

Schedule 5

***n*‑BUTYL ALCOHOL**

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**BUTYL AMINOBENZOATE**cross reference BUTAMBEN

**BUTYL BENZYL PHTHALATE**

cross reference: CAS No. 85-68-7

Schedule 10

***n*‑BUTYL BUTYRATE**

Appendix B, clause 3

***n*‑BUTYL LACTATE**

Appendix B, clause 3

**BUTYL NITRITE**

Schedule 4  
Appendix E, clause 3

**BUTYLCHLORAL HYDRATE**

Schedule 4

**BUTYRIC ACID**

Schedule 6

**C**

**CABAZITAXEL**

Schedule 4

**CABERGOLINE**

Schedule 4

**CABOTEGRAVIR**

Schedule 4

**CABOZANTINIB**

Schedule 4

**CACALIA spp.**

Schedule 10

**CACODYLIC ACID**

Schedule 7  
Schedule 6

**CADMIUM COMPOUNDS**cross reference: CADMIUM, CADMIUM ACETATE, CADMIUM CHLORIDE, CADMIUM NITRATE

Schedule 6  
Schedule 4  
Appendix E, clause 3

**CADUSAFOS**

Schedule 7  
Schedule 6

**CAFFEINE**cross reference: PARACETAMOL, ASPIRIN, SALICYLAMIDE

Schedule 6  
Schedule 4

**CAJUPUT OIL**

Schedule 6  
Appendix E, clause 3

**CALCIFEDIOL**

Schedule 4

**CALCIFEROL**

Schedule 7  
Schedule 6  
Appendix J, clause 1

**CALCIPOTRIOL**

Schedule 4

**CALCITONIN SALMON**

Schedule 4

**CALCITRIOL**

Schedule 4

**CALCIUM CARBIMIDE**

Schedule 4

**CALCIUM HYDROXYLAPATITE**

Schedule 4

**CALCIUM POLYSTYRENE SULPHONATE**

Schedule 4

**CALOTROPIS GIGANTEA**

Schedule 4

**CALOTROPIS PROCERA**

Schedule 4

**CALUSTERONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**CAMBENDAZOLE**

Schedule 6

**CAMPHOR**cross reference: ESSENTIAL OILS, LAVANDIN OIL, ROSEMARY OIL, SHUI OIL

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**CAMPHORATED OIL**

Schedule 4

**CAMPHOTAMIDE**

Schedule 4

**CANAGLIFLOZIN**

Schedule 4

**CANAKINUMAB**

Schedule 4

**CANDESARTAN CILEXETIL**

Schedule 4

**CANDICIDIN**

Schedule 4

**CANINE TICK ANTI‑SERUM**

Schedule 4

**CANNABICHROMENE**cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

**CANNABIDIOL**cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

Schedule 4  
Schedule 3  
Appendix F, clause 4

**CANNABIDIOLIC ACID**cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

**CANNABIDIVAROL**cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

**CANNABIGEROL**cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

**CANNABINOIDS**cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

**CANNABINOL**cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS

**CANNABIS**cross reference: CANNABIS SATIVA, HEMP, HEMP SEED OIL, TETRAHYDROCANNABINOLS

Schedule 9  
Schedule 8  
Appendix D, clause 1  
Appendix K, clause 1

**CANTHARIDIN**

Schedule 4  
Appendix G, clause 1

**CAPECITABINE**

Schedule 4

**CAPREOMYCIN**

Schedule 4

**CAPROMORELIN**

Schedule 4

Appendix D, clause 5

**CAPTAFOL**

Schedule 7  
Appendix J, clause 1

**CAPTAN**

Schedule 6

**CAPTODIAME**

Schedule 4

**CAPTOPRIL**

Schedule 4

**CAPURIDE**

Schedule 4

**CARAMIPHEN**

Schedule 4

**CARBACHOL**

Schedule 4

**CARBADOX**

Schedule 7  
Appendix J, clause 1

**CARBAMAZEPINE**

Schedule 4

**CARBAMIDE PEROXIDE**

cross reference: CAS No. 124-43-6

Schedule 10  
Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**CARBARYL**

Schedule 6  
Schedule 5  
Schedule 4

**CARBAZOCHROME**

Schedule 4

**CARBENDAZIM**

Schedule 7

**CARBENICILLIN**

Schedule 4

**CARBENOXOLONE**

Schedule 4

**CARBETAMIDE**

Schedule 6

**CARBETAPENTANE**

Schedule 2

**CARBETOCIN**

Schedule 4

**CARBIDOPA**

Schedule 4

**CARBIMAZOLE**

Schedule 4

**CARBOCISTEINE**

Schedule 2

**CARBOCROMEN**

Schedule 4

**CARBOFURAN**

Schedule 7

**CARBON DISULFIDE**

Schedule 6  
Appendix E, clause 3

**CARBON TETRACHLORIDE**

Schedule 7  
Appendix E, clause 3  
Appendix F, clause 4  
Appendix J, clause 1

**CARBONYL SULFIDE**

Schedule 7

Appendix J, clause 1

**CARBOPHENOTHION**

Schedule 7

**CARBOPLATIN**

Schedule 4

**CARBOPROST**

Schedule 4

**CARBOSULFAN**

Schedule 7

**CARBOXIN**

Appendix B, clause 3

**CARBROMAL**

Schedule 4

**CARBUTAMIDE**

Schedule 4

**CARBUTEROL**

Schedule 4

**CARDARINE**

cross reference: CAS No. 317318-70-0

Schedule 10

**CARFENTANYL**

Schedule 8

**CARFENTRAZONE‑ETHYL**

Appendix B, clause 3

**CARFILZOMIB.**

Schedule 4

**CARGLUMIC ACID**

Schedule 4

**CARINDACILLIN**

Schedule 4

**CARIPRAZINE**

Schedule 4

**CARISOPRODOL**

Schedule 4

**CARMUSTINE**

Schedule 4

**CARNIDAZOLE**

Schedule 4

**CARPROFEN**

Schedule 4

**CARVEDILOL**

Schedule 4

**CASIRIVIMAB**

Schedule 4

**CASPOFUNGIN**

Schedule 4

**CASSIA OIL**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**CASTOR OIL, MONOMALEATE**

Schedule 6

**CATHINE**

Schedule 4

**CATHINONES**cross reference: SYNTHETIC CATHINONES

Schedule 9

**CATUMAXOMAB**

Schedule 4

**CEDAZURIDINE**

Schedule 4

**CEFACETRILE**cross reference: CEPHACETRILE

Schedule 4

**CEFACLOR**

Schedule 4

**CEFADROXIL**

Schedule 4

**CEFALEXIN**cross reference: CEPHALEXIN

Schedule 4

**CEFALORIDINE**cross reference: CEPHALORIDINE

Schedule 4

**CEFALOTIN**cross reference: CEPHALOTHIN, CEFALOTHIN

Schedule 4

**CEFAMANDOLE**cross reference: CEPHAMANDOLE

Schedule 4

**CEFAPIRIN**cross reference: CEPHAPIRIN

Schedule 4

**CEFAZOLIN**cross reference: CEPHAZOLIN

Schedule 4

**CEFEPIME**

Schedule 4

**CEFETAMET**

Schedule 4

**CEFIXIME**

Schedule 4

**CEFODIZIME**

Schedule 4

**CEFONICID**

Schedule 4

**CEFOPERAZONE**

Schedule 4

**CEFOTAXIME**

Schedule 4

**CEFOTETAN**

Schedule 4

**CEFOTIAM**

Schedule 4

**CEFOVECIN**

Schedule 4

**CEFOXITIN**

Schedule 4

**CEFPIROME**

Schedule 4

**CEFPODOXIME**

Schedule 4

**CEFQUINOME**

Schedule 4

**CEFSULODIN**

Schedule 4

**CEFTAROLINE FOSAMIL**

Schedule 4

**CEFTAZIDIME**

Schedule 4

**CEFTIBUTEN**

Schedule 4

**CEFTIOFUR**

Schedule 4

**CEFTRIAXONE**

Schedule 4

**CEFUROXIME**

Schedule 4

**CELECOXIB**

Schedule 4  
Schedule 3  
Appendix H, clause 1

**CELIPROLOL**

Schedule 4

**CELLULASE derived from Aspergillus niger**

Appendix B, clause 3

**CENEGERMIN**

Schedule 4

**CEPHAELIS ACUMINATA**cross reference: IPECACUANHA, CARAPICHEA IPECACUANHA

Schedule 4

**CEPHAELIS IPECACUANHA**cross reference: IPECACUANHA, CARAPICHEA IPECACUANHA

Schedule 4

**CEPHALEXIN**cross reference: CEFALEXIN

**CEPHALONIUM**

Schedule 4

**CEPHALOTHIN**cross reference: CEFALOTIN

**CEPHRADINE**

Schedule 4

**CERAMICS**

Appendix A, clause 1

**CERITINIB**

Schedule 4

**CERIVASTATIN**

Schedule 4

**CERLIPONASE ALFA**

Schedule 4

**CERTOLIZUMAB PEGOL**

Schedule 4

**CERULETIDE**

Schedule 4

**CETIRIZINE**

Schedule 4  
Schedule 2  
Appendix K, clause 1

**CETRORELIX**

Schedule 4

**CETUXIMAB**

Schedule 4

**CETYL ALCOHOL**

Appendix B, clause 3

**CHAMOMILE OIL**

Appendix B, clause 3

**CHEMISTRY SETS**

Appendix A, clause 1

**CHENODEOXYCHOLIC ACID**

Schedule 4

**CHINA CLAY**

Appendix B, clause 3

**CHLOPHEDIANOL**

Schedule 2

**CHLORAL FORMAMIDE**

Schedule 4

**CHLORAL HYDRATE**

Schedule 4  
Appendix K, clause 1

**CHLORALOSE**cross reference: ALPHA‑CHLORALOSE

Schedule 6  
Schedule 4

**CHLORAMBUCIL**

Schedule 4

**CHLORAMPHENICOL**

Schedule 4  
Schedule 3

**CHLORANDROSTENOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**CHLORANTRANILIPROLE**

Appendix B, clause 3

**CHLORAZANIL**

Schedule 4

**CHLORBUTANOL**

Schedule 3  
Schedule 2

**CHLORBUTOL**cross reference: CHLOROBUTANOL

**CHLORCYCLIZINE**

Schedule 4

**CHLORDANE**

Schedule 6

**CHLORDECONE**

Schedule 7  
Appendix J, clause 1

**CHLORDIAZEPOXIDE**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)  
Appendix K, clause 1

**CHLORDIMEFORM**

Schedule 7  
Appendix J, clause 1

**CHLORFENAC**

Schedule 5

**CHLORFENAPYR**

Schedule 7  
Schedule 6  
Schedule 5

**CHLORFENETHOL**

Schedule 6

**CHLORFENSON**

Schedule 5

**CHLORFENVINPHOS**

Schedule 7

**CHLORFLUAZURON**

Appendix B, clause 3

**CHLORFLURENOL**

Appendix B, clause 3

**CHLORHEXIDINE**

Schedule 7  
Schedule 6  
Schedule 5

**CHLORIDAZON**

Appendix B, clause 3

**CHLORIDE**

Appendix E, clause 3

**CHLORINATING COMPOUNDS**cross reference:BLEACHES, BROMOCHLORODIMETHYLHYDANTOIN, TRICHLOROISOCYANURIC ACID, CALCIUM HYPOCHLORITE, CHLORINE, DICHLOROETHYL ETHER, SODIUM HYPOCHLORITE

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4  
Appendix J, clause 1

**CHLORINE**cross reference: CHLORINATING COMPOUNDS, DICHLOROISOCYANURATES, DICHLOROISOCYANURIC ACID

Schedule 7  
Appendix G, clause 1  
Appendix J, clause 1

**CHLORMEQUAT**

Schedule 6

**CHLORMERODRIN**

Schedule 4

**CHLORMETHIAZOLE**

Schedule 4  
Appendix K, clause 1

**CHLORMEZANONE**

Schedule 4

**CHLORNIDINE**

Schedule 5

**CHLOROACETAMIDE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**CHLOROCRESOL**

Schedule 5  
Appendix E, clause 3

**2‑CHLORO‑6‑(ETHYLAMINO)‑4‑NITROPHENOL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**CHLOROFORM**

Schedule 6  
Schedule 4  
Schedule 2  
Appendix E, clause 3  
Appendix F, clause 4

**4‑CHLOROMETHANDIENONE**

Schedule 4  
Appendix D, clause D (Anabolic and/or androgenic steroidal agents)

**CHLOROMETHIURON**

Schedule 7  
Appendix J, clause 1

**5‑CHLORO‑3‑METHYL‑4‑NITROPYRAZOLE**

Schedule 7

**2‑CHLORO‑5‑NITRO‑N‑HYDROXYETHYL‑*p*‑PHENYLENEDIAMINE**  
cross reference: PHENYLENEDIAMINES

**CHLOROPHACINONE**

Schedule 6

**2‑(4‑CHLOROPHENYL)‑(1,2,4)TRIAZOLO[5,1‑A]ISOQUINOLINE**

Schedule 4

**CHLOROPICRIN**

Schedule 7  
Schedule 6

**CHLOROPICRIN**

Appendix J, clause 1

**CHLOROQUINE**

Schedule 4

**CHLOROTHALONIL**

Schedule 6

**CHLOROTHIAZIDE**

Schedule 4

**4‑CHLORO‑*o*‑TOLUIDINE**

Schedule 7  
Appendix J, clause 1

**CHLOROTRIANISENE**

Schedule 4

**2‑CHLORO‑6‑(TRICHLOROMETHYL)‑PYRIDINE**

Schedule 6

**CHLOROXYDIENONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**CHLOROXYLENOLS**

Appendix B, clause 3

**CHLORPHENAMINE**cross reference: CHLORPHENIRAMINE

Schedule 4  
Schedule 3  
Schedule 2  
Appendix K, clause 1

**CHLORPHENIRAMINE**cross reference: CHLORPHENAMINE

**CHLORPHENTERMINE**

Schedule 4

**CHLORPROMAZINE**

Schedule 4  
Appendix K, clause 1

**CHLORPROPAMIDE**

Schedule 4

**CHLORPROPHAM**

Schedule 5

**CHLORPROTHIXENE**

Schedule 4

**CHLORPYRIFOS**

Schedule 6  
Schedule 5

**CHLORPYRIFOS‑METHYL**

Schedule 6

**CHLORQUINALDOL**

Schedule 4

**CHLORSULFURON**

Schedule 5

**CHLORTALIDONE**

Schedule 4

**CHLORTETRACYCLINE**

Schedule 5  
Schedule 4

**CHLORTHAL‑DIMETHYL**

Schedule 5

**CHLORTHALIDONE**cross reference: CHLORTALIDONE

**CHLORTHIAMID**

Schedule 6

**CHLORTHIOPHOS**

Schedule 7

**CHLORZOXAZONE**

Schedule 4

**CHOLECALCIFEROL**cross reference: COLECALCIFEROL

Schedule 7  
Appendix J, clause 1

**CHOLERA VACCINE**

Schedule 4

**CHOLESTYRAMINE**cross reference: COLESTYRAMINE

**CHOLIC ACID**

Schedule 4

**CHOLINE SALICYLATE**

Schedule 2

**CHROMATES**cross reference: AMMONIUM CHROMATE, BARIUM CHROMATE, CHROMIUM, COPPER‑CHROME‑ARSENIC, DICHROMATES, POTASSIUM CHROMATE, ZINC CHROMATE SODIUM CHROMATE, STRONTIUM CHROMATE

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**CHROMIUM TRICHLORIDE HEXAHYDRATE**

Schedule 6

**CHROMIUM TRIOXIDE**cross reference: CHROMIC ACID

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**CHRYSOIDINE BASE**

cross reference: CAS No. 495-54-5

Schedule 10  
Schedule 6  
Appendix E, clause 3

**CHYMOPAPAIN**

Schedule 4

**CICLACILLIN**

Schedule 4

**CICLESONIDE**

Schedule 4

**CICLOPIROX**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix H, clause 1

**CICLOSPORIN**

Schedule 4

**CIDOFOVIR**

Schedule 4

**CILASTATIN**

Schedule 4

**CILAZAPRIL**

Schedule 4

**CILGAVIMAB**

Schedule 4

**CILOSTAZOL**

Schedule 4

**CIMETIDINE**

Schedule 4  
Schedule 3  
Appendix F, clause 4

**CIMICOXIB**

Schedule 4

**CINACALCET**

Schedule 4

**CINCHOCAINE**

Schedule 4  
Schedule 2

**CINCHOPHEN**

cross reference: CAS No. 132-60-5, CINCHOPHEN HYDROCHLORIDE (CAS No. 132-58-1), CINCHOPHEN SODIUM (CAS No. 5949-18-8)

Schedule 10

**CINEOLE**cross reference: CAMPHOR OIL (white), ROSEMARY OIL

Schedule 7  
Appendix E, clause 3

**CINMETHYLIN**

Schedule 5

**CINNAMEDRINE**

Schedule 2

**CINNAMON BARK OIL**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**CINNAMON LEAF OIL**

Schedule 6  
Appendix E, clause 3

**CINNARIZINE**

Schedule 4

**CINOXACIN**

Schedule 4

**CIPROFLOXACIN**

Schedule 4

**CISAPRIDE**

Schedule 4

**CISATRACURIUM BESILATE**cross reference: CISATRACURIUM BESYLATE

Schedule 4

**CIS‑JASMONE**cross reference: (Z)‑JASMONE

Schedule 5

**CISPLATIN**

Schedule 4

**CITALOPRAM**

Schedule 4

**CITRONELLA OIL**

Appendix B, clause 3

**CJC‑1295 (CAS No. 863288‑34‑0)**

Schedule 4  
Appendix D, clause 5

**CLADRIBINE**

Schedule 4

**CLANOBUTIN**

Schedule 4

**CLARITHROMYCIN**

Schedule 4

**CLARY SAGE OIL**

Appendix B, clause 3

**CLASCOTERONE**

Schedule 4

**CLAVULANIC ACID**

Schedule 4

**CLEMASTINE**

Schedule 4  
Schedule 3  
Appendix K, clause 1

**CLEMIZOLE**

Schedule 4

**CLENBUTEROL**

Schedule 4

**CLETHODIM**

Schedule 5

**CLEVIDIPINE**

Schedule 4

**CLIDINIUM BROMIDE**

Schedule 4

**CLIMBAZOLE**

Schedule 6  
Schedule 5  
Appendix E, clause 3

**CLINDAMYCIN**

Schedule 4

**CLIOQUINOL**  
cross reference: OXYQUINOLINE, CHLORQUINALDOL, HALQUINOL (CAS No. 130-26-7)

Schedule 10  
Schedule 4

**CLITORIA TERNATEA EXTRACT**

Appendix B, clause 3

**CLOBAZAM**

Schedule 4

**CLOBETASOL**

Schedule 4

**CLOBETASONE**

Schedule 4  
Schedule 3  
Appendix F, clause 4

Appendix H, clause 1

**CLOCORTOLONE**

Schedule 4

**CLODINAFOP‑PROPARGYL**

Schedule 6

**CLODRONIC ACID**cross reference: SODIUM CLODRONATE

Schedule 4

**CLOFARABINE**

Schedule 4

**CLOFAZIMINE**

Schedule 4

**CLOFENAMIDE**

Schedule 4

**CLOFENTEZINE**

Schedule 5

**CLOFIBRATE**

Schedule 4

**CLOMAZONE**

Schedule 6

**CLOMIFENE**cross reference: CLOMIPHENE

Schedule 4  
Appendix D, clause 1

**CLOMIPHENE**cross reference: CLOMIFENE

**CLOMIPRAMINE**

Schedule 4  
Appendix K, clause 1

**CLOMOCYCLINE**

Schedule 4

**CLONAZEPAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)  
Appendix K, clause 1

**CLONAZOLAM**

cross reference: CAS No. 33887-02-4

Schedule 9

**CLONIDINE**

Schedule 4  
Appendix K, clause 1

**CLONITAZENE**

cross reference: CAS No. 3861-76-5

Schedule 9

**CLOPAMIDE**

Schedule 4

**CLOPIDOGREL**

Schedule 4

**CLOPIDOL**

Appendix B, clause 3

**CLOPROSTENOL**

Schedule 4

**CLOPYRALID**

Schedule 5

**CLOQUINTOCET**

Schedule 5

**CLORAZEPATE**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)  
Appendix K, clause 1

**CLOREXOLONE**

Schedule 4

**CLORPRENALINE**

Schedule 4

**CLORSULON**

Schedule 5

**CLOSANTEL**

Schedule 6

**CLOSTEBOL**cross reference: 4‑CHLOROTESTOSTERONE

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**CLOTHIANIDIN**

Schedule 6  
Schedule 5

**CLOTRIMAZOLE**

Schedule 6  
Schedule 4  
Schedule 3  
Schedule 2  
Appendix F, clause 4  
Appendix H, clause 1

**CLOVE OIL**

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**CLOXACILLIN**

Schedule 4

**CLOZAPINE**

Schedule 4  
Appendix D, clause 1  
Appendix K, clause 1

**COAL TAR**

Schedule 10

**COBALT**cross reference: DICOBALT EDETATE

Schedule 4

**COBALT NAPHTHENATE**

Appendix B, clause 3

**COBICISTAT**

Schedule 4

**COBIMETINIB**

Schedule 4

**COCA LEAF**

Schedule 9

**COCAINE**

Schedule 8

***N*‑COCO‑1,3‑DIAMINOPROPANE**

Schedule 6

**COCOYL GLYCINATE**

Schedule 6  
Appendix E, clause 3

**COCOYL METHYL GLUCAMAIDE**cross reference: 1‑DEOXY‑1‑(METHYLAMINO)‑D‑GLUCITOL *N*‑COCO ACYL DERIVATIVES

**CODEINE**

Schedule 8  
Schedule 4  
Appendix K, clause 1

**CODEINE‑*N*‑OXIDE**

Schedule 8

**CO‑DERGOCRINE**

Schedule 4

**CODOXIME**

cross reference: CAS No. 7125-76-0

Schedule 9

**COLASPASE**cross reference:ASPARAGINASE

**COLCHICINE**

Schedule 4

**COLCHICUM AUTUMNALE**

Schedule 4

**COLECALCIFEROL**cross reference: CHOLECALCIFEROL

Schedule 7  
Appendix J, clause 1

**COLESTIPOL**

Schedule 4

**COLESTYRAMINE**

Schedule 4

**COLFOSCERIL PALMITATE**

Schedule 4

**COLISTIN**

Schedule 4

**COLLAGEN**

Schedule 4

**COLLAGENASE CLOSTRIDIUM HISTOLYTICUM**

Schedule 4

**COLURACETAM**cross reference: RACETAMS

Schedule 4

**CONCENTRATE OF POPPY STRAW**

Schedule 8

**CONCIZUMAB**

Schedule 4

**CONIUM MACULATUM**cross reference: CONIINE (CAS No. 3238-60-6), CONIINE R-ISOMER (CAS No. 5985-99-9), CONIINE S-ISOMER (CAS No. 458-88-8)

Schedule 10

**CONVALLARIA KEISKI**

Schedule 4

**CONVALLARIA MAJALIS**

Schedule 4

**COPPER ACETATE**

Schedule 6  
Schedule 5

**COPPER COMPOUNDS**cross reference: COPPER

Schedule 6  
Schedule 5  
Schedule 4  
Appendix A, clause 1

**COPPER HYDROXIDE**

Schedule 6  
Schedule 5

**COPPER NITRATE**cross reference: COPPER CHLORIDE

Schedule 6

**COPPER OXIDES**

Schedule 6  
Schedule 5

**COPPER OXYCHLORIDE**

Schedule 6  
Schedule 5

**COPPER SULFATE**

Schedule 6  
Schedule 5  
Appendix E, clause 3

**CORIFOLLITROPIN ALFA**cross reference: FOLLICLE STIMULANT, RECOMBINANT

Schedule 4  
Appendix D, clause 1

**CORONILLA spp.**

Schedule 4

**CORTICOSTERONE**

Schedule 4

**CORTICOTROPHIN**

Schedule 4

**CORTISONE**

Schedule 4

**COTARNINE**

cross reference: CAS No. 82-54-2, COTARNINE HYDROCHLORIDE (CAS No. 36647-02-6), COTARNINE CHLORIDE (CAS No. 10018-19-6)

Schedule 10

**CO‑TRIMOXAZOLE**

Schedule 4

**COUMAPHOS**

Schedule 7  
Schedule 6

**COUMARIN**

Schedule 4

**COUMATETRALYL**

Schedule 7  
Schedule 6  
Schedule 5   
Appendix J, clause 1

**4‑CPA**

Schedule 5

**CREOSOTE**cross reference: BEECHWOOD, PHENOL, WOOD

Schedule 7  
Schedule 6  
Schedule 2  
Appendix E, clause 3

**CRESOLS**

Appendix E, clause 3

**CRISABOROLE**

Schedule 4

**CRIZOTINIB**

Schedule 4

**CROFELEMER**

Schedule 4

**CROSPOVIDONE**

Appendix B, clause 3

**CROTALARIA spp.**

Schedule 10

**CROTON TIGLIUM**cross reference: CROTON OIL

Schedule 10  
Appendix G, clause 1

**CROTOXYPHOS**

Schedule 6

**CRUFOMATE**

Schedule 6

**CRYSTAL VIOLET**cross reference: METHYLROSANILINIUM CHLORIDE, GENTIAN VIOLET

**CULICINOMYCES CLAVOSPORUS**

Appendix B, clause 3

**CUPRIMYXIN**

Schedule 4

**CURARE**

Schedule 4

**13C‑UREA**

Appendix B, clause 3

**CYANAMIDE**

Schedule 6

**CYANATRYN**

Schedule 5

**CYANAZINE**

Schedule 6

**CYANIDES**cross reference: FERRICYANIDES, FERROCYANIDES

Schedule 7  
Appendix E, clause 3  
Appendix F, clause 4

**CYANOACRYLATE ESTERS**

Schedule 5

**CYANOACRYLIC ACID ESTERS**

Appendix E, clause 3

**4‑CYANO‑2‑DIMETHYLAMINO‑4,4**'**‑DIPHENYLBUTANE**cross reference: METHADONE INTERMEDIATE (CAS No. 125-79-1)

Schedule 9

**CYANOGEN**cross reference: ETHANEDINITRILE, OXALONITRILE

Schedule 7  
Appendix J, clause 1

**4‑CYANO‑1‑METHYL‑4‑PHENYLPIPERIDINE**cross reference: PETHIDINE INTERMEDIATE A

Schedule 8

**CYANTRANILIPROLE**

Schedule 5

**CYANURIC ACID**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**CYAZOFAMID**

Schedule 5

**CYCLAMIC ACID**

Appendix B, clause 3

**CYCLANDELATE**

Schedule 4

**CYCLANILIDE**

Schedule 6

**CYCLANILIPROLE**

Appendix B

**CYCLIZINE**

Schedule 4  
Schedule 3  
Appendix K, clause 1

**CYCLOBARBITAL**

Schedule 8  
Appendix K, clause 1

**CYCLOBARBITONE**  
cross reference: CYCLOBARBITAL

**CYCLOBENZAPRINE**

Schedule 4

**CYCLOBUTRIFLURAM**

Appendix B, clause 3

**CYCLOFENIL**

Schedule 4  
Appendix D, clause 1

**CYCLOHEXANE**

Appendix B, clause 3

**CYCLOHEXANOL ACETATE**

Appendix B, clause 3

**CYCLOHEXANONE PEROXIDE**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**CYCLOHEXIMIDE**

Schedule 4

**N‑CYCLOHEXYLDIAZENIUMDIOXY‑POTASSIUM**cross reference: K‑HDO

Schedule 6

**CYCLOHEXYLPHENOLS**

Schedule 9

**CYCLOPENTHIAZIDE**

Schedule 4

**CYCLOPENTOLATE**

Schedule 4

**CYCLOPHOSPHAMIDE**

Schedule 4

**CYCLOPROPANE**

Schedule 4

**CYCLOPROTHRIN**

Schedule 5

**CYCLOSERINE**

Schedule 4  
Appendix J, clause 1

**CYCLOSILAZANES, DI‑ME, ME HYDROGEN, POLYMERS WITH DI‑ME, ME HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3‑(TRIETHOXYSILYL)‑1‑PROPANAMINE (CAS 475645‑84‑2)**

Schedule 7  
Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**CYCLOSPORIN**cross reference: CICLOSPORIN

**CYCLOTHIAZIDE**

Schedule 4

**CYCLOXYDIM**

Schedule 5

**CYCRIMINE**

Schedule 4  
Appendix E, clause 3  
Appendix F, clause 4

**CYFLUFENAMID**

Schedule 5

**CYFLUMETOFEN**

Schedule 5

**CYFLUTHRIN**

Schedule 6  
Schedule 5

**CYHALOFOP‑BUTYL**

Schedule 5

**CYHALOTHRIN**

Schedule 7

**CYHEXATIN**

Schedule 7

**CYMARIN**

Schedule 4

**CYMIAZOLE**

Schedule 5

**CYNOGLOSSUM spp.**

Schedule 10

**CYOMETRINIL**

Schedule 6

**CYPERMETHRIN**cross reference: ALPHA‑CYPERMETHRIN AND BETA‑CYPERMETHRIN, ZETA‑CYPERMETHRIN

Schedule 6  
Schedule 5

**CYPHENOTHRIN**

Schedule 6  
Schedule 5

***CYPRINID HERPESVIRUS‑3***

Appendix B, clause 3

**CYPROCONAZOLE**

Schedule 5

**CYPRODINIL**

Schedule 5

**CYPROHEPTADINE**

Schedule 4  
Schedule 3  
Appendix K, clause 1

**CYPROTERONE**

Schedule 4

**CYROMAZINE**

Appendix B, clause 3

**CYSTEAMINE**cross reference: MERCAPTAMINE

**CYTARABINE**

Schedule 4

**CYTHIOATE**

Schedule 6  
Schedule 5

**D**

**2,4‑D**

Schedule 6  
Schedule 5

**DABIGATRAN**

Schedule 4

**DABRAFENIB MESILATE**

Schedule 4

**DACARBAZINE**

Schedule 4

**DACLATASVIR**

Schedule 4

**DACLIZUMAB**

Schedule 4

**DACTINOMYCIN**

Schedule 4

**DALFOPRISTIN**

Schedule 4

**DALTEPARIN**

Schedule 4

**DAMINOZIDE**

Schedule 5

**DANAPAROID**

Schedule 4

**DANAZOL**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**DANTHRON**

Schedule 4

**DANTROLENE**

Schedule 4

Appendix K, clause 1

**DAPAGLIFLOZIN**

Schedule 4

**DAPOXETINE**

Schedule 4

**DAPSONE**

Schedule 4

**DAPTOMYCIN**

Schedule 4

**DARATUMUMAB**

Schedule 4

**DARBEPOETIN**

Schedule 4  
Appendix D, clause 5

**DARIFENACIN**

Schedule 4

**DAROLUTAMIDE**

Schedule 4

**DARUNAVIR**

Schedule 4

**DASABUVIR**

Schedule 4

**DASATINIB**

Schedule 4

**DATURA spp.**

Schedule 4  
Schedule 2

**DATURA STRAMONIUM**cross reference: STRAMONIUM

Schedule 4  
Schedule 2

**DATURA TATULA**cross reference: STRAMONIUM

Schedule 4  
Schedule 2

**DAUNORUBICIN**

Schedule 4

**DAZOMET**

Schedule 6

**2,4‑DB**

Schedule 5

**DEANOL**cross reference: 2‑(DIMETHYLAMINO)ETHANOL, DMEA, DIMETHYL MEA

Schedule 4

**DEBRISOQUINE**

Schedule 4

**DECAMETHONIUM**

Schedule 4

**DECITABINE**

Schedule 4

**DECOQUINATE**

Schedule 5

**DEFERASIROX**

Schedule 4

**DEFERIPRONE**

Schedule 4

**DEFIBROTIDE**

Schedule 4

**DEFLAZACORT**

Schedule 4

**DEGARELIX**

Schedule 4

**DEHYDROCHLOROMETHYLTESTOSTERONE**cross reference: CHLOROMESTERONE

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**DEHYDROCORTICOSTERONE**

Schedule 4

**DELAVIRDINE**cross reference: DELAVIRDINE MESILATE

**DELAVIRDINE MESILATE**

Schedule 4

**DELPHINIUM STAPHISAGRIA**cross reference: STAPHISAGRIA

Schedule 2

**DELTAMETHRIN**

Schedule 7  
Schedule 6  
Schedule 5

**DEMBREXINE**

Schedule 5  
Schedule 4

**DEMECARIUM**

Schedule 4

**DEMECLOCYCLINE**

Schedule 4

**DEMETON**

Schedule 7

**DEMETON‑O‑METHYL**

Schedule 7

**DEMETON‑S‑METHYL**

Schedule 7

**DENGUE VACCINE**  
cross reference: LIVE ATTENUATED CHIMERIC DENGUE VIRUS (SEROTYPES 1, 2, 3 and 4)

Schedule 4

**DENOSUMAB**

Schedule 4

**DEOXYCHOLIC ACID**

Schedule 4

**DEOXYCORTONE**

Schedule 4

**1‑DEOXY‑1‑(METHYLAMINO)‑*D*‑GLUCITOL *N*‑COCO ACYL DERIVATIVES**  
cross reference: COCOYL METHYL GLUCAMAIDE

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**DEOXYRIBONUCLEASE**

Schedule 4

**DERACOXIB**

Schedule 4

**DERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE EXTRACT**

Schedule 4

**DERQUANTEL**

Schedule 6

**2,4‑DES**

Schedule 5

**DESCHLOROETIZOLAM**

cross reference: CAS No. 40054-73-7

Schedule 9

**DESFERRIOXAMINE**

Schedule 4

**DESFLURANE**

Schedule 4

**DESIPRAMINE**

Schedule 4  
Appendix K, clause 1

**DESIRUDIN**

Schedule 4

**DESLANOSIDE**

Schedule 4

**DESLORATADINE**

Schedule 4  
Schedule 2

**DESLORELIN**

Schedule 4

**DESMOPRESSIN**cross reference: D.D.A.V.P.

Schedule 4

**DESOGESTREL**

Schedule 4

**DESOMORPHINE**

cross reference: CAS No. 427-00-9

Schedule 9

**DESONIDE**

Schedule 4

**DESOXYMETHASONE**

Schedule 4

**DESVENLAFAXINE**

Schedule 4

**DETOMIDINE**

Schedule 4

**DEUCRAVACITINIB**

Schedule 4

**DEUTETRABENAZINE**

Schedule 4  
Appendix K, clause 1

**DEXAMETHASONE**

Schedule 4

**DEXAMFETAMINE**cross reference: DEXAMPHETAMINE

Schedule 8

**DEXCHLORPHENAMINE**cross reference: DEXCHLORPHENIRAMINE

Schedule 4  
Schedule 3  
Schedule 2  
Appendix K, clause 1

**DEXCHLORPHENIRAMINE**cross reference: DEXCHLORPHENAMINE

**DEXFENFLURAMINE**

Schedule 4

**DEXMEDETOMIDINE**

Schedule 4

**DEXTRANS**

Appendix A

**DEXTROMETHORPHAN**

Schedule 4  
Schedule 2

**DEXTROMORAMIDE**cross reference: MORAMIDE

Schedule 8  
Appendix K, clause 1

**DEXTROPROPOXYPHENE**

Schedule 8  
Schedule 4  
Appendix D, clause 5  
Appendix K, clause 1

**DEXTRORPHAN**

Schedule 4

***N*,*N*‑DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES**  
cross reference: 3,4‑DICHLORO‑N‑[(1*R*,2*R*)‑2‑(DIMETHYLAMINO)CYCLOHEXYL]‑*N*‑METHYLBENZAMIDE \*(U‑47700) (CAS No. 82657-23-6)

Schedule 9

***N*,*N*‑DIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES**   
Cross reference: 3,4‑DICHLORO‑*N*‑{[1‑(DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE \*(AH‑7921) (CAS No. 55154-30-8)

Schedule 9

**4,4‑DIAMINODIPHENYLMETHANE**cross reference: METHYLENE DIANILINE

Schedule 7  
Appendix F, clause 4  
Appendix J, clause 1

**2,4‑DIAMINO‑5‑METHYLPHENETOLE**  
cross reference: PHENYLENEDIAMINES

**2,4‑DIAMINOPHENOXYETHANOL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**DIAFENTHIURON**

Schedule 5

**DIALIFOS**

Schedule 7

***N*,*N*‑DIALLYLDICHLOROACETAMIDE**

Schedule 5

**DIAMPROMIDE**

cross reference: CAS No. 552-25-0

Schedule 9

**DIAMTHAZOLE**

Schedule 4

**DIAVERIDINE**

Schedule 4

**DIAZEPAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)  
Appendix K, clause 1

**DIAZINON**

Schedule 6  
Schedule 5

**DIAZOXIDE**

Schedule 4

**DIBENZEPIN**

Schedule 4

**DIBENZOPYRANS**

Schedule 9

**DIBOTERMIN**

Schedule 4

**1,2‑DIBROMO‑3‑CHLOROPROPANE**

Schedule 7  
Appendix J, clause 1

**DIBROMOPROPAMIDINE**

Schedule 4  
Schedule 2

**DIBUTYL PHTHALATE**

cross reference: CAS No. 84-74-2

Schedule 10

**DICAMBA**

Schedule 6  
Schedule 5

**DICLAZEPAM**

cross reference: CAS No. 2894-68-0

Schedule 9

**DICHLOBENIL**

Schedule 6

***o*‑DICHLOROBENZENE**

Appendix F, clause 4

**DICHLOEOETHYL ETHER**

Appendix F, clause 4

**DICHLOFENTHION**

Schedule 6

**DICHLOFLUANID**

Schedule 6

**DICHLONE**

Schedule 5

**DICHLORALPHENAZONE**

Schedule 4

**DICHLOROBENZENE**

Schedule 6  
Schedule 5  
Appendix E, clause 3

**3,4‑DICHLORO‑N‑[(1*R*,2*R*)‑2‑(DIMETHYLAMINO)CYCLOHEXYL]*‑N*‑METHYLBENZAMIDE (U‑47700)**cross reference: *N,N*‑DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES (CAS No. 82657-23-6)

Schedule 9

**DICHLOROETHYL ETHER**

Schedule 6  
Appendix E, clause 3

**DICHLOROETHYLENE**

Appendix F, clause 4

**DICHLOROISOCYANURIC ACID**cross reference: CHLORINE, CHLORINATING COMPOUNDS, DICHLOROISOCYANURATES, SODIUM DICHLOROISOCYANURATE

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**DICHLOROMETHANE**cross reference: METHYLENE CHLORIDE

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**3,4‑DICHLORO‑*N*‑{[1‑DIMETHYLAMINO)CYCLOHEXYL]METHYL}  
BENZAMIDE**cross reference: AH‑7921 (CAS No. 55154-30-8)

Schedule 9

**4,5‑DICHLORO‑2‑N‑OCTYL‑3(2H)‑ISOTHIAZOLONE**

Schedule 6

**DICHLOROPHEN**

Schedule 6  
Schedule 5  
Schedule 4

**2,4‑DICHLORPROP**

Schedule 6

**1,2‑DICHLOROPROPANE**

Schedule 6

**1,3‑DICHLOROPROPENE**

Schedule 7  
Appendix J, clause 1

**DICHLORPHENAMIDE**

Schedule 4

**DICHLORVOS**

Schedule 7  
Schedule 6  
Schedule 5

**DICHROMATES**

Appendix E, clause 3

**DICLAZURIL**

Appendix B, clause 3

**DICLOBUTRAZOL**

Schedule 5

**DICLOFENAC**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix F, clause 4  
Appendix H, clause 1

**DICLOFOP‑METHYL**

Schedule 6

**DICLORAN**

Schedule 5

**DICLOXACILLIN**

Schedule 4

**DICOFOL**

Schedule 5

**DICOPHANE**cross reference: DDT (CAS No. 50-29-3)

Schedule 10

**DICROTOPHOS**

Schedule 7

**DICYCLANIL**

Schedule 6

**DICYCLOMINE**

Schedule 4

**DIDANOSINE**

Schedule 4

**DIDECYLDIMETHYLAMMONIUM SALTS**

Schedule 6

**DIELDRIN**

Schedule 6

**DIENESTROL**

Schedule 4  
Appendix F, clause 4  
Appendix L, clause 2

**DIENOGEST**

Schedule 4

**DIESEL**

Appendix E, clause 3

**DIETHANOLAMINE**

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**DIETHAZINE**

Schedule 4

**DIETHYL CARBONATE**

Appendix B, clause 3

**DIETHYLCARBAMAZINE**

Schedule 4

**DIETHYLENE GLYCOL**cross reference: DENATONIUM BENZOATE (CAS No. 111-46-6)

Schedule 10  
Schedule 6  
Schedule 5

**DIETHYLENE GLYCOL MONOBUTYL ETHER**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**DIETHYLENE GLYCOL MONOMETHYL ETHER**

cross reference: CAS No. 111-77-3

Schedule 10  
Schedule 6

**DIETHYLHEXYL PHTHALATE**

cross reference: DEHP (CAS No. 117-81-7)

Schedule 10

**DIETHYLPHTHALATE**

cross reference: CAS No. 84-66-2

Schedule 10

**DIETHYLPROPION**

Schedule 4

**DIETHYLTHIAMBUTENE**

cross reference: CAS No. 86-14-6, DIETHYLTHIAMBUTENE HYDROCHLORIDE (CAS No. 132-19-4)

Schedule 9

**DIETHYLTOLUAMIDE (DEET)**

Schedule 5  
Appendix F, clause 4

***N,N*‑DIETHYLTRYPTAMINE**cross reference: DET (CAS No. 61-51-8)

Schedule 9

**DIFELIKEFALIN**

Schedule 4  
Appendix K, clause 1

**DIFENACOUM**

Schedule 7  
Schedule 6  
Appendix J, clause 1

**DIFENOCONAZOLE**

Schedule 5

**DIFENOXIN**

Schedule 8  
Schedule 4  
Appendix K, clause 1

**DIFENZOQUAT**

Schedule 6

**DIFETHIALONE**

Schedule 7  
Schedule 6

**DIFLORASONE**

Schedule 4

**DIFLOXACIN**

Schedule 4

**DIFLUBENZURON**

Schedule 5

**DIFLUCORTOLONE**

Schedule 4

**DIFLUFENICAN**

Appendix B, clause 3

**DIFLUNISAL**

Schedule 4

**DIGITALIS LANATA**

Schedule 4

**DIGITALIS PURPUREA**

Schedule 4

**DIGITOXIN**

Schedule 4

**DIGOXIN**

Schedule 4

**DIGOXIN‑SPECIFIC ANTIBODY FRAGMENT F (Ab)**

Schedule 4

**DIHYDRALAZINE**

Schedule 4

**DIHYDROCODEINE**

Schedule 8  
Schedule 4  
Schedule 3  
Appendix K, clause 1

**DIHYDROERGOTOXINE**

Schedule 4

**DIHYDROLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**2,5‑DIHYDRO‑2‑(1‑METHYL‑1‑PHENYLETHYL)‑5‑PENTYL‑1H‑PYRIDO[4,3‑B]INDOL‑1‑ONE (SGT‑151)**cross reference: SGT‑151, CUMYL‑PEGACLONE (CAS No. 2160555-55-3)

Schedule 9

**DIHYDROMORPHINE**

Schedule 8

**DIHYDROSTREPTOMYCIN**

Schedule 4

**DIHYDROTACHYSTEROL**

Schedule 4

**5,6‑DIHYDROXYINDOLINE**

cross reference: CAS No. 29539-03-5, 5,6-DIHYDROXYINDOLINE HYDROBROMIDE (CAS No. 138937-28-7)

Schedule 10  
Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**DIIODOHYDROXYQUINOLINE**cross reference: IODOQUINOL (CAS No. 83-73-8)

Schedule 10  
Schedule 4  
Schedule 3

**DI‑IODOHYDROXYQUINOLINE**cross reference: DIIODOHYDROXYQUINOLINE

**DIISOBUTYL PHTHALATE**

cross reference: CAS No. 84-69-5

Schedule 10

**DIISOPROPYLAMINE DICHLOROACETATE**

Schedule 4

**DIKEGULAC‑SODIUM**

Appendix B, clause 3

**DILTIAZEM**

Schedule 4

**DIMEFOX**

Schedule 7

**DIMENHYDRINATE**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix H, clause 1  
Appendix K, clause 1

**DIMENOXADOL**

cross reference: CAS No. 509-78-4, DIMENOXADOL HYDROCHLORIDE (CAS No. 2424-75-1)

Schedule 9

**DIMEPHEPTANOL**

cross reference: CAS No. 545-90-4

Schedule 9

**DIMERCAPROL**

Schedule 4

**DIMETHANDROSTANOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**DIMETHAZINE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**DIMETHENAMID‑P**

Schedule 6

**DIMETHICODIETHYLBENZALMALONATE**cross reference: POLYSILICONE‑15

Schedule 5

**DIMETHICONE**cross reference: DIMETICONE

**DIMETHINDENE**

Schedule 4  
Appendix K, clause 1

**DIMETHIPIN**

Schedule 6

**DIMETHIRIMOL**

Schedule 5

**DIMETHOATE**

Schedule 6

**DIMETHOMORPH**

Schedule 5

**DIMETHOTHIAZINE**

Schedule 4

**DIMETHOXANATE**

Schedule 4

**2,5‑DIMETHOXYAMFETAMINE**cross reference: 2,5‑DIMETHOXYAMPHETAMINE, DMA (CAS No. 2801-68-5), DMA HYDROCHLORIDE (CAS No. 24973-25-9)

Schedule 9

**2,5‑DIMETHOXY‑4‑BROMOAMFETAMINE**cross reference: 2,5‑DIMETHOXY‑4‑BROMOAMPHETAMINE, DOB (CAS No. 64638-07-9)

Schedule 9

**2,5‑DIMETHOXY‑4‑ETHYL‑a‑AMFETAMINE**cross reference: 2,5‑DIMETHOXY‑4‑ETHYL‑a‑AMPHETAMINE, DOET (CAS No. 22004-32-6), DOET HYDROCHLORIDE (CAS No. 22139-65-7)

Schedule 9

**2,5‑DIMETHOXY‑4‑ETHYLTHIOPHENETHYLAMINE**cross reference: 2C‑T‑2 (CAS No. 207740-24-7)

Schedule 9

**2,5‑DIMETHOXY‑4‑IODOPHENETHYLAMINE**cross reference: 2C‑I (CAS No. 69587-11-7)

Schedule 9

**2,5‑DIMETHOXY‑4‑(*N*)‑PROPYLTHIOPHENETHYLAMINE**cross reference: 2C‑T‑7 (CAS No. 207740-26-9)

Schedule 9

**2,6‑DIMETHOXY‑3,5‑PYRIDINEDIAMINE**

Schedule 6  
Appendix F, clause 4

**DIMETHYLACETAMIDE**

Schedule 6  
Schedule 5

***N,N*‑DIMETHYLAMFETAMINE**cross reference: *N,N*‑DIMETHYLAMPHETAMINE, DIMETAMFETAMINE (CAS No. 4075-96-1), DIMETAMFETAMINE S-ISOMER (CAS No. 17279-39-9)

Schedule 9

**4‑DIMETHYLAMINOAZOBENZENE**cross reference: MOCA, *N,N*‑DIMETHYL‑4‑[PHENYLAZO]‑BENZENAMINE

Schedule 7  
Appendix J, clause 1

**3‑(2‑DIMETHYLAMINOETHYL)‑4‑HYDROXYINDOLE**cross reference: PSILOCINE, PSILOTSIN (CAS No. 520-53-6)

Schedule 9

**1,3‑DIMETHYLAMYLAMINE**cross reference: 4‑METHYLHEXANE‑2‑AMINE, DMAA (CAS No. 105-41-9)

Schedule 10

**1,3‑DIMETHYLBUTYLAMINE (DMBA)**cross reference: OCTODRINE, 1‑AMINOISOHEPTANE, DMHA, 1,5‑DIMETHYLHEXYLAMINE, 4‑METHYLHEXANE‑2‑AMINE, 1,3‑DIMETHYLAMYLAMINE, DMAA, 4‑AMINO‑2‑METHYLPENTANE CITRATE (AMP CITRATE), (CAS No. 108-09-8)

Schedule 10

**4,4‑DIMETHYL‑1‑CYCLOHEXENE‑1‑PROPANAL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**N,N‑DIMETHYLDECANAMIDE**

Schedule 6

**DIMETHYL ETHER**

Appendix B, clause 3

**1‑(1,1‑DIMETHYLETHYL)‑2‑METHOXY‑4‑METHYL‑3,5‑DINITROBENZENE (musk ambrette)**cross reference: AMBER MUSK (CAS No. 83-66-9)

Schedule 10

**DI(METHYLOXYETHYL) PHTHALATE**

cross reference: CAS No. 117-82-8

Schedule 10

**1,4‑DIMETHYLPENTYLAMINE (DMPA)**cross reference: 1,4‑DIMETHYLAMYLAMINE (DMAA) (CAS No. 28292-43-5)

Schedule 10

**DIMETHYLFORMAMIDE**cross reference: DESIGNATED SOLVENT

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**DIMETHYL FUMARATE**

Schedule 4

**3‑(1,2‑DIMETHYLHEPTYL)‑1‑HYDROXY‑7,8,9,10‑TETRAHYDRO‑6,6,9‑ TRIMETHYL‑6*H*‑DIBENZO (b,d) PYRAN**cross reference: DMHP (CAS No. 32904-22-6)

Schedule 9

**1,5‑DIMETHYLHEXYLAMINE (DMHA)**cross reference: 1,3‑DIMETHYLBUTYLAMINE, DMBA, OCTODRINE, 1‑AMINOISOHEPTANE, DMHA, 4‑METHYLHEXANE‑2‑AMINE, 1,3‑DIMETHYLAMYLAMINE, DMAA, 4‑AMINO‑2‑METHYLPENTANE CITRATE (AMP CITRATE), (CAS No. 543-82-8), 1,5-DIMETHYLHEXYLAMINE HYDROCHLORIDE (CAS No. 5984-59-8), 1,5-DIMETHYLHEXYLAMINE S-ISOMER (CAS No. 70419-10-2), 1,5-DIMETHYLHEXYLAMINE R-ISOMER (CAS No. 70419-11-3)

Schedule 10

***N, α* ‑DIMETHYL‑3,4‑(METHYLENEDIOXY)PHENYLETHYLAMINE \*(MDMA)**cross reference: 3,4‑METHYLENEDIOXY‑*N‑α*‑DIMETHYLPHENYLETHYLAMINE, MDMA, MIDOMAFETAMINE (CAS No. 42542-10-9), MDMA HYDROCHLORIDE (CAS No. 64057-70-1)

Schedule 9  
Schedule 8  
Appendix D, clause 5  
Appendix D, clause 10

**3,7‑DIMETHYL‑2,6‑OCTADIENAL**cross reference: CITRAL, NERAL, GERANIAL

Schedule 5

**3,7‑DIMETHYL‑2,6‑OCTADIEN‑1‑OL**  
cross reference: GERANIOL, NEROL, CITROL

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

***N,N*‑DIMETHYLOCTANAMIDE**

Schedule 6

**DIMETHYLPHTHALATE**

cross reference: CAS No. 131-11-3

Schedule 10

**DIMETHYL SULFATE**

Schedule 7  
Appendix F, clause 4

**DIMETHYL SULFOXIDE**cross reference: COPPER SALICYLATE, METHYL SALICYLATE

Schedule 6  
Schedule 4  
Appendix E, clause 3  
Appendix F, clause 4

**DIMETHYLTHIAMBUTENE**

cross reference: CAS No. 524-84-5

Schedule 9

***N,N*‑DIMETHYLTRYPTAMINE**cross reference: DMT (CAS No. 61-50-7)

Schedule 9

**DIMETICONE**cross reference: DIMETHICONE

Appendix B, clause 3

**DIMETILAN**

Schedule 7

**DIMETRIDAZOLE**

Schedule 4

**DIMIRACETAM**cross reference: RACETAMS

Schedule 4

**DIMPROPYRIDAZ**

Schedule 6

Schedule 5

**DINICONAZOLE**

Schedule 5

**2,4‑DINITROCHLOROBENZENE**

Schedule 4

**DINITROCRESOLS**

Schedule 7  
Schedule 6  
Schedule 4  
Appendix E, clause 3  
Appendix J, clause 1

**DINITRONAPHTHOLS**

Schedule 4

**2,4‑DINITROPHENOL**cross reference: CAS No. 51‑28‑5Schedule 10

**DINITROPHENOLS**

Schedule 10

Schedule 7  
Schedule 6  
Schedule 4  
Appendix E, clause 3  
Appendix F, clause 4  
Appendix J, clause 1

**DINITROTHYMOLS**

Schedule 4

**DINOCAP**

Schedule 7  
Appendix F, clause 4

**DINOPROST**

Schedule 4  
Appendix D, clause 1

**DINOPROSTONE**

Schedule 4  
Appendix D, clause 1

**DINOSEB**

Schedule 7  
Appendix J, clause 1

**DINOTEFURAN**

Schedule 5

**DI‑*n*‑PROPYL ISOCINCHOMERONATE** (previously di‑*N* propyl isocinchomeronate)

Schedule 5

**DIOXACARB**

Schedule 6

**DIOXANE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**DIOXAPHETYL BUTYRATE**

cross reference: CAS No. 467-86-7

Schedule 9

**DIPERODON**

Schedule 4

**DIPHACINONE**

Schedule 6

**DIPHEMANIL**

Schedule 4

**DIPHENAMID**

Schedule 5

**DIPHENHYDRAMINE**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix K, clause 1

**DIPHENIDOL**

Schedule 4

**DIPHENOXYLATE**

Schedule 8  
Schedule 4  
Schedule 3  
Appendix F, clause 4  
Appendix H, clause 1  
Appendix K, clause 1

**DIPHENYLAMINE**

Appendix B, clause 3

**DIPHENYLPYRALINE**

Schedule 4  
Appendix K, clause 1

**DIPHTHERIA TOXOID**

cross reference: TRIPLE ANTIGEN VACCINE

Schedule 4

**DIPIPANONE**

Schedule 8

**DIPIVEFRIN**

Schedule 4

**DIPROPYLENE GLYCOL**

Appendix B, clause 3

**DIPYRIDAMOLE**

Schedule 4

**DIQUAT**

Schedule 7  
Schedule 6

**DIRECT RED 254**  
cross reference: 2‑NAPHTHALENESULFONIC ACID, 7‑AMINO‑4‑HYDROXY‑3‑[[*p*‑[(*p*‑SULFOPHENYL)AZO]PHENYL]AZO]‑, (3*Z*)‑7‑AMINO‑4‑OXO‑3‑[[4‑[(4‑SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE‑2‑SULFONIC ACID, (3*Z*)‑7‑AMINO‑4‑OXO‑3‑[[4‑[(4‑SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE‑2‑SULFONIC ACID BIS(TRIETHANOLAMINE) SALT, (3*Z*)‑7‑AMINO‑4‑OXO‑3‑[[4‑[(4‑SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE‑2‑SULFONIC ACID DISODIUM SALT

Schedule 6  
Schedule 5

**DIRITHROMYCIN**

Schedule 4

**DIRLOTAPIDE**

Schedule 4

**DIROXIMEL FUMARATE**

Schedule 4

**DISODIUM MANGANESE EDTA**

Appendix B, clause 3

**DISOPHENOL**

Schedule 4

**DISOPYRAMIDE**

Schedule 4

**DISPERSE YELLOW 3**

cross reference: CAS No. 2832-40-8

Schedule 10  
Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**DISTIGMINE**

Schedule 4

**DISTILLATE**

Appendix E, clause 3

**DISULFIRAM**

Schedule 6  
Schedule 4

**DISULFOTON**

Schedule 7  
Schedule 6

**DISULPHAMIDE**

Schedule 4

**DITHIANON**

Schedule 6

**DITHIAZANINE**

Schedule 6  
Schedule 4

**DITHIOPYR**

Schedule 5

**DITHRANOL**

Schedule 3

**DITIOCARB**

Schedule 4

**DIUREDOSAN**

Schedule 6

**DIURON**

Appendix B, clause 3

**DOBUTAMINE**

Schedule 4

**DOCETAXEL**

Schedule 4

**DOCUSATE SODIUM**cross reference: DIOCTYL SODIUM SULFOSUCCINATE

Appendix B, clause 3

***N*‑(*N*‑DODECYL)‑2‑PYRROLIDONE**cross reference: DESIGNATED SOLVENT, *N*‑(*N*‑OCTYL)‑2‑PYRROLIDONE, *N*‑METHYL‑2‑PYRROLIDONE

Schedule 6  
Schedule 5  
Appendix E, clause 3

**DODINE**

Schedule 6

**DOFETILIDE**

Schedule 4

**DOLASETRON**

Schedule 4

**DOLUTEGRAVIR**

Schedule 4

**DOMPERIDONE**

Schedule 4

**DONEPEZIL**

Schedule 4

**DOPAMINE**

Schedule 4

**DOPEXAMINE**

Schedule 4

**DORAMECTIN**

Schedule 7  
Schedule 6  
Schedule 5

**DORAVIRINE**

Schedule 4

**DORIPENEM**

Schedule 4

**DORNASE**

Schedule 4

**DORZOLAMIDE**

Schedule 4

**DOSULEPIN**cross reference: DOTHIEPIN.

Schedule 4  
Appendix K, clause 1

**DOTHIEPIN**cross reference: DOSULEPIN

**DOXANTRAZOLE**

Schedule 4

**DOXAPRAM**

Schedule 4

**DOXAZOSIN**

Schedule 4

**DOXEPIN**

Schedule 4  
Appendix K, clause 1

**DOXORUBICIN**

Schedule 4

**DOXYCYCLINE**

Schedule 4

**DOXYLAMINE**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix K, clause 1

**2,2‑DPA**cross reference: SODIUM 2,2‑DICHLOROPROPIONATE

Appendix B, clause 3

**DROMETRIZOLE TRISILOXANE**

Appendix B, clause 3

**DRONABINOL**cross reference: DELTA‑9‑TETRAHYDROCANNABINOL, NABIXIMOLS

Schedule 8  
Appendix D, clause 3  
Appendix K, clause 1

**DRONEDARONE**

Schedule 4

**DROPERIDOL**

Schedule 4  
Appendix K, clause 1

**DROSPIRENONE**

Schedule 4

**DROSTANOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**DROTEBANOL**

Schedule 8

**DROTRECOGIN**

Schedule 4

**DSMA**

Schedule 7  
Schedule 6

**DUBOISIA LEICHHARDTII**

Schedule 4  
Schedule 2

**DUBOISIA MYOPOROIDES**

Schedule 4  
Schedule 2

**DUDDINGTONIA FLAGRANS, STRAIN IAH 1297**

Appendix B, clause 3

**DULAGLUTIDE**

Schedule 4

**DULCIN**

cross reference: CAS No. 150-69-6

Schedule 10

**DULOXETINE**

Schedule 4  
Appendix K, clause 1

**DUPILUMAB**

Schedule 4

**DURVALUMAB**

Schedule 4

**DUTASTERIDE**

Schedule 4

**DYDROGESTERONE**

Schedule 4

**E**

**(*E*)‑(*S*)‑1‑(4‑CHLOROPHENYL)‑4,4‑DIMETHYL‑2‑(1H‑1,2,4‑TRIAZOL‑1‑YL)PENT‑1‑EN‑3‑OL**cross reference: UNICONAZOLE‑P

Schedule 6

**ECGONINE**

cross reference: CAS No. 481-37-8, ECGONINE HYDROCHLORIDE (CAS No. 5796-31-6), ECGONINE RACEMATE (CAS No. 876657-17-9)

Schedule 9

**ECONAZOLE**

Schedule 6  
Schedule 4  
Schedule 3  
Schedule 2  
Appendix F, clause 4  
Appendix H, clause 1

**ECOTHIOPATE**cross reference: ECOTHIOPATE IODIDE

Schedule 4

**ECTYLUREA**

Schedule 4

**ECULIZUMAB**

Schedule 4

**EDARAVONE**

Schedule 4

**EDETIC ACID**cross reference: DICOBALT EDETATE

Schedule 4

**EDOXUDINE**

Schedule 4

**EDROPHONIUM**

Schedule 4

**EFALIZUMAB**

Schedule 4

**EFAVIRENZ**

Schedule 4

**EFLORNITHINE**

Schedule 4

**EFORMOTEROL**cross reference: FORMOTEROL

**ELBASVIR**

Schedule 4

**ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS**

Appendix A, clause 1

**ELECTRONIC COMPONENTS**

Appendix A, clause 1

**ELETRIPTAN**

Schedule 4  
Schedule 3  
Appendix H, clause 1

**ELEXACAFTOR**

Schedule 4

**ELOSULFASE ALFA**

Schedule 4

**ELOTUZUMAB**

Schedule 4

**ELRANATAMAB**

Schedule 4

**ELTENAC**

Schedule 4

**ELTROMBOPAG**

Schedule 4

**ELUXADOLINE**

Schedule 4

**ELVITEGRAVIR**

Schedule 4

**EMAMECTIN**

Schedule 7  
Schedule 6  
Schedule 5

**EMEPRONIUM**

Schedule 4

**EMETINE**cross reference: CEPHAELIS ACUMINATA

Schedule 4

**EMODEPSIDE**

Schedule 6  
Schedule 5

**EMPAGLIFLOZIN**

Schedule 4

**EMTRICITABINE**

Schedule 4

**ENALAPRIL**

Schedule 4

**ENASIDENIB**

Schedule 4

**ENCORAFENIB**

Schedule 4

**ENDOSULFAN**

Schedule 7  
Schedule 6

**ENDOTHAL**

Schedule 7  
Schedule 6

**ENDRIN**

Schedule 7

**ENESTEBOL**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**ENFLURANE**

Schedule 4

**ENFORTUMAB VEDOTIN**

Schedule 4

**ENFUVIRTIDE**

Schedule 4

**ENHANCING AGENTS**cross reference: MAGNETIC RESONANCE IMAGING ENHANCING AGENTS, ULTRASONIC AND MAGNETIC RESONANCE IMAGING ENHANCING

Appendix A, clause 1

**ENOBOSARM**

Schedule 4  
Appendix D, clause 5 (SELECTIVE ANDROGEN RECEPTOR MODULATORS)

**ENOXACIN**

Schedule 4

**ENOXAPARIN**

Schedule 4

**ENOXIMONE**

Schedule 4

**ENPROSTIL**

Schedule 4

**ENROFLOXACIN**

Schedule 4

**ENTACAPONE**

Schedule 4

**ENTECAVIR**

Schedule 4

**ENTRECTINIB**

Schedule 4

**ENZALUTAMIDE**

Schedule 4  
Appendix D, clause 6  
Appendix F, clause 4  
Appendix L, clause 2

**EPHEDRA spp.**

Schedule 4

**EPHEDRINE**cross reference: EPHEDRA

Schedule 4  
Appendix D, clause 5  
Appendix F, clause 4

**EPICHLOROHYDRIN**

Schedule 7  
Appendix F, clause 4  
Appendix J, clause 1

**EPICILLIN**

Schedule 4

**EPIDERMAL GROWTH FACTOR**cross reference: SH‑OLIGOPEPTIDE‑1, RH‑OLIGOPEPTIDE‑1

Schedule 7  
Appendix G, clause 1  
Appendix J, clause 1

**EPINASTINE**

Schedule 4

**EPINEPHRINE**cross reference: ADRENALINE

**EPIRUBICIN**

Schedule 4

**EPITIOSTANOL**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**EPLERENONE**

Schedule 4

**EPOETINS**cross reference: METHOXY POLYETHYLENE GLYCOL‑EPOETIN BETA

Schedule 4  
Appendix D, clause 5

**EPOPROSTENOL**

Schedule 4

**EPOXICONAZOLE**

Schedule 5

**EPOXY RESINS, LIQUID**cross reference: RESINS

Schedule 5  
Appendix E, clause 3   
Appendix F, clause 4

**EPRINOMECTIN**

Schedule 7  
Schedule 6  
Schedule 5

**EPROSARTAN**

Schedule 4

**EPSIPRANTEL**

Appendix B, clause 3

**EPTC**

Schedule 6

**EPTIFIBATIDE**

Schedule 4

**EQUINE ANTI‑HUMAN THYMOCYTE IMMUNOGLOBULIN**cross reference: IMMUNOGLOBULINSERGOMETRINE

Schedule 4

**ERENUMAB**

Schedule 4

**ERGOT**

Schedule 4

**ERGOTAMINE**

Schedule 4

**ERGOTOXINE**

Schedule 4

**ERIBULIN MESILATE**cross reference: ERIBULIN MESYLATE

Schedule 4

**ERLOTINIB**

Schedule 4

**ERTAPENEM**

Schedule 4

**ERTUGLIFLOZIN**

Schedule 4

**ERYSIMUM spp.**

Schedule 4  
Appendix G, clause 1

**ERYTHRITYL TETRANITRATE**

Schedule 3

**ERYTHROMYCIN**

Schedule 4

**ERYTHROPOIETIN**

Schedule 4  
Appendix D, clause 5

**ERYTHROPOIETINS**

Schedule 4  
Appendix D, clause 5

**ESBIOTHRIN**

Schedule 6  
Schedule 5

**ESCITALOPRAM**

Schedule 4

**ESFENVALERATE**

Schedule 6  
Schedule 5

**ESKETAMINE**

Schedule 8  
Appendix K, clause 1

**ESLICARBAZEPINE ACETATE**

Schedule 4

**ESMOLOL**

Schedule 4

**ESOMEPRAZOLE**

Schedule 4  
Schedule 2  
Appendix H, clause 1

**ESTETROL MONOHYDRATE**

Schedule 4

**ESTRADIOL**

Schedule 5  
Schedule 4  
Appendix G, clause 1

**ESTRAMUSTINE**

Schedule 4

**ESTRIOL**

Schedule 4

**ESTROGENS**

Schedule 4

**ESTRONE**

Schedule 4  
Appendix G, clause 1

**ESTROPIPATE**cross reference: PIPERAZINE ESTRONE SULFATE

Schedule 4

**ETACONAZOLE**

Schedule 7  
Appendix J, clause 1

**ETACRYNIC ACID**

Schedule 4

**ETAFEDRINE**

Schedule 2

**ETANERCEPT**

Schedule 4

**ETHACRYNIC ACID**cross reference: ETACRYNIC ACID

**ETHALFLURALIN**

Schedule 7

**ETHAMBUTOL**

Schedule 4

**ETHAMETSULFURON‑METHYL**

Appendix B, clause 3

**ETHAMIVAN**

Schedule 4

**1,2‑ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE AND *N*‑METHYLMETHANAMINE**cross reference: *N*‑METHYLMETHANAMINE

Schedule 5

**ETHANOL**cross reference: ETHYL ALCOHOL

**ETHANOLAMINE**cross reference: MONOETHANOLAMINE

**ETHCHLORVYNOL**

Schedule 4

**ETHEPHON**

Schedule 6

**ETHER**

Schedule 6  
Schedule 5  
Schedule 4  
Schedule 2  
Appendix E, clause 3  
Appendix F, clause 4

**ETHERIFIED STARCHES**

Appendix A

**ETHINAMATE**

Schedule 4

**ETHINYLESTRADIOL**

Schedule 4

**ETHINYLOESTRADIOL**cross reference: ETHINYLESTRADIOL

**ETHIOFENCARB**

Schedule 6

**ETHION**

Schedule 7

**ETHIONAMIDE**

Schedule 4

**ETHISTERONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**ETHOATE‑METHYL**

Schedule 6

**ETHOFUMESATE**

Schedule 5

**ETHOGLUCID**

Schedule 4

**ETHOHEPTAZINE**

Schedule 4

**ETHOPABATE**

Appendix B, clause 3

**ETHOPROPAZINE**

Schedule 4

**ETHOPROPHOS**cross reference: LINSEED OIL

Schedule 7  
Schedule 6

**ETHOSUXIMIDE**

Schedule 4

**ETHOTOIN**

Schedule 4

**2‑ETHOXYETHANOL**

Schedule 7  
Appendix F, clause 4

**ETHOXYETHYLMERCURIC CHLORIDE**

Appendix F, clause 4

**ETHOXYQUIN**

Schedule 5

**ETHOXYSULFURON**

Schedule 5

**ETHOXZOLAMIDE**

Schedule 4

**ETHYL ACETATE**

Appendix B, clause 3

**ETHYL ALCOHOL**

Appendix B, clause 3

**ETHYL BROMIDE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**ETHYL BUTYRATE**

Appendix B, clause 3

**ETHYL CHLORIDE**

Schedule 4

**ETHYL FORMATE**

Schedule 6

**ETHYL LACTATE**

Appendix B, clause 3

**ETHYL METHACRYLATE**

Schedule 5  
Appendix F, clause 4

**ETHYLAMFETAMINE**cross reference: ETHYLAMPHETAMINE

Schedule 8

**ETHYLBUTYLACETYL‑**

Appendix B, clause 3

**ETHYLDIENOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**ETHYLENE CHLOROHYDRIN**

Schedule 6  
Appendix F, clause 4

**ETHYLENE DIBROMIDE**

Schedule 7  
Appendix J, clause 1

**ETHYLENE DICHLORIDE**

Schedule 6

**ETHYLENE GLYCOL**cross reference: DENATONIUM BENZOATE (CAS No. 107-21-1)

Schedule 10  
Schedule 6  
Schedule 5  
Appendix E, clause 3

**ETHYLENE GLYCOL MONOALKYL ETHERS**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**ETHYLENE OXIDE**

Schedule 7  
Appendix E, clause 3  
Appendix F, clause 4  
Appendix J, clause 1

**ETHYLESTRENOL**cross reference: ETHYLOESTRENOL

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**ETHYLHEXANEDIOL**

cross reference: ETHOHEXADIOL  
Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**2‑ETHYLHEXANOIC ACID**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**ETHYLMERCURIC CHLORIDE**

Appendix F, clause 4

***N*‑ETHYL‑α‑METHYL‑3,4‑(METHYLENEDIOXY)PHENETHYLAMINE**cross reference: *N*‑ETHYL MDA (CAS No. 82801-81-8), N-ETHYL MDA HYDROCHLORIDE (CAS No. 74341-78-9)

Schedule 9

**ETHYLMETHYLTHIAMBUTENE**

cross reference: CAS No: 441-61-2

Schedule 9

**ETHYLMORPHINE**

Schedule 8  
Schedule 4  
Schedule 2  
Appendix K, clause 1

**ETHYLOESTRENOL**cross reference: ETHYLESTRENOL

**ETHYNODIOL**cross reference: ETYNODIOL

**ETICYCLIDINE**cross reference: PCE (CAS No. 2201-15-2)

Schedule 9

**ETIDOCAINE**

Schedule 4

**ETIDRONIC ACID**cross reference: ETIDRONATE DISODIUM

Schedule 4

**ETILEFRIN**

Schedule 4

**ETIPROSTON**

Schedule 4

**ETODESNITAZENE**

cross reference: CAS No. 14030-76-3, ETAZENE

Schedule 9

**ETODOLAC**

Schedule 4

**ETOFENAMATE**

Schedule 4  
Schedule 2

**ETOFENPROX**

Appendix B, clause 3

**ETONITAZENE**

cross reference: CAS No. 911-65-9

Schedule 9

**ETONITAZEPIPNE**

cross reference: CAS No. 734496-28-7, N-PIPERIDINO ETONITAZENE

Schedule 9

**ETONITAZEPYNE**

cross reference: CAS No. 2785346-75-8, N-PYRROLIDINO ETONITAZENE

Schedule 9

**ETONOGESTREL**

Schedule 4

**ETOPOSIDE**

Schedule 4

**ETORICOXIB**

Schedule 4

**ETORPHINE**

cross reference: CAS No. 14521-96-1

Schedule 9

**ETOXAZOLE**

Appendix B, clause 3

**ETOXERIDINE**

cross reference: CAS No. 469-82-9

Schedule 9

**ETRANACOGENE DEZAPARVOVEC**

Schedule 4

**ETRASIMOD**

Schedule 4

**ETRAVIRINE**

Schedule 4

**ETRETINATE**

Schedule 4  
Appendix D, clause 5  
Appendix F, clause 4  
Appendix L, clause 2

**ETRIDIAZOLE**

Schedule 5

**ETRIMFOS**

Schedule 6

**ETYNODIOL**cross reference: ETHYNODIOL

Schedule 4

**EUBACTERIUM sp. strain DSM11798**

Appendix B, clause 3

**EUCALYPTUS OIL**

Schedule 6  
Appendix E, clause 3

**EUGENOL**

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**EUPATORIUM CANNABINUM**cross reference: HEMP AGRIMONY

Schedule 10

**EVEROLIMUS**

Schedule 4

**EXEMESTANE**

Schedule 4

**EXENATIDE**

Schedule 4

**EXPLOSIVES**

Appendix A, clause 1

**EXTRACT OF LEMON EUCALYPTUS**cross reference: CORYMBIA CITRIODORA, OIL OF LEMON EUCALYPTUS

Schedule 5

**EZETIMIBE**

Schedule 4

**F**

**FAMCICLOVIR**

Schedule 4  
Schedule 3

Appendix H, clause 1

**FAMOTIDINE**

Schedule 4  
Schedule 2  
Appendix F, clause 4

**FAMOXADONE**

Schedule 6

**FAMPHUR**

Schedule 7  
Schedule 6

**FARFUGIUM JAPONICUM**

Schedule 10

**FARICIMAB**

Schedule 4  
Appendix L, clause 2

**FASORACETAM**cross reference: RACETAMS

Schedule 4

**FEBANTEL**

Schedule 6

**FEBUXOSTAT**

Schedule 4

**FELBINAC**

Schedule 4  
Schedule 2

**FELODIPINE**

Schedule 4

**FELYPRESSIN**

Schedule 4

**FENAMIPHOS**

Schedule 7  
Schedule 6

**FENARIMOL**

Schedule 5

**FENAZAFLOR**

Schedule 6

**FENBENDAZOLE**

Schedule 5

**FENBUCONAZOLE**

Schedule 5

**FENBUFEN**

Schedule 4

**FENBUTATIN OXIDE**

Schedule 6

**FENCAMFAMIN**

Schedule 4

**FENCHLORAZOLE‑ETHYL**

Schedule 5

**FENCHLORPHOS**

Schedule 6

**FENCLOFENAC**

Schedule 4

**FENETYLLINE**

cross reference: CAS No. 3736-08-1, FENETYLLINE HYDROCHLORIDE (CAS No. 1892-80-4)

Schedule 9

**FENFLURAMINE**

Schedule 4  
Appendix K, clause 1

**FENFURAM**

Appendix B, clause 3

**FENHEXAMID**

Appendix B, clause 3

**FENITROTHION**

Schedule 6

**FENNEL OIL**

Schedule 5  
Appendix E, clause 3

**FENOFIBRATE**

Schedule 4

**FENOLDOPAM**

Schedule 4

**FENOPROFEN**

Schedule 4

**FENOPROP**

Schedule 5

**FENOTEROL**

Schedule 4

**FENOXACRIM**

Schedule 7  
Schedule 6

**FENOXAPROP‑ETHYL**

Schedule 5

**FENOXAPROP‑*p*‑ETHYL**

Schedule 5

**FENOXYCARB**

Appendix B, clause 3

**FENPIPRAMIDE**

Schedule 4

**FENPIPRANE**

Schedule 4

**FENPROPIDIN**

Schedule 6

**FENPROPOREX**

Schedule 4

**FENPROSTALENE**

Schedule 4

**FENPYRAZAMINE**

Schedule 5

**FENPYROXIMATE**

Schedule 6

**FENSON**

Schedule 5

**FENSULFOTHION**

Schedule 7

**FENTANYL**

Schedule 8  
Appendix K, clause 1

**FENTEROL**

Appendix F, clause 4

**FENTHION**

Schedule 7  
Schedule 6  
Schedule 5

**FENTHION‑ETHYL**

Schedule 7

**FENVALERATE**

Schedule 6

**FERRIC DERISOMALTOSE**

Schedule 4

**FEXOFENADINE**

Schedule 4  
Schedule 2

**FEZOLINETANT**

Schedule 4

**FIBRINOLYSIN**

Schedule 4

**FIBROBLAST GROWTH FACTORS**

Schedule 4  
Appendix D, clause 5

**FIDAXOMICIN**

Schedule 4

**FILGOTINIB**

Schedule 4

**FILGRASTIM**

Schedule 4

**FINASTERIDE**

Schedule 4

**FINERENONE**

Schedule 4

Appendix L, clause 2

**FINGOLIMOD**

Schedule 4  
Appendix L, clause 2

**FIPRONIL**

Schedule 6  
Schedule 5

**FIROCOXIB**

Schedule 4

**FLAMPROP‑METHYL**

Schedule 5

**FLAMPROP‑M‑METHYL**

Schedule 5

**FLAVOXATE**

Schedule 3

**FLAZASULFURON**

Schedule 5

**FLECAINIDE**

Schedule 4

**FLEROXACIN**

Schedule 4

**FLOCOUMAFEN**

Schedule 7  
Schedule 6

**FLOCTAFENINE**

Schedule 4

**FLONICAMID**

Schedule 6

**FLORASULAM**

Schedule 5

**FLORFENICOL**

Schedule 4

**FLORPYRAUXIFEN‑BENZYL**

Appendix B, clause 3

**FLORYLPICOXAMID**

Appendix B, clause 3

**FLUANISONE**

Schedule 4

**FLUAZAINDOLIZINE**

Schedule 6  
Schedule 5

**FLUAZIFOP‑BUTYL**

Schedule 6

**FLUAZIFOP‑*p*‑BUTYL**

Schedule 6

**FLUAZINAM**

Schedule 6

**FLUAZURON**

Schedule 5

**FLUBENDAZOLE**

Schedule 5

**FLUBENDIAMIDE**

Schedule 5

**FLUBROMAZEPAM**

cross reference: CAS No. 2647-50-9

Schedule 9

**FLUBROMAZOLAM**

cross reference: CAS No. 612526-40-6

Schedule 9

**FLUCHLORALIN**

Schedule 5

**FLUCLOROLONE**

Schedule 4

**FLUCLOXACILLIN**

Schedule 4

**FLUCOFURON**

Schedule 7  
Schedule 6

**FLUCONAZOLE**

Schedule 4  
Schedule 3  
Appendix F, clause 4  
Appendix H, clause 1

**FLUCYTHRINATE**

Schedule 7

**FLUCYTOSINE**

Schedule 4

**FLUDARABINE**

Schedule 4

**FLUDIOXONIL**

Schedule 5

**FLUDROCORTISONE**

Schedule 4

**FLUENSULFONE**

Schedule 6

**FLUFENAMIC ACID**

Schedule 4

**FLUFENOXURON**

Appendix B, clause 3

**FLUMAZENIL**

Schedule 4

**FLUMETASONE**cross reference: FLUMETHASONE

Schedule 4

**FLUMETHASONE**cross reference: FLUMETASONE

**FLUMETHIAZIDE**

Schedule 4

**FLUMETHRIN**

Schedule 6  
Schedule 5

**FLUMETSULAM**

Appendix B, clause 3

**FLUMICLORAC PENTYL**

Schedule 5

**FLUMIOXAZIN**

Schedule 7  
Schedule 6

**FLUNISOLIDE**

Schedule 4

**FLUNITAZENE**

cross reference: CAS No. 2249-36-7, FLUNITAZENE HYDROCHLORIDE (CAS No. 2728-91-8)  
Schedule 9

**FLUNITRAZEPAM**

Schedule 8  
Appendix D, clause 5 (Benzodiazepine derivatives)  
Appendix K, clause 1

**FLUNIXIN MEGLUMINE**

Schedule 4

**FLUOCINOLONE**

Schedule 4

**FLUOCINONIDE**

Schedule 4

**FLUOCORTIN**

Schedule 4

**FLUOCORTOLONE**

Schedule 4

**FLUOMETURON**

Appendix B, clause 3

**FLUOPICOLIDE**

Appendix B, clause 3

**FLUOPYRAM**

Schedule 5

**FLUORESCEIN**

Schedule 4

**FLUORIDES**cross reference: SILICOFLUORIDES

Schedule 6  
Schedule 5  
Schedule 4  
Schedule 3  
Schedule 2  
Appendix E, clause 3  
Appendix F, clause 4

Appendix H, clause 1

**FLUOROACETAMIDE**

Schedule 7

**FLUOROACETIC ACID**

Schedule 7  
Appendix J, clause 1

**FLUOROMETHOLONE**

Schedule 4

**4‑FLUORO‑*N*‑METHYLAMFETAMINE**cross reference: 4‑FLUORO‑*N*‑METHYLAMPHETAMINE, 4‑FLUORO‑*N*‑METHAMFETAMINE (CAS No. 351-03-1)

Schedule 9

**1‑(5‑FLUOROPENTYL)‑3‑(2‑IODOBENZOYL)INDOLE**cross reference: AM‑694 (CAS No. 335161-03-0)

Schedule 9

**FLUOROURACIL**

Schedule 4

**FLUOXETINE**

Schedule 4

**FLUOXYMESTERONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**FLUPENTIXOL**cross reference: FLUPENTHIXOL

Schedule 4  
Appendix K, clause 1

**FLUPHENAZINE**

Schedule 4  
Appendix K, clause 1

**FLUPROPANATE**cross reference: TETRAPION

Schedule 6

**FLUPROSTENOL**

Schedule 4

**FLUPYRADIFURONE**

Schedule 6

**FLUQUINCONAZOLE**

Schedule 6

**FLURALANER**cross‑reference: CARBAMOYL BENZAMIDE, PHENYL ISOXAZOLINE

Schedule 5

Schedule 4

**FLURANDRENOLONE**

Schedule 4

**FLURAZEPAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)  
Appendix K, clause 1

**FLURBIPROFEN**

Schedule 4  
Schedule 2

**FLUOROACETAMIDE**

Appendix J, clause 1

**FLUOXAPIPROLIN**

Appendix B, clause 3

**FLUROXENE**

Schedule 4

**FLUROXYPYR**

Appendix B, clause 3

**FLUSILAZOL**

Schedule 6

**FLUSPIRILENE**

Schedule 4

**FLUTAMIDE**

Schedule 4

**FLUTICASONE**cross reference: FLUTICASONE FUROATE, FLUTICASONE PROPIONATE

Schedule 4

**FLUTICASONE FUROATE**  
cross reference FLUTICASONE

**FLUTICASONE PROPIONATE**

cross reference: FLUTICASONE

Schedule 4  
Schedule 2

**FLUTOLANIL**

Appendix B, clause 3

**FLUTRIAFOL**

Schedule 6

**FLUVALINATE**

Schedule 6  
Schedule 5

**FLUVASTATIN**

Schedule 4

**FLUVOXAMINE**

Schedule 4

**FLUXAPYROXAD**

Schedule 5

**FOLIC ACID**

Schedule 4  
Schedule 2

**FOLINIC ACID**cross reference: CALCIUM FOLINATE

Schedule 4  
Schedule 2

**FOLLICLE‑STIMULATING HORMONE**

Schedule 4  
Appendix D, clause 1

**FOLLISTATIN**

Schedule 4  
Appendix D, clause 5

**FOLLITROPIN ALFA**cross reference: FOLLICLE‑STIMULATING HORMONE, RECOMBINANT HUMAN

Schedule 4  
Appendix D, clause 1

**FOLLITROPIN BETA**cross reference: FOLLICLE‑STIMULATING HORMONE, RECOMBINANT HUMAN

Schedule 4  
Appendix D, clause 1

**FOLLITROPIN DELTA**cross reference: FOLLICLE‑STIMULATING HORMONE, RECOMBINANT HUMAN

Schedule 4  
Appendix D, clause 1

**FOLPET**

Schedule 7  
Appendix J, clause 1

**FOMEPIZOLE**

Schedule 4

**FOMESAFEN SODIUM**

Schedule 6

**FOMIVIRSEN**

Schedule 4

**FONDAPARINUX**

Schedule 4

**FOOD**

Appendix A, clause 1

**FORAMSULFURON**

Schedule 5

**FORCHLORFENURON**

Appendix B, clause 3

**FORMALDEHYDE**cross reference: FORMALDEHYDE CONDENSATION PRODUCT, FREE FORMALDEHYDE, METACRESOLSULPHONIC ACID, METHYLENE GLYCOL (CAS No. 50-00-0)

Schedule 10  
Schedule 6  
Schedule 2  
Appendix E, clause 3  
Appendix F, clause 4

**FORMALDEHYDE CONDENSATION PRODUCT**

Schedule 6

**FORMEBOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**FORMESTANE**

Schedule 4

**FORMETANATE**

Schedule 7

**FORMIC ACID**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**FORMOTEROL**

Schedule 4

**FORMOTHION**

Schedule 6

**FOSAMPRENAVIR**

Schedule 4

**FOSAPREPITANT**

Schedule 4

**FOSCARNET**

Schedule 4

**FOSFESTROL**cross reference: DIETHYLSTILBESTROL DIPHOSPHATE

Schedule 4

**FOSFOMYCIN**

Schedule 4

**FOSINOPRIL**

Schedule 4

**FOSNETUPITANT**

Schedule 4

**FOSPHENYTOIN**

Schedule 4

**FOSPIRATE**

Schedule 6  
Schedule 5

**FOSTEMSAVIR**

Schedule 4

**FOSTHIAZATE**

Schedule 7

**FOTEMUSTINE**

Schedule 4

**FRAMYCETIN**

Schedule 4

**FRITTED GLAZING OR ENAMELLING PREPARATIONS**

Appendix A, clause 1

**FULLERS EARTH**

Appendix B, clause 3

**FULVESTRANT**

Schedule 4

**FUMAGILLIN**

Schedule 6

**FUNGAL PROTEASE derived from Aspergillus niger**

Appendix B, clause 3

**FURALAXYL**

Schedule 5

**FURALTADONE**

Schedule 4

**FURATHIOCARB**

Schedule 7  
Schedule 5

**FURAZABOL**

Schedule 4

**FURAZOLIDONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**FURETHIDINE**

cross reference: CAS No. 2385-81-1

Schedule 9

**FURFURAL**cross reference: 2‑FURANCARBOXALDEHYDE

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**FUROSEMIDE**cross reference: FRUSEMIDE

Schedule 4

**FUSIDIC ACID**

Schedule 4

**G**

**GABAPENTIN**

Schedule 4  
Appendix K, clause 1

**GALANTAMINE**

Schedule 4

**GALANTHUS spp.**

Schedule 4

**GALCANEZUMAB**

Schedule 4

**GALLAMINE**

Schedule 4

**GALSULFASE**

Schedule 4

**GAMMA BUTYROLACTONE**

cross reference: CAS No. 96-48-0

Schedule 10

**GAMMA HYDROXYBUTYRATE**cross reference: 4‑HYDROXYBUTANOIC ACID, GHB, SODIUM OXYBATE

Schedule 9

**GAMMA‑CYHALOTHRIN**

Schedule 7  
Schedule 5

**GANCICLOVIR**

Schedule 4

**GANIRELIX**

Schedule 4

**GATIFLOXACIN**

Schedule 4

**GEFITINIB**

Schedule 4

**GELATIN – SUCCINYLATED**

Appendix A

**GELSEMIUM SEMPERVIRENS**

Schedule 2  
Appendix G, clause 1

**GEMCITABINE**

Schedule 4  
Appendix K, clause 1

**GEMEPROST**

Schedule 4

**GEMFIBROZIL**

Schedule 4

**GEMIFLOXACIN**

Schedule 4

**GEMTUZUMAB OZOGAMICIN**

Schedule 4

**GENTAMICIN**

Schedule 4

**GENTIAN VIOLET**  
cross reference: METHYLROSANILINIUM CHLORIDE, CRYSTAL VIOLET

**GERANIUM OIL**

Appendix B, clause 3

**GESTODENE**

Schedule 4

**GESTONORONE**

Schedule 4

**GESTRINONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**GHRH INJECTABLE PLASMID**

Schedule 4

**GIBBERELLIC ACID**

Appendix B, clause 3

**GILTERITINIB**

Schedule 4

**GITALIN**

Schedule 4

**GIVOSIRAN**

Schedule 4

**GLASS**cross reference: CRYSTAL WARE

Appendix A, clause 1

**GLATIRAMER ACETATE**

Schedule 4

**GLAZED POTTERY**

Appendix A, clause 1

**GLECAPREVIR**

Schedule 4

**GLIBENCLAMIDE**

Schedule 4

**GLIBORNURIDE**

Schedule 4

**GLICLAZIDE**

Schedule 4

**GLIMEPIRIDE**

Schedule 4

**GLIPIZIDE**

Schedule 4

**GLIPTINS**

cross reference: DIPEPTIDYL PEPTIDASE-4 (DDP-4) INHIBITORS  
Schedule 4

**GLISOXEPIDE**

Schedule 4

**GLOFITAMAB**

Schedule 4

**GLUCAGON**

Schedule 3  
Appendix G, clause 1

Appendix H, clause 1

**α‑GLUCANASE derived from *Aspergillus niger***

Appendix B, clause 3

**GLUFOSINATE‑AMMONIUM**

Schedule 5

**GLUTARAL**

Schedule 6  
Schedule 5  
Schedule 2  
Appendix E, clause 3  
Appendix F, clause 4

**GLUTARALDEHYDE**cross reference: GLUTARAL

**GLUTATHIONE**

Schedule 4

**GLUTETHIMIDE**

Schedule 4  
Appendix D, clause 5  
Appendix K, clause 1

**GLYCERYL THIOGLYCOLLATE**

Schedule 6

**GLYCERYL TRINITRATE**

Schedule 4  
Schedule 3  
Appendix G, clause 1  
Appendix H, clause 1

**GLYCOLIC ACID**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**GLYCOPYRRONIUM**

Schedule 4

Schedule 3

**GLYCOSYLATED HYDROQUINONE**  
cross reference: HYDROQUINONE

**GLYMIDINE**

Schedule 4

**GLYPHOSATE**

Schedule 5

**GnRH VACCINE**

Schedule 4

**GOLIMUMAB**

Schedule 4

**GONADORELIN**

Schedule 4

**GONADOTROPHIC HORMONES**

Schedule 4

**GOSERELIN**

Schedule 4

**GRAMICIDIN**

Schedule 4

**GRANISETRON**

Schedule 4

**GRAPIPRANT**

Schedule 4

**GRAZOPREVIR**

Schedule 4

**GREPAFLOXACIN**

Schedule 4

**GRISEOFULVIN**

Schedule 4

**GROWTH HORMONE RELEASING HORMONES \*(GHRHs)**

Schedule 4  
Appendix D, clause 5

**GROWTH HORMONE RELEASING PEPTIDE‑6 (GHRP‑6)**

Schedule 4  
Appendix D, clause 5

**GROWTH HORMONE RELEASING PEPTIDE \*(GHRPs)**

Schedule 4  
Appendix D, clause 5

**GROWTH HORMONE SECRETAGOGUES \*(GHSs)**

Schedule 4  
Appendix D, clause 5

**GUAIFENESIN**   
cross reference: PARACETAMOL

Schedule 4  
Schedule 2

**GUAIPHENESIN**cross reference: GUAIFENESIN

**GUANABENZ**

Schedule 4

**GUANACLINE**

Schedule 4

**GUANETHIDINE**

Schedule 4

**GUANFACINE**

Schedule 4  
Appendix K, clause 1

**GUANIDINE**

Schedule 6  
Schedule 4  
Appendix E, clause 3

**GUAZATINE**

Schedule 6

**GUSELKUMAB**

Schedule 4

**H**

**HACHIMYCIN**

Schedule 4

**HAEMATIN**

Schedule 4

**HAEMOPHILUS INFLUENZAE VACCINE**

Schedule 4

**HALAUXIFEN METHYL**

Appendix B, clause 3

**HALCINONIDE**

Schedule 4

**HALOFANTRINE**

Schedule 4

**HALOFENATE**

Schedule 4

**HALOFUGINONE**

Schedule 7  
Schedule 4  
Appendix J, clause 1

**HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS**cross reference: DIBENZODIOXINS, HALOGENATED ‑ DIBENZOFURANS, HALOGENATED, DIOXINS

Schedule 7  
Appendix J, clause 1

**HALOPERIDOL**cross reference: BUTYPHENONES

Schedule 4  
Appendix G, clause 1  
Appendix K, clause 1

**HALOSULFURON‑METHYL**

Schedule 5

**HALOTHANE**

Schedule 4

**HALOXON**

Schedule 6

**HALOXYFOP**

Schedule 6

**HARMALA ALKALOIDS**

Schedule 9

**HC RED 13**  
cross reference: 2,2'‑[(4‑AMINO‑3‑NITROPHENYL)IMINO]BISETHANOL

**HC VIOLET 1**   
cross reference: 2‑[(4‑AMINO‑2‑METHYL‑5‑NITROPHENYL)AMINO]‑ETHANOL

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**HCB**

Schedule 7  
Appendix J, clause 1

**HELIONAL**

Appendix B, Part 3

**HELIOTROPIUM spp.**

Schedule 10

**HEMEROCALLIS**

Schedule 4

**HEMP SEED OIL**cross reference: CANNABIDIOL, CANNABIS, TETRAHYDROCANNABINOLS

**HEPARINS**

Schedule 4

**HEPATITIS A VACCINE**

Schedule 4

**HEPATITIS B VACCINE**

Schedule 4

**HEPTACHLOR**

Schedule 6

**HEROIN**

cross reference: CAS No. 561-27-3, HEROIN HYDROCHLORIDE (CAS No. 1502-95-0)

Schedule 9

**HETACILLIN**

Schedule 4

**HEXACHLOROPHANE**cross reference: HEXACHLOROPHENE

**HEXACHLOROPHENE**cross reference: HCB

Schedule 6  
Schedule 4  
Schedule 2  
Appendix E, clause 3  
Appendix F, clause 4

**HEXACONAZOLE**

Schedule 5

**HEXAFLURON**

Appendix B, clause 3

**HEXAMETHONIUM**

Schedule 4

**HEXARELIN**

Schedule 4  
Appendix D, clause 5

**HEXAZINONE**

Schedule 6  
Schedule 5

**HEXETIDINE**

Schedule 4

**HEXLOXYETHANOL**

Appendix F, clause 4

**HEXOBENDINE**

Schedule 4

**HEXOCYCLIUM**

Schedule 4

**HEXOPRENALINE**

Schedule 4

**HEXYL ACETATE**

Appendix B, clause 3

**HEXYL AMINOLEVULINATE (AS HYDROCHLORIDE)**

Schedule 4

**HEXYL CINNAMALDEHYDE**

Appendix B, clause 3

**3‑HEXYL‑1‑HYDROXY‑7,8,9,10‑TETRAHYDRO‑6,6,9‑TRIMETHYL‑6H‑DIBENZO (b,d) PYRAN**cross reference: PARAHEXYL (CAS No. 117-51-1)

Schedule 9

**HEXYLOXYETHANOL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**HEXYTHIAZOX**

Appendix B, clause 3

**HISTAMINE**

Schedule 4

**HMG‑CoA REDUCTASE INHIBITORS**cross reference: STATINS

Schedule 4

**HOMATROPINE**

Schedule 4

**HUMAN BLOOD PRODUCTS**cross reference: ALBUMIN, ANTICOAGULATION COMPLEX, C1 ESTERASE INHIBITORS, CLOTTING FACTORS, CRYOPRECIPITATE, FIBRINOGEN, PLASMA, PLATELETS, PROTEIN C, PROTHROMBIN COMPLEX CONCENTRATE (PCC), RED CELLS, THROMBIN, WHOLE BLOOD, STEM CELLS

Appendix A, clause 1

**HUMAN CHORIONIC GONADOTROPHIN**

Schedule 4

**HUMAN OSTEOGENIC PROTEIN‑1 (OP‑1)**

Appendix B, clause 3

**HUMAN PAPILLOMAVIRUS VACCINE**

Schedule 4

**HYALURONIC ACID**

Schedule 4

**HYALURONIC ACID AND ITS POLYMERS**

Schedule 4

**HYDRALAZINE**

Schedule 4

**HYDRAMETHYLNON**

Schedule 6  
Schedule 5

**HYDRARGAPHEN**

Schedule 4

**HYDRAZINE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**HYDROCARBONS LIQUID AROMATIC**cross reference: AROMATIC EXTRACT OILS,

Schedule 7  
Appendix F, clause 4

**HYDROCARBONS, LIQUID**cross reference: BENZENE, DESIGNATED SOLVENT, DIESEL (DISTILLATE), DRY CLEANING FLUID, KEROSENE, LAMP OIL, LIGHT MINERAL OILS, LIQUID HYDROCARBONS, MINERAL OILS, MINERAL TURPENTINE, NAPHTHALENE, PARAFFIN OILS, PETROL, PETROLEUM OILS, REDUCERS, THINNERS, TOLUENE, WHITE SPIRIT, WHITE PETROLEUM SPIRIT, WHITE MINERAL OILS, XYLENE

Schedule 5  
Appendix E, clause 3

**HYDROCHLORIC ACID**

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**HYDROCHLOROTHIAZIDE**

Schedule 4

**HYDROCODONE**

Schedule 8  
Appendix K, clause 1

**HYDROCORTISONE**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix F, clause 4  
Appendix H, clause 1

**HYDROCORTISONE ACETATE**

Schedule 3  
Schedule 2

**HYDROCYANIC ACID**cross reference: CYANIDES, APRICOT KERNELS

Schedule 7  
Schedule 4  
Appendix F, clause 4  
Appendix G, clause 1  
Appendix J, clause 1

**HYDROFLUMETHIAZIDE**

Schedule 4

**HYDROFLUORIC ACID**cross reference: HYDROGEN FLUORIDE

Schedule 7  
Schedule 6  
Schedule 5

Appendix E, clause 3

Appendix F, clause 4  
Appendix J, clause 1

**HYDROGEN PEROXIDE**

cross reference: CAS No. 7722-84-1

Schedule 10  
Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**HYDROGEN SULFIDE**

Schedule 7

**HYDROMORPHINOL**

Schedule 8

**HYDROMORPHONE**

Schedule 8  
Appendix K, clause 1

**HYDROPRENE**

Appendix B, clause 3

**HYDROQUINONE**cross reference: ARBUTIN, GLYCOSYLATED HYDROQUINONE, MONOBENZONE

Schedule 6  
Schedule 4  
Schedule 2  
Appendix E, clause 3  
Appendix F, clause 4

**HYDROSILICOFLUORIC ACID**cross reference: FLUOROSILICIC ACID, HEXAFLUOROSILIC ACID, HYDROFLUOSILICIC ACID, SILICOFLUORIC ACID

Schedule 7  
Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**4‑HYDROXYBUTANOIC ACID**

cross reference: CAS No. 591-81-1, SODIUM OXYBATE (CAS No. 502-85-2)

Schedule 9

**HYDROXYCARBAMIDE**

Schedule 4

**HYDROXYCHLOROQUINE**

Schedule 4  
Appendix D, clause 8

**2‑[(1*R*,3*S*)‑3‑HYDROXYCYCLOHEXYL]‑5‑(2‑METHYLNONAN‑2‑YL)PHENOL**cross reference: CANNABICYCLOHEXANOL (CAS No. 70434-92-3), CP 47,497 C8 HOMOLOGUE, CP 47,497 (CAS No. 70434-82-1)

Schedule 9

**HYDROXYEPHEDRINE**

Schedule 4

**4‑[(2‑HYDROXYETHYL)AMINO]‑3‑NITROPHENOL**cross reference: 3‑NITRO‑*p*‑HYDROXYETHYLAMINOPHENOL

**2‑HYDROXYETHYL METHACRYLATE**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**HYDROXYETHYL‑3,4‑METHYLENEDIOXYANILINE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**[7‑HYDROXY‑8‑[(2‑ METHOXYPHENYL)AZO]‑2‑NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391‑30‑0)**cross reference: BASIC RED 76 (CAS No. 68391‑30‑0)

**HYDROXYPETHIDINE**

cross reference: CAS No. 468-56-4

Schedule 9

**HYDROXYPHENAMATE**

Schedule 4

**HYDROXYPROGESTERONE**

Schedule 4

**HYDROXYPROPYL CELLULOSE**

Appendix B, clause 3

**2‑HYDROXYPROPYL METHACRYLATE**

Schedule 5

**8‑HYDROXYQUINOLINE**cross reference: OXYQUINOLINE

**HYDROXYSTENOZOL**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**HYDROXYUREA**cross reference: HYDROXYCARBAMIDE

**HYDROXYZINE**

Schedule 4  
Appendix K, clause 1

**HYGROMYCIN**

Schedule 4

**HYOSCINE**cross reference: HYOSCINE BUTYLBROMIDE

Schedule 4  
Schedule 2  
Appendix G, clause 1

**HYOSCINE BUTYLBROMIDE**

Schedule 4

Schedule 3

Schedule 2

Appendix H, clause 1

**HYOSCYAMINE**

Schedule 4

Schedule 2

Appendix G, clause 1

**HYOSCYAMUS NIGER**

Schedule 4

Schedule 2

Appendix G, clause 1

**HYPOTHALAMIC RELEASING FACTORS**

Schedule 4  
Appendix G, clause 1

**HYPROMELLOSE**

Schedule 4

**I**

**IBAFLOXACIN**

Schedule 4

**IBANDRONIC ACID**

Schedule 4

**IBOGAINE**

Schedule 4

**IBOTENIC ACID**

cross reference: MUSCIMOL

Schedule 9

**IBRITUMOMAB**

Schedule 4

**IBRUTINIB**

Schedule 4

**IBUFENAC**

Schedule 4

**IBUPROFEN**cross reference: PARACETAMOL

Schedule 4  
Schedule 3  
Schedule 2  
Appendix F, clause 4  
Appendix H, clause 1

**IBUTAMOREN**cross reference: MK‑677, NUTROBAL

Schedule 4  
Appendix D, clause 5

**IBUTEROL**

Schedule 4

**IBUTILIDE**

Schedule 4

**ICATIBANT**

Schedule 4

**ICODEXTRIN**

Appendix B, clause 3

**IDARUBICIN**

Schedule 4

**IDARUCIZUMAB**

Schedule 4

**IDEBENONE**

Schedule 4

**IDOXURIDINE**

Schedule 4

**IDURSULFASE**

Schedule 4

**IFOSFAMIDE**

Schedule 4

**ILOPROST**

Schedule 4

**IMATINIB**

Schedule 4

**IMAZALIL**cross reference: ENILCONAZOLE

Schedule 5

**IMAZAMOX**

Schedule 5

**IMAZAPIC**

Schedule 5

**IMAZAPYR**

Schedule 5

**IMAZETHAPYR**

Schedule 5

**IMDEVIMAB**

Schedule 4

**IMEPITOIN**

Schedule 4

**IMIDACLOPRID**

Schedule 6  
Schedule 5

**IMIDAPRIL**

Schedule 4

**IMIDOCARB**

Schedule 6

**IMIGLUCERASE**

Schedule 4

**IMINOCTADINE TRIALBESILATE**

Schedule 6

**IMIPENEM**

Schedule 4

**IMIPRAMINE**

Schedule 4  
Appendix K, clause 1

**IMIPROTHRIN**

Schedule 6  
Schedule 5

**IMIQUIMOD**

Schedule 4

**IMLIFIDASE**

Schedule 4

**IMMUNOGLOBULINS**cross reference: EQUINE ANTI‑HUMAN THYMOCYTE IMMUNOGLOBULIN, POLYCLONAL ANTIBODIES

Schedule 4

***IN VITRO* DIAGNOSTIC AND ANALYTICAL PREPARATIONS**

Appendix A, clause 1

**INCLISIRAN**

Schedule 4

**INDACATEROL**

Schedule 4

**INDANAZOLINE**

Schedule 2

**INDAPAMIDE**

Schedule 4

**INDAZIFLAM**

Schedule 6

**INDINAVIR**

Schedule 4

**INDOLE‑3‑ACETIC ACID**

Appendix B, clause 3

**INDOMETACIN**

Schedule 4  
Schedule 2  
Appendix G, clause 1

**INDOMETHACIN**cross reference: INDOMETACIN

**INDOPROFEN**

Schedule 4

**INDORAMIN**

Schedule 4

**INDOXACARB**

Schedule 6  
Schedule 5

**INFIGRATINIB**

Schedule 4

**INFLIXIMAB**

Schedule 4

**INFLUENZA AND CORYZA VACCINES**cross reference: H5N1 INFLUENZA VIRUS HAEMAGGLUTININ

Schedule 4

**INGENOL MEBUTATE**

Schedule 4

**INOTUZUMAB OZOGAMICIN**

Schedule 4

**INOSITOL NICOTINATE**

Schedule 3

**INPYRFLUXAM**

Schedule 6

**INSULIN DEGLUDEC**

Schedule 4

**INSULIN GLARGINE**

Schedule 4

**INSULIN‑LIKE GROWTH FACTOR I**

Schedule 4

**INSULIN‑LIKE GROWTH FACTORS**

Schedule 4  
Appendix D, clause 5

**INSULINS**

Schedule 4

**INTERFERONS**

Schedule 4

**INTERLEUKINS**

Schedule 4

**INTRAOCULAR VISCOELASTIC PRODUCTS**

Appendix A, clause 1

**IODINE**cross reference: IODOPHORS

Schedule 6  
Schedule 2  
Appendix E, clause 3  
Appendix F, clause 4

**IODOMETHANE**

Schedule 7  
Appendix J, clause 1

**IODOPHORS**cross reference: IODINE

Schedule 6  
Appendix E, clause 3

**3‑IODO‑2‑PROPYNYL BUTYL CARBAMATE**cross reference: IODOCARB

Schedule 6  
Schedule 5

**IODOSULFURON‑METHYL‑SODIUM**

Schedule 5

**IODOTHIOURACIL**

Schedule 4

**IOXYNIL**

Schedule 6

**IPAMORELIN**

Schedule 4,  
Appendix D, clause 5

**IPCONAZOLE**

Schedule 6  
Schedule 5

**IPFLUFENOQUIN**

Appendix B, Part 3

**IPILIMUMAB**

Schedule 4

**IPRATROPIUM**

Schedule 4  
Schedule 2

**IPRATROPIUM BROMIDE**

Appendix F, clause 4

**IPRIFLAVONE**

Schedule 4

**IPRINDOLE**

Schedule 4

**IPRODIONE**

Appendix B, clause 3

**IPRONIAZID**

Schedule 4

**IRBESARTAN**

Schedule 4

**IRINOTECAN**

Schedule 4

**IRON COMPOUNDS**cross reference: IRON OXIDES

Schedule 6  
Schedule 5  
Schedule 4  
Schedule 2

**ISAVUCONAZOLE**

Schedule 4  
Appendix L, clause 2

**ISETHIONATE**

Appendix B, clause 3

**ISOAMINILE**

Schedule 4

**ISOAMYL NITRITE**

Schedule 4  
Appendix E, clause 3

**ISOBUTYL NITRITE**

Schedule 4  
Appendix E, clause 3

**ISOCARBOPHOS**

Schedule 7

**ISOCARBOXAZID**

Schedule 4

**ISOCONAZOLE**

Schedule 6  
Schedule 4  
Schedule 3  
Schedule 2  
Appendix H, clause 1

**ISOCYANATES**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**ISOCYCLOSERAM**

Schedule 6

**ISOETARINE**

Schedule 4

**ISOEUGENOL**

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**ISOFENPHOS**

Schedule 7

**ISOFETAMID**

Appendix B, clause 3

**ISOFLURANE**

Schedule 4

**ISOMETHADONE**

cross reference: CAS No. 466-40-0

Schedule 9

**ISOMETHEPTENE**

Schedule 4

**ISONIAZID**

Schedule 4

**ISOPHORONE**

Schedule 5  
Appendix E, clause 3

**ISOPRENALINE**

Schedule 4  
Appendix F, clause 4

**ISOPRENE ALCOHOL**

Appendix B, clause 3

**ISOPRINOSINE**

Schedule 4

**ISOPROPAMIDE**

Schedule 4  
Schedule 2

**ISOPROPYL NITRITE**

cross reference: CAS No. 541-42-4

Schedule 10

**ISOPROTURON**

Schedule 7

**ISOPYRAZAM**

Schedule 6

**ISOSORBIDE DINITRATE**

Schedule 4  
Schedule 3

**ISOSORBIDE MONONITRATE**

Schedule 4

**ISOSTEARYL ALCOHOL ETHOXYLATE**

Appendix B, clause 3

**ISOTIANIL**

Schedule 6

**ISOTONITAZENE**

cross reference: CAS No. 14188-81-9

Schedule 9

**ISOTRETINOIN**

Schedule 4  
Appendix D, clause 5  
Appendix F, clause 4  
Appendix L, clause 2

**ISOXABEN**

Schedule 5

**ISOXAFLUTOLE**

Schedule 5

**ISOXICAM**

Schedule 4

**ISOXSUPRINE**

Schedule 4

**ISRADIPINE**

Schedule 4

**ITRACONAZOLE**

Schedule 4

**IVABRADINE**

Schedule 4

**IVACAFTOR**

Schedule 4

**IVERMECTIN**

Schedule 7  
Schedule 5  
Schedule 4

**IVOSIDENIB**

Schedule 4

**IXABEPILONE**

Schedule 4

**IXAZOMIB**

Schedule 4

**IXEKIZUMAB**

Schedule 4

**J**

**JAPANESE ENCEPHALITIS VACCINE**

Schedule 4

**JUNIPERUS SABINE**cross reference: SAVIN(E)

Schedule 10

**K**

**KAMBO**cross reference: Secretion of the South American Giant Leaf Frog or Giant Monkey Frog (*Phyllomedusa bicolor*)

Schedule 10

**KANAMYCIN**

Schedule 4

**KAOLIN**

Appendix B, clause 3

**KEROSENE**

Appendix E, clause 3

**KETAMINE**

Schedule 8

**KETANSERIN**

Schedule 4

**KETAZOLAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)

**KETOBEMIDONE**

cross reference: CAS No. 469-79-4, KETOBEMIDONE HYDROCHLORIDE (CAS No. 5965-49-1)

Schedule 9

**KETOCONAZOLE**

Schedule 4  
Schedule 2

**KETOPROFEN**

Schedule 4  
Schedule 3

Appendix H, clause 1

**KETOROLAC**

Schedule 4

**KETOTIFEN**

Schedule 4  
Schedule 2

**KHELLIN**

Schedule 4

**KINETIN**

Appendix B, clause 3

**KITASAMYCIN**

Schedule 5  
Schedule 4

**KRATOM**

cross reference: MITRAGYNA SPECIOSA, MITRAGYNINE

**KRESOXIM‑METHYL**

Appendix B, clause 3

**KUNZEA OIL**

Appendix B, clause 3

**L**

**LABETALOL**

Schedule 4

**LACIDIPINE**

Schedule 4

**LACOSAMIDE**

Schedule 4

**LAMBDA‑CYHALOTHRIN**

Schedule 7  
Schedule 6  
Schedule 5

**LAMIVUDINE**

Schedule 4

**LAMOTRIGINE**

Schedule 4  
Appendix K, clause 1

**LANADELUMAB**

Schedule 4

**LANATOSIDES**

Schedule 4

**LANREOTIDE**

Schedule 4

**LANSOPRAZOLE**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix H, clause 1

**LANTHANUM**

Schedule 4

**LAPATINIB**

Schedule 4

**LARONIDASE**

Schedule 4

**LAROPIPRANT**

Schedule 4

**LAROTRECTINIB**

Schedule 4

**LASALOCID**

Schedule 6

**LASIODIPLODIA PSEUDOTHEOBROMAE**

Schedule 5

**LATAMOXEF**

Schedule 4

**LATANOPROST**

Schedule 4

**LAUDEXIUM**

Schedule 4

**LAURETH CARBOXYLIC ACIDS**

Schedule 6  
Appendix E, clause 3

**LAURIC ACID**

Appendix B, clause 3

**LAUROMACROGOLS**cross reference: LAURETH‑9

Schedule 4

**LAURYL ALCOHOL**cross reference: 1‑DODECANOL

Appendix B, clause 3

**LAURYL ISOQUINOLINIUM BROMIDE**

Schedule 6  
Appendix E, clause 3

**LAURYL SULFATE SALTS**cross reference: SODIUM LAURYL SULPHATE, DODECYL SULFATES

Schedule 6  
Appendix E, clause 3

**LAVANDIN OIL**cross reference: CAMPHOR

Appendix B, clause 3

**LAVENDER OIL**

Appendix B, clause 3

**LEAD COMPOUNDS**cross reference: GLAZING PREPARATIONS, PRINTING INKS or INK ADDITIVES, SELENIUM

Schedule 10  
Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4 (in glazing preparations)  
Appendix F, clause 4

**LEAD METALLIC**

Appendix B, clause 3

**LEBRIKIZUMAB**

Schedule 4

**LECANEMAB**

Schedule 4

**LEDIPASVIR**

Schedule 4

**LEFETAMINE**

Schedule 4

**LEFLUNOMIDE**

Schedule 4  
Appendix F, clause 4  
Appendix L, clause 2

**LEMBOREXANT**

Schedule 4  
Appendix K, clause 1

**LEMON OIL**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**LEMONGRASS OIL**

Schedule 5

**LENACAPAVIR**

Schedule 4

**LENALIDOMIDE**

Schedule 4  
Appendix D, clause 4  
Appendix F, clause 4  
Appendix L, clause 2

**LENOGRASTIM**

Schedule 4

**LENVATINIB**

Schedule 4

**LEPIDOPTEROUS SEX PHEROMONES**

Appendix B, clause 3

**LEPIRUDIN**

Schedule 4

**LEPTAZOL**

Schedule 4

**LEPTOPHOS**

Schedule 7

**LEPTOSPERMUM SCOPARIUM OIL**cross reference: MANUKA OIL

Schedule 6  
Appendix E, clause 3

**LERCANIDIPINE**

Schedule 4

**LESINURAD**

Schedule 4

**LETERMOVIR**

Schedule 4

**LETROZOLE**

Schedule 4

**LEUPRORELIN**

Schedule 4

**LEVALLORPHAN**

Schedule 4

**LEVAMISOLE**

Schedule 6  
Schedule 5  
Schedule 4

**LEVAMFETAMINE**cross reference: LEVAMPHETAMINE

Schedule 8

**LEVETIRACETAM**

cross reference: RACETAMS

Schedule 4  
Appendix K, clause 1

**LEVOBUNOLOL**

Schedule 4

**LEVOBUPIVACAINE**

Schedule 4

**LEVOCABASTINE**

Schedule 4  
Schedule 2  
Appendix F, clause 4  
Appendix L, clause 2

**LEVOCETIRIZINE**

Schedule 4  
Schedule 2  
Appendix K, clause 1

**LEVODOPA**

Schedule 4

**LEVOMEPROMAZINE**cross reference: METHOTRIMEPRAZINE

Schedule 4

**LEVOMETHAMFETAMINE**cross reference: LEVOMETHAMPHETAMINE

Schedule 8

**LEVOMETHORPHAN**

cross reference: CAS No. 125-70-2

Schedule 9

**LEVOMILNACIPRAN**

Schedule 4

**LEVOMORAMIDE**

Schedule 8

**LEVONORGESTREL**

Schedule 4  
Schedule 3

Appendix H, clause 1

**LEVOPHENACYLMORPHAN**

cross reference: CAS No. 10061-32-2

Schedule 9

**LEVORPHANOL**

Schedule 8

**LEVOSIMENDAN**

Schedule 4

**LIDOCAINE**

Schedule 5  
Schedule 4  
Schedule 2

**LIDOFLAZINE**

Schedule 4

**LIFITEGRAST**

Schedule 4

**LIGNOCAINE**cross reference: LIDOCAINE

**LIGULARIA DENTATA**

Schedule 10

**LIME OIL**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**LIMONENE**cross reference: DIPENTENE

Appendix B, clause 3

**LINACLOTIDE**

Schedule 4

**LINAGLIPTIN**

Schedule 4

**LINCOMYCIN**

Schedule 4

**LINDANE**cross reference: BHC

Schedule 6  
Schedule 5  
Schedule 4  
Schedule 2

**LINEZOLID**

Schedule 4

**LINOLEIC ACID**

Appendix B, clause 3

**LINSEED FATTY ACIDS**

Appendix B, clause 3

**LINURON**

Appendix B, clause 3

**LIOTHYRONINE**cross reference: TRIIODOTHYRONINE

Schedule 4

**LIPEGFILGRASTIM**

Schedule 4

**LIQUORICE, DEGLYCYRRHISINISED**

Appendix B, clause 3

**LIRAGLUTIDE**

Schedule 4

**LISDEXAMFETAMINE**

Schedule 8

**LISINOPRIL**

Schedule 4

**LISURIDE**

Schedule 4

**LITHIUM**

Schedule 4  
Schedule 2

**LITHIUM PERFLUOROOCTANE SULFONATE**

Schedule 7

**LIXISENATIDE**

Schedule 4

**LOBELIA INFLATA**

Schedule 2

**LOBELINE**

Schedule 2

**LODOXAMIDE**

Schedule 4  
Schedule 2

**LOFEXIDINE**

Schedule 4

**LOGIPARIN**

Schedule 4

**LOMEFLOXACIN**

Schedule 4

**LOMUSTINE**

Schedule 4

**LOPERAMIDE**

Schedule 4  
Schedule 2  
Appendix F, clause 4

**LOPINAVIR**

Schedule 4

**LOPRAZOLAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)

**LORACARBEF**

Schedule 4

**LORATADINE**

Schedule 4  
Schedule 2

**LORAZEPAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)  
Appendix K, clause 1

**LORLATINIB**

Schedule 4

**LORMETAZEPAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)

**LOSARTAN**

Schedule 4

**LOTEPREDNOL**

Schedule 4

**LOTILANER**

Schedule 5

**LOXAPINE**

Schedule 4

**LUBRICANTS**

Appendix A, clause 1

**LUFENURON**

Schedule 5

**LUMACAFTOR**

Schedule 4

**LUMEFANTRINE**

Schedule 4

**LUMIRACOXIB**

Schedule 4

**LURASIDONE**

Schedule 4  
Appendix K, clause 1

**LURBINECTEDIN**

Schedule 4

**LUSPATERCEPT**

Schedule 4

**LUTEINISING HORMONE**

Schedule 4  
Appendix D, clause 1

**LYMECYCLINE**

Schedule 4

**LYSERGIC ACID**

cross reference: CAS No. 82-58-6

Schedule 9

**LYSERGIDE**

cross reference: CAS No. 50-37-3

Schedule 9

**M**

**MACITENTAN**

Schedule 4  
Appendix D, clause 6  
Appendix L, clause 2

**MACROGOLS**

Schedule 3  
Schedule 2

**MACROPHOMINA PHASEOLINA**

Schedule 5

**MADURAMICIN**

Schedule 7  
Schedule 5  
Appendix J, clause 1

**MAFENIDE**

Schedule 6  
Schedule 4

**MAGNESIUM CHLORATE**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**MAGNESIUM HYDROXIDE**

Appendix B, clause 3

**MAGNESIUM SULFATE**

Schedule 3

**MALACHITE GREEN**

Schedule 7  
Schedule 5

**MALATHION**cross reference: MALDISON, ORGANOPHOSPHORUS COMPOUNDS

Schedule 6  
Schedule 5  
Schedule 3  
Appendix E, clause 3

**MALEIC HYDRAZIDE**

Appendix B, clause 3

**MANCOZEB**

Schedule 5

**MANDESTROBIN**

Schedule 5

**MANDIPROPAMID**

Schedule 5

**MANDRAGORA OFFICINARUM**

Schedule 4

**MANGANESE DIOXIDE**

Appendix B, clause 3

**MANNITYL HEXANITRATE**

Schedule 3

**MANNOMUSTINE**

Schedule 4

**MAPROTILINE**

Schedule 4

**MARAVIROC**

Schedule 4

**MARBOFLOXACIN**

Schedule 4

**MARIBAVIR**

Schedule 4

**MARJORAM OIL**

Schedule 5Appendix E, clause 3

**MAROPITANT**

Schedule 4

**MATCHES**

Appendix A, clause 1

**MAVACAMTEN**

Schedule 4

**MAVACOXIB**

Schedule 4

**MAZIDOX**

Schedule 7

**MAZINDOL**

Schedule 4  
Appendix K, clause 1

**MCPA**

Schedule 6  
Schedule 5

**MCPB**  
cross reference: (4‑(4‑CHLORO‑2‑METHYLPHENOXY)BUTANOIC ACID

Schedule 6

**MEASLES VACCINE**

Schedule 4

**MEBANAZINE**

Schedule 4

**MEBENDAZOLE**

Schedule 6Schedule 5  
Schedule 2

**MEBEVERINE**

Schedule 4

**MEBHYDROLIN**

Schedule 4  
Appendix K, clause 1

**MEBOLAZINE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**MEBUTAMATE**

Schedule 4

**MECAMYLAMINE**

Schedule 4

**MECARBAM**

Schedule 7

**MECASERMIN**

Schedule 4

**MECILLINAM**

Schedule 4

**MECLOCYCLINE**

Schedule 4

**MECLOFENAMATE**

Schedule 4

**MECLOFENAMIC ACID**

Schedule 5

**MECLOFENOXATE**

Schedule 4

**MECLONAZEPAM**

cross reference: CAS No. 58662-84-3

Schedule 9

**MECLOQUALONE**

cross reference: CAS No. 340-57-8

Schedule 9

**MECLOZINE**  
cross reference: MECLIZINE

Schedule 4  
Schedule 2  
Appendix K, clause 1

**MECOPROP**

Schedule 6  
Schedule 5

**MECOPROP‑P**

Schedule 6

**MEDAZEPAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)  
Appendix K, clause 1

**MEDETOMIDINE**

Schedule 4

**MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS**

Appendix A, clause 1

**MEDICAL DEVICES**cross reference: ANTICOAGULANT MEDICAL DEVICES, ARTIFICIAL TEARS, COLLAGEN, INJECTABLE TISSUE RECONSTRUCTIVE, AUGMENTATION AND RESTORATION MATERIALS, INTRA‑ARTICULAR FLUIDS, URINARY CATHETERS

Appendix A, clause 1

**MEDIGOXIN**cross reference: METHYLDIGOXIN

Schedule 4

**MEDROXYPROGESTERONE**

Schedule 4

**MEDRYSONE**

Schedule 4

**MEFENAMIC ACID**

Schedule 4  
Schedule 2  
Appendix F, clause 4

**MEFENOREX**

Schedule 4

**MEFENPYR‑DIETHYL**

Schedule 5

**MEFENTRIFLUCONAZOLE**

Schedule 5

**MEFLOQUINE**

Schedule 4

**MEFLUIDIDE**

Schedule 6

**MEFRUSIDE**

Schedule 4

**MEGASPHAERA ELSDENII strain 41125**

Appendix B, clause 3

**MEGESTROL**

Schedule 4

**MELAGATRAN**

Schedule 4

**MELALEUCA OIL**cross reference: TEA TREE OIL

Schedule 6  
Appendix E, clause 3

**MELANOTAN II**  
cross reference: α–MELANOCYTE STIMULATING HORMONE

Schedule 4

**MELATONIN**

Schedule 4  
Schedule 3  
Appendix H, clause 1

**MELENGESTROL**

Schedule 4

**MELENGESTROL ACETATE**

Schedule 6

**MELIA AZEDARACH**

Schedule 10

**MELOXICAM**

Schedule 6

Schedule 4

**MELPHALAN**

Schedule 4

**MEMANTINE**

Schedule 4

**MENAZON**

Schedule 6

**MENINGOCOCCAL VACCINE**

Schedule 4

**MENINGOCOCCAL GROUP B VACCINE**  
cross reference: Neisseria Meningitidis Serogroup B Recombinant LP2086 (MnB rLP2086) Subfamily A Protein and Subfamily B Protein

Schedule 4

**MENOTROPHIN**

cross reference: HUMAN MENOPAUSAL GONADOTROPHIN

Schedule 4

**MEPACRINE**

Schedule 4

**MEPENZOLATE**

Schedule 4

**MEPHENESIN**

Schedule 4

**MEPHENTERMINE**

Schedule 4

**MEPINDOLOL**

Schedule 4

**MEPIQUAT**

Schedule 5

**MEPITIOSTANE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**MEPIVACAINE**

Schedule 4

**MEPROBAMATE**

Schedule 4  
Appendix K, clause 1

**MEPTAZINOL**

Schedule 4

**MEPYRAMINE**

Schedule 4  
Schedule 3   
Schedule 2  
Appendix K, clause 1

**MEQUITAZINE**

Schedule 4

**MERCAPTAMINE**cross reference: CYSTEAMINE

Schedule 6  
Schedule 5  
Schedule 4  
Appendix K, clause 1

**MERCAPTOACETIC ACID**cross reference: THIOGLYCOLIC ACID

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**2‑MERCAPTOETHANOL**

Schedule 6

**MERCAPTOMERIN**

Schedule 4

**MERCAPTOPURINE**

Schedule 4

**MERCURIC CHLORIDE**cross reference: CALOMEL

Schedule 7  
Appendix E, clause 3

**MERCURIC IODIDE**

Appendix E, clause 3

**MERCURIC NITRATE**

Appendix E, clause 3

**MERCURIC OXIDE**

Schedule 6Appendix E, clause 3

**MERCURIC POTASSIUM IODIDE**

Appendix E, clause 3

**MERCURIC THIOCYANATE**

Appendix E, clause 3  
Appendix F, clause 4

**MERCUROCHROME**

Schedule 6  
Schedule 4  
Schedule 2  
Appendix E, clause 3

**MERCUROUS CHLORIDE**cross reference: CORROSIVE SUBLIMATE

Appendix E, clause 3

**MERCURY**cross reference: ETHOXYETHYLMERCURIC CHLORIDE, ETHOXYQUIN, PHENYL MERCURIC CHLORIDE

Schedule 7  
Schedule 4  
Schedule 2  
Appendix G, clause 1  
Appendix J, clause 1

**MERCURY metallic**

Appendix E, clause 3

**MERCURY, organic compounds**

Appendix E, clause 3

**MEROPENEM**

Schedule 4

**MERSALYL**

Schedule 4

**MESABOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**MESALAZINE**

Schedule 4

**MESNA**

Schedule 4

**MESOSULFURON‑METHYL**

Appendix B, clause 3

**MESOTRIONE**

Schedule 5

**MESTANOLONE**cross reference: ANDROSTALONE

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**MESTEROLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**MESTRANOL**

Schedule 4

**METACRESOLSULPHONIC ACID**

Schedule 6  
Appendix F, clause 4

**METAFLUMIZONE**

Schedule 5

**METALAXYL**

Schedule 6  
Schedule 5

**METALDEHYDE**

Schedule 6  
Schedule 5  
Appendix E, clause 3

**METAMFETAMINE**cross reference: METHAMFETAMINE, METHAMPHETAMINE, METHYLAMFETAMINE**,** METHYLAMPHETAMINE

Schedule 8

**METAMITRON**

Schedule 6

**METANDIENONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**METARAMINOL**

Schedule 4

**METARHIZIUM ANISOPLIAE**

Appendix B, clause 3

**METAZACHLOR**

Schedule 5

**METAZOCINE**

cross reference: CAS No. 3734-52-9, METAZOCINE RACEMATE CIS-FORM (CAS No. 25144-79-0)

Schedule 9

**METCAMIFEN**

Appendix B, clause 3

**METENOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**METERGOLINE**

Schedule 4

**METFORMIN**

Schedule 4

**METHABENZTHIAZURON**

Schedule 5

**METHACHOLINE**

Schedule 4

**METHACRIFOS**

Schedule 7Schedule 6  
Appendix J, clause 1

**METHACYCLINE**

Schedule 4

**METHADONE**

Schedule 8  
Appendix K, clause 1

**METHALLENESTRIL**cross reference: METHALLENOESTRIL

Schedule 4

**METHAM**cross reference: METHAM SODIUM

Schedule 6

**METHAMIDOPHOS**

Schedule 7

**METHANDRIOL**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**METHANOL**

cross reference: CAS No. 67-56-1

Schedule 10

Schedule 6

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**METHANTHELINIUM**

Schedule 4

**METHAPYRILENE**

Schedule 7

**METHAQUALONE**

cross reference: CAS No. 72-44-6, METHAQUALONE HYDROCHLORIDE (CAS No. 340-56-7)

Schedule 9

**METHAZOLAMIDE**

Schedule 4

**METHAZOLE**

Schedule 7

**METHCATHINONE**

cross reference: CAS No. 5650-44-2, METHCATHINONE HYDROCHLORIDE (CAS No. 49656-78-2)

Schedule 9

**METHDILAZINE**

Schedule 4  
Schedule 3  
Appendix K, clause 1

**METHENAMINE**cross reference: 1,3,5,7‑TETRAAZATRICYLO[3.3.1.13,7] DECANE, HEXAMINE, HEXAMETHYLENETETRAMINE

Schedule 5

**METHENOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**METHICILLIN**

Schedule 4

**METHIDATHION**

Schedule 7

**METHIMAZOLE**cross reference: THIAMAZOLE

Schedule 4

**METHIOCARB**

Schedule 7  
Schedule 6  
Schedule 5

**METHISAZONE**

Schedule 4

**METHIOZOLIN**

Schedule 5

**METHIXENE**

Schedule 4

**METHOCARBAMOL**

Schedule 4  
Appendix K, clause 1

**METHOFLUTHRIN**

Schedule 5

**METHOHEXITONE**

Schedule 4

**METHOIN**

Schedule 4

**METHOMYL**cross reference: DENATONIUM BENZOATE

Schedule 7Schedule 6

**METHOPRENE**

Appendix B, clause 3

**METHOTREXATE**

Schedule 4

**METHOXAMINE**

Schedule 4  
Schedule 2  
Appendix F, clause 4

**METHOXSALEN**

Schedule 4

**METHOXYCHLOR**

Schedule 5

**2‑METHOXYETHANOL**

Schedule 7  
Appendix F, clause 4

**METHOXYETHYLMERCURIC ACETATE**

Schedule 7  
Appendix J, clause 1

**METHOXYETHYLMERCURIC CHLORIDE**

Schedule 7  
Appendix J, clause 1

**METHOXYFENOZIDE**

Appendix B, clause 3

**METHOXYFLURANE**

Schedule 4

**5‑METHOXY‑3,4‑METHYLENEDIOXYAMFETAMINE**cross reference: 5‑METHOXY‑3,4‑METHYLENEDIOXYAMPHETAMINE, MMDA (CAS No. 13674-05-0), MMDA HYDROCHLORIDE (CAS No. 60676-84-8)

Schedule 9

**4‑METHOXY‑ α –METHYLPHENYLETHYLAMINE**cross reference: PMA (CAS No. 64-13-1), PMA HYDROCHLORIDE (CAS No. 3706-26-1)

Schedule 9

**5‑METHOXY‑ α –METHYLTRYPTAMINE**cross reference: 5‑MeO‑AMT (CAS No. 1137-04-8)

Schedule 9

**6‑METHOXY‑N2‑METHYL‑2,3‑PYRIDINEDIAMINE**

Schedule 6

**2‑METHOXY‑5‑NITROPHENOL**

Schedule 6

**METHOXYPHENAMINE**

Schedule 2

**2‑(2‑METHOXYPHENYL)‑1‑(1‑PENTYLINDOL‑3‑YL)ETHANONE**cross reference: JWH‑250 (CAS No. 864445-43-2)

Schedule 9

**METHSUXIMIDE**

Schedule 4

**METHYCLOTHIAZIDE**

Schedule 4

**METHYL ACETATE**

Appendix B, clause 3

**METHYL (2*S*, 4a*R*, 6a*R*, 7*R*, 9*S*, 10a*S*, 10b*R*)‑9‑ACETOXY‑6a,10b‑DIMETHYL‑4,10‑DIOXO‑DODECAHYDRO‑2‑(3‑FURYL)‑2H‑NAPHTHO[2,1‑c]PYRAN‑7‑CARBOXYLATE**cross reference: SALVINORIN A (CAS No. 83729-01-5)

Schedule 9

**METHYL AMINOLEVULINATE**

Schedule 4

***p*‑METHYLAMINOPHENOL**

Schedule 6  
Appendix F, clause 4

**4‑METHYLAMINOREX**

cross reference: CAS No. 3568-94-3

Schedule 9

**METHYLANDROSTANOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**METHYLATED SPIRIT(S)**cross reference: DENATONIUM BENZOATE, ETHANOL, FLUORESCEIN

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**METHYL BENZOQUATE**

Appendix B, clause 3

**METHYL BROMIDE**

Schedule 7  
Appendix J, clause 1

**METHYL CHLORIDE**

Appendix F, clause 4

**METHYLCHLOROISOTHIAZOLINONE**   
cross reference: METHYLISOTHIAZOLINONE

Schedule 6  
Appendix F, clause 4

**METHYLCLOSTEBOL**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL**

Schedule 7Schedule 6

**1‑METHYLCYCLOPROPENE**

Appendix B, clause 3

**METHYLDESORPHINE**

cross reference: CAS No. 16008-36-9

Schedule 9

**METHYLDIBROMO GLUTARONITRILE**

cross reference: CAS No. 35691-65-7

Schedule 10  
Schedule 6  
Appendix F, clause 4

**METHYLDIHYDROMORPHINE**

Schedule 8

**METHYLDOPA**

Schedule 4

**4,4**'**‑METHYLENEBIS[2‑CHLOROANILINE]**

Schedule 7  
Appendix J, clause 1

**METHYLENE BISTHIOCYANATE**

Schedule 6  
Appendix F, clause 4

**METHYLENE BLUE**

Schedule 7  
Schedule 5  
Schedule 4

**3,4‑METHYLENEDIOXYAMFETAMINE**cross reference: 3,4‑METHYLENEDIOXYAMPHETAMINE, MDA, TENAMFETAMINE (CAS No. 4764-17-4)

Schedule 9

**3,4‑METHYLENEDIOXYPYROVALERONE**cross reference: MDPV (CAS No. 687603-66-3)

Schedule 9

**METHYLEPHEDRINE**

Schedule 2

**METHYLERGOMETRINE**

Schedule 4

**METHYL ETHYL KETONE**cross reference: DESIGNATED SOLVENT

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**METHYL ETHYL KETONE OXIME**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**METHYL ETHYL KETONE PEROXIDE**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**METHYLEUGENOL**

Schedule 6  
Appendix E, clause 3,  
Appendix F, clause 4

**3‑METHYLFENTANYL**

cross reference: CAS No. 42045-86-3

Schedule 9

**METHYLPHENYLPIRACETAM**  
cross reference: RACETAMS

Schedule 4

**METHYL *p*‑HYDROXYBENZOATE**

Appendix B, clause 3

**METHYL ISOAMYL KETONE**cross reference: DESIGNATED SOLVENT

Schedule 5  
Appendix E, clause 3

**METHYL ISOBUTYL KETONE**cross reference: DESIGNATED SOLVENT, METHYLATED SPIRIT(S)

Schedule 5  
Appendix E, clause 3

**METHYL ISOTHIOCYANATE**

Schedule 6

**METHYLISOTHIAZOLINONE**  
cross reference: METHYLCHLOROISOTHIAZOLINONE

Schedule 6  
Appendix F, clause 4

**METHYLMERCURY**

Schedule 4  
Appendix G, clause 1

**METHYL METHACRYLATE**

cross reference: CAS No. 80-62-6

Schedule 10  
Schedule 6   
Appendix F, clause 4

**4‑METHYLMETHCATHINONE**cross reference: MEPHEDRONE (CAS No. 1189805-46-6)

Schedule 9

**N‑METHYL‑1‑(3,4‑METHYLENEDIOXYPHENYL)‑2‑BUTANAMINE**cross reference: MBDB (CAS No. 135795-90-3)

Schedule 9

***N*‑ α ‑[METHYL‑3,4‑(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE**cross reference: N‑HYDROXY MDA (CAS No. 74698-47-8)

Schedule 9

**2‑METHYL‑3‑MORPHOLINO‑1, 1‑DIPHENYLPROPANE CARBOXYLIC ACID**cross reference: MORAMIDE INTERMEDIATE (CAS No. 3626-55-9)

Schedule 9

**METHYLNALTREXONE**

Schedule 4

**METHYL NEODECANAMIDE**

Schedule 6

**METHYLNORBORNYLPYRIDINE**

Schedule 6

**METHYLONE \*(MDMC)**

cross reference: CAS No. 186028-79-5, MDMC HYDROCHLORIDE (CAS No. 186028-80-8)

Schedule 9

**METHYLPENTYNOL**

Schedule 4

**METHYLPHENIDATE**

Schedule 8

**METHYLPHENOBARBITAL**cross reference: BARBITURATE METHYLPREDNISOLONE

Schedule 4  
Appendix K, clause 1

**METHYLPHENOBARBITONE**cross reference: METHYLPHENOBARBITAL, BARBITURATE METHYLPREDNISOLONE

**1‑METHYL‑4‑PHENYL‑4‑PIPERIDINOL PROPIONATE**cross reference: ACIDMPPP (CAS No. 13147-09-6), MPPP HYDROCHLORIDE (CAS No. 4968-48-3)

Schedule 9

**1‑METHYL‑4‑PHENYLPIPERIDINE‑4‑CARBOXYLIC ACID**cross reference: PETHIDINE INTERMEDIATE C

Schedule 8

**METHYLPREDNISOLONE**

Schedule 4

***N*‑METHYL‑2‑PYRROLIDONE**

Schedule 6

Schedule 5  
Appendix E, clause 3

**2‑METHYLRESORCINOL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**METHYLROSANILINIUM CHLORIDE**cross reference: CRYSTAL VIOLET (CAS No. 548-62-9), GENTIAN VIOLET, ACID VIOLET 49 (CAS No. 1694-09-3), ETHYL VIOLET (CAS No. 2390-59-2), BASIC BLUE 7 (CAS No. 2390-60-5), BASIC BLUE 26 (CAS No. 2580-56-5)

Schedule 10  
Schedule 6  
Schedule 4

**METHYL SALICYLATE**

Schedule 6  
Schedule 5Schedule 4

**METHYL SALICYLATE LIQUID**

Appendix E, clause 3

**METHYLTESTOSTERONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**4‑METHYLTHIOAMFETAMINE**cross reference: 4‑METHYLTHIOAMPHETAMINE (CAS No. 14116-06-4)

Schedule 9

**3‑METHYLTHIOFENTANYL**

cross reference: CAS No. 86052-04-2

Schedule 9

**2‑METHYLTHIO‑4‑(2‑METHYLPROP‑2‑YL) AMINO‑6‑CYCLOPROPYLAMINO‑5‑ TRIAZINE**

Schedule 5

**METHYLTHIOURACIL**

Schedule 4

**METHYLTRIENOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**METHYPRYLONE**

Schedule 4

**METHYSERGIDE**

Schedule 4

**METIRAM**

Schedule 5

**METOBROMURON**

Schedule 5

**METOCLOPRAMIDE**

Schedule 4  
Schedule 3

**METODESNITAZENE**

cross reference: CAS No. 14030-77-4, METAZENE

Schedule 9

**METOFLUTHRIN**

Schedule 6  
Schedule 5

**METOLACHLOR**

Schedule 5

**METOLAZONE**

Schedule 4

**METONITAZENE**

cross reference: CAS No. 14680-51-4

Schedule 9

**METOPON**

cross reference: CAS No. 143-52-2

Schedule 9

**METOPROLOL**

Schedule 4

**METOSULAM**

Schedule 6

**METRAFENONE**

Schedule 6  
Schedule 5

**METRIBOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**METRIBUZIN**

Schedule 6

**METRIFONATE**cross reference: TRICHLORFON

Schedule 4

**METRONIDAZOLE**cross reference: BENZOYL METRONIDAZOLE

Schedule 4

**METSULFURONMETHYL**

Appendix B, clause 3

**METYRAPONE**

Schedule 4

**MEVINPHOS**

Schedule 7

**MEXILETINE**

Schedule 4

**MEZLOCILLIN**

Schedule 4

**MIANSERIN**

Schedule 4  
Appendix K, clause 1

**MIBEFRADIL**

Schedule 4

**MIBOLERONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**MICAFUNGIN**

Schedule 4

**MICONAZOLE**

Schedule 6  
Schedule 4  
Schedule 3  
Schedule 2  
Appendix F, clause 4Appendix H, clause 1

**MIDAZOLAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)

Appendix K, clause 1

**MIDODRINE**

Schedule 4

**MIDOSTAURIN**

Schedule 4

**MIFEPRISTONE**

Schedule 4

**MIGALASTAT**

Schedule 4

**MIGLITOL**

Schedule 4

**MIGLUSTAT**

Schedule 4

**MILBEMECTIN**

Schedule 6  
Schedule 5

**MILNACIPRAN**

Schedule 4

**MILBEMYCIN OXIME**

Schedule 5  
Schedule 4

**MILRINONE**

Schedule 4

**MINOCYCLINE**

Schedule 4

**MINOXIDIL**

Schedule 4  
Schedule 2

**MIPAFOX**

Schedule 7

**MIRABEGRON**

Schedule 4

**MIREX**

Schedule 7  
Appendix J, clause 1

**MIRIKIZUMAB**

Schedule 4

**MIRTAZAPINE**

Schedule 4  
Appendix K, clause 1

**MISOPROSTOL**

Schedule 4  
Appendix F, clause 4  
Appendix L, clause 2

**MITOBRONITOL**

Schedule 4

**MITOMYCIN**

Schedule 4

**MITOTANE**

Schedule 4

**MITOXANTRONE**

Schedule 4

**MITRAGYNA SPECIOSA**  
cross reference: KRATOM; MITRAGYNINE (CAS No. 4098-40-2)  
Schedule 9

**MITRAGYNINE**cross reference: (CAS No. 4098-40-2), KRATOM; MITRAGYNA SPECIOSA

Schedule 9

**MITRATAPIDE**

Schedule 4

**MIVACURIUM CHLORIDE**

Schedule 4

**MOBOCERTINIB**

Schedule 4

**MOCLOBEMIDE**

Schedule 4

**MODAFINIL**

Schedule 4

**MOLGRAMOSTIM**

Schedule 4

**MOLINATE**

Schedule 7  
Appendix J, clause 1

**MOLINDONE**

Schedule 4

**MOLNUPIRAVIR**

Schedule 4

**MOMETASONE**

Schedule 4

Schedule 3  
Schedule 2

**MOMFLUOROTHRIN**

Schedule 6

**MONENSIN**

Schedule 6  
Schedule 5  
Schedule 4

**MONEPANTEL**

Schedule 5

**MONOBENZONE**cross reference: HYDROQUINONE

Schedule 4

**MONOCLONAL ANTIBODIES**

Schedule 4

**MONOCROTOPHOS**

Schedule 7

**MONOETHANOLAMINE**

Schedule 6  
Schedule 5  
Schedule 4  
Appendix E, clause 3  
Appendix F, clause 4

**MONTELUKAST**

Schedule 4

**MOPERONE**

Schedule 4

**MORANTEL**

Schedule 6  
Schedule 5

**MORAZONE**

Schedule 4

**MORICIZINE**

Schedule 4

**MORPHERIDINE**

cross reference: CAS No. 469-81-8

Schedule 9

**MORPHINE**

Schedule 8Appendix K, clause 1

**MORPHINE METHOBROMIDE**

Schedule 8

**MORPHINE‑N‑OXIDE**

Schedule 8

**(1‑(2‑MORPHOLIN‑4‑YLETHYL)INDOL‑3‑YL)‑NAPTHALEN‑1‑ YLMETHANONE**cross reference: JWH‑200 (CAS No. 103610-04-4)

Schedule 9

**MOTOR, HEATING or FURNACE FUELS**cross reference: FUELS, FUELS, HOBBY ‑ FUELS, TOY, KEROSENE, METHANOL, PETROL

Appendix A, clause 1

**MOTRAZEPAM**

Schedule 4

**MOTRETINIDE**

Schedule 4

**MOXIDECTIN**

Schedule 7  
Schedule 6  
Schedule 5  
Schedule 4

**MOXIFLOXACIN**

Schedule 4

**MOXONIDINE**

Schedule 4

**MSMA**

Schedule 7  
Schedule 6

**MUMPS VACCINE**

Schedule 4

**MUPIROCIN**

Schedule 4

**MURAGLITAZAR**

Schedule 4

**MUROMONAB**

Schedule 4

**MUSCIMOL**

cross reference: CAS No. 2763-96-4, MUSCIMOL HYDROBROMIDE (CAS No. 18174-72-6)

Schedule 9

**MUSTINE**cross reference: NITROGEN MUSTARD

Schedule 4

**MYCLOBUTANIL**

Schedule 5

**MYCOPHENOLIC ACID**cross reference: MYCOPHENOLATE MOFETIL

Schedule 4

**MYRISTIC ACID**

Appendix B, clause 3

**MYROPHINE**

cross reference: CAS No. 467-18-5

Schedule 9

**N**

**NAA**cross reference: NAPTHALENEACETIC ACID

Schedule 5

**NABILONE**

Schedule 8

**NABIXIMOLS**cross reference: CANNABICHROMENE, CANNABIDIOL, CANNABIDIOLIC ACID, CANNABIDIVAROL, CANNABIGEROL, CANNABINOIDS, CANNABINOL, CANNABIS SATIVA, TETRAHYDROCANNABINOLIC ACID, TETRAHYDROCANNABINOLS, TETRAHYDROCANNABIVAROL

Schedule 8  
Appendix D, clause 1  
Appendix K, clause 1

**NABUMETONE**

Schedule 4

**NADOLOL**

Schedule 4

**NADROPARIN**

Schedule 4

**NAFARELIN**

Schedule 4

**NAFTIDROFURYL**

Schedule 4

**NALBUPHINE**

Schedule 4  
Appendix K, clause 1

**NALED**

Schedule 6  
Schedule 5

**NALIDIXIC ACID**

Schedule 4

**NALMEFENE**

Schedule 4

**NALORPHINE**

Schedule 4

**NALOXEGOL**

Schedule 4

**NALOXONE**

Schedule 4  
Schedule 3

Appendix H, clause 1

**NALTREXONE**

Schedule 4

**NANDROLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**NAPHAZOLINE**

Schedule 2  
Appendix F, clause 4

**NAPHTHALENE**

cross reference: CAS No. 91-20-3

Schedule 10  
Schedule 6   
Appendix E, clause 3   
Appendix F, clause 4   
Appendix G, clause 1

**1,5‑NAPHTHALENEDIOL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**2,7‑NAPTHALENEDIOL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**NAPHTHALEN‑1‑YL‑(1‑BUTYLINDOL‑3‑YL)METHANONE**cross reference: JWH‑073 (CAS No. 208987-48-8)

Schedule 9

**NAPHTHALOPHOS**

Schedule 7

Schedule 6

**1‑NAPHTHOL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**NAPHTHOYLINDOLES**

Schedule 9

**NAPHTHOYLPYRROLES**

Schedule 9

**NAPHTHYLMETHYLINDENES**

Schedule 9

**NAPHTHYLMETHYLINDOLES**

Schedule 9

**NAPROPAMIDE**

Appendix B, clause 3

**NAPROXEN**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix F, clause 4  
Appendix H, clause 1

**NAPTALAM**

Schedule 5

**NAPTHYL ACETAMIDE**

Appendix B, clause 3

**NARASIN**

Schedule 6  
Schedule 4

**NARATRIPTAN**

Schedule 4

Schedule 3

Appendix H, clause 1

**NATALIZUMAB**

Schedule 4

**NATAMYCIN**cross reference: PIMARCIN

Schedule 4

**NATEGLINIDE**

Schedule 4

**NEBACUMAB**

Schedule 4

**NEBIVOLOL**

Schedule 4

**NEBRACETAM**cross reference: RACETAMS

Schedule 4

**NEDOCROMIL**

Schedule 4

**NEFAZODONE**

Schedule 4

**NEFIRACETAM**  
cross reference: RACETAMS

Schedule 4

**NEFOPAM**

Schedule 4

**NELARABINE**

Schedule 4

**NELFINAVIR**

Schedule 4

**NEOMYCIN**

Schedule 4

**NEOSCYTALIDIUM NOVAEHOLLANDIAE**

Schedule 5

**NEOSTIGMIN**

Schedule 4

**NEPAFENAC**

Schedule 4

**NERATINIB**

Schedule 4

**NERIUM OLEANDER**

Schedule 4  
Appendix G, clause 1

**NEROLI OIL**

Appendix B, clause 3

**NESIRITIDE**

Schedule 4

**NETILMICIN**

Schedule 4

**NETOBIMIN**

Schedule 6  
Schedule 5

**NETUPITANT**

Schedule 4

**NEVIRAPINE**

Schedule 4

**NIALAMIDE**

Schedule 4

**NICARBAZIN**

Appendix B, clause 3

**NICARDIPINE**

Schedule 4

**NICERGOLINE**

Schedule 4

**NICKEL SULFATE**

Schedule 6

**NICLOSAMIDE**

Schedule 2

**NICOCODINE**

cross reference: CAS No. 3688-66-2, NICOCODINE HYDROCHLORIDE (CAS No. 58263-01-7)

Schedule 9

**NICODICODINE**

cross reference: CAS No. 808-24-2

Schedule 9

**NICOFURANOSE**

Schedule 4

**NICOMORPHINE**

cross reference: CAS No. 639-48-5, NICOMORPHINE HYDROCHLORIDE (CAS No. 12040-41-4)

Schedule 9

**NICORANDIL**

Schedule 4

**NICOTINE**

Schedule 7  
Schedule 4  
Appendix D, clause 5  
Appendix F, clause 4  
Appendix J, clause 1

**NICOTINIC ACID**cross reference: NICOTINAMIDE

Schedule 4  
Schedule 3

**NICOTINYL ALCOHOL**

Schedule 3

**NICOUMALONE**

Schedule 4

**NIFEDIPINE**

Schedule 4

**NIFENAZONE**

Schedule 4

**NIFOXIPAM**

cross reference: CAS No. 74723-10-7

Schedule 9

**NIKETHAMIDE**

Schedule 4

**NILOTINIB**

Schedule 4

**NILUTAMIDE**

Schedule 4

**NIMESULIDE**

Schedule 4

**NIMIDANE**

Schedule 7  
Schedule 6

**NIMODIPINE**

Schedule 4

**NIMORAZOLE**

Schedule 4

**NINTEDANIB**

Schedule 4

**NIRAPARIB**

Schedule 4

**NIRIDAZOLE**

Schedule 4

**NIRMATRELVIR**

Schedule 4

**NIRSEVIMAB**

Schedule 4

**NISIN**

Appendix B, clause 3

**NISOLDIPINE**

Schedule 4

**NITENPYRAM**

Schedule 6

**NITISINONE**

Schedule 4

**NITRAZEPAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)  
Appendix K, clause 1

**NITRENDIPINE**

Schedule 4

**NITRIC ACID**

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**NITRIC OXIDE**

Schedule 4

**NITROBENZENE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**NITROFEN**

Schedule 7  
Appendix J, clause 1

**NITROFURANTOIN**

Schedule 4

**NITROFURAZONE**

Schedule 4

**3‑NITRO‑*p*‑HYDROXYETHYLAMINOPHENOL**  
cross reference: 4‑[(2‑HYDROXYETHYL)AMINO]‑3‑NITROPHENOL

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**NITROPHENOLS**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**NITROPRUSSIDES**

Schedule 7  
Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**NITROSCANATE**

Schedule 5

**2‑NITROTOLUENE**

Schedule 7

**NITROUS OXIDE**

Schedule 4

Schedule 6

Appendix E, clause 3

Appendix F, clause 4

**NITROXOLINE**

Schedule 4

**NITROXYNIL**

Schedule 6

**NIVOLUMAB**

Schedule 4

**NIZATIDINE**

Schedule 4  
Schedule 2  
Appendix F, clause 4

**NOMEGESTROL**

Schedule 4

**NOMIFENSINE**

Schedule 4

**NONANOIC ACID**

Schedule 5

**NONOXINOL 9**

Schedule 6  
Schedule 5  
Appendix E, clause 3

**NORACYMETHADOL**

cross reference: CAS No. 1477-39-0, NORACYMETHADOL HYDROCHLORIDE (CAS No. 5633-25-0)

Schedule 9

**NORADRENALINE**

Schedule 4  
Appendix F, clause 4

**19‑NORANDROSTENEDIOL**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**19‑NORANDROSTENEDIONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**NORANDROSTENOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**NORBOLETHONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**NORBORMIDE**

Schedule 5

**NORCLOSTEBOL**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**NORCODEINE**

Schedule 8

**NORELGESTROMIN**

Schedule 4

**NOREPINEPHRINE**cross reference: NORADRENALINE

**NORETHANDROLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**NORETHISTERONE**

Schedule 4

**NORFLOXACIN**

Schedule 4

**NORFLURAZON**

Appendix B, clause 3

**NORGESTREL**

Schedule 4

**NORIBOGAINE**

Schedule 4

**NORLEVORPHANOL**

cross reference: CAS No. 1531-12-0, NORLEVORPHANOL HYDROBROMIDE (CAS No. 63732-85-4), NORLEVORPHANOL RACEMATE (CAS No. 39131-41-4)

Schedule 9

**NORMAL HUMAN IMMUNOGLOBULIN**

Schedule 4

**NORMETHADONE**

Schedule 8  
Appendix K, clause 1

**NORMETHANDRONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**NORMORPHINE**

cross reference: CAS No. 466-97-7, NORMORPHINE HYDROCHLORIDE (CAS No. 3372-02-9)

Schedule 9

**NORPIPANONE**

cross reference: CAS No. 561-48-8, NORPIPANONE HYDROCHLORIDE (CAS No. 6033-41-6), NORPIPANONE HYDROBROMIDE (CAS No. 6033-42-7)

Schedule 9

**NORTRIPTYLINE**

Schedule 4  
Appendix K, clause 1

**NOSCAPINE**

Schedule 2

**NOVALURON**

Appendix B, clause 3

**NOVOBIOCIN**

Schedule 4

**NOXIPTYLINE**

Schedule 4

**NUCLEAR POLYHEDROSIS VIRUS OF *Helicoverpa armigera* occlusion bodies**

Appendix B, clause 3

**NUSINERSEN**

Schedule 4

**NUTMEG OIL**

Schedule 5

**NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION**

Appendix A, clause 1

**NYSTATIN**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix F, clause 4  
Appendix H, clause 1

**O**

**OBETICHOLIC ACID**

Schedule 4

**OCLACITINIB**

Schedule 4

**OCRELIZUMAB**

Schedule 4

**OCRIPLASMIN**

Schedule 4

**OCTAMYLAMINE**

Schedule 4

**OCTATROPINE**

Schedule 4

**1‑OCTEN‑3‑OL**

Schedule 6

**OCTHILINONE**

Schedule 6

**OCTREOTIDE**

Schedule 4

**OCTYL ALCOHOLS**

Appendix B, clause 3

***N*‑OCTYL BICYCLOHEPTENE DICARBOXIMIDE**

cross reference: OCTYLBICYCLOHEPTENEDICARBOXIMIDE

Schedule 5

**OCTYL NITRITE**

Schedule 4  
Appendix E, clause 3

***N*‑(*N*‑OCTYL)‑2‑PYRROLIDONE**cross reference: DESIGNATED SOLVENT, *N*‑(*N*‑DODECYL)‑2‑PYRROLIDONE, *N*‑METHYL‑2‑PYRROLIDONE

Schedule 6  
Schedule 5  
Appendix E, clause 3

**OESTRADIOL**cross reference: ESTRADIOL

**OESTRIOL**cross reference: ESTRIOL

**OESTROGENS**cross reference: ESTROGENS

**OESTRONE**cross reference: ESTRONE

**OFATUMUMAB**

Schedule 4

**OFLOXACIN**

Schedule 4

**OLANZAPINE**

Schedule 4  
Appendix K, clause 1

**OLAPARIB**

Schedule 4

**OLAQUINDOX**

Schedule 6

**OLARATUMAB**

Schedule 4

**OLEANDOMYCIN**

Schedule 5  
Schedule 4

**OLEANDRIN**

Schedule 4

**OLEIC ACID**

Appendix B, clause 3

***N*‑OLEYL‑1,3‑DIAMINOPROPANE**

Schedule 6

**OLIPUDASE ALFA**

Schedule 4

**OLMESARTAN**

Schedule 4

**OLODATEROL**

Schedule 4

**OLOPATADINE**

Schedule 4  
Schedule 2

**OLSALAZINE**

Schedule 4

**OMBERACETAM**cross reference: RACETAMS, NOOPEPT, N‑PHENYLACETYL‑L‑PROLYLGLYCINE ETHYL ESTER

Schedule 4

**OMBITASVIR**

Schedule 4

**OMALIZUMAB**

Schedule 4

**OMEGA‑3‑ACID ETHYL ESTERS**

Schedule 4

**OMEPRAZOLE**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix H, clause 1

**OMETHOATE**

Schedule 7  
Schedule 6  
Schedule 5

**ONASEMNOGENE ABEPARVOVEC**

Schedule 4

**ONDANSETRON**

Schedule 4

**OPICAPONE**

Schedule 4

**OPIPRAMOL**

Schedule 4

**OPIUM**cross reference: NOSCAPINE, PAPAVERINE

Schedule 8  
Appendix K, clause 1

**ORANGE OIL (BITTER)**

Schedule 5  
Appendix E, clause 3

**ORANGE OIL, SWEET**

Appendix B, clause 3

**ORBIFLOXACIN**

Schedule 4

**ORCIPRENALINE**

Schedule 4  
Appendix F, clause 4

**ORGANOPHOSPHORUS COMPOUNDS**cross reference: MALATHION

Schedule 4

**ORLISTAT**

Schedule 4  
Schedule 3

**ORNIDAZOLE**

Schedule 4

**ORNIPRESSIN**

Schedule 4

**ORPHENADRINE**

Schedule 4

**ORTHOPTERIN**

Schedule 4

**OSELTAMIVIR**

Schedule 4

**OSILODROSTAT**

Schedule 4

**OSIMERTINIB**

Schedule 4

**OUABAIN**

Schedule 4

**OVANDROTONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**OXABETRINIL**

Appendix B, clause 3

**OXABOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**OXACILLIN**

Schedule 4

**OXADIARGYL**

Schedule 5

**OXADIAZON**

Schedule 6

**OXADIXYL**

Schedule 5

**OXALATES**

Appendix F, clause 4

**OXALIC ACID**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**OXALIPLATIN**

Schedule 4

**OXAMYL**

Schedule 7

**OXANDROLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**OXANTEL EMBONATE**

Schedule 5

**OXAPROZIN**

Schedule 4

**OXAZEPAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)  
Appendix K, clause 1

**OXCARBAZEPINE**

Schedule 4

**OXATHIAPIPROLIN**

Appendix B, clause 3

**OXEDRINE**cross reference: SYNEPHRINE

Schedule 4

**OXETACAINE**cross reference: OXETHAZAINE

Schedule 4  
Schedule 2

**OXFENDAZOLE**

Schedule 5

**OXIBENDAZOLE**

Schedule 5

**OXICONAZOLE**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix H, clause 1

**OXIRACETAM**cross reference: RACETAMS

Schedule 4

**OXITROPIUM**

Schedule 4

**OXOLAMINE**

Schedule 4

**OXOLINIC ACID**

Schedule 4

**OXPENTIFYLLINE**cross reference: PENTOXIFYLLINE

**OXPRENOLOL**

Schedule 4

**OXYBUPROCAINE**

Schedule 4

**OXYBUTYNIN**

Schedule 4

**OXYCARBOXIN**

Schedule 5

**OXYCLOZANIDE**

Schedule 6

**OXYCODONE**

Schedule 8  
Appendix K, clause 1

**OXYDEMETON METHYL**

Schedule 7

**OXYFLUORFEN**

Appendix B, clause 3

**OXYMESTERONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**OXYMETAZOLINE**

Schedule 2  
Appendix F, clause 4

**OXYMETHOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**OXYMORPHONE**

Schedule 8

**OXYPHENBUTAZONE**

Schedule 4

**OXYPHENCYCLIMINE**

Schedule 4

**OXYPHENISATIN**

cross reference: CAS No. 125-13-3

Schedule 10

**OXYPHENONIUM**

Schedule 4

**OXYQUINOLINE**

Schedule 2  
Appendix F, clause 4

**OXYTETRACYCLINE**

Schedule 5  
Schedule 4

**OXYTHIOQUINOX**

Schedule 5

**OXYTOCIN**

Schedule 4  
Appendix G, clause 1

**OZANIMOD**

Schedule 4

**P**

**PACLITAXEL**

Schedule 4

**PACLOBUTRAZOL**

Schedule 5

**PAECILOMYCES LILACINUS STRAIN 251**

Schedule 6

**PAINT**

Appendix F, clause 4

**PALBOCICLIB**

Schedule 4

**PALIFERMIN**

Schedule 4

**PALIPERIDONE**

Schedule 4  
Appendix K, clause 1

**PALIVIZUMAB**

Schedule 4

**PALMAROSA OIL**

Appendix B, clause 3

**PALMITIC ACID**

Appendix B, clause 3

**PALONOSETRON**

Schedule 4

**PALOVAROTENE**

Schedule 4  
Appendix F, clause 4  
Appendix L, clause 2

**PAMAQUIN**

Schedule 4

**PAMIDRONIC ACID**cross reference: PAMIDRONATE DISODIUM

Schedule 4

**PANCREATIC ENZYMES**cross reference: LIPASE

Schedule 4

**PANCURONIUM**

Schedule 4

**PANITUMUMAB**

Schedule 4

**PANOBINOSTAT**

Schedule 4

**PANTOPRAZOLE**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix H, clause 1

**PAPAVERETUM**

Appendix K, clause 1

**PAPAVERINE**cross reference: OPIUM

Schedule 4  
Schedule 2

**PAPER**

Appendix A, clause 1

**PARA‑AMINOPROPIOPHENONE (PAPP)**cross reference: 4‑AMINOPROPIOPHENONE

**PARACETAMOL**cross reference: ASPIRIN, IBUPROFEN, METOCLOPRAMIDE, SALICYLAMIDE, CAFFEINE

Schedule 4  
Schedule 3  
Schedule 2  
Appendix F, clause 4

Appendix H, clause 1

**para‑DICHLOROBENZENE**cross reference: PDB

Appendix F, clause 4

**PARA‑FLUOROFENTANYL**

cross reference: CAS No. 90736-23-5

Schedule 9

**PARAFORMALDEHYDE**cross reference: FREE FORMALDEHYDE (CAS No. 30525-89-4)

Schedule 10  
Schedule 6  
Schedule 2  
Appendix E, clause 3

**PARALDEHYDE**

Schedule 4

**PARAMETHADIONE**

Schedule 4

**PARAMETHASONE**

Schedule 4

**PARAQUAT**

Schedule 7

**PARATHION**

Schedule 7

**PARATHION‑METHYL**

Schedule 7  
Schedule 6

**PARBENDAZOLE**

Schedule 6

**PARECOXIB**

Schedule 4

**PARICALCITOL**

Schedule 4

**PARITAPREVIR**

Schedule 4

**PAROMOMYCIN**

Schedule 4

**PAROXETINE**

Schedule 4

**PASIREOTIDE**

Schedule 4

**PATCHOULI OIL**

Appendix B, clause 3

**PATIROMER SORBITEX CALCIUM**

Schedule 4

**PATISIRAN**

Schedule 4

**PAZOPANIB**

Schedule 4

**PEBULATE**

Schedule 6

**PECAZINE**

Schedule 4

**PECTINASE derived from Aspergillus niger**

Appendix B, clause 3

**PEFLOXACIN**

Schedule 4

**PEGAPTANIB**

Schedule 4

**PEGASPARGASE**

Schedule 4

**PEGBOVIGRASTIM**

Appendix B, clause 3

**PEGCETACOPLAN**

Schedule 4

**PEGFILGRASTIM**

Schedule 4

**PEGINTERFERON**

Schedule 4

**PEGVALIASE**

Schedule 4

**PEGVISOMANT**

Schedule 4

**PEMIGATINIB**

**Schedule 4**

**PERAMIVIR**

Schedule 4

**PHENOLS**

Appendix E, clause 3

**PEMBROLIZUMAB**

Schedule 4

**PEMETREXED**

Schedule 4

**PEMOLINE**

Schedule 4

**PEMPIDINE**

Schedule 4

**PENBUTOLOL**

Schedule 4

**PENCICLOVIR**

Schedule 4

**PENCONAZOLE**

Schedule 5

**PENCYCURON**

Appendix B, clause 3

**PENDIMETHALIN**

Schedule 5

**PENETHAMATE**

Schedule 4

**PENFLUFEN**

Schedule 5

**PENICILLAMINE**

Schedule 4

**PENNYROYAL OIL**

Schedule 6  
Appendix E, clause 3

**PENTACHLOROPHENOL**

Schedule 7  
Schedule 6  
Appendix F, clause 4

**PENTADECANOIC ACID**

Appendix B, clause 3

**PENTAERYTHRITYL TETRANITRATE**

Schedule 4

**PENTAGASTRIN**

Schedule 4

**PENTAMETHONIUM**

Schedule 4

**PENTAMIDINE**

Schedule 4

**PENTAZOCINE**

Schedule 8  
Appendix K, clause 1

**PENTHIENATE**

Schedule 4

**PENTHIOPYRAD**

Schedule 5

**PENTOBARBITONE**cross reference: PENTOBARBITAL

**PENTOBARBITAL**

Schedule 8  
Schedule 4  
Appendix D, clause 9  
Appendix K, clause 1

**PENTOLINIUM**

Schedule 4

**PENTOSAN POLYSULFATE SODIUM**

Schedule 4

**PENTOXIFYLLINE**

Schedule 4

**1‑PENTYL‑3‑(1‑NAPHTHOYL)INDOLE**cross reference: JWH‑018 (CAS No. 209414-07-3)

Schedule 9

**1‑PENTYL‑3‑(4‑METHYL‑1‑NAPTHOYL)INDOLE**cross reference: JWH‑122 (CAS No. 619294-47-2)

Schedule 9

**PEPPERMINT OIL**

Appendix B, clause 3

**PERACETIC ACID**

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**PERAMPANEL**

Schedule 4  
Appendix D, clause 5  
Appendix K, clause 1

**PERFLUIDONE**

Schedule 6

**PERGOLIDE**

Schedule 4

**PERHEXILINE**

Schedule 4

**PERICIAZINE**

Schedule 4  
Appendix K, clause 1

**PERICYAZINE**cross reference: PERICIAZINE

**PERINDOPRIL**

Schedule 4

**PERMANGANATES**cross reference: POTASSIUM PERMANGANATE

Schedule 6  
Appendix F, clause 4

**PERMETHRIN**

Schedule 6  
Schedule 5  
Schedule 4

**PERPHENAZINE**

Schedule 4  
Appendix K, clause 1

**PERTUSSIS ANTIGEN**

cross reference: TRIPLE ANTIGEN VACCINE

Schedule 4

**PERTUZUMAB**

Schedule 4

**PETASITES spp.**

Schedule 10

**PETHIDINE**

Schedule 8  
Appendix K, clause 1

**PETROL**

Schedule 5  
Appendix E, clause 3

**PHEDRAZINE**

Schedule 2

**PHENACEMIDE**

Schedule 4

**PHENACETIN**

Schedule 4

**PHENADOXONE**

cross reference: CAS No. 467-84-5, PHENADOXONE HYDROCHLORIDE (CAS No. 545-91-5)

Schedule 9

**PHENAGLYCODOL**

Schedule 4

**PHENAMPROMIDE**

cross reference: CAS No. 129-83-9

Schedule 9

**PHENAZOCINE**

cross reference: CAS No. 127-35-5, PHENAZOCINE RACEMATE (CAS No. 58073-76-0), PHENOAZOCINE HYDROBROMIDE (CAS No. 1239-04-9)

Schedule 9

**PHENAZONE**

Schedule 5  
Schedule 4  
Schedule 2

**PHENAZOPYRIDINE**

Schedule 4

**PHENCYCLIDINE**cross reference: PCP (CAS No. 77-10-1), PHENCYCLIDINE HYDROCHLORIDE (CAS No. 956-90-1)

Schedule 9

**PHENDIMETRAZINE**

Schedule 8

**PHENELZINE**

Schedule 4  
Appendix K, clause 1

**N‑PHENETHYL‑4‑PIPERIDONE**

cross reference: CAS No. 39742-60-4

Schedule 9

**PHENETICILLIN**

Schedule 4

**PHENFORMIN**

Schedule 4

**PHENGLUTARIMIDE**

Schedule 4

**PHENIBUT**cross reference: BETA‑PHENYL‑GAMMA‑AMINOBUTYRIC ACID (CAS No. 1078-21-3), PHENIBUT HYDROCHLORIDE (CAS No. 3060-41-1), PHENIBUT HYDROBROMIDE (CAS No. 103095-38-1)

Schedule 9

**PHENINDIONE**

Schedule 4

**PHENIRAMINE**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix K, clause 1

**PHENISATIN**

Schedule 4

**PHENISOPHAM**

Schedule 5

**PHENMEDIPHAM**

Appendix B, clause 3

**PHENMETRAZINE**

Schedule 8

**PHENOBARBITAL**

Schedule 4  
Appendix K, clause 1

**PHENOBARBITONE**cross reference: PHENOBARBITAL

**PHENOL**cross reference: CREOSOTE, PHENOLS, TAR, XYLENOLS

Schedule 6  
Schedule 5  
Schedule 4  
Schedule 2  
Appendix E, clause 3  
Appendix F, clause 4

**PHENOLPHTHALEIN**

Schedule 4

**PHENOMORPHAN**

cross reference: CAS No. 468-07-5

Schedule 9

**PHENOPERIDINE**

Schedule 8  
Appendix K, clause 1

**PHENOTHIAZINE**

Schedule 6

**d‑PHENOTHRIN**

Appendix B, clause 3

**PHENOXYBENZAMINE**

Schedule 4

**2‑PHENOXYETHANOL**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**PHENOXYMETHYL OXIRANE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**PHENOXYMETHYLPENICILLIN**

Schedule 4

**PHENPROMETHAMINE**

cross reference: CAS No. 93-88-9

Schedule 10

**PHENSUXIMIDE**

Schedule 4

**PHENTERMINE**

Schedule 4  
Appendix D, clause 5

**PHENTHIMENTONIUM**

Schedule 4

**PHENTOLAMINE**

Schedule 4

**PHENYLACETYLINDOLES**

Schedule 9

**PHENYLBUTAZONE**

Schedule 4

**PHENYLENEDIAMINES**cross reference: ALKYLATED, ARYLATED, HALOGENATED and NITRO‑PHENYLENEDIAMINES, DIETHYL‑PARA‑PHENYLENEDIAMINE, DIMETHYL‑PARA‑PHENYLENEDIAMINE

Schedule 10  
Schedule 6Appendix E, clause 3  
Appendix F, clause 4

**PHENYLEPHRINE**cross reference: CODEINE, IBUPROFEN, PARACETAMOL

Schedule 4  
Schedule 2  
Appendix F, clause 4

**1‑PHENYLETHYL‑4‑PHENYL‑4‑PIPERIDINOL ACETATE**cross reference: PEPAP (CAS No. 64-52-8)

Schedule 9

**PHENYLMERCURIC ACETATE**cross reference: MERCURY

Schedule 7  
Appendix J, clause 1

**PHENYL METHYL KETONE**cross reference: DESIGNATED SOLVENT

Schedule 5  
Appendix E, clause 3

***o*‑PHENYLPHENOL**

Schedule 5

Appendix E, clause 3  
Appendix F, clause 4

**4‑PHENYLPIPERIDINE‑4‑CARBOXYLIC ACID ETHYL ESTER**cross reference: PETHIDINE INTERMEDIATE B

Schedule 8

**PHENYL METHYL PYRAZOLONE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**PHENYLPIRACETAM**  
cross reference: RACETAMS

Schedule 4

**PHENYLPROPANOLAMINE**

Schedule 4

**PHENYLTOLOXAMINE**

Schedule 4  
Appendix K, clause 1

**PHENYTOIN**

Schedule 4  
Appendix F, clause 4

**PHLEUM PRATENSE POLLEN EXTRACT (Timothy‑grass pollen extract)**

Schedule 4

**PHOLCODINE**

Schedule 8  
Schedule 4  
Schedule 2  
Appendix K, clause 1

**PHORATE**

Schedule 7

**PHOSALONE**

Schedule 6

**PHOSFOLAN**

Schedule 7

**PHOSMET**

Schedule 6

**PHOSPHIDES, METALLIC**cross reference: ALUMINIUM PHOSPHIDE, MAGNESIUM PHOSPHIDE, ZINC PHOSPHIDE

Schedule 7  
Appendix J, clause 1

**PHOSPHINE**

Schedule 7  
Appendix J, clause 1

**PHOSPHODIESTERASE TYPE 5 INHIBITORS**

Schedule 4

**PHOSPHONIC ACID**cross reference: PHOSPHOROUS ACID

Schedule 5Appendix E, clause 3  
Appendix F, clause 4

**PHOSPHORIC ACID**

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**PHOSPHORUS**

Appendix G, clause 1

**PHOSPHORUS, YELLOW**

Schedule 7

Appendix E, clause 3

Appendix F, clause 4

**PHOTOGRAPHIC PAPER or FILM**

Appendix A, clause 1

**PHOXIM**

Schedule 6

***o*‑PHTHALADEHYDE**

Appendix F, clause 4

***o*‑PHTHALALDEHYDE**

Appendix E, clause 3

**PHTHALALDEHYDE**

Schedule 6  
Schedule 5

**PHTHALYLSULFATHIAZOLE**

Schedule 4

**PHYSOSTIGMINE**

Schedule 4

**PHYTASE**

Appendix B, clause 3

**PIBRENTASVIR**

Schedule 4

**PICARIDIN**

Schedule 5

**PICLORAM**

Appendix B, clause 3

**PICOLINAFEN**

Appendix B, clause 3

**PICRAMIC ACID (including its salts)**cross reference: 2‑AMINO‑4,6‑DINITROPHENOL

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**PICRIC ACID**

Appendix E, clause 3  
Appendix F, clause 4

**PICROTOXIN**

Schedule 4

**PIGMENTS**

Appendix A, clause 1

**PILOCARPINE**

Schedule 4

**PIMECROLIMUS**

Schedule 4

**PIMELIC ACID**

Appendix B, clause 3

**PIMINODINE**

cross reference: CAS No. 13495-09-5, PIMINODINE DIHYDROCHLORIDE (CAS No. 113862-30-9). PIMINODINE ESILATE (CAS No. 7081-52-9)

Schedule 9

**PIMOBENDAN**

Schedule 4

**PIMOZIDE**

Schedule 4  
Appendix K, clause 1

**PINACIDIL**

Schedule 4

**PINDOLOL**

Schedule 4

**PINDONE**

Schedule 6

**PINE OILS**

Schedule 6  
Schedule 5

**PINOXADEN**

Schedule 6  
Schedule 5

**PIOGLITAZONE**

Schedule 4

**PIPECURONIUM**

Schedule 4

**PIPEMIDIC ACID**

Schedule 4

**PIPENZOLATE**

Schedule 4

**PIPER METHYSTICUM**cross reference: KAVA, KAVALACTONES

Schedule 4

**PIPERACILLIN**

Schedule 4

**PIPERAZNE**

Schedule 5  
Schedule 2

**PIPERIDINE**

Schedule 4

**PIPERIDOLATE**

Schedule 4

**PIPERONYL BUTOXIDE**

Appendix B, clause 3

**PIPEROPHOS**

Schedule 6

**PIPOBROMAN**

Schedule 4

**PIPOTHIAZINE**

Schedule 4

**PIPRADROL**

Schedule 4

**PIRACETAM**

cross reference: RACETAMS

Schedule 4

**PIRBUTEROL**

Schedule 4

**PIRENOXINE**cross reference: CATALIN

Schedule 4

**PIRENZEPINE**

Schedule 4

**PIRETANIDE**

Schedule 4

**PIRFENIDONE**

Schedule 4

**PIRIMICARB**

Schedule 6

Schedule 5

**PIRIMIPHOS‑ETHYL**

Schedule 6

**PIRIMIPHOS‑METHYL**

Schedule 6

**PIRITRAMIDE**

Schedule 8

**PIROXICAM**

Schedule 4

**PIRPROFEN**

Schedule 4

**PITAVASTATIN**

Schedule 4

**PITUITARY HORMONES**

Schedule 4

**PIVAMPICILLIN**

Schedule 4

**PIZOTIFEN**

Schedule 4  
Appendix K, clause 1

**PLASMID DNA (rE. coli DH5α pINGhT)**cross reference: VACCINES – PLASMID DNA

**PLERIXAFOR**

Schedule 4

**PLICAMYCIN**

Schedule 4

**PLITIDEPSIN**

Schedule 4  
Appendix L, clause 2

**PNEUMOCOCCAL VACCINE**

Schedule 4

**PODOPHYLLOTOXIN**cross reference: PODOPHYLLIN

Schedule 4  
Schedule 3  
Schedule 2  
Appendix F, clause 4

Appendix H, clause 1

**PODOPHYLLUM EMODI**cross reference: PODOPHYLLIN

Schedule 4  
Schedule 3  
Schedule 2  
Appendix F, clause 4

Appendix H, clause 1

**PODOPHYLLUM PELTATUM**cross reference: PODOPHYLLIN

Schedule 4  
Schedule 3

Schedule 2  
Appendix F, clause 4

Appendix H, clause 1

**PODOPHYLLUM RESIN**cross reference: PODOPHYLLIN

Appendix G, clause 1

**POLIHEXANIDE**

cross reference: 1‑(DIAMINOMETHYLIDENE)‑2‑HEXYLGUANIDINE, POLY (IMINOCARBONIMIDOYLIMINOCARBONIMIDOYL IMINO‑1,6‑HEXANEDIYL), POLYHEXAMETHYLENE BIGUANIDE (PHMB)

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**POLIOMYELITIS VACCINE**

Schedule 4

**POLIXETONIUM SALTS**

Schedule 6  
Schedule 5

**POLOXALENE**

Appendix B, clause 3

**POLY (GNRF) OVALBUMIN**

Appendix B, clause 3

**POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE**cross reference: POLYDADMAC

Appendix B, clause 3

**POLY(OXY‑1,2‑ETHANEDIYL), α ‑[2‑[(2‑HYDROXYETHYL)AMINO]‑2‑OXOETHYL]‑ α ‑HYDROXY‑,MONO‑C13‑15‑ALKYL ETHERS**

Schedule 5  
Appendix E, clause 3

**POLYACRYLAMIDE**

Schedule 4

**POLYCAPROLACTONE**

Schedule 4

**POLYESTRADIOL**

Schedule 4

**POLYETHANOXY (15) TALLOW AMINE**

Schedule 5  
Appendix E, clause 3

**POLYHEDROSIS VIRUS of *Helico zea* occlusion bodies**

Appendix B, clause 3

**POLYLACTIC ACID**

Schedule 4

**POLYMYXIN**

Schedule 4

**POLYOXIN D ZINC SALT**

Schedule 5

**POLYSORBATE 20**

Appendix B, clause 3

**POLYSULFATED GLYCOSAMINOGLYCANS**

Schedule 4

**POLYTHIAZIDE**

Schedule 4

**POMALIDOMIDE**

Schedule 4  
Appendix D, clause 4  
Appendix F, clause 4  
Appendix L, clause 2

**PONATINIB**

Schedule 4

**PONESIMOD**

Schedule 4

Appendix L, clause 2

**PORACTANT**

Schedule 4

**PORCELAIN**

Appendix A, clause 1

**PORCINE SOMATOTROPHIN**

Appendix B, clause 3

**POSACONAZOLE**

Schedule 4

**POTASSIUM AZELOYL DIGLYCINATE**

Schedule 6

**POTASSIUM BICARBONATE**

Appendix B, clause 3

**POTASSIUM BROMATE**

Schedule 6  
Appendix E, clause 3

**POTASSIUM BROMIDE**

Schedule 4

**POTASSIUM CHLORATE**

Schedule 5  
Schedule 2  
Appendix E, clause 3

**POTASSIUM CHLORIDE**

Schedule 4

**POTASSIUM CYANATE**

Schedule 6  
Appendix E, clause 3

**POTASSIUM HYDROXIDE**

cross reference: CAS No. 1310-58-3

Schedule 10  
Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**POTASSIUM METABISULPHITE**

Schedule 5  
Appendix F, clause 4

**POTASSIUM NITRITE**

Schedule 7  
Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**POTASSIUM PERCHLORATE**

Schedule 4

**POTASSIUM PEROXOMONOSULFATE TRIPLE SALT**

Schedule 6  
Schedule 5

**POTASSIUM PERSULFATE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**POTASSIUM SORBATE**

Appendix B, clause 3

**POTASSIUM SULFIDE**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**PRACTOLOL**

Schedule 4

**PRADOFLOXACIN**

Schedule 4

**PRALATREXATE**

Schedule 4

**PRALIDOXIME**

Schedule 4

**PRALLETHRIN**

Schedule 6  
Schedule 5

**PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE‑2) (GHRP‑2)**

Schedule 4  
Appendix D, clause 5

**PRALSETINIB**

Schedule 4

**PRAMIPEXOLE**

Schedule 4

**PRAMIRACETAM**

cross reference: RACETAMS

Schedule 4

**PRAMOCAINE**

Schedule 4

**PRAMPINE**

Schedule 4

**PRASTERONE**cross reference: DEHYDROEPIANDROSTERONE, DEHYDROISOANDROSTERONE

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**PRASUGREL**

Schedule 4

**PRAVASTATIN**

Schedule 4

**PRAZEPAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)  
Appendix K, clause 1

**PRAZIQUANTEL**

Schedule 4

**PRAZOSIN**

Schedule 4

**PREDNISOLONE**

Schedule 4

**PREDNISONE**

Schedule 4

**PREGABALIN**

Schedule 4  
Appendix K, clause 1

**PREGNENOLONE**

Schedule 4

**PRENALTEROL**

Schedule 4

**PRENYLAMINE**

Schedule 4

**PRILOCAINE**

Schedule 4  
Schedule 2

**PRIMAQUINE**

Schedule 4

**PRIMIDONE**

Schedule 4

**PRINTING INKS or INK ADDITIVES**

Appendix A, clause 1

**PROBENECID**

Schedule 4

**PROBUCOL**

Schedule 4

**PROCAINAMIDE**

Schedule 4

**PROCAINE**

Schedule 4

**PROCAINE BENZYLPENICILLIN**

Schedule 4

**PROCAINE PENICILLIN**cross reference: PROCAINE BENZYLPENICILLIN

**PROCARBAZINE**

Schedule 4

**PROCHLORAZ**

Schedule 6

**PROCHLORPERAZINE**

Schedule 4  
Schedule 3  
Appendix K, clause 1

**PROCYCLIDINE**

Schedule 4  
Schedule 2

**PROCYMIDONE**

Schedule 7

**PROFENOFOS**

Schedule 6

**PROFOXYDIM**

Schedule 5

**PROGESTERONE**

Schedule 5  
Schedule 4  
Appendix G, clause 1

**PROGESTOGENS**

Schedule 4

**PROGLUMIDE**

Schedule 4

**PROGUANIL**

Schedule 4

**PROHEPTAZINE**

cross reference: CAS No. 77-14-5

Schedule 9

**PROHEXADIONE CALCIUM**

Schedule 5

**PROLINTANE**

Schedule 4

**PROMACYL**

Schedule 6

**PROMAZINE**

Schedule 4  
Appendix K, clause 1

**PROMETHAZINE**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix K, clause 1

**PROMETRYN**

Schedule 5

**PROMOXOLANE**

Schedule 4

**PROPACHLOR**

Schedule 6

**PROPAFENONE**

Schedule 4

**PROPAMIDINE**

Schedule 4Schedule 2

**PROPAMOCARB**

Schedule 5

**PROPANIDID**

Schedule 4

**PROPANIL**

Schedule 5

**PROPANTHELINE**

Schedule 4

**PROPAQUIZAFOP**

Schedule 5

**PROPARGITE**

Schedule 6

**PROPENTOFYLLINE**

Schedule 4

**PROPERIDINE**

cross reference: CAS No. 561-76-2

Schedule 9

**PROPETAMPHOS**

Schedule 6

**PROPETANDROL**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**PROPICONAZOLE**

Schedule 6  
Schedule 5

**PROPINEB**

Schedule 6

**PROPIONIBACTERIUM ACNES**

Schedule 4

**PROPIONIC ACID**

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**PROPIRAM**

Schedule 8

**PROPOFOL**

Schedule 4

**PROPOXUR**

Schedule 6  
Schedule 5

**PROPRANOLOL**

Schedule 4  
Appendix G, clause 1

**PROPYL ACETATES**

Appendix B, clause 3

**n‑PROPYL ALCOHOL**

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

***n*‑PROPYL NITRITE**

cross reference: CAS No. 543-67-9

Schedule 10

**PROPYLENE GLYCOL**

Appendix B, clause 3

**2‑PROPYLENE GLYCOL 1‑MONOMETHYL**

Appendix B, clause 3

**PROPYLENE OXIDE**

Schedule 7  
Appendix J, clause 1

**PROPYLHEXEDRINE**

Schedule 4

**PROPYLTHIOURACIL**

Schedule 4

**PROPYPHENAZONE**

Schedule 4

**PROPYZAMIDE**

Schedule 5

**PROQUAZONE**

Schedule 4

**PROQUINAZID**

Schedule 6

**PROSCILLARIDIN**

Schedule 4

**PROSTAGLANDINS**

Schedule 4

**PROSTIANOL**

Schedule 4

**PROSULFOCARB**

Schedule 6

**PROSULFURON**

Schedule 6

**PROTAMINE**

Schedule 4

**PROTHIOCONAZOLE**

Appendix B, clause 3

**PROTHIOCONAZOLE‑DESCHLORO**

Schedule 5

**PROTHIOCONAZOLE‑TRIAZOLIDINETHIONE**

Schedule 5

**PROTHIOFOS**

Schedule 6

**PROTHIONAMIDE**

Schedule 4

**PROTHIPENDYL**

Schedule 4

**PROTIRELIN**

Schedule 4

**PROTONITAZENE**

cross reference: CAS No. 95958-84-2

Schedule 9

**PROTOVERATRINES**

Schedule 4

**PROTRIPTYLINE**

Appendix K, clause 1

**PROTRIPTYLINE**

Schedule 4

**PROXYMETACAINE**

Schedule 4

**PRUCALOPRIDE**

Schedule 4

**PSEUDOEPHEDRINE**

Schedule 4  
Schedule 3

**PSEUDOMONAS FLUORESCENS**

Appendix B, clause 3

**PSILOCYBINE**

cross reference: PSILOCYBIN, CAS No. 520-52-5

Schedule 9  
Schedule 8  
Appendix D, clause 5  
Appendix D, clause 10

**PTERIDIUM spp.**

Schedule 10

**d‑PULEGONE**

Schedule 6  
Appendix E, clause 3

**PULMONARIA spp.**

Schedule 10

**PYDIFLUMETOFEN**

Appendix B, clause 3

**PYMETROZINE**

Schedule 5

**PYRACLOFOS**

Schedule 6

**PYRACLOSTROBIN**

Schedule 5

**PYRAFLUFEN‑ETHYL**

Schedule 5

**PYRANTEL**

Schedule 2

**PYRASULFOTOLE**

Schedule 5

**PYRAZINAMIDE**

Schedule 4

**PYRAZOLAM**

cross reference: CAS No. 39243-02-2

Schedule 9

**PYRAZOPHOS**

Schedule 6

**PYRETHRINS**cross reference: CHRYSANTHEMIC ACID ESTERS, CINEROLONE, JASMOLONE, PYRETHRIC ACIDS, PYRETHROLONE

Schedule 5  
Schedule 2

**PYRIDABEN**

Schedule 6  
Schedule 5

**PYRIDALYL**

Schedule 6

**PYRIDATE**

Schedule 6

**PYRIDINOLCARBAMATE**

Schedule 4

**PYRIDOSTIGMINE**

Schedule 4

**PYRIDOXAL**

Schedule 4

**PYRIDOXAMINE**

Schedule 4

**PYRIDOXINE**

Schedule 4

**PYRIFENOX**

Schedule 5

**PYRIMETHAMINE**

Schedule 4

**PYRIMETHANIL**

Appendix B, clause 3

**PYRINURON**

Schedule 7  
Appendix J, clause 1

**PYRIOFENONE**

Schedule 6  
Schedule 5

**PYRIPROLE**

Schedule 6

**PYRIPROXYFEN**

Appendix B, clause 3

**PYRITHIOBAC SODIUM**

Schedule 5

**PYRITHIONE COPPER**

Schedule 6

**PYRITHIONE ZINC**

Schedule 6  
Schedule 5  
Schedule 2  
Appendix E, clause 3

**PYROVALERONE**

Schedule 4

**PYROXASULFONE**

Schedule 6

**PYROXSULAM**

Schedule 6

**PYRVINIUM**cross reference: VIPRYNIUMA

Schedule 4

**Q**

**QUASSIA**

Appendix B, clause 3

**QUATERNARY AMMONIUM COMPOUNDS**cross reference: BENZALKONIUM CHLORIDE, DIALKYL and DIALKOYL QUATERNARY AMMONIUM COMPOUNDS

Schedule 6  
Schedule 5

Appendix E, clause 3

**QUAZEPAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)

**QUETIAPINE**

Schedule 4  
Appendix K, clause 1

**QUINAGOLIDE**

Schedule 4

**QUINALBARBITONE**cross reference: SECOBARBITAL

**QUINAPRIL**

Schedule 4

**QUINBOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**QUINCLORAC**

Schedule 5

**QUINETHAZONE**

Schedule 4

**QUINIDINE**

Schedule 4

**QUININE**cross reference: QUININE (CAS No. 130‑95‑0), QUININE SULFATE (1:1) (CAS No. 549‑56‑4), QUININE SULFATE (2:1) (CAS No. 804‑63‑7), QUININE SULFATE (2:1) DIHYDRATE (CAS No. 6119‑70‑6), QUININE SULFATE (1:1) HEPTAHYDRATE (CAS No. 6183‑68‑2), QUININE DIHYDROCHLORIDE (CAS No. 60‑93‑5), QUININE MONOHYDROCHLORIDE (CAS No. 130‑89‑2), QUININE HYDROCHLORIDE DIHYDRATE (CAS No. 6119‑47‑7), QUININE HYDROCHLORIDE (UNSPECIFIED) (CAS No. 7549‑43‑1)

Schedule 7  
Schedule 6  
Schedule 5  
Schedule 4  
Appendix F, clause 4

**QUINISOCAINE**cross reference: DIMETHISOQUINE

Schedule 4

**QUINOLINE**cross reference: 2,3‑BENZAPYRIDINE

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**QUINOXYFEN**

Appendix B, clause 3

**QUINTOZENE**cross reference: PENTACHLORONITROBENZENE

Schedule 5

**QUINUPRISTIN**

Schedule 4

**QUIZALOFOP ETHYL**cross reference: QUIZALOFOP ETHYL (D + ISOMER)

Schedule 6

**QUIZALOFOP‑*p*‑ETHYL**

Schedule 6  
Schedule 5

**QUIZALOFOP‑*p*‑TEFURYL**

Schedule 6

**R**

**RABEPRAZOLE**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix H, clause 1

**RABIES VACCINE**

Schedule 4

**RACEMETHORPHAN**

cross reference: CAS No. 510-53-2

Schedule 9

**RACEMORAMIDE**

Schedule 8

**RACEMORPHAN**

cross reference: CAS No. 297-90-5

Schedule 9

**RACETAMS**

Schedule 4

**RACTOPAMINE**

Schedule 5  
Schedule 4

**RADIOGRAPHIC CONTRAST MEDIA**cross reference: RADIOPAQUES

Appendix A, clause 1

**RADIOISOTOPES**

Appendix A, clause 1

**RALOXIFENE**

Schedule 4

**RALTEGRAVIR**

Schedule 4

**RALTITREXED**

Schedule 4

**RAMIPRIL**

Schedule 4

**RAMUCIRUMAB**

Schedule 4

**RANIBIZUMAB**

Schedule 4

**RANITIDINE**

Schedule 4  
Schedule 2  
Appendix F, clause 4

**RANOLAZINE**

Schedule 4

**RAPACURONIUM**

Schedule 4

**RASAGILINE**

Schedule 4

**RASBURICASE**

Schedule 4

**RAUWOLFIA SERPENTINA**

Schedule 4

**RAUWOLFIA VOMITORIA**

Schedule 4

**RAZOXANE**

Schedule 4

**REBOXETINE**

Schedule 4

**RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN**

Schedule 4

**RED YEAST RICE**

Schedule 4

**REGDANVIMAB**

Schedule 4

**REGORAFENIB**

Schedule 4

**RELUGOLIX**

Schedule 4

**REMIFENTANIL**

Schedule 8

**REMDESIVIR**

Schedule 4

**REMOXIPRIDE**

Schedule 4

**REPAGLINIDE**

Schedule 4

**RESCALURE**

cross reference: (3S,6R)‑(3S,6S)‑6‑isopropenyl‑3‑methyldec‑9‑en‑1‑yl acetate

Schedule 6

**RESERPINE**

Schedule 4

**RESLIZUMAB**

Schedule 4

**RESMETHRIN**

Schedule 6  
Schedule 5

**RESORCINOL**  
cross reference: 1,3‑BENZENEDIOL

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**RETAPAMULIN**

Schedule 4

**RETEPLASE**

Schedule 4

**RETIGABINE**

Schedule 4  
Appendix K, clause 1

**RHIZOBIUM RHIZOGENES**

Appendix B, clause 3

**RIBAVIRIN**

Schedule 4

**RIBOCICLIB**

Schedule 4

**RIDAFOROLIMUS**

Schedule 4

**RIFABUTIN**

Schedule 4

**RIFAMPICIN**

Schedule 4

**RIFAMYCIN**

Schedule 4

**RIFAPENTINE**

Schedule 4

**RIFAXIMIN**

Schedule 4

**RILPIVIRINE**

Schedule 4

**RILUZOLE**

Schedule 4

**RIMEGEPANT**

Schedule 4

**RIMEXOLONE**

Schedule 4

**RIMITEROL**

Schedule 4

**RIMONABANT**

Schedule 4

**RIMSULFURON**

Schedule 5

**RIOCIGUAT**

Schedule 4  
Appendix D, clause 4  
Appendix L, clause 2

**RIPRETINIB**

Schedule 4

**RISANKIZUMAB**

Schedule 4

**RISDIPLAM**

Schedule 4

**RISEDRONIC ACID**

Schedule 4

**RISPERIDONE**

Schedule 4  
Appendix K, clause 1

**RITODRINE**

Schedule 4

**RITONAVIR**

Schedule 4

**RITUXIMAB**

Schedule 4

**RIVAROXABAN**

Schedule 4

**RIVASTIGMINE**

Schedule 4

**RIZATRIPTAN**

Schedule 4  
Schedule 3  
Appendix H, clause 1

**ROBENACOXIB**

Schedule 4

**ROBENIDINE**

Schedule 5

**ROFECOXIB**

Schedule 4

**ROFLUMILAST**

Schedule 4

**ROLICYCLIDINE**cross reference: PCPY, PHP (CAS No. 2201-39-0)

Schedule 9

**ROLITETRACYCLINE**

Schedule 4

**ROLZIRACETAM**

cross reference: RACETAMS

Schedule 4

**ROMIDEPSIN**

Schedule 4

**ROMIFIDINE**

Schedule 4

**ROMIPLOSTIM**

Schedule 4

**ROMOSOZUMAB**

Schedule 4

**RONIDAZOLE**

Schedule 4

**ROPINIROLE**

Schedule 4

**ROPIVACAINE**

Schedule 4

**ROSEMARY OIL**

Appendix B, clause 3

**ROSIGLITAZONE**

Schedule 4

**ROSIN**cross reference: COLOPHONY

Schedule 5

**ROSOXACIN**

Schedule 4

**ROSUVASTATIN**

Schedule 4

**ROTENONE**cross reference: CUBE

Schedule 6

**ROTIGOTINE**

Schedule 4  
Appendix K, clause 1

**ROXIBOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**ROXITHROMYCIN**

Schedule 4

**RUBELLA VACCINE**

Schedule 4

**RUBOXISTAURIN**

Schedule 4

**RUFINAMIDE**

Schedule 4  
Appendix K, clause 1  
Appendix L, clause 2

**RUPATADINE**

Schedule 4  
Appendix K, clause 1

**RUXOLITINIB**

Schedule 4

**S**

**SACITUZUMAB GOVITECAN**

Schedule 4

**SACUBITRIL**

Schedule 4

**SAFINAMIDE**

Schedule 4

**SAFLUFENACIL**

Schedule 7  
Schedule 5

**SAFROLE**cross reference: CAS No. 94-59-7, SASSAFRAS OIL

Schedule 10  
Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**SAGE OIL**cross reference: DALMATIAN, THUJONE

Schedule 6  
Appendix E, clause 3

**SAGE OIL (Spanish)**cross reference: CAMPHOR

Appendix B, clause 3

**SALBUTAMOL**

Schedule 4  
Schedule 3  
Appendix F, clause 4

**SALCATONIN**cross reference: CALCITONIN SALMON

**SALICYLAMIDE**cross reference: ASPIRIN, CAFFEINE, PARACETAMOL

Schedule 4  
Schedule 2  
Appendix F, clause 4

**SALICYLANILIDE**

Schedule 5

**SALICYLIC ACID**cross reference: CHOLINE SALICYLATE

Schedule 3

Appendix H, clause 1

**SALINOMYCIN**

Schedule 6  
Schedule 4

**SALMETEROL**

Schedule 4

**SALVIA DIVINORUM**

Schedule 9

**SANDALWOOD OIL**

Appendix B, clause 3

**SANGUINARIA CANADENSIS (bloodroot)**

Schedule 10

**SANGUINARINE**cross reference: CAS No. 2447-54-3, SANGUINARIA CANADENSIS (bloodroot)

**SANTONIN**

Schedule 3

**SAPROPTERIN**

Schedule 4

**SAQUINAVIR**

Schedule 4

**SARILUMAB**

Schedule 4

**SAROLANER**

Schedule 6  
Schedule 5

**SARS‑COV‑2 (COVID‑19) VACCINE**

Schedule 4

**SASSAFRAS OIL**cross reference: SAFROLE

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**SAXAGLIPTIN**

Schedule 4

**SCHOENOCAULON OFFICINALE**cross reference: SABADILLA

Schedule 4

**SCHRADAN**

Schedule 7

**SCOPOLIA CARNIOLICA**

Schedule 4

**SEAWEED**

Appendix B, clause 3

**SEBELIPASE ALFA**

Schedule 4

**SECBUTOBARBITAL**

Schedule 8  
Appendix K, clause 1

**SECBUTOBARBITONE**cross reference: SECBUTOBARBITAL

**SECOBARBITAL**

Schedule 8  
Appendix K, clause 1

**SECUKINUMAB**

Schedule 4

**SEDAXANE**

Schedule 5

**SEEDS**

Appendix A, clause 1

**SELAMECTIN**

Schedule 5

**SELECTIVE ANDROGEN RECEPTOR MODULATORS**cross reference: SARM

Schedule 4  
Appendix D, clause 5

**SELEGILINE**

Schedule 4

**SELENIUM**cross reference: BARIUM SELENATE, SELENIUM COMPOUNDS, SELENIUM ARSENIDE, SELENIUM SULFIDE

Schedule 7  
Schedule 6  
Schedule 4  
Schedule 2  
Appendix E, clause 3  
Appendix F, clause 4  
Appendix G, clause 1

**SELETRACETAM**

Cross reference RACETAMS

Schedule 4  
Appendix K, clause 1

**SELEXIPAG**

Schedule 4

**SELINEXOR**

Schedule 4

Appendix L, clause 2

**SELPERCATINIB**

Schedule 4

**SELUMETINIB**

Schedule 4

Appendix L, clause 2

**SEMAGLUTIDE**

Schedule 4

**SEMDURAMICIN**

Schedule 7  
Schedule 6

**SENECIO spp.**

Schedule 10

**SERELAXIN**

Schedule 4

**SERMORELIN**

Schedule 4

**SERTINDOLE**

Schedule 4

**SERTRALINE**

Schedule 4

**SETHOXYDIM**

Schedule 5

**SEVELAMER**

Schedule 4

**SEVOFLURANE**

Schedule 4

**SEX HORMONES**

Schedule 4

**SH‑OLIGOPEPTIDE‑1, RH‑OLIGOPEPTIDE‑1**cross reference: EPIDERMAL GROWTH FACTOR

**SIBUTRAMINE**

Schedule 4

**SIDURON**

Schedule 5

**SILANDRONE**

Schedule 4  
Appendix D, clause 5 (Anabolic steroidal agent)

**SILDENAFIL**

Schedule 4

**SILICOFLUORIDES**cross reference: BARIUM SILICOFLUORIDE, FLUORIDES, FLUOROSILICATES, HEXAFLUOROSILICATES MAGNESIUM FLUOSILICATE,

Schedule 6  
Schedule 5

**SILICONES**

Schedule 10  
Schedule 4  
Appendix F, clause 4

**SILODOSIN**

Schedule 4

**SILTUXIMAB**

Schedule 4

**SILVER**

Schedule 2

**SILVER NITRATE**cross reference: SILVER SALTS

Schedule 6  
Appendix E, clause 3

**SILVER OXIDE**

Appendix B, clause 3

**SILVER SULFADIAZINE**

Schedule 4

**SIMAZINE**

Appendix B, clause 3

**SIMEPREVIR**

Schedule 4

**SIMVASTATIN**

Schedule 4

**SINBIOALLETHRIN**

Schedule 6  
Schedule 5

**SINGLE‑USE TUBES**

Appendix A, clause 1

**SIPONIMOD**

Schedule 4

**SIROLIMUS**

Schedule 4

**SISOMICIN**

Schedule 4

**SITAGLIPTIN**

Schedule 4

**SITAXENTAN**

Schedule 4  
Appendix D, clause 6  
Appendix F, clause 4  
Appendix L, clause 2

**SLIMICIDES**

Appendix A, clause 1

**SODIUM ALUMINATE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**SODIUM BICARBONATE**

Appendix B, clause 3

**SODIUM BROMATE**

Schedule 6  
Appendix E, clause 3

**SODIUM BROMIDE**

Schedule 5  
Schedule 4

**SODIUM CELLULOSE PHOSPHATE**

Schedule 4

**SODIUM CHLORATE**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**SODIUM CROMOGLYCATE**

Schedule 4  
Schedule 2

**SODIUM DIACETATE**

Schedule 5  
Appendix E, clause 3

**SODIUM DICHLOROISOCYANURATE**

Appendix E, clause 3

**SODIUM DODECYLBENZENE SULFONATE**

Schedule 5  
Appendix E, clause 3, Part   
Appendix F, clause 4

**SODIUM FLUORIDE**

Appendix F, clause 4

**SODIUM GLYCEROPHOSPHATE HYDRATE**

Schedule 4

**SODIUM HYDROGEN SULFATE**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**SODIUM HYDROSULFITE**

Schedule 5  
Appendix F, clause 4

**SODIUM HYDROXIDE**cross reference: CAS No. 1310-73-2, LYE WATER

Schedule 10  
Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**SODIUM LAURETH‑6 CARBOXYLATE**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**SODIUM METABISULPHITE**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**SODIUM MORRHUATE**

Schedule 4

**SODIUM NITRITE**

Schedule 7  
Schedule 6  
Schedule 5  
Schedule 2  
Appendix E, clause 3  
Appendix F, clause 4

**SODIUM NITROPRUSSIDE**

Schedule 4

**SODIUM OXYBATE**

Schedule 8  
Appendix D, clause 1  
Appendix K, clause 1

**SODIUM PERCARBONATE**

Schedule 6  
Schedule 5

Appendix E, clause 3

**SODIUM PERSULFATE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**SODIUM PHENYLBUTYRATE**

Schedule 4

**SODIUM PHOSPHATE**

Schedule 4  
Schedule 3

**SODIUM PICOSULFATE**

Schedule 3

**SODIUM POLYSTYRENE SULPHONATE**

Schedule 5  
Schedule 4

**SODIUM PROPIONATE**

Appendix B, clause 3

**SODIUM SALICYLATE**

Schedule 4

**SODIUM STANNATE**

Schedule 5,   
Appendix E, clause 3

**SODIUM SULFIDE**

Schedule 6

Schedule 5

Appendix E, clause 3

Appendix F, clause 4

**SODIUM TETRADECYLSULFATE**

Schedule 4

**SODIUM TRICHLOROACETATE**

Appendix E, clause 3

**SODIUM ZIRCONIUM CYCLOSILICATE.**

Schedule 4

**SODIUMHYDROSULFITE**

Appendix E, clause 3

**SOFOSBUVIR**

Schedule 4

**SOLASODINE**

Schedule 4

**SOLIFENACIN**

Schedule 4

**SOMAPACITAN**

Schedule 4

**SOMATOSTATIN**

Schedule 4

**SOMATOTROPIN EQUINE**

Schedule 4

**SOMATROPIN**cross reference: HUMAN GROWTH HORMONE

Schedule 4  
Appendix D, clause 5

**SONIDEGIB**

Schedule 4

**SONTOQUINE**

Schedule 4

**SORAFENIB**

Schedule 4

**SOTALOL**

Schedule 4

**SOTORASIB**

Schedule 4

**SOTROVIMAB**

Schedule 4

**SPARFLOXACIN**

Schedule 4

**SPARTEINE**

Schedule 4

**SPECTINOMYCIN**

Schedule 4

**SPESOLIMAB**

Schedule 4

**SPINETORAM**

Schedule 5

**SPINOSAD**

Schedule 5

**SPIRAMYCIN**

Schedule 4

**SPIRAPRIL**

Schedule 4

**SPIROMESIFEN**

Schedule 5

**SPIRONOLACTONE**

Schedule 4

**SPIROPIDION**

Schedule 6

**SPIROTETRAMAT**

Schedule 6

**SPIROXAMINE**

Schedule 6

**SQUILL**

Schedule 2

**STANOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**STANOZOLOL**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**STAR ANISE OIL**

Schedule 5

**STAVUDINE**

Schedule 4

**STENABOLIC (SR9009) and other synthetic REV‑ERB agonists**cross reference: SR9011, GSK2945, GSK0999, GSK5072, GSK2667

Schedule 4  
Appendix D, clause 5

**STENBOLONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**STERIC ACID**

Appendix B, clause 3

**STEROID HORMONES**

Schedule 4

**STILBESTROL**cross reference: STILBOESTROL, DIETHYLSTILBESTROL

Schedule 4

**STIRIPENTOL**

Schedule 4  
Appendix K, clause 1

**STREPTODORNASE**

Schedule 4

**STREPTOKINASE**

Schedule 4

**STREPTOMYCES LYDICUS WYEC 108**

Appendix B, clause 3

**STREPTOMYCIN**

Schedule 4

**STRONTIUM RANELATE**

Schedule 4

**STROPHANTHINS**

Schedule 4

**STROPHANTHUS spp.**

Schedule 4  
Appendix G, clause 1

**STRYCHNINE**cross reference: NUX VOMICA

Schedule 7  
Schedule 4  
Appendix E, clause 3  
Appendix G, clause 1  
Appendix J, clause 1

**STRYCHNOS spp.**

Schedule 4

**STYRAMATE**

Schedule 4

**STYRENE**cross reference: DESIGNATED SOLVENT

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**SUCCIMER**

Schedule 4

**SUCRALFATE**

Appendix B, clause 3

**SUCROFERRIC OXYHYDROXIDE**

Schedule 4

**SUFENTANIL**

Schedule 8

**SUGAMMADEX**

Schedule 4

**SULBACTAM**

Schedule 4

**SULCOFURON**

Schedule 7  
Schedule 6  
Appendix E, clause 3  
Appendix J, clause 1

**SULCONAZOLE**

Schedule 4  
Schedule 2

**SULESOMAB**

Appendix B, clause 3

**SULFACETAMIDE**

Schedule 5  
Schedule 4  
Schedule 3

**SULFADIAZINE**

Schedule 5  
Schedule 4

**SULFADIMETHOXINE**

Schedule 4

**SULFADIMIDINE**

Schedule 5  
Schedule 4

**SULFADOXINE**

Schedule 4

**SULFAFURAZOLE**

Schedule 4

**SULFAGUANIDINE**

Schedule 4

**SULFAMERAZINE**

Schedule 5  
Schedule 4

**SULFAMETHIZOLE**

Schedule 4

**SULFAMETHOXAZOLE**

Schedule 4

**SULFAMETHOXYDIAZINE**

Schedule 4

**SULFAMETHOXYPYRIDAZINE**

Schedule 4

**SULFAMETROLE**

Schedule 4

**SULFAMIC ACID**

Schedule 6  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**SULFAMONOMETHOXINE**

Schedule 4

**SULFAMOXOLE**

Schedule 4

**SULFAPHENAZOLE**

Schedule 4

**SULFAPYRIDINE**

Schedule 4

**SULFAQUINOXALINE**

Schedule 4

**SULFASALAZINE**

Schedule 4

**SULFATHIAZOLE**

Schedule 5  
Schedule 4

**SULFATROXAZOLE**

Schedule 4

**SULFENTRAZONE**

Schedule 7

**SULFINPYRAZONE**

Schedule 4

**SULFLURAMID**

Schedule 6

**SULFOMETURON‑METHYL**

Schedule 5

**SULFOMYXIN**

Schedule 4

**SULFONAMIDES**cross reference: SULFACETAMIDE, SULPHANILAMIDE

Schedule 4

**SULFONMETHANE**cross reference: ALKYL SULFONALS, SULFONAL

Schedule 4

**SULFOSULFURON**

Appendix B, clause 3

**SULFOTEP**

Schedule 7

**SULFOXAFLOR**

Schedule 6  
Schedule 5

**SULFURIC ACID**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**SULFURYL FLUORIDE**

Schedule 6

**SULINDAC**

Schedule 4

**SULPHATED POLYSACCHARIDES**

Appendix B, clause 3

**SULPROFOS**

Schedule 6

**SULTAMICILLIN**

Schedule 4

**SULTHIAME**

Schedule 4

**SUMATRIPTAN**

Schedule 4  
Schedule 3  
Appendix H, clause 1

**SUNIFIRAM**

cross reference: RACETAMS

Schedule 4

**SUNITINIB**

Schedule 4

**SUPROFEN**

Schedule 4

**SUTILAINS**

Schedule 4

**SUVOREXANT**

Schedule 4  
Appendix K, clause 1

**SUXAMETHONIUM**

Schedule 4

**SUXETHONIUM**

Schedule 4

**SYMPHYTUM spp.**cross reference: COMFREY

Schedule 10  
Schedule 5  
Appendix F, clause 4

**SYNTHETIC CANNABINOMIMETICS**

Schedule 9

**T**

**2,4,5‑T**

Schedule 6

**TACRINE**

Schedule 4

**TACROLIMUS**

Schedule 4

**TADALAFIL**

Schedule 4

**TAFAMIDIS**

Schedule 4

**TAFASITAMAB**

Schedule 4

**TAFENOQUINE SUCCINATE**

Schedule 4

**TAFLUPROST**

Schedule 4

**TAGRAXOFUSP**

Schedule 4

**TALAZOPARIB**

Schedule 4

**TALIGLUCERASE ALFA**

Schedule 4

**TALIMOGENE LAHERPAREPVEC**

Schedule 4

**TALLOW ALKYLAMINE ACETATES**

Schedule 6

***N*‑TALLOW ALKYL‑1,3‑PROPANEDIAMINE DIACETATE**

Schedule 6

**TAMOXIFEN**

Schedule 4

**TAMSULOSIN**

Schedule 4

**TANACETUM VULGARE**cross reference: OIL OF TANSY, TANSY OIL

Schedule 4

**TANNIC ACID**

Appendix B, clause 3

**TANNIC ACID/BENZYL ALCOHOL PRODUCT**

Appendix B, clause 3

**TAPENTADOL**

Schedule 8  
Appendix K, clause 1

**TAR ACIDS**

Schedule 6

**TASONERMIN**

Schedule 4

**TAZAROTENE**

Schedule 4  
Appendix F, clause 4

**TAZOBACTAM**

Schedule 4

**TB‑500**

Schedule 4   
Appendix D, clause 5

**2,3,6‑TBA**

Schedule 5

**T‑CELL RECEPTOR ANTIBODY**

Schedule 4

**TCMTB**cross reference: 2‑[THIOCYANOMETHYLTHIO]BENZOTHIAZOLE

Schedule 6

**TDE**cross reference: 1,1‑DICHLORO‑2,2‑BIS[4‑CHLOROPHENYL]ETHANE

Schedule 6  
Schedule 5

**TEBENTAFUSP**

Schedule 4

**TEBUCONAZOLE**cross reference: TERBUCONAZOLE

Schedule 5

**TEBUFENOZIDE**

Schedule 5

**TEBUFENPYRAD**

Schedule 6

**TEBUTHIURON**

Schedule 6

**TECLISTAMAB**

Schedule 4

**TEDUGLUTIDE**

Schedule 4

**TEFLUTHRIN**

Schedule 7  
Schedule 5

**TEGAFUR**

Schedule 4

**TEGASEROD**

Schedule 4

**TEICOPLANIN**

Schedule 4

**TELAPREVIR**

Schedule 4

**TELBIVUDINE**

Schedule 4

**TELITHROMYCIN**

Schedule 4

**TELMISARTAN**

Schedule 4

**TELOTRISTAT ETHYL**

Schedule 4

**TEMAZEPAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)

Appendix K, clause 1

**TEMEPHOS**

Schedule 6  
Schedule 5

**TEMOZOLOMIDE**

Schedule 4

**TEMSIROLIMUS**

Schedule 4

**TENECTEPLASE**

Schedule 4

**TENIPOSIDE**

Schedule 4

**TENOCYCLIDINE**cross reference: TCP (CAS No. 21500-98-1)

Schedule 9

**TENOFOVIR**

Schedule 4

**TENOXICAM**

Schedule 4

**TEPOTINIB**

Schedule 4

**TEPOXALIN**

Schedule 4

**TEPP**

Schedule 8

**TEPRALOXYDIM**

Schedule 5

**TERAZOSIN**

Schedule 4

**TERBACIL**

Appendix B, clause 3,Part 3

**TERBINAFINE**

Schedule 4  
Schedule 2

**TERBUFOS**

Schedule 7

**TERBUTALINE**

Schedule 4Schedule 3  
Appendix F, clause 4

**TERBUTHYLAZINE**

Schedule 6

**TERBUTRYN**

Schedule 5

**TERFENADINE**

Schedule 4Appendix F, clause 4

**TERIFLUNOMIDE**

Schedule 4Appendix F, clause 4  
Appendix L, clause 2

**TERIPARATIDE**

Schedule 4  
Appendix D, clause 1

**TERLIPRESSIN**

Schedule 4

**TERMITE BARRIERS**

Appendix A, clause 1

**TERODILINE**

Schedule 4

**TEROPTERIN**

Schedule 4

**TERPENES, CHLORINATED**cross reference: CHLORINATED TERPENES

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**TESTOLACTONE**

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**TESTOSTERONE**

Schedule 6  
Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)  
Appendix G, clause 1

**TETANUS ANTITOXIN**

Schedule 4

**TETANUS TOXOID**

cross reference: TRIPLE ANTIGEN VACCINE

Schedule 4

**1,3,5,7‑TETRAAZATRICYLO[3.3.1.13,7] DECANE**  
cross reference: HEXAMINE, HEXAMETHYLENETETRAMINE, METHENAMINE

Schedule 5

**TETRABENAZINE**

Schedule 4

**TETRACAINE**cross reference: AMETHOCAINE

Schedule 4   
Schedule 2

**TETRACHLOROETHANE**

Schedule 7  
Appendix E, clause 3  
Appendix F, clause 4  
Appendix J, clause 1

**TETRACHLOROETHYLENE**cross reference: DESIGNATED SOLVENT

Schedule 6  
Schedule 5  
Schedule 2  
Appendix E, clause 3  
Appendix F, clause 4

**TETRACHLORVINPHOS**

Schedule 5

**TETRACONAZOLE**

Schedule 6  
Schedule 5

**TETRACOSACTIDE**

Schedule 4

**TETRACOSACTRIN**cross reference: TETRACOSACTIDE

**TETRACYCLINE**

Schedule 5  
Schedule 4

**TETRADIFON**

Schedule 6

**TETRAETHYLAMMONIUM**

Schedule 4

**TETRAHYDROCANNABINOLIC ACID**cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS

**TETRAHYDROCANNABINOLS**cross reference: CANNABIS, HEMP SEED OIL, NABIXIMOLS

Schedule 9  
Schedule 8  
Appendix D, clause 1  
Appendix K, clause 1

**TETRAHYDROCANNABIDIVAROL**cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS

**TETRAHYDROFURFURYL ALCOHOL**

Schedule 6

**TETRAHYDROZOLINE**cross reference: TETRYZOLINE

**2,2**'**,6,6**'**‑TETRAISOPROPYL‑DIPHENYL‑CARBODIIMIDE**cross reference: STABAXOL

Schedule 7

Schedule 6  
Appendix J, clause 1

**TETRAMETHRIN**

Schedule 5

**TETRAMISOLE**

Schedule 6

**TETRANILIPROLE**

Schedule 5

**TETROXOPRIM**

Schedule 4

**TETRYZOLINE**cross reference: TETRAHYDROZOLINE

Schedule 2  
Appendix F, clause 4

**TEZACAFTOR**

Schedule 4

**THALIDOMIDE**

Schedule 4Appendix D, clause 2  
Appendix F, clause 4  
Appendix L, clause 2

**THALLIUM**cross reference: THALLIUM SULFATE

Schedule 7  
Appendix J, clause 1

**THAUMATIN**

Appendix B, clause 3

**THEBACON**

Schedule 8

**THEBAINE**

Schedule 8

**THENYLDIAMINE**

Schedule 4  
Appendix K, clause 1

**THEOPHYLLINE**

Schedule 4  
Schedule 3

**THEVETIA PERUVIANA**

Schedule 4

**THEVETIN**

Schedule 4

**THIABENDAZOLE**

Schedule 5  
Schedule 2

**THIACETARSAMIDE**

Schedule 4

**THIACLOPRID**

Schedule 6

**THIAMBUTOSINE**

Schedule 4

**THIAMETHOXAM**

Schedule 6  
Schedule 5

**THIAZAFLURON**

Schedule 6

**THIAZOPYR**

Schedule 5

**THIAZOSULFONE**

Schedule 4

**THIDIAZURON**

Appendix B, clause 3

**THIETHYLPERAZINE**

Schedule 4Appendix K, clause 1

**THIFENSULFURON**

Schedule 5

**THIOACETAZONE**

Schedule 4

**THIOBENCARB**

Schedule 5

**THIOCARLIDE**

Schedule 4

**THIODICARB**

Schedule 6  
Schedule 5

**THIOFANOX**

Schedule 7

**THIOFENTANYL**

cross reference: CAS No. 1165-22-6

Schedule 9

**THIOGUANINE**cross reference: TIOGUANINE

**THIOMESTERONE**cross reference: TIOMESTERONE

Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**THIOMETON**

Schedule 6

**THIOPENTAL**

Schedule 4

**THIOPENTONE**cross reference: THIOPENTAL

**THIOPHANATE‑METHYL**

Schedule 6Schedule 5

**THIOPROPAZATE**

Schedule 4Appendix K, clause 1

**THIOPROPERAZINE**

Schedule 4

**THIORIDAZINE**

Schedule 4Appendix K, clause 1

**THIOSTREPTON**

Schedule 4

**THIOTEPA**cross reference: TRIETHYLENE THIOPHOSPHORAMIDE

Schedule 4

**THIOTHIXENE**

Schedule 4Appendix K, clause 1

**THIOURACIL**

Schedule 4

**THIOUREA**cross reference: ALKYL THIOUREAS

Schedule 6  
Schedule 4Appendix E, clause 3  
Appendix F, clause 4

**THIRAM**

Schedule 6

**THUJONE**

Schedule 6  
Appendix E, clause 3

**THYME OIL**

Schedule 5  
Appendix E, clause 3

**THYMOL**

Schedule 6

**THYMOSIN BETA 4 (THYMOSIN β4)**

Schedule 4  
Appendix D, clause 5

**THYMOXAMINE**

Schedule 4

**THYROID**

Schedule 4

**THYROTROPHIN**cross reference: TSH

Schedule 4

**THYROXINE**

Schedule 4Appendix G, clause 1

**TIAFENACIL**

Appendix B, clause 3

**TIAGABINE**

Schedule 4

**TIAMULIN**

Schedule 4

**TIANEPTINE**

Schedule 4  
Appendix D, clause 5

**TIAPROFENIC ACID**

Schedule 4

**TIARAMIDE**

Schedule 4

**TIBOLONE**

Schedule 4

**TICAGRELOR**

Schedule 4

**TICARCILLIN**

Schedule 4

**TICLOPIDINE**

Schedule 4

**TIEMONIUM**

Schedule 4

**TIENILIC ACID**

Schedule 4

**TIGECYCLINE**

Schedule 4

**TIGILANOL TIGLATE**

Schedule 4

**TIGLOIDINE**

Schedule 4

**TIGOLANER**

Schedule 6Schedule 5

**TILDIPIROSIN**

Schedule 4

**TILETAMINE**

Schedule 4

**TILIDINE**

Schedule 8

**TILMANOCEPT**

Schedule 4

**TILMICOSIN**

Schedule 4

**TILUDRONIC ACID**cross reference: DISODIUM TILUDRONATE

Schedule 4

**TIMBER**cross reference: WALLBOARD

Appendix A, clause 1

**TIMOLOL**

Schedule 4

**TIMOTHY‑GRASS POLLEN EXTRACT**   
cross reference: PHLEUM PRATENSE POLLEN EXTRACT

Schedule 4

**TIN ORGANIC COMPOUNDS**cross reference: DIALKYL TIN COMPOUNDS, DIBUTYL TIN COMPOUNDS, DIETHYL TIN COMPOUNDS, DIMETHYL TIN DICHLORIDE, DIMETHYL TIN COMPOUNDS, DIPROPYL TIN COMPOUNDS, FENBUTATIN OXIDE, ORGANO TIN‑COMPOUNDS, TBTO, TRIALKYL TIN COMPOUNDS, TRIBUTYL TIN COMPOUNDS, TRIETHYL TIN COMPOUNDS, TRIMETHYL TIN COMPOUNDS, TRIPHENYL TIN COMPOUNDS, TRIPROPYL TIN COMPOUNDS

Schedule 7

**TINIDAZOLE**

Schedule 4

**TINZAPARIN**

Schedule 4

**TIOCARBAZIL**

Schedule 5

**TIOCONAZOLE**

Schedule 4  
Schedule 3  
Schedule 2

Appendix H, clause 1

**TIOGUANINE**cross reference: THIOGUANINE

Schedule 4

**TIOTROPIUM**

Schedule 4

**TIPEPIDINE**

Schedule 4

**TIPIRACIL**

Schedule 4

**TIPRANAVIR**

Schedule 4

**TIRBANIBULIN**

Schedule 4

**TIRILAZAD**

Schedule 4

**TIROFIBAN**

Schedule 4

**TIRZEPATIDE**

Schedule 4

Appendix L, clause 2

**TISLELIZUMAB**

Schedule 4

**TIXAGEVIMAB**

Schedule 4

**TOBRAMYCIN**

Schedule 4

**TOCAINIDE**

Schedule 4

**TOCERANIB**

Schedule 4

**TOCILIZUMAB**

Schedule 4

**TOFACITINIB**

Schedule 4

**TOLAZAMIDE**

Schedule 4

**TOLAZOLINE**

Schedule 4

**TOLBUTAMIDE**

Schedule 4

**TOLCAPONE**

Schedule 4

**TOLCLOFOS‑METHYL**

Schedule 5

**TOLFENAMIC ACID**

Schedule 4

***o*‑TOLIDINE**

Schedule 7  
Appendix E, clause 3  
Appendix J, clause 1

**TOLMETIN**

Schedule 4

**TOLONIUM**

Schedule 4

**TOLPROPAMINE**

Schedule 4

**TOLRESTAT**

Schedule 4

**TOLTERODINE**

Schedule 4

**TOLTRAZURIL**

Schedule 5

**TOLUENE**cross reference: XYLENE

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**2,4‑TOLUENEDIAMINE**

cross reference: CAS No. 95-80-7

Schedule 10

**TOLUENEDIAMINES**

Schedule 10  
Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**o‑TOLUIDINE**

cross reference: CAS No. 95-53-4

Schedule 10

**TOLVAPTAN**

Schedule 4

**TOLYLFLUANID**

Schedule 6

**TOPIRAMATE**

Schedule 4

**TOPOTECAN**

Schedule 4

**TOPRAMEZONE**

Schedule 5

**TORASEMIDE**

Schedule 4

**TOREMIFENE**

Schedule 4

**TOXOIDS**

Schedule 4

**TRABECTEDIN**

Schedule 4  
Appendix K, clause 1

**TRALKOXYDIM**

Schedule 5

**TRAMADOL**

Schedule 4  
Appendix K, clause 1

**TRAMAZOLINE**

Schedule 2  
Appendix F, clause 4

**TRAMETINIB DIMETHYL SULFOXIDE**

Schedule 4

**TRANDOLAPRIL**

Schedule 4

**TRANEXAMIC ACID**cross reference: CETYL TRANEXAMATE

Schedule 4

**TRANSFLUTHRIN**

Schedule 6

**TRANYLCYPROMINE**

Schedule 4  
Appendix K, clause 1

**TRASTUZUMAB**

Schedule 4

**TRASTUZUMAB DERUXTECAN**

Schedule 4

Appendix L, clause 2

**TRASTUZUMAB EMTANSINE**

Schedule 4

**TRAVOPROST**

Schedule 4

**TRAZODONE**

Schedule 4

**TRENBOLONE**cross reference: TRIENBOLONE, TRIENOLONE

Schedule 5  
Schedule 4  
Appendix D, clause 5 (Anabolic and/or androgenic steroidal agents)

**TREOSULPHAN**

Schedule 4

**TREPROSTINIL**

Schedule 4

**TRESTOLONE**

Schedule 4  
Appendix D, clause 5 (androgenic steroidal agents)

**TRETAMINE**

Schedule 4

**TRETINOIN**

Schedule 4  
Appendix D, clause 4  
Appendix F, clause 4  
Appendix L, clause 2

**TRIACETYLOLEANDOMYCIN**

Schedule 4

**TRIADIMEFON**

Schedule 6  
Schedule 5

**TRIADIMENOL**

Schedule 5

**TRI‑ALLATE**

Schedule 5

**TRIAMCINOLONE**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix F, clause 4, Part 2

Appendix H, clause 1

**TRIAMIPHOS**

Schedule 7

**TRIAMTERENE**

Schedule 4

**TRIASULFURON**

Appendix B, clause 3

**TRIAZBUTIL**

Schedule 7

**TRIAZIQUONE**

Schedule 4

**TRIAZOLAM**

Schedule 4  
Appendix D, clause 5 (Benzodiazepine derivatives)

**TRIBENURON‑METHYL**

Schedule 5

**TRIBUFOS**cross reference: s,s,s‑TRIBUTYLPHOSPHOROTRITHIOATE

Schedule 7

**TRICHLORFON**cross reference: METRIFONATE

Schedule 6

**TRICHLORMETHIAZIDE**

Schedule 4

**TRICHLOROACETIC ACID**

Schedule 6  
Schedule 5  
Schedule 4  
Appendix E, clause 3  
Appendix F, clause 4

**TRICHLOROACETIC ACID ALKALI SALTS**

Schedule 5  
Appendix E, clause 3

**1,1,1‑TRICHLOROETHANE**cross reference: CAS No. 71-55-6, DESIGNATED SOLVENT

Schedule 10  
Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**TRICHLOROETHYLENE**cross reference: TRICHLOROETHENE

Schedule 6  
Schedule 4  
Appendix E, clause 3  
Appendix F, clause 4

**TRICHLOROISOCYANURIC ACID**cross reference: CHLORINATING COMPOUNDS

Appendix E, clause 3

**TRICHLOROPHENOL**

Schedule 6  
Appendix F, clause 4

**TRICHODERMA HARZIANUM**

Appendix B, clause 3

**TRICHODESMA AFRICANA**

Schedule 10

**TRICLABENDAZOLE**

Schedule 6

**TRICLOFOS**

Schedule 4

**TRICLOPYR**

Schedule 6

**TRICLOSAN**

Schedule 6

**TRICYCLAMOL**

Schedule 4

**TRIDEMORPH**

Schedule 6

**TRIDIHEXETHYL**

Schedule 4

**TRIDIPHANE**

Schedule 5

**TRIENTINE**

Schedule 4

**TRIETAZINE**

Schedule 5

**TRIETHANOLAMINE**cross reference: TROLAMINE

**TRIETHYL PHOSPHATE**

Schedule 6  
Appendix E, clause 3

**TRIETHYLENE GLYCOL**

Appendix B, clause 3

**TRIFAROTENE**

Schedule 4

**TRIFLOXYSTROBIN**

Schedule 5

**TRIFLOXYSULFURON**

Appendix B, clause 3

**TRIFLUDIMOXAZIN**

Schedule 5

**TRIFLUMIZOLE**

Schedule 5

**TRIFLUMURON**

Schedule 5

**TRIFLUOPERAZINE**

Schedule 4  
Appendix K, clause 1

**TRIFLUOROMETHANESULFONIC ACID**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**1‑(3‑TRIFLUOROMETHYLPHENYL)PIPERAZINE**cross reference: TFMPP (CAS No. 15532-75-9), TFMPP HYDROCHLORIDE (CAS No. 16015-69-3)

Schedule 9

**TRIFLUPERIDOL**

Schedule 4

**TRIFLUPROMAZINE**

Schedule 4

**TRIFLURALIN**

Appendix B, clause 3

**TRIFLURIDINE**

Schedule 4

**TRIFORINE**

Appendix B, clause 3

**TRIHEXYPHENIDYL**cross reference: BENZHEXOL

Schedule 4

**TRIISOPROPANOLAMINE LAURYL ETHER SULFATE**

Schedule 5  
Appendix E, clause 3  
Appendix F, clause 4

**TRILOSTANE**

Schedule 4

**TRIMEPERIDINE**

cross reference: CAS No. 29606-10-8

Schedule 9

**TRIMEPRAZINE**cross reference: ALIMEMAZINE

**TRIMETAPHAN**

Schedule 4

**TRIMETHOPRIM**

Schedule 4

**3,4,5‑TRIMETHOXY‑ α –METHYLPHENYLETHYLAMINE**cross reference: TMA (CAS No. 1082-88-8), TMA HYDROCHLORIDE (CAS No. 5688-80-2)

Schedule 9

**3,4,5‑TRIMETHOXYPHENETHYLAMINE**cross reference: MESCALINE, METHOXYPHENAMINE, METHOXY‑PHENYLETHYLAMINE (CAS No. 54-04-6), MESCALINE HYDROCHLORIDE (CAS No. 832-92-8), MESCALINE HYDROGEN SULFATE (CAS No. 5967-42-0), MESCALINE HEMISULFATE (CAS No. 642-73-9)

Schedule 9

**1‑(3,4,5‑TRIMETHOXYPHENYL)‑2‑AMINOBUTANE**

cross reference: CAS No. 17097-73-3

Schedule 9

**TRIMIPRAMINE**

Schedule 4  
Appendix K, clause 1

**TRIMUSTINE**

Schedule 4

**TRINEXAPAC‑ETHYL**

Schedule 5

**TRINITROPHENOL**

Schedule 6  
Schedule 4

**3,6,9‑TRIOXAUNDECANEDIOIC ACID**

Schedule 5  
Appendix F, clause 4

**TRIOXYSALEN**

Schedule 4

**TRIPARANOL**

cross reference: CAS No. 78-41-1

Schedule 10

**TRIPELENNAMINE**

Schedule 4

**TRIPLE ANTIGEN VACCINE**

cross reference:DIPHTHERIA TOXOID, PERTUSSIS ANTIGEN, TETANUS TOXOID

**TRIPROLIDINE**

Schedule 4  
Schedule 3  
Schedule 2  
Appendix K, clause 1

**TRIPTORELIN**

Schedule 4

**TRISODIUM NITRILOTRIACETATE**

Schedule 6

**TRITICONAZOLE**

Schedule 5

**TROGLITAZONE**

Schedule 4

**TROLAMINE**

Schedule 5  
Schedule 4  
Appendix E, clause 3  
Appendix F, clause 4

**TROMETAMOL**

Schedule 4

**TROPICAMIDE**

Schedule 4

**TROPISETRON**

Schedule 4

**TROVAFLOXACIN**

Schedule 4

**TROXIDONE**

Schedule 4

**TRYPTOPHAN**

Schedule 4

**TUAMINOHEPTANE**

Schedule 2

**TUCATINIB**

Schedule 4

**TUBERCULIN**

Schedule 4

**TUBOCURARINE**

Schedule 4

**TULATHROMYCIN**

Schedule 4

**TULOBUTEROL**

Schedule 4

**TURPENTINE OIL**cross reference: OIL OF TURPENTINE

Schedule 5  
Appendix E, clause 3

**TUSSILAGO FARFARA**cross reference: COLTSFOOT

Schedule 10

**TYLOSIN**

Schedule 4

**TYMAZOLINE**

Schedule 4  
Appendix F, clause 4

**TYPHOID VACCINE**

Schedule 4

**U**

**ULIPRISTAL**

Schedule 4  
Schedule 3  
Appendix H, clause 1

**ULOCLADIUM OUDEMANSII**

Appendix B, clause 3

**UMECLIDINIUM**

Schedule 4

**UNIFIRAM**

cross reference: RACETAMS

Schedule 4

**UNOPROSTONE**

Schedule 4

**UPADACITINIB**

Schedule 4

**URACIL**

Schedule 4

**URAPIDIL**

Schedule 4

**UREA**

Appendix B, clause 3

**URETHANE**

Schedule 4

**UROFOLLITROPIN**cross reference: FOLLICLE‑STIMULATING HORMONE, HUMAN

Schedule 4Appendix D, clause 1

**UROKINASE**

Schedule 4

**URSODEOXYCHOLIC ACID**

Schedule 4

**USTEKINUMAB**

Schedule 4

**V**

**VACCINES**

Schedule 4

**VACCINES – PLASMID DNA**  
cross reference: PLASMID DNA (r*E. coli* DH5α pINGhT)

Schedule 4

**VACCINIA VIRUS VACCINE**

Schedule 4

**VADADUSTAT**

Schedule 4  
Appendix D, clause 5

**VALACICLOVIR**

Schedule 4

**VALDECOXIB**

Schedule 4

**VALGANCICLOVIR**

Schedule 4

**VALNOCTAMIDE**

Schedule 4

**VALPROIC ACID**

Schedule 4

**VALSARTAN**

Schedule 4

**VAMIDOTHION**

Schedule 6

**VANCOMYCIN**

Schedule 4

**VANDETANIB**

Schedule 4

**VARDENAFIL**

Schedule 4

**VARENICLINE**

Schedule 4

**VARICELLA VACCINE**

Schedule 4

**VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN (RECOMBINANT)**

cross reference: RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN

**VASOPRESSIN**

Schedule 4

**VECURONIUM**

Schedule 4

**VEDAPROFEN**

Schedule 4

**VEDOLIZUMAB**

Schedule 4

**VELAGLIFLOZIN**

Schedule 4

**VELAGLUCERASE ALFA**

Schedule 4

**VELPATASVIR**

Schedule 4

**VEMURAFENIB**

Schedule 4

**VENETOCLAX**

Schedule 4

**VENLAFAXINE**

Schedule 4

**VERAPAMIL**

Schedule 4

**VERATRUM**

Schedule 4

**VERICIGUAT**

Schedule 4

**VERNAKALANT**

Schedule 4

**VERNOLATE**

Schedule 5

**VERTEPORFIN**

Schedule 4

**VETIVER OIL**

Appendix B, clause 3

**VIDARABINE**

Schedule 4

**VIGABATRIN**

Schedule 4

**VILANTEROL**

Schedule 4

**VILDAGLIPTIN**

Schedule 4

**VILOXAZINE**

Schedule 4

**VINBLASTINE**

Schedule 4

**VINCAMINE**

Schedule 4

**VINCLOZOLIN**

Schedule 6  
Appendix F, clause 4

**VINCRISTINE**

Schedule 4

**VINDESINE**

Schedule 4

**VINFLUNINE**

Schedule 4

**VINORELBINE**

Schedule 4

**VINYL ACETATE MONOMER**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**VINYL CHLORIDE**

Schedule 7  
Appendix J, clause 1

**VINYL ETHER**

Schedule 4

**VIRGINIAMYCIN**

Schedule 5  
Schedule 4

**VISMODEGIB**

Schedule 4

**VISNADINE**

Schedule 4

**VITAMIN A**

Schedule 4

**VITAMIN D**cross reference: COLECALCIFEROL, ERGOCALCIFEROL

Schedule 4  
Schedule 3  
Appendix H, clause 1

**VITAMIN K**cross reference: PHYTOMENADIONE

Appendix B, clause 3

**VITREOUS ENAMELS**

Appendix A, clause 1

**VORAPAXAR**

Schedule 4

**VORETIGENE NEPARVOVEC**

Schedule 4

**VORICONAZOLE**

Schedule 4

**VORINOSTAT**

Schedule 4

**VORTIOXETINE**

Schedule 4

**VOSORITIDE**

Schedule 4

**VOXILAPREVIR**

Schedule 4

**W**

**WALLBOARD**cross reference: TIMBER

Appendix A, clause 1

**WARFARIN**

Schedule 6  
Schedule 5  
Schedule 4

**WRITING CORRECTION PENS**

Appendix A, clause 1

**X**

**XAMOTEROL**

Schedule 4

**XANTHINOL NICOTINATE**

Schedule 4

**XANTHOPHYLL**cross reference: LUTEIN

Appendix B, clause 3

**XIMELAGATRAN**

Schedule 4

**XIPAMIDE**

Schedule 4

**XYLANASE derived from Aspergillus niger**

Appendix B, clause 3

**XYLAZINE**

Schedule 4

**XYLENE**cross reference: TOLUENE

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**XYLOMETAZOLINE**

Schedule 2  
Appendix F, clause 4

**Y**

**YLANG YLANG OIL**

Appendix B, clause 3

**YOHIMBINE**cross reference: ASPIDOSPERMA QUEBRACHO

Schedule 4

**Z**

**(*Z*)‑9‑TRICOSENE**cross reference: TRICOSENE

Appendix B, clause 3

**ZAFIRLUKAST**

Schedule 4

**ZALCITABINE**

Schedule 4

**ZALEPLON**

Schedule 4

**ZANAMIVIR**

Schedule 4

**ZANUBRUTINIB**

Schedule 4

**ZERANOL**

Schedule 6  
Schedule 4

**ZETA‑CYPERMETHRIN**

Schedule 7  
Schedule 6

**ZIDOVUDINE**

Schedule 4

**ZILPATEROL**

Schedule 4

**ZILUCOPLAN**

Schedule 4

**ZIMELDINE**

Schedule 4

**ZINC BORATE**

Schedule 6

**ZINC CHLORIDE**

Schedule 4

Schedule 2

Appendix E, clause 3

**ZINC COMPOUNDS**

Schedule 4

**ZINC LACTATE**

Schedule 6  
Appendix F, clause 4

**ZINC NAPHTHENATE**

Appendix B, clause 3

**ZINC para‑PHENOLSULFONATE**

Schedule 6

**ZINC SULFATE**

Schedule 6  
Appendix E, clause 3  
Appendix F, clause 4

**ZINEB**cross reference: DITHIOCARBAMATES, MANCOZEB, PROPINEB, THIRAM

Schedule 5

**ZIPRASIDONE**

Schedule 4  
Appendix K, clause 1

**ZIRAM**

Schedule 7  
Schedule 6

**ZOLAZEPAM**

Schedule 4

**ZOLEDRONIC ACID**

Schedule 4

**ZOLMITRIPTAN**

Schedule 4  
Schedule 3  
Appendix H, clause 1

**ZOLPIDEM**

Schedule 4  
Appendix K, clause 1

**ZONISAMIDE**

Schedule 4  
Appendix K, clause 1

**ZOPICLONE**

Schedule 4  
Appendix K, clause 1

**ZOXAZOLAMINE**

Schedule 4

**ZUCLOPENTHIXOL**

Schedule 4

1. “Cultivation”, “production” and “manufacture” have the same meaning as in the *Narcotic Drugs Act 1967* [↑](#footnote-ref-1)